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Abstract and Summary of Thesis: 
Background: 
Individuals with Major Mental Illness (such as schizophrenia and bipolar disorder) 
experience increased rates of physical health comorbidity compared to the general 
population. They also experience inequalities in access to certain aspects of healthcare. 
This ultimately leads to premature mortality. Studies detailing patterns of physical health 
comorbidity are limited by their definitions of comorbidity, single disease approach to 
comorbidity and by the study of heterogeneous groups. To date the investigation of 
possible sources of healthcare inequalities experienced by individuals with Major Mental 
Illness (MMI) is relatively limited. Moreover studies detailing the extent of premature 
mortality experienced by individuals with MMI vary both in terms of the measure of 
premature mortality reported and age of the cohort investigated, limiting their 
generalisability to the wider population. Therefore local and national data can be used to 
describe patterns of physical health comorbidity, investigate possible reasons for health 
inequalities and describe mortality rates. These findings will extend existing work in this 
area.     
Aims and Objectives: 
To review the relevant literature regarding: patterns of physical health comorbidity, 
evidence for inequalities in physical healthcare and evidence for premature mortality for 
individuals with MMI. To examine the rates of physical health comorbidity in a large 
primary care database and to assess for evidence for inequalities in access to healthcare 
using both routine primary care prescribing data and incentivised national Quality and 
Outcome Framework (QOF) data. Finally to examine the rates of premature mortality in a 
local context with a particular focus on cause of death across the lifespan and effect of 
International Classification of Disease Version 10 (ICD 10) diagnosis and socioeconomic 
status on rates and cause of death. 
Methods: 
A narrative review of the literature surrounding patterns of physical health comorbidity, 
the evidence for inequalities in physical healthcare and premature mortality in MMI was 
undertaken. Rates of physical health comorbidity and multimorbidity in schizophrenia and 
bipolar disorder were examined using a large primary care dataset (Scottish Programme for 
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Improving Clinical Effectiveness in Primary Care (SPICE)). Possible inequalities in access 
to healthcare were investigated by comparing patterns of prescribing in individuals with 
MMI and comorbid physical health conditions with prescribing rates in individuals with 
physical health conditions without MMI using SPICE data. Potential inequalities in access 
to health promotion advice (in the form of smoking cessation) and prescribing of Nicotine 
Replacement Therapy (NRT) were also investigated using SPICE data. Possible 
inequalities in access to incentivised primary healthcare were investigated using National 
Quality and Outcome Framework (QOF) data. Finally a pre-existing case register 
(Glasgow Psychosis Clinical Information System (PsyCIS)) was linked to Scottish 
Mortality data (available from the Scottish Government Website) to investigate rates and 
primary cause of death in individuals with MMI. Rate and primary cause of death were 
compared to the local population and impact of age, socioeconomic status and ICD 10 
diagnosis (schizophrenia vs. bipolar disorder) were investigated. 
Results: 
Analysis of the SPICE data found that sixteen out of the thirty two common physical 
comorbidities assessed, occurred significantly more frequently in individuals with 
schizophrenia. In individuals with bipolar disorder fourteen occurred more frequently. The 
most prevalent chronic physical health conditions in individuals with schizophrenia and 
bipolar disorder were: viral hepatitis (Odds Ratios (OR) 3.99 95% Confidence Interval (CI) 
2.82-5.64 and OR 5.90 95% CI 3.16-11.03 respectively), constipation (OR 3.24 95% CI 
3.01-3.49 and OR 2.84 95% CI 2.47-3.26 respectively) and Parkinson’s disease (OR 3.07 
95% CI 2.43-3.89 and OR 2.52 95% CI 1.60-3.97 respectively). Both groups had 
significantly increased rates of multimorbidity compared to controls: in the schizophrenia 
group OR for two comorbidities was 1.37 95% CI 1.29-1.45 and in the bipolar disorder 
group OR was 1.34 95% CI 1.20-1.49.  
In the studies investigating inequalities in access to healthcare there was evidence of: 
under-recording of cardiovascular-related conditions for example in individuals with 
schizophrenia: OR for Atrial Fibrillation (AF) was 0.62 95% CI 0.52 - 0.73, for 
hypertension 0.71 95% CI 0.67 - 0.76, for Coronary Heart Disease (CHD) 0.76 95% CI 
0.69 - 0.83 and for peripheral vascular disease (PVD) 0.83 95% CI 0.72 - 0.97. Similarly in 
individuals with bipolar disorder OR for AF was 0.56 95% CI 0.41-0.78, for hypertension 
0.69 95% CI 0.62 - 0.77 and for CHD 0.77 95% CI 0.66 - 0.91. 
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There was also evidence of less intensive prescribing for individuals with schizophrenia 
and bipolar disorder who had comorbid hypertension and CHD compared to individuals 
with hypertension and CHD who did not have schizophrenia or bipolar disorder. Rate of 
prescribing of statins for individuals with schizophrenia and CHD occurred significantly 
less frequently than in individuals with CHD without MMI (OR 0.67 95% CI 0.56-0.80). 
Rates of prescribing of 2 or more anti-hypertensives were lower in individuals with CHD 
and schizophrenia and CHD and bipolar disorder compared to individuals with CHD 
without MMI (OR 0.66 95% CI 0.56-0.78 and OR 0.55 95% CI 0.46-0.67, respectively). 
Smoking was more common in individuals with MMI compared to individuals without 
MMI (OR 2.53 95% CI 2.44-2.63) and was particularly increased in men (OR 2.83 95% CI 
2.68-2.98). Rates of ex-smoking and non-smoking were lower in individuals with MMI 
(OR 0.79 95% CI 0.75-0.83 and OR 0.50 95% CI 0.48-0.52 respectively). However 
recorded rates of smoking cessation advice in smokers with MMI were significantly lower 
than the recorded rates of smoking cessation advice in smokers with diabetes (88.7% vs. 
98.0%, p<0.001), smokers with CHD (88.9% vs. 98.7%, p<0.001) and smokers with 
hypertension (88.3% vs. 98.5%, p<0.001) without MMI. The odds ratio of NRT 
prescription was also significantly lower in smokers with MMI without diabetes compared 
to smokers with diabetes without MMI (OR 0.75 95% CI 0.69-0.81). Similar findings were 
found for smokers with MMI without CHD compared to smokers with CHD without MMI 
(OR 0.34 95% CI 0.31-0.38) and smokers with MMI without hypertension compared to 
smokers with hypertension without MMI (OR 0.71 95% CI 0.66-0.76).  
At a national level, payment and population achievement rates for the recording of body 
mass index (BMI) in MMI was significantly lower than the payment and population 
achievement rates for BMI recording in diabetes throughout the whole of the UK 
combined: payment rate 92.7% (Inter Quartile Range (IQR) 89.3-95.8 vs. 95.5% IQR 93.3-
97.2, p<0.001 and population achievement rate 84.0% IQR 76.3-90.0 vs. 92.5% IQR 89.7-
94.9, p<0.001 and for each country individually: for example in Scotland payment rate was 
94.0% IQR 91.4-97.2 vs. 96.3% IQR 94.3-97.8, p<0.001. Exception rate was significantly 
higher for the recording of BMI in MMI than the exception rate for BMI recording in 
diabetes for the UK combined: 7.4% IQR 3.3-15.9 vs. 2.3% IQR 0.9-4.7, p<0.001 and for 
each country individually. For example in Scotland exception rate in MMI was 11.8% IQR 
5.4-19.3 compared to 3.5% IQR 1.9-6.1 in diabetes.  
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Similar findings were found for Blood Pressure (BP) recording: across the whole of the 
UK payment and population achievement rates for BP recording in MMI were also 
significantly reduced compared to payment and population achievement rates for the 
recording of BP in chronic kidney disease (CKD): payment rate: 94.1% IQR 90.9-97.1 
vs.97.8% IQR 96.3-98.9 and p<0.001 and population achievement rate 87.0% IQR 81.3-
91.7 vs. 97.1% IQR 95.5-98.4, p<0.001.  Exception rates again were significantly higher 
for the recording of BP in MMI compared to CKD (6.4% IQR 3.0-13.1 vs. 0.3% IQR 0.0-
1.0, p<0.001). There was also evidence of differences in rates of recording of BMI and BP 
in MMI across the UK. BMI and BP recording in MMI  were significantly lower in 
Scotland compared to England (BMI:-1.5% 99% CI -2.7 to -0.3%, p<0.001 and BP: -1.8% 
99% CI -2.7 to -0.9%, p<0.001). While rates of BMI and BP recording in diabetes and 
CKD were similar in Scotland compared to England (BMI: -0.5 99% CI -1.0 to 0.05, 
p=0.004 and BP: 0.02 99% CI -0.2 to 0.3, p=0.797).  
Data from the PsyCIS cohort showed an increase in Standardised Mortality Ratios (SMR) 
across the lifespan for individuals with MMI compared to the local Glasgow and wider 
Scottish populations (Glasgow SMR 1.8 95% CI 1.6-2.0 and Scotland SMR 2.7 95% CI 
2.4-3.1). Increasing socioeconomic deprivation was associated with an increased overall 
rate of death in MMI (350.3 deaths/10,000 population/5 years in the least deprived quintile 
compared to 794.6 deaths/10,000 population/5 years in the most deprived quintile). No 
significant difference in rate of death for individuals with schizophrenia compared with 
bipolar disorder was reported (6.3% vs. 4.9%, p=0.086), but primary cause of death varied: 
with higher rates of suicide in individuals with bipolar disorder (22.4% vs. 11.7%, p=0.04).  
Discussion: 
Local and national datasets can be used for epidemiological study to inform local practice 
and complement existing national and international studies. While the strengths of this 
thesis include the large data sets used and therefore their likely representativeness to the 
wider population, some limitations largely associated with using secondary data sources 
are acknowledged.  
While this thesis has confirmed evidence of increased physical health comorbidity and 
multimorbidity in individuals with MMI, it is likely that these findings represent a 
significant under reporting and likely under recognition of physical health comorbidity in 
this population. This is likely due to a combination of patient, health professional and 
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healthcare system factors and requires further investigation. Moreover, evidence of 
inequality in access to healthcare in terms of: physical health promotion (namely smoking 
cessation advice), recording of physical health indices (BMI and BP), prescribing of 
medications for the treatment of physical illness and prescribing of NRT has been found at 
a national level.  
While significant premature mortality in individuals with MMI within a Scottish setting 
has been confirmed, more work is required to further detail and investigate the impact of 
socioeconomic deprivation on cause and rate of death in this population. It is clear that 
further education and training is required for all healthcare staff to improve the recognition, 
diagnosis and treatment of physical health problems in this population with the aim of 
addressing the significant premature mortality that is seen.  
Conclusions: 
Future work lies in the challenge of designing strategies to reduce health inequalities and 
narrow the gap in premature mortality reported in individuals with MMI. Models of care 
that allow a much more integrated approach to diagnosing, monitoring and treating both 
the physical and mental health of individuals with MMI, particularly in areas of social and 
economic deprivation may be helpful. Strategies to engage this “hard to reach” population 
also need to be developed. While greater integration of psychiatric services with primary 
care and with specialist medical services is clearly vital the evidence on how best to 
achieve this is limited. While the National Health Service (NHS) is currently undergoing 
major reform, attention needs to be paid to designing better ways to improve the current 
disconnect between primary and secondary care. This should then help to improve 
physical, psychological and social outcomes for individuals with MMI.  
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Chapter 1 Introduction: 
Since the recognition of schizophrenia in its modern concept from the early nineteenth 
century, the high morbidity and premature mortality associated with this severe condition 
has been recognised worldwide (Bleuer, 1950; Malzburg, 1934; Alstrom, 1942). The work 
by Emil Kraepelin as early as the 18th Century, where he dichotomised manic-depressive 
illness (later named bipolar disorder) and dementia praecox (later named schizophrenia) 
based on illness prognosis also recognised the poor outcomes associated with 
schizophrenia (Kraepelin, 1919). More recently the increased morbidity and premature 
mortality associated with bipolar disorder too has become recognised (Osby at al., 2001; 
Roshanaei-Moghaddam et al., 2009). Inequalities in access to and the provision of 
healthcare for individuals with schizophrenia and bipolar disorder have been highlighted as 
potential explanatory factors for the increased morbidity and premature mortality reported 
(Druss et al., 2001) however the exact mechanism for this is poorly understood. 
While increased morbidity and premature mortality are recognised within individuals with 
Major Mental Illness (namely schizophrenia and bipolar disorder), there are significant 
gaps in the understanding of the precise patterns of physical health comorbidity and 
multimorbidity within these individuals. A detailed understanding of how inequalities in 
healthcare access and provision manifest in primary care for individuals with Major Mental 
Illness (MMI) is also lacking. Moreover the cause of mortality across the adult lifespan and 
in particular the effects of gender and socioeconomic deprivation on mortality are also 
poorly understood. The effect of socioeconomic deprivation is particularly pertinent at a 
local Glasgow and wider Scottish level, given Scotland’s place as the “Sick Man of 
Europe” (GCPH Still the Sick Man of Europe? 2012).  
This chapter provides a review of the current evidence for the increased rates of physical 
health comorbidity in individuals with MMI compared to individuals without MMI. The 
research to date investigating multimorbidity in individuals with MMI will also be 
explored and gaps in research within these fields will be highlighted. Evidence for the 
inequalities in healthcare access and provision experienced by individuals with MMI will 
be explored. Finally the evidence of premature mortality for individuals with MMI will 
also be detailed along with the evidence for the increasing gap in mortality between 
individuals with MMI and individuals without MMI.  
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1.1 Methodology: 
A narrative review of the literature was undertaken. Narrative reviews are useful in 
providing an overview and summary of existing literature (Collins and Fauser, 2005). 
Although an explicit, systematic search protocol was not used, a thorough review of the 
literature was undertaken by using well defined search terms (detailed in Appendix 1) and 
multiple search engines namely: Pubmed, Google Scholar and MEDLINE. Study suitability 
was determined by reading the titles and abstracts of the identified papers and where 
necessary the full paper was retrieved. Further potential sources were identified from 
reference lists. All peer-reviewed publications were considered. Studies were included 
based on their quality and relevance as determined by: their definition of Major Mental 
Illness (MMI), sample size, duration of follow up, and where relevant: physical 
comorbidity/comorbidities included, measure of inequality in healthcare provision or 
access and measure of mortality. While it is recognised that narrative reviews can be prone 
to author bias, care was taken to minimise this by using extensive search terms and 
multiple databases. 
1.2 Evidence for increased physical comorbidity in Major 
Mental Illness (MMI): 
1.2.1 Evidence for increased physical comorbidity in 
schizophrenia: 
Multiple studies reporting increased rates of physical comorbidity in individuals with 
schizophrenia were identified. In particular studies exploring the increased rates of: 
diabetes (Dixon et al., 2000), obesity (Wirshing and Meyer, 2003), hyperlipidaemia 
(McGreadie, 2003), hypertension and metabolic syndrome (Heiskanen et al., 2003; Cohn et 
al., 2004) were all found.  
It is estimated that diabetes is twice as prevalent in individuals with schizophrenia 
compared to the general population (Vancampfort et al., 2013). While an association 
between antipsychotics and diabetes is well recognised, rates of diabetes are not 
appreciably increased in aged matched, drug naïve individuals with a first episode 
psychosis (Vancampfort et al., 2013; Mitchell et al., 2013). It is therefore generally 
appreciated that the majority of metabolic abnormalities occur fairly rapidly after the 
initiation of treatment (De Hert et al., 2011) and several studies have suggested that the 
differing weight gain potential of different antipsychotics contribute to the differing 
25 
 
relative risks (RRs) of diabetes associated with them (Fiedorowicz et al., 2012). However 
antipsychotics may also induce diabetes independently of weight gain and adiposity (Deng, 
2013; Ballon et al., 2014) potentially by inducing insulin resistance (Weston-Green et al., 
2013). There is also some evidence to suggest that genetic polymorphisms may increase 
susceptibility to both diabetes and schizophrenia (Alkelai et al., 2012).  
For metabolic syndrome: Heiskenan and colleagues reported a prevalence of 37% in 
individuals with schizophrenia, which was 2 to 4 times that of the general population 
(Heiskenan et al., 2003). Similarly Vancampfort and colleagues (2013) reported an 
increased odds ratio (OR) of 2.35 (95% CI 1.68-3.29; p<0.001). Increased risk of: 
hypertension (OR 1.36 95%CI 1.21-1.53; p<0.001), reduced high-density lipoprotein 
(HDL) cholesterol (OR 2.35 95% CI 1.78-3.10; p<0.001) and hypertriglyceridemia (OR 
2.73 95% CI 1.95-3.83; p<0.001) were also found (Vancampfort et al., 2013).  
It is recognised that metabolic disturbances occur quickly after antipsychotic exposure, 
with data from the Recover After an Initial Schizophrenia Episode (RAISE) study 
observing significant cardiometabolic abnormalities (dyslipidaemia, hyperglycaemia and 
Blood Pressure changes) after only 47 days of antipsychotic exposure (Correll et al., 2014). 
This finding of accumulation of cardiometabolic risk has also been reported by Mitchell 
and colleagues (2013) who reported a 10% rate of metabolic syndrome in unmedicated 
individuals with first episode psychosis compared to 32.5% in individuals with more 
established schizophrenia (Mitchell et al., 2013).  
Inflammation is also important in psychosis and the development of cardiometabolic risk 
factors. A preliminary study by Russell and colleague (2015) reported that individuals who 
had increased levels of inflammation (as measured by high sensitivity C-reactive protein 
hsCRP) early in their course of illness, had increased risk of metabolic abnormalities (such 
as dyslipidaemia) independent of weight gain (Russell et al., 2015). Clearly this potential 
relationship requires further investigation.  
Rates of obesity in individuals with schizophrenia are also increased (Zipursky et al., 2005) 
with estimates that compared to the general population individuals with schizophrenia are 
2.8-4.4 times more likely to be obese (Suburamaniam et al., 2014; Correll et al., 2015). 
Some studies have suggested that women with schizophrenia have higher rates of obesity 
that men with schizophrenia (Gardner-Sood et al., 2015) and that obesity may be a factor 
in non-compliance with medication, especially if associated with distress (Weiden et al., 
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2004). Increased rates of obesity in individuals with schizophrenia appears be a global 
phenomenon, as studies from China (Suburamaniam et al., 2014), Nigeria, Japan, 
Switzerland, Germany and Denmark (Larsen et al., 2013) have all reported similar 
findings.  
Higher rates of angina, compared to the general population (Filik et al., 2006) have also 
been reported in individuals with Severe Mental Illness (SMI) (including schizophrenia). 
Increased odds ratios of: arrhythmia, (OR 1.5 95% CI 1.2 -1.8); syncope, (OR 4.0 95% CI 
2.0-7.9); heart failure, (OR 1.7 95% CI 1.4 - 2.2) and transient cerebral ischemia, (OR 2.6 
95% CI 1.7-3.7) have also been reported in a cohort of individuals with schizophrenia 
compared to the general population in Canada (Curkendall et al., 2004). Risk of 
cerebrovascular disease has also reported to be increased- with one study estimating that 
young individuals (under 45) with schizophrenia had a two fold increase of developing 
stroke during the 5 years after hospitalisation compared to the comparison group (Lin et 
al., 2008). 
In addition to the physical health problems associated with increased cardiometabolic risk, 
there is also evidence for increased rates of irritable bowel syndrome (IBS) (Gutpa et al., 
1997), infections such as HIV, hepatitis (Goff et al., 2005) and tuberculosis (Mishin et al., 
2008) and higher rates of smoking related diseases such as Chronic Obstructive Pulmonary 
Disease (COPD) (Hsu et al., 2013). Poorer lung function compared to the general 
population has also been reported (Filik et al., 2006). Obstructive sleep apnoea (OSA) was 
also found to be more common in individuals with schizophrenia compared to the general 
population (Naqvi et al., 2014) and there is also evidence of poorer outcomes for 
individuals with schizophrenia who develop pneumonia (Chen et al., 2011). Evidence for 
increased rates of osteoporosis (Howard et al., 2007) and fractures (Stubbs et al., 2015) for 
individuals with schizophrenia have also been reported.  
Dental problems too have been reported to be more prevalent- with significantly more 
young individuals with schizophrenia being edentate compared to the general population 
(McGreadie et al., 2004). Skin disorders: particularly dermatitis and fungal infections are 
also more prevalent in individuals with schizophrenia (Wu et al., 2014). Sexual 
dysfunction (Schottle et al., 2009), rates of sexually transmitted infections (STIs) in part 
due to “risky” sexual behaviour (Carey et al., 2004) and obstetric complications during 
pregnancy (Leucht et al., 2007) were also more common in individuals with schizophrenia 
compared to the general population.  
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Despite high rates of obesity and other risk factors which may be associated with increased 
rates of cancer- such as low energy expenditure (Fair and Montgomery, 2009), the 
evidence for increased rates of cancer in individuals with schizophrenia was mixed- with 
some studies reporting increased rates (Hippisley-Cox et al., 2007: Lichtermann et al., 
2001) and others reporting lower rates (Barak et al., 2005: Grinshpoon et al., 2005). A 
meta-analysis of incidence of cancer by Catts and colleagues (2008), reported that pooled 
overall rates of cancer incidence were not significantly increased in individuals with 
schizophrenia compared to controls (Standardised Incidence Rate (SIR) 1.05 95% CI 0.95-
1.15). They also found that although incidence of lung cancer was increased, when 
adjusted for smoking there was no difference in incidence rates. This study also reported 
that the incidence of several cancers unrelated to smoking was reduced in individuals with 
schizophrenia (Catts et al., 2008).  
1.2.2 Gaps in the evidence for increased physical comorbidity in 
Schizophrenia: 
Although there are a number of studies detailed above, which investigate the prevalence of 
certain chronic diseases in individuals with schizophrenia compared to the general 
population, these studies are frequently carried out in small numbers of hospitalised 
individuals in countries outside of Europe for example in Canada (Cohn et al., 2004; 
Curkendall et al., 2004) and the US (Gutpa et al., 1997). Therefore their findings are 
limited in terms of their generalisability to the wider outpatient UK population with 
schizophrenia.  
Although there are a few studies carried out in the UK, using primary care data, they 
investigate rates and patterns of one or two specific comorbidities in individuals with 
schizophrenia. To date there have been no studies which have systematically compared 
rates of a wide range of physical health problems in individuals with schizophrenia to the 
general population in Scotland. This thesis will systematically investigate the prevalence of 
a wide range of physical health problems (thirty-two common comorbidities) within a large 
Scottish cohort of individuals with schizophrenia within primary care. The effect of age, 
gender and socioeconomic status on physical health comorbidity will also be considered. 
This thesis will therefore add to the gaps in understanding of the patterns of physical health 
comorbidity in individuals with schizophrenia.   
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1.2.3 Evidence for increased physical comorbidity in Bipolar 
Disorder: 
As described in schizophrenia, a number of conditions associated with cardiovascular 
disease were also increased in individuals with bipolar disorder. In particular rates of 
obesity were increased 1.2-1.7 fold (Goldstien et al.,2011) and rates of diabetes were 
increased three fold (Calkin et al., 2013). Rates of metabolic syndrome were also increased 
compared to the general population (OR 1.98 95% CI 1.74-2.25) (Vancampfort et al., 
2013). This relationship appeared to be bi-directional, where individuals with bipolar 
disorder often displayed poor choices in terms of healthy living- with low rates of exercise, 
high calorie diets and subsequent increased risk of type II diabetes and obesity (Kilbourne 
et al., 2007). However there was also evidence that specific cardiometabolic conditions 
(such as obesity) predisposed to the development of depressive symptoms (Vogelzangs et 
al., 2010) and were associated with longer and more severe episodes of mood disorder and 
shorter times to illness recurrence (Kemp et al., 2014).  
The findings regarding risk of myocardial infarction (MI) in individuals with bipolar 
disorder was mixed. With some finding increased risk of MI in individuals with a history 
of a manic or hypomanic episode (OR 2.97 95% CI: 1.40 - 6.34) (Ramsey et al., 2010), and 
others finding no evidence for a significant increase in the risk of MI for individuals with 
bipolar disorder compared to controls: relative risk (RR): 1.09 95% CI 0.96-1.24 (Preito et 
al., 2014). However problems with heterogeneity in study methodology has been noted. 
For risk of stroke, there was some evidence to suggest that in individuals with bipolar 
disorder the risk is significantly increased compared to controls (RR 1.74 95% CI 1.29-
2.35) (Preito et al., 2014). However again studies in this area are largely limited by 
methodological heterogeneity.   
In addition to cardiometabolic disease, other physical health comorbidities have been 
reported; a study by Crump and colleagues (2013) reported that after adjusting for age and 
other sociodemographic factors, individuals with bipolar disorder had increased risk of 
influenza or pneumonia (2.4 fold in women and 1.9 fold in men) and COPD (2.1 fold in 
women and 1.7 fold in men). Higher rates of thyroid disease (Krishnan, 2005), asthma 
(Schoepf and Heun, 2014), lower back pain (Kilbourne et al., 2004), hepatitis C (Matthews 
et al., 2008), renal disease and HIV (Carney et al., 2006) in individuals with bipolar 
disorder have also been reported. Sleep apnoea is also thought to be prevalent in 
individuals with bipolar I disorder (Soreca et al., 2012) and there have been studies to 
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suggest an association between bipolar disorder and multiple sclerosis (MS) (Kosmidis et 
al., 2012).  
Although bipolar disorder was previously thought to have a more benign course than 
schizophrenia (Kraepelin, 1918), one small study of 192 inpatients with schizophrenia and 
97 inpatients with bipolar disorder reported that individuals with bipolar disorder had both 
more somatic (67.1% vs. 50.6%) and more psychiatric (29.9% vs. 10.9%) comorbidity than 
individuals with schizophrenia (Oreški et al., 2012). This is clearly worthy of further 
exploration given the paucity of research in this area.  
1.2.4 Gaps in the evidence for increased physical comorbidity in 
Bipolar Disorder: 
Although there are studies available which investigate the physical health of individuals 
with bipolar disorder, they often focus solely on bipolar I disorder. Single physical 
illnesses and are also often centred on distinct patient groups, such as the elderly and 
inpatients, and so findings may not be widely generalisable to the general adult outpatient 
population. Therefore similarly to that seen in schizophrenia, there remain significant gaps 
in the detailed understanding of patterns and rates of physical health comorbidities in a 
large group of individuals with bipolar disorder compared to the general population. The 
impact of age, gender and socioeconomic status on rates of physical health comorbidity 
have also not been fully explored as to date large scale, systematic population based 
studies describing rates of physical health comorbidity in detail in bipolar disorder are 
lacking. This thesis will attempt to add to the current understanding of the patterns of 
physical comorbidity in bipolar disorder, by investigating rates of a range of physical 
health comorbidities in a large primary care dataset within Scotland.  
1.2.5 Multimorbidity research within Schizophrenia and Bipolar 
disorder:  
Multimorbidity, defined as two or more long-term conditions co-occurring in an 
individual, is common and is often the norm rather than the exception in individuals with 
long-term conditions (van den Akker et al., 1998). It is a significant and growing issue for 
patients, health professionals and healthcare systems worldwide. Multimorbidity was 
previously considered a problem of elderly populations but recent work has found this not 
to be the case. A study of almost 1.8 million people within 314 primary care practices in 
Scotland found that more people with multimorbidity were aged below 65 than were aged 
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above 65 (Barnett et al., 2012) and similar findings have been observed internationally 
(Brett et al., 2013). Socioeconomic deprivation has a strong and consistent association with 
multimorbidity: in the Scottish primary care study, prevalence rates of physical and mental 
health comorbidity were almost twice as high in the most deprived areas (11.0%) 
compared with the most affluent areas (5.9%) (Barnett et al., 2012). Furthermore, the onset 
of multimorbidity occurred up to 15 years earlier in the most deprived areas compared with 
the most affluent areas. Therefore multimorbidity is likely an important issue for 
individuals with MMI, who often live in more socioeconomic deprived areas- due to both 
an increased incidence of psychosis in individuals living in deprived backgrounds 
(Dohrewend et al., 1992) and due to the socioeconomic drift of individuals with 
schizophrenia (Timms, 1998).  
To date only a handful of studies have investigated the burden of multimorbidity in 
individuals with MMI. One such study investigated rates of medical comorbidity in 
individuals with schizophrenia and alcohol dependence (Batki et al., 2009) and found that 
the average number of medical diagnoses in the cohort was 2.9. A further study by Tsan 
and colleagues (2012) investigating mortality and guideline concordant care for veterans 
with schizophrenia reported that on average, four additional chronic diseases were 
recorded for veterans with schizophrenia. Using data from the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) Chwastiak and colleagues (2006) reported 
that 9% of individuals had four or more medical conditions. While all three studies have 
reported that rates of multimorbidity are increased: the groups included in these studies 
may not be representative of the wider outpatient adult population of individuals with 
schizophrenia.   
For bipolar disorder, even less work exploring rates and patterns of multimorbidity has 
been undertaken: one study by Carney and colleagues (2006) reported that individuals with 
bipolar I disorder were significantly more likely to have medical comorbidity, including 
three or more chronic conditions compared to controls (41% vs. 12%, p<0.001). This was a 
retrospective study using claims data from 3,357 individuals and so generalisability may be 
limited.  
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1.2.6 Gaps in multimorbidity research within Schizophrenia and 
Bipolar disorder:  
Although some preliminary work as outlined above has been undertaken, rates of 
multimorbidity in individuals with MMI compared to individuals without MMI have been 
poorly described throughout the literature. For individuals with schizophrenia, 
multimorbidity studies have been in individuals with comorbid alcohol dependence, in 
veterans and in individuals enrolled in the CATIE trial. The findings reported for these 
specific sub-populations may not be generalisable to the wider UK outpatient population. 
For individuals with bipolar disorder, only one, retrospective study has been undertaken 
and again generalisability may be limited. The role of age, gender and socioeconomic 
status in multimorbidity has also not been fully explored. Clearly further work detailing 
rates of multimorbidity in both individuals with bipolar disorder and schizophrenia is 
important. This thesis therefore aims to describe both the patterns of multimorbidity in 
individuals with schizophrenia and bipolar disorder in more detail and aims to investigate 
the role of age, gender and socioeconomic status on these patterns. 
1.3 Evidence for potential inequalities in physical 
healthcare in individuals with Major Mental Illness 
(MMI): 
There are many potential reasons for the adverse physical health outcomes experienced by 
individuals with MMI. For example it is recognised that these individuals are more likely 
than the wider population to lead unhealthy, physically inactive lifestyles (Faulkner et al., 
2006), have poor diets in terms of high levels of fat intake (McGreadie, 2003), high rates 
of smoking (Myles et al., 2012) and elevated rates of alcohol misuse. The side effects of 
psychotropic medications are also associated with significant increased risks of physical 
health problems: such as obesity (O’Donoghue et al., 2013), type II diabetes (Cassidy et 
al., 1999) and metabolic syndrome (Correll et al., 2008). However there is also increasing 
evidence to suggest that unequal access to healthcare provision, plays an important role in 
this health inequality.  
1.3.1 Evidence for the potential inequalities in physical health 
investigations, treatments, prescribing and outcomes in 
individuals with Major Mental Illness (MMI): 
This potential health inequality has been reported across a wide range of chronic physical 
health problems and in both primary and secondary care. For example, while rates of 
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cardiometabolic risk factors are higher in individuals with MMI compared to the general 
population, there is evidence that individuals with MMI do not receive the same level of 
guideline consistent treatment. In a study by Kisely and colleagues (2009) of 49,248 
admissions for ischaemic heart disease (IHD), individuals with a history of psychosis, 
despite experiencing a higher one year mortality rate, had lower rates of coronary artery 
bypass grafting (CABG) (adjusted odds ratio (OR) 0.35 95% CI 0.25-0.48) and lower rates 
of prescription of beta blockers and statins (adjusted OR 0.82 95% CI 0.71-0.95 and 
adjusted OR 0.51 95% CI 0.41-0.63). This increased mortality post myocardial infarction 
(MI) for individuals with schizophrenia has also been reported by Boden and colleagues, 
where the 30-day mortality OR was 2.58 95% CI 1.88-3.54 and 1-year mortality was OR 
2.55 95% CI 1.98-3.29 when compared to individuals without MMI (Boden et al., 2015) 
and has been replicated in Canada (Kurdyak et al., 2012). A similar pattern was also seen 
for admission for strokes, where individuals with a history of psychosis were less likely to 
receive cerebrovascular arteriography or warfarin prescription (Kisely et al., 2009).  
For individuals with MMI and diabetes there is evidence of poorer adherence to HbA1c 
testing (OR 1.24 95% CI 1.22-1.27), Low Density Lipoprotein (LDL) testing (OR 1.25 
95% CI 1.22-1.27) and retinal examination (OR 1.05 95% CI 1.03-1.07), with subsequent 
poorer glycaemic control (defined as HbA1c ≥ 9.5%: OR 1.32 95% CI 1.30-1.35) and 
poorer lipid control (defined as LDL ≥3.37 mmoll-1 : OR 1.17 95% CI 1.15-1.20).  For 
older individuals with MMI inequality in access to healthcare provision has also been 
reported; in individuals with MMI and heart failure, there was evidence of lower rates of 
Left Ventricle Ejection Fraction (LVEF) evaluation (53.0% vs. 47.3%, p<0.001), higher 
ORs for one year all cause readmission (OR 1.30 95% CI 1.21-1.39) and higher one year 
mortality (OR 1.20 95% CI 1.12-1.28) (Rathore et al., 2008).  
In Ontario, Canada where over 1.3 million residents aged 65 or over, had their 
prescriptions reviewed, it was reported that individuals with psychosis were less likely to 
receive medical treatment for arthritis (OR 0.59 95% CI 0.57-0.62, p<0.001) and for 
individuals with psychosis and emphysema, rates of lipid lowering medication were also 
significantly lower compared to individuals with emphysema alone (OR 0.69 95% CI 0.67-
0.72, p<0.001) (Redelmeier et al., 1998). The authors concluded that the differences in 
prescribing patterns were evidence for the under treatment of unrelated chronic physical 
illnesses in individuals with MMI. Similarly in the UK, Mitchell and colleagues (2012) 
reported that in individuals with severe mental illness the adjusted odds ratio (OR) for 
equitable prescription was 0.74 (95% CI 0.63–0.86), with lower than expected 
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prescriptions for angiotensin-converting enzyme (ACE) inhibitors or angiotensin II 
receptor blockers (ARBs), beta-blockers and statins (Mitchell et al., 2012).  
1.3.2 Evidence for the potential inequalities in health promotion 
and screening in individuals with Major Mental Illness 
(MMI): 
Given the increased burden of physical illness and adverse outcomes seen in individuals 
with MMI, preventative healthcare and screening along with effective targeted health 
promotion, which addresses the environmental, behavioural and iatrogenic risks to health 
in individuals with MMI, may be an effective strategy in promoting the health and 
wellbeing of individuals with MMI.  
In terms of preventative healthcare and screening, it has been reported that women with 
any mental disorder are significantly less likely to receive mammography compared to 
women without a mental disorder. Carney and Jones (2006) reported that the severity of 
mental illness (where high severity was defined as psychiatric hospitalisation and a dual 
diagnosis of substance misuse disorder and a non-substance misuse disorder and moderate 
severity was defined as either psychiatric hospitalisation or a dual diagnosis) contributed to 
the reduced rates of screening. They found that the OR for mammography was 0.38 (95% 
CI 0.33-0.43) in women with high severity mental illness and 0.62 (95% CI 0.59-0.66) in 
women with moderate severity mental illness. In another study by Xiong and colleagues 
(2008), which reviewed screening for breast, cervical, prostate and colorectal cancer: 
lifetime screening for cervical cancer was found to be higher than for breast, prostate and 
colorectal cancers. However the study concluded that “routine, timely cancer screening 
was low, especially for colorectal cancer in individuals with mental illness” (Xiong et al., 
2008). In a study in Switzerland, there was also evidence that individuals with 
schizophrenia received less preventative care than individuals without schizophrenia (Streit 
et al., 2014). These studies all provide evidence of potential inequalities in healthcare 
screening for individuals with MMI.  
Studies investigating the effectiveness of life-style interventions to promote the physical 
health of individuals with MMI are limited. Large, population cohort intervention studies, 
often exclude individuals with MMI and so the evidence base is limited. In the UK, the 
Department of Health, has set the improvement of the physical health of individuals with 
MMI as a national priority and as such the UK government has encouraged the NHS and 
local authorities to develop health promotion programmes (HPPs). However when these 
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have been evaluated, there is some evidence to suggest that they are unequally distributed 
and may set admission conditions which actually impede access (O’Brien et al., 2014). 
Therefore more work in this area is required to improve equity and access to these 
interventions.  
There is evidence to suggest that lifestyle interventions are effective when smaller studies 
specifically targeting individuals with MMI are reviewed. For example one study by 
McCreadie and colleagues (2005) investigated the impact of giving free fruit and 
vegetables, with and without instruction, to a cohort of individuals with schizophrenia 
living in Scotland. They found that although individuals who were given free fruit and 
vegetables consumed more fruit and vegetables immediately after the intervention, their 
consumption fell back to pre-intervention levels 12 months after the intervention stopped 
(McGreadie  et al., 2005).Studies investigating the effect of exercise intervention on 
weight in the form of: organised cardiovascular workouts (Scheewe et al., 2013), walking 
(Beebe et al., 2005; Methapatara et al., 2011), stationary cycles (Poulin et al., 2007) and 
football practice (Battaglia et al., 2013) have all been undertaken. All five studies, showed 
that exercise had a weight reducing effect as well as beneficial effects on physical health. 
Two further studies which investigated the effect of combination exercise (walking) and 
nutritional advice; reported weight loss in the intervention group compared to the control 
group (Jean-Baptiste et al., 2007; Direck and Ucok, 2008). Other studies using mixed 
interventions (such as diet, exercise and behavioural interventions) to reduce obesity in 
individuals with schizophrenia, found that all interventions were associated with weight 
loss and improved physical health parameters (Hjorth et al., 2014). A meta-analysis by 
Gaughran and Lally (2013), also reported that non pharmacological interventions (NPIs) 
were effective in reducing antipsychotic associated weight (-3.2kg 95% CI -4.03 to -2.21, 
p<0.0001 I2= 42%) and BMI gain (-0.94 kg/m2 95% CI -1.45 to -0.43, p=0.0003, I2= 75%), 
but these effects were restricted to outpatients only (Gaughran and Lally, 2013).  
For individuals with bipolar disorder, interventions to target obesity have also been shown 
to be effective. Daumit and colleagues (2013), reported that a behavioural weight-loss 
intervention significantly reduced weight over a period of 18 months in overweight and 
obese adults with serious mental illness (of which 19.4% of the intervention group had a 
diagnosis of bipolar disorder) (Daumit et al., 2013). These studies all clearly show that 
health promotion interventions can be effective in individuals with schizophrenia and 
bipolar disorder. However more has to be done to ensure that these individuals are given 
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equal opportunity to engage in health promotion and screening interventions in both an 
inpatient and outpatient setting.  
Cigarette smoking is the leading cause of preventable poor health and premature death 
worldwide (Koplan and MacKay, 2012) and in Scotland alone, tobacco use is associated 
with over 13,000 deaths and around 56,000 hospital admissions every year (Scot PHO, 
2011). Although it is recognised that the prevalence of smoking in the general population 
in Scotland has decreased over time (from 30.7% in 1999 to 22.9% in 2012) (The Scottish 
Government,2013), reducing smoking further remains a national public health priority.  
It is estimated that 70% of individuals with schizophrenia and 45% of individuals with 
bipolar disorder smoke compared to 20% of the general population (Myles et al., 2012) and 
in England, a third of all cigarettes smoked, are by individuals with a mental disorder 
(Royal College of Psychiatrists Council Report CR178, 2013). It is also recognised that 
individuals with MMI are likely to smoke more cigarettes and extract more nicotine from 
cigarettes compared to the general population (Olincy et al., 1997). While rates of smoking 
have declined in the general population, rates of smoking in individuals with mental health 
disorders have remained static (Royal College of Psychiatrists Council Report CR178, 
2013). This divergence in smoking rates between individuals with MMI and individuals 
without MMI is of great concern due to the negative health consequences associated with 
smoking.   
Potential reasons for the high rates of smoking in individuals with MMI are complex and 
multifactorial. It has been argued that smoking has been part of psychiatry’s culture. 
Clinicians have historically, smoked with patients (Dickerson et al., 2004), used cigarettes 
to reduce agitation (Lawn, 2004) and encourage treatment compliance (Wye et al., 2009). 
This may have partly contributed to the high smoking rates. Psychiatric patients too have 
not been afforded equal protection from tobacco exposure. For example while smoking 
within public places was banned in Scotland on the 26th of March 2006 (Smoking, Health 
and Social Care (Scotland) Act 2005), psychiatric units were exempt from this. This 
exemption for psychiatric units also occurred in the US (Brown-Johnson et al., 2014). 
However smoke-free psychiatric units, may act as an opportunity for discussion regarding 
initiation of smoking cessation therapy (Schuck et al., 2014) and this may occur when the 
smoking ban is extended to include psychiatric units from the 1st of October 2015 in 
Scotland.  
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Nicotine replacement therapy (NRT) is recognised as being effective in promoting 
smoking cessation. A meta-analysis by Stead and colleagues (2012) reported that the 
relative risk (RR) of abstinence using any form of NRT (including gum, lozenges, patches, 
inhaler and nasal spray) was 1.60 (95% CI 1.53-1.68) (Stead et al., 2012). For individuals 
with MMI, it has been recognised that social influences such as others' approval of 
treatment significantly predicted use of smoking cessation medication (Aschbrenner et al., 
2015). Given that other anti-smoking medications such as varenicline are not 
recommended in individuals with a history of mental illness, NRT may be an especially 
important and effective tool in promoting smoking cessation in individuals with MMI.  
One recent meta-analysis of seven studies, looking at rates of smoking cessation advice in 
individuals with and without a mental illness reported that there was no significance 
difference in rates of advice given (relative risk (RR) 1.02 95% CI 0.94-1.11) (Mitchell et 
al., 2015). The same was also true for individuals with schizophrenia (RR 1.09 95% CI 
0.68-1.70) and bipolar disorder (RR 1.14 95% CI 0.85-1.50) (Mitchell et al., 2015). 
However given the disparities in prescribing of physical health medications for individuals 
with MMI (Mitchell et al., 2012 and Redelmeier et al., 1998) further investigation 
reviewing rates of prescription of NRT within primary care would be of importance given 
the limited evidence in this area.  
Ecigarettes, too are becoming increasingly used to aid smoking cessation. While the long 
term health risks associated with them remain unclear, there is some evidence to suggest 
that they appear to be “equally effective, safe, and acceptable for people with and without 
mental illness” (O’Brien et al., 2015).  Moreover for individuals with  mental illness, 
Ecigarettes may be as effective and safe as patches, yet more acceptable, and associated 
with greater smoking reduction (O’Brien et al., 2015). Clearly further investigation into 
strategies to reduce the high rates of smoking in  individuals with MMI is of importance.  
While there is evidence for potential inequalities in healthcare in terms of: investigations, 
treatments, prescribing, outcomes, health promotion and screening, for individuals with 
MMI, reasons for the potential inequalities reported, require further consideration.  
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1.3.3 Evidence for the potential reasons for the inequalities in 
healthcare provision reported for individuals with Major 
Mental Illness (MMI): 
Barriers to healthcare are generally considered at a patient, provider and service level. 
Possible barriers to healthcare for individuals with MMI and potential reasons for the 
inequalities seen can therefore be considered in this way. 
1.3.3.1 Potential patient reasons for inequalities in healthcare provision: 
A recent review by Lawrence and Kisely (2010) identified some potential patient factors 
which may contribute to difficulties in accessing healthcare for individuals with MMI. 
These included; cognitive impairment associated with the mental disorder, social isolation, 
lack of family support, suspiciousness or fear of seeking advice, self-neglect, poor 
motivation (potentially due to the negative features of a psychotic illness), socioeconomic 
factors and difficulties in communicating health needs. These issues are all particularly 
pertinent when considering Zola’s help seeking model (Zola, 1973).  
While there are difficulties in individuals with MMI accessing healthcare, there is also 
evidence to suggest that they when they do access healthcare, they are less compliant with 
the medical care they receive (Hennekens, 2007). This can subsequently result in 
premature discharge from outpatient clinics and loss to follow up. For individuals 
receiving care, consent issues, particularly for more complex, high risk procedures may be 
particularly relevant; as at times, assessing capacity in individuals with MMI can be 
challenging, especially when the individual refuses treatment or care while reporting 
residual psychotic symptoms. These factors likely contribute to the inequalities in 
healthcare provision that are reported.  
1.3.3.2 Potential provider reasons for inequalities in healthcare provision:  
Potential provider reasons for inequalities in healthcare provision are complex and multi-
factorial and may include stigmatisation of individuals with mental illness. While negative 
attitudes to mental illness, with particular negative attitudes to schizophrenia, occur 
worldwide (Thornicroft et al., 2009), and are likely affected by cultural and historical 
factors (Fabrega Jr, 1991), stigmatisation may still play an important role in the potential 
reasons for inequalities in healthcare for individuals with MMI within the UK health 
service (Jones et al., 2008). Stigmatisation is a problem that has been reported worldwide. 
In a recent cross-sectional survey of 777 individuals with schizophrenia from 27 countries, 
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17% reported experiencing discrimination when treated for physical health problems 
(Harangozo et al., 2013), with higher rates in post-communist countries. Indeed 
stigmatisation as a barrier to healthcare has been reported in the US, Australia and The 
Netherlands (Happell et al., 2012). 
It is also recognised that time and resource constraints play an important role in healthcare 
provision. For General Practioners (GPs), it is recognised that over recent years, the 
complexity of their consultations has increased (Freeman et al., 2002) and while in the UK 
the length of the average consultation has also increased: from 8.4 minutes in 1992, to 11.7 
minutes in 2006/2007 (GP Workload Survey, 2007), the time to fully assess the physical 
health of an individual with MMI may still be impossible within this tight consultation 
framework. GPs, who may be inexperienced in mental health issues, may also feel 
uncomfortable due to a perceived inadequacy in expertise, and so this too can inadvertently 
result in inequalities in provision of healthcare.  
The issue of diagnostic over-shadowing, whereby physical health complaints are attributed 
as psychosomatic symptoms (van Nieuwenhuizen et al., 2013) is also important. For 
example, individuals with MMI presenting with palpitations, may have their symptoms put 
down to anxiety rather than an arrhythmia and so may consequently miss out on 
appropriate healthcare and treatment. These factors all contribute to potential provider 
causes of the inequalities in healthcare provision experienced by individuals with MMI.  
1.3.3.3 Potential system reasons for inequalities in healthcare provision:  
System issues undoubtedly contribute to the inequalities in healthcare provision for 
individuals with MMI. Current healthcare systems throughout the world (including the 
UK) are predominantly organised around a ‘single-disease’ approach to both physical and 
mental disorder. Given that most individuals with long-term conditions are likely to have 
more than one (Barnett et al., 2012) this can lead to fragmented and disorganised care. The 
current separation of physical and mental healthcare facilities, can lead to a lack of clarity 
regarding who is responsible for the physical healthcare of individuals with MMI- as often 
psychiatrists are reluctant to and inadequately resourced to take responsibility for this, 
while GPs can feel overwhelmed.  
The separation between mental and physical healthcare as a barrier to good physical 
healthcare of individuals with MMI has been reported worldwide in countries such as the 
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US, Australia and the Netherlands (Happell et al., 2012). Current under-resourcing of 
mental healthcare in particular, also provides little opportunity for specialists to focus on 
care outside their core speciality (Druss, 2007), and as a result, the physical healthcare may 
be delegated back to primary care.  
For psychiatric inpatients the fragmentation of physical and mental healthcare has 
important costs both for the patient and for the health service. In a recent study by Lally 
and colleagues (2015) over the course of a full year, of 4676 psychiatric inpatients, 16.0% 
were admitted to a general hospital and 18.0% attended Accident and Emergency (A&E) 
while an inpatient in psychiatry. Therefore simultaneously occupying beds in both the 
general and psychiatric hospitals for a total of approximately 5163 bed days at a cost of 
£2.4 million over the year (Lally et al., 2015). While liaison psychiatrists review, assess 
and treat the mental health needs of individuals with physical health problems, there is a 
potential gap in the assessment and treatment of the physical health needs for people with 
MMI (Doherty and Gaughran, 2014).  
The challenge therefore is to gather evidence for new integrated innovations in service 
organisation and delivery in order to minimise inequalities in healthcare driven by 
limitations in service design and improve cost.   
1.3.4 Gaps in the evidence for potential inequalities in physical 
healthcare in individuals with Major Mental Illness (MMI): 
While there have been studies detailing prescribing inequalities in individuals with MMI 
work in this field is limited. Redelmeier and colleagues (1998) looked at older adults (>65) 
and Mitchell and colleagues (2012), undertook a meta-analysis of prescribing patterns in 
individuals with and without severe mental illness in studies with high heterogeneity 
(I2=97.2). Therefore further investigation of possible inequalities in prescribing for 
comorbid physical health problems within a primary care setting in Scotland would be of 
interest and of clinical relevance. This thesis therefore aims to examine in more detail 
possible inequalities in prescribing for comorbid chronic physical health problems using a 
large primary care data set. The chronic physical health problems investigated will include 
hypertension and coronary heart disease (CHD) and the drugs compared will include anti-
hypertensives, statins and anti-platelets. 
Smoking cessation programs are recognised as being highly cost effective (Warner, 1997) 
and given the high smoking rates in MMI combined with the fact that smokers with mental 
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disorders are as likely as those without mental disorders to want to quit (Royal College of 
Psychiatrists Council Report CR178, 2013), targeting individuals with mental illness, is 
potentially a good way to reach smokers and promote smoking cessation. Although there is 
evidence to suggest that smoking cessation interventions are effective in individuals with 
schizophrenia (Stubbs et al., 2015; Peckham et al., 2015), little work in this area has been 
carried out. To date there has been no investigation of the rates of recording of smoking 
cessation advice and NRT prescribing in a large cohort of individuals with MMI in primary 
care in Scotland. Given the importance of smoking cessation as a public health 
intervention, further investigation in this area is warranted. This thesis will attempt to 
explore, in detail the recording of smoking cessation advice and the prescribing equity of 
NRT within primary care in Scotland.   
Despite evidence that lifestyle interventions appear to be effective in promoting weight 
loss in MMI, it is unclear to what extent health promotion and weight monitoring for 
individuals with MMI is occurring routinely in UK primary care. One study, compared 
recording of Body Mass Index (BMI), blood pressure (BP), blood glucose and cholesterol 
in individuals with severe mental illness to individuals with diabetes using incentivised 
Quality and Outcome Framework (QOF) Data from England. They found that screening 
was “higher among patients with diabetes than among those with severe mental illness 
(97.3% versus 74.7%, p<0.001)” (Mitchell and Hardy, 2013). Thus suggesting evidence of 
inequalities in incentivised healthcare. However this study used only QOF data from 
England. Therefore further examination of incentivised QOF data particularly in Scotland 
(as well as elsewhere in the UK) would be helpful to determine if this possible inequality is 
consistent both across the UK and compared to other chronic diseases (other than 
diabetes). This thesis will explore potential inequalities in health promotion and screening 
by investigating the rates of recording of BMI and Blood Pressure (BP) in individuals with 
MMI compared to individuals with other chronic diseases (namely diabetes and chronic 
kidney disease (CKD)), in primary care using incentivised QOF data from the whole of the 
UK.     
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1.4 Evidence of Premature mortality in Major Mental 
Illness (MMI): 
1.4.1 Markers of Premature Mortality: 
To date the literature, which has investigated premature mortality in Major Mental 
Illnesses (MMI), has used a number of different measurements of premature mortality. The 
most commonly used measurements include mortality rate ratios (MMRs), hazard ratios 
(HRs), reduction in life expectancy, life expectancy at 20 years, years of potential life lost 
(YPLL) and average age at death. Each measurement used has its own advantages and 
disadvantages. Given the variety of measures of mortality used throughout the literature, 
interpretation and synthesis of large quantities of data has been limited. This restricts 
generalisability of results and limits interpretation.  
1.4.1.1 Mortality Rate Ratios (MRR): 
Mortality Rate Ratios (MRR) are a useful tool to quantify the increase in mortality 
experienced by individuals with MMI compared to the general population. The MRR is 
calculated by dividing the mortality rate in the group of interest by the mortality rate in a 
comparison population. For example the mortality rate in a cohort of individuals with 
schizophrenia could be divided by the mortality rate of a group of individuals living in the 
general population without schizophrenia to determine the MRR associated with 
schizophrenia. By doing this mortality rates for different population subgroups and 
different causes of death can be calculated; for example for males and females, for certain 
ages for example those under 25, or aged 25-24 and for certain causes of death for example 
death due to suicide, cardiovascular deaths etc. Most commonly within MRR, Standardised 
Mortality Ratios (SMR) are used. 
SMR is a ratio between the observed number of deaths in a study population and the 
number of deaths which would be expected in the same population, based on the age and 
sex specific rates in a standard population with the same age and sex distribution as the 
study population (Everitt et al., 2010). If the ratio of the observed: expected deaths is 
greater than 1.0, there is said to be “excess deaths” in the study population. The ratio can 
be expressed as a percentage by multiplying by 100.  
There are however a number of limitations associated with the use of MRR and SMR; 
firstly given the low rate of death in younger age groups in the general population, the 
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MRR and SMR between the group of interest and the general population are often 
dramatically elevated particularly at younger ages and this difference decreases as age 
increases. This phenomenon, known as “effect modification by age”, is important to 
consider when calculating and interpreting MRR and SMR especially in younger age 
groups. This effect also needs to be carefully considered when comparing MRR and SMR 
across groups and between different countries, as the age distribution of the populations 
need to be carefully considered to avoid biasing results.  
1.4.1.2 Reduction in life expectancy and Years of Potential Life Lost (YLL): 
Another useful measurement tool, to quantify the increase in mortality experienced by 
individuals with MMI is reduction in life expectancy. Reduction in life expectancy is a 
similar measurement tool to Years of Potential Life Lost (YLL) (Health Knowledge 
Research Methods, 2009). Reduction in life expectancy is the difference in the number of 
years that an individual with the condition of interest lives compared to an individual living 
in the general population. Therefore if an individual with schizophrenia dies at 48 years of 
age and the expected age of death in the population is 78, there is a reduction in life 
expectancy of 30 years. Years of Potential Life Lost (YLL), is the sum of the gap between 
all premature deaths in the cohort of interest and the average life expectancy of the general 
population. Both measures give greater weight to deaths at younger age and a lower weight 
to deaths at an older age, and so are helpful in raising awareness of the common causes of 
death in younger people. A further advantage of these tools is that the increase in mortality 
represented by a reduction in life expectancy is a clear and understandable measure of the 
magnitude of excess mortality.  
YLL and reduction in life expectancy also allows comparisons between different 
populations (for example individuals with schizophrenia or bipolar disorder) and 
comparisons of causes of death to be made: for example YLL and reduction in life 
expectancy associated with cardiovascular disease, suicide, cancer etc. within a well-
defined population.  Both reduction in life expectancy and YLL are used in public health 
planning to compare the relative importance of different causes of death and so can be used 
to identify priorities for prevention and intervention. This will then help aid distribution 
and allocation of healthcare resources.   
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1.4.1.3 Healthy Life Expectancy (HALE): 
Healthy life expectancy (HALE) is the number of years an individual is expected to live in 
“full health” and therefore takes into account the years lived in less than full health due to 
disease and/or injury. It is recognised as an important measure of health due to its ability 
“to capture fatal and non-fatal health outcomes in a summary measure of average levels of 
population health” (WHO Health Status Statistics, 2004). Healthy Life Expectancy at birth 
adds up expectation of life for different health states adjusted for severity and is therefore 
sensitive to changes over time and differences between countries. This measure, although 
used by the WHO in mortality statistics, is not routinely used in the literature surrounding 
premature mortality in MMI. 
1.4.1.4 Hazard Ratios (HRs): 
Hazard Ratios (HRs) are another measurement of mortality that are often used to compare 
mortality between groups. It is defined as the hazard or chance of an event occurring in the 
group of interest compared to the hazard or chance of an event occurring in another 
(control) group. For example the chance of death in a group of individuals with bipolar 
disorder compared to a group of individuals without bipolar disorder. Hazard ratios are 
distinct from the relative risk ratio which is a measure of the proportion of events (for 
example deaths) which have occurred in a group (for example individuals with bipolar 
disorder) expressed as a ratio of the proportion of events (deaths) occurring in the control 
group (for example individuals without bipolar disorder). Hazard ratios allow the risk of an 
event occurrence between two groups within a selected timeframe to be compared and so is 
a useful tool to measure mortality. One disadvantage associated with this measurement is 
that the time until an event (such as death) is not detailed. In studies, where there is a long 
lag period between exposure and outcome measure (for example death), care must be taken 
to ensure that the timeframe is long enough to give a true measure of the increased risk. 
This “sleeper effect” (Hackim, 1987) can be more readily captured if the study is 
longitudinal in design.    
1.4.1.5 Life Expectancy: 
Life expectancy is the calculated expected duration of survival using statistical models and 
life tables and is often reported in the medical literature as a measure of mortality. It can be 
calculated at any age, by gender and by country. Life expectancy may be calculated from 
birth (as is commonly reported) or it can be calculated from any age, for example at age 
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20. Life expectancy at age 20 is used to compare life expectancy in individuals with MMI 
to that of individuals without MMI. The life expectancy calculated is an average and so 
care in its interpretation is required. For example in countries, where there is high infant 
and child mortality, average life expectancy at birth may be low (for example life 
expectancy at birth may be 40), however survival over the age of 60, may occur in the 
population, especially if survival of the early hazards occur. Therefore interpretation of life 
expectancy at birth should be taken within a wider context and often other measurements 
such as infant mortality rates are required to help contextualise the life expectancy 
calculation. 
1.4.1.6 Average age at Death: 
Average age at death is another commonly used public health statistic to compare mortality 
across populations and between genders. It is readily understood by clinicians and is 
helpful in showing disparities between cohorts. Patterns in average age of death over time 
can also be compared relatively easily. This measure has been used to compare average 
age of death in individuals with MMI to the general population.  
1.4.2  Work to date in Schizophrenia describing premature 
mortality: 
It is now largely well recognised that individuals with schizophrenia have increased 
standardised mortality rates (SMR) and reduced life expectancy compared to the general 
population and that the excess in mortality reported cannot be explained by increased 
suicide rate alone. This excess mortality has been reported throughout the literature in 
many different countries (Hoang et al., 2011; Wahlbeck et al., 2011; Laursen et al., 2011; 
Crump et al., 2013).  
For example, Harris and Barraclough, (1998), reported an overall SMR of 1.6 (95% CI 1.5-
1.6), using data from twenty papers on a population of almost 36,000 from nine countries.  
Black, (1998) using data from the Iowa Record linking study reported an overall SMR of 
2.7 and a SMR of 1.8 for natural deaths for individuals with schizophrenia. In Australia the 
SMR for all psychotic disorders was calculated at 5.5 (Saha and Whiteford, 2013) and 
Mortensen and Juel, (1993) reported that the increase in SMR for both men and women 
with schizophrenia could be seen, across the lifespan until the age of 80 in women and 84 
in men. In a landmark study by Laursen and colleagues (2007) which reported Mortality 
Rate Ratios, by age group and ICD 10 diagnosis for 1,480,608 deaths from a cohort of 
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5,558,959 individuals, an elevated MRR across both genders and all age groups for 
individuals with schizophrenia was found (Laursen et al., 2007).  
A further study by Fors and colleagues, (2007) in Uppsala, Sweden, reported that the 10 
year mortality rate for individuals with schizophrenia was higher than for the general 
population (23.0% vs. 11.2%) (Fors et al., 2007). A recent meta-analysis by Walker and 
colleagues, (2015) (using data from 65 studies) reported that for all-cause mortality, the 
pooled relative risk (RR) among individuals with psychoses was 2.54 (95% CI 2.35-2.75) 
(Walker et al., 2015).  
Studies measuring premature mortality using reduction in life expectancy calculations have 
generally found that on average, men with schizophrenia die 20 years earlier and women 
die 15 years earlier than the general population (Laursen et al., 2013). A study by Morden 
and colleagues, (2012) which described years of potential life lost (YLL) due to 
cardiovascular disease found that in 2007, 14.0 years were lost due to cardiometabolic 
disease in individuals without Severe Mental Illness (SMI) while in individuals with SMI, 
15.4 years were lost due to cardiometabolic disease (Morden et al., 2012). Studies using 
hazard ratios as a measure of mortality have also reinforced the premature mortality in 
individuals with MMI. One such study by Chen and colleagues, (2010) found that for 
individuals with schizophrenia, the adjusted risks of dying during the 6 year follow up 
were 4.6 times higher than that for the control group (Chen et al., 2010).  
In terms of the causes of the premature mortality it is recognised that much of the excess 
mortality is due to cardiovascular disease, unnatural deaths (such as suicide), respiratory 
disease and cancers (Bushe et al., 2010). However it is really only in the last ten years that 
a heightened awareness of the contribution of the “natural” causes of death to the 
premature mortality has been recognised. To date, studies which examine premature 
mortality by cause are limited due to a combination of small sample size, differing lengths 
of follow up and differences in age of the cohorts described.  
Nevertheless there is a growing body of evidence to suggest that cardiovascular disease 
(CVD) is an important cause of premature mortality in individuals with schizophrenia.  
Osborn and colleagues, (2007) reported that in the UK, CVD mortality was elevated 
almost four fold (HR 3.61) in individuals aged 18-49 years with a doubling of risk in those 
aged 50-75 (HR 1.96) (Osborn et al., 2007). The finding of premature cardiovascular 
mortality, has also been reported by Mortensen and Juel, (1993) who reported a SMR for 
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CVD of 1.69 in young men (modal age of diagnosis was 25-29 years with a 8 year follow 
up period) and Kiviniemi and colleagues, (2010) who reported a SMR of about 16 for 
CVD mortality of in individuals aged 20-24 years (Kiviniemi et al., 2010).  These studies 
not only reinforce the increased cardiovascular risk and subsequent mortality in individuals 
with schizophrenia, but suggest that it may have a premature onset.  
1.4.3 Gaps in the work to date describing premature mortality in 
Schizophrenia: 
Despite an increased awareness of the premature mortality from “natural” causes, there 
remain significant gaps in not only the underlying causes of “natural” deaths but also the 
deeper understanding of the impact of age, gender and socioeconomic status on cause and 
rate of death. For example the reported contribution of death from cancer to the increased 
mortality experienced by individuals with schizophrenia is unclear. Data from Australia 
(Lawrence et al., 2001) and Denmark (Dalton et al., 2008) has reported an increase in 
cancer deaths in individuals with MMI compared to the general population, while work 
from Kredentser  and colleagues, (2014) reported that although the mortality rate for 
individuals with schizophrenia was double that of the population (20.0% vs. 9.4%) overall 
cancer deaths were similar (28.6 vs. 27.3 per 1,000, p=0.42). (Kredentser et al., 2014)  
Other causes of death in individuals with MMI such as: respiratory disease (Capasso et al., 
2008), cerebrovascular disease (Mortensen and Juel, 1993; Dean and Thuras, 2009) and 
“other natural causes” (Brown et al., 2000; Chong et al., 2009) have been recognised as 
being increased, but the number of studies in which they are described to a significant 
extent are limited. Therefore detailed investigation into specific causes of deaths in 
individuals with schizophrenia is warranted to further aid the understanding of the elevated 
mortality reported in these individuals. This thesis will attempt to address these issues.  
In terms of understanding the effect of age on cause of death in schizophrenia, little work 
has assessed different causes of mortality across the life-span. While suicide has been 
recognised as a major contributor to excess mortality in certain groups of individuals with 
schizophrenia on a population level (for example, young males) (Gunnell and Middleton, 
2003), there is limited research exploring other patterns of mortality in an age-specific 
manner. This thesis will also attempt to explore this relationship and aim to contribute to 
the gaps in knowledge within this field.  
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The effect of socioeconomic deprivation on rate and cause of death in individuals with 
MMI has also not been explored in detail. While it is generally recognised that individuals 
from more deprived areas commonly experience more adverse outcomes and reduced life 
expectancy compared to individuals from more affluent areas (Hosseinpoor et al., 2012; 
MacIntyre and Ellaway, 2003), the impact of deprivation specifically on rate and cause of 
death in individuals with schizophrenia has not been examined. Given the unique mortality 
challenges experienced by both Glasgow and the wider Scottish population, investigation 
into the impact of deprivation on mortality rates in individuals with schizophrenia in a 
Glasgow setting is worthy of further detailed exploration. This thesis will attempt to 
provisionally examine this relationship.   
While the evidence detailing the increased mortality associated with schizophrenia when 
suicide is excluded is relatively consistent, it has not been universally reported. For 
example Drew, (2005) in Australia, reported that although deaths due to suicide were 
greatly increased compared to the general population, deaths from “all cause” were only 
mildly increased (Drew, 2005). They highlighted the need to interpret population based 
mortality studies cautiously and reinforced the idea that more work in this area is required. 
Therefore a study of mortality in the local Scottish population which specifically addresses 
the impact of age and deprivation on cause and rate of death will be of significant scientific 
and clinical merit.  
1.4.4 Work to date in Bipolar Disorder describing premature 
mortality: 
As reported in schizophrenia, it is recognised that individuals with bipolar disorder have 
increased mortality compared to the general population. This finding has been described in 
the medical literature from as early as 1979- where SMR was noted to be elevated in 
individuals with unipolar or bipolar depression at 1.69 (Weeke, 1979). Most of the initial 
studies investigating the excess mortality associated with bipolar disorder, grouped all 
affective disorders together (i.e. unipolar and bipolar depression), for example in 1982 
Eastwood and colleagues reported an increased SMR associated with affective disorders 
(1.37) (Eastwood et al., 1982) and in Denmark in 1986, an increase in SMR of 1.73 for 
individuals with unipolar or bipolar depression was reported (Weeke, 1986).  
Later work, by Harris and Barraclough, (1998), separated unipolar and bipolar depression. 
Their study, a systematic review of six papers from four countries totalling 4,547 
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individuals with a follow up period ranging from 0-40 years, described an overall SMR for 
bipolar disorder for both genders of 2.02 (95% CI 1.9-2.7). They also reported that 
mortality from unnatural causes was nine times that of the expected mortality rate and 
deaths from natural causes were 1.5 times more than expected (Harris and Barraclough, 
1998). A recent meta-analysis (of 19 studies) by Walker and colleagues, (2015) reported 
that for all-cause mortality, the pooled relative risk of mortality among individuals with 
bipolar disorder was 2.00 (95% CI 1.70-2.34) (Walker et al., 2015). 
Tsuang and colleagues, (1980) reported that natural deaths in all individuals with bipolar 
disorder were increased and deaths due to cardiovascular disease were particular elevated 
in females with mania (Tsuang et al., 1980). This finding of increased SMR in bipolar 
disorder has been reproduced by Osby and colleagues, (2001) who reported a SMR of 1.9 
for bipolar males and 2.1 for bipolar females for all natural causes of death (Osby et al., 
2001). While Laursen and colleagues, (2007) reported a SMR of 4.5 for individuals with 
bipolar disorder aged under 24 (Laursen et al., 2007).  Elevated hazard ratios have also 
been described in bipolar disorder- most notably by Chen and colleagues, (2010) who 
reported an adjusted hazard ratio of dying of 3.87 times that of appendectomy patients 
(Chen et al., 2010). Studies investigating differences in mortality using reduction in life 
expectancy have reported that life expectancy was reduced by approximately 10 years in 
men and 11 years in women with bipolar disorder (Chang et al., 2011). 
More recently comparisons of rates of mortality within affective disorders have been 
undertaken. For example Chang and colleagues, (2012) compared mortality in bipolar 
depression with mortality in other types of depression (OTD). They found that bipolar 
depression was associated with a significantly greater risk in all-cause mortality compared 
to other types of depression even after controlling for demographic features and comorbid 
disorders (adjusted hazard ratio 1.3 95% CI 1.1-1.5). They also found that bipolar 
depression was associated with twice the risk of suicide and accidental death compared 
with other types of depression (Chang et al., 2012). This finding of increased mortality in 
bipolar depression compared to unipolar depression was also reported by Black, (1998) in 
the Iowa Record linking study. Although there is consistent evidence to suggest that 
mortality is significantly increased in individuals with bipolar disorder compared to both 
the general population and individuals with other types of depression, there remain 
significant gaps in our understanding of specific causes of death across the lifespan and the 
impact of age, gender and deprivation on rate and cause of death.  
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1.4.5 Gaps in the work to date describing premature mortality in 
Bipolar Disorder: 
Similarly to the understanding of premature mortality in schizophrenia, there remain 
significant gaps in not only the underlying causes of “natural” deaths but also the deeper 
understanding of the impact of age, gender and socioeconomic status on cause and rate of 
death in individuals with bipolar disorder. In terms of specific causes of death, few large 
scale studies have investigated this in detail. For example Osby and colleagues, (2001) 
reported that SMRs for infectious diseases (3.4 and 2.4), respiratory diseases (3.1 and 3.2), 
cardiovascular diseases (1.9 and 2.6) and gastrointestinal diseases (2.0 and 1.9) were all 
increased in men and women with bipolar disorder, while SMR due to cancer was not 
significantly elevated (1.1 and 1.2) (Osby et al., 2001). However Kisely and colleagues, 
(2005) reported an increase in MRR due to cancer (1.76 and 1.50) for men and women 
with bipolar disorder (Kisely et al., 2005). Additionally the large scale studies investigating 
specific causes of death in individuals with bipolar disorder have been carried out in 
Scandinavia (Fors et al., 2007; Capasso et al., 2008; Crump et al., 2013; Wahlbeck et al., 
2011; Laursen et al., 2007), Canada (Kredentser et al., 2014) and Australia (Saha and 
Whiteford, 2013; Lawrence et al., 2000) and so generalisability to the UK population may 
be limited. 
Reports of cause of death using Scottish data are limited: one study by Sharma and 
Makara, (1994), of 472 individuals with bipolar disorder who were followed up 
retrospectively over 17 years, found that individuals with bipolar disorder had greater 
mortality from suicide, cardiovascular and respiratory disease than the general population 
(Sharma and Makara, 1994). One further study exploring mortality in a Scottish context, 
reported mortality for a cohort of individuals on lithium, rather than for individuals with 
bipolar disorder specifically (Norton and Whalley, 1984). Over 9 years for individuals on 
lithium, SMR was elevated at 2.83, with excess mortality attributable to suicide and 
cardiovascular disease. Given the limited studies to date, a detailed exploration of the 
specific causes and rates of death for individuals with bipolar disorder within a Scottish 
context will be of scientific and clinical interest. This thesis will attempt to explore this in 
detail.      
As is seen in schizophrenia, investigation into the rate of death throughout the adult 
lifespan in individuals with bipolar disorder is also limited- with only one study by Laursen 
and colleagues, (2007), using Danish data, reporting SMR across the lifespan. To date no 
50 
 
studies have specifically investigated the impact of socioeconomic status on rate or cause 
of death in bipolar disorder. Therefore detailed understanding of how cause of death may 
vary by age and socioeconomic status in bipolar disorder is worthy of further investigation.  
A meta-analysis by Walker and colleagues, (2015) reported higher, pooled relative risk of 
all-cause mortality among individuals with psychoses compared to bipolar disorder (2.54 
(95% CI 2.35-2.75) vs. 2.00 (95% CI 1.70-2.34)) (Walker et al., 2015). Work directly 
comparing mortality in individuals with bipolar disorder and schizophrenia is limited. 
Further comparison of rate and cause of death between individuals with schizophrenia and 
bipolar disorder in a Scottish setting would be of interest, especially given the historical 
viewpoint that schizophrenia has a worse prognosis than bipolar disorder (Kraepelin, 
1918). Consequently this thesis will attempt to address these important gaps in current 
understanding.   
1.4.6 Recent trends in the gap in Life expectancy of individuals 
with MMI and the General Population: 
While there is recognition of the premature mortality experienced by individuals with 
MMI, possibly of more concern is that recent work has suggested that the mortality gap 
may be getting worse. Morden and colleagues, (2012) in the United States reported that the 
mortality gap of individuals with schizophrenia widened from 12.8 to 15.4 years over a 7 
year period (2000 to 2007) and a retrospective linked analysis of hospital admissions in 
England has also shown that one-year post-discharge standardised mortality ratios (SMR) 
for individuals with schizophrenia have increased from 1.6 (95% CI 1.5 -1.8) in 1999 to 
2.2 (95% 2.0-2.4) in 2006 (Morden et al., 2012). Similar findings were reported by Dutta 
and colleagues, (2012), where there was an increase in SMR for circulatory disease (from 
1.6 to 2.5), and respiratory disease (from 3.1 to 4.7) (Dutta et al., 2012). This increase in 
SMR over recent years has been replicated elsewhere by Saha and colleagues, (2007) and 
Hoye and colleagues, (2011) in Norway.   
However an increase in the life expectancy gap has not been universally reported. Tiihonen 
and colleagues, (2009) reported that the gap in life expectancy between individuals with 
schizophrenia and the general population did not widen between 1996 (25 years), and 2006 
(22·5 years) (Tiihonen et al., 2009) and Rantanen and colleagues, (2009) reported a 
significant reduction in mortality of individuals hospitalised for schizophrenia between 
1995-1998 and 1980-1984 (Rantanen et al., 2009).  
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Table 1-1 summaries the evidence for a widening gap in life expectancy for individuals 
with schizophrenia and the general population, while Table 1-2 summaries the evidence 
which supports either no change in mortality or possible improvement in mortality rate for 
individuals with schizophrenia. 
Table 1-3 summaries the evidence for a widening gap in life expectancy for individuals 
with bipolar disorder. To date there is no evidence to support either no change in mortality 
or possible improvement in mortality rate for individuals with bipolar disorder.  
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Table 1-1 Recent Studies in Schizophrenia suggesting that the mortality gap is widening: 
 
Author, Year 
& Journal 
Study methodology Sample Size Measurement of mortality 
used 
Measurement of 
change in mortality 
rates 
Main Findings 
Brown, 1997 
BJPsych 
Meta-analysis of studies 
from the UK, 
Netherlands, Israel, 
Scandinavia and US 
18 studies,  
66,161 
individuals  
SMR for all  cause, all  
unnatural, all  natural and 
specific causes with 95% CI 
were calculated. 
SMRs for men & women 
calculated separately  
Aggregate SMR from 
1970s, 1980s and 
1990s. 
Significantly higher aggregate SMR in 1980 compared to the 
1970s (1.91 95% CI 1.83-1.99 vs.1.52 95% CI 1.44-1.60 
p<0.001).  
 
Osby et al., 
2000 
BMJ 
Linkage to the national 
causes of death register 
allowing comparison of 
mortality rates for 
individuals with 
schizophrenia to the 
general Stockholm 
population between 
1976 and 1995 
Residents of 
Stockholm (pop 
1.8 mill ion) with 
a first hospital 
admission with a 
diagnosis of 
schizophrenia:   
3001 men and 
2801 women 
SMRs for natural, unnatural, 
and specific causes of death 
(suicide, cardiovascular 
disease and unspecified 
violence) were calculated. 
 
SMRs for men & women 
calculated separately 
SMRs were 
compared by 
consecutive  5 year 
periods 76-80, 81-85, 
86-90 & 91-95 
SMR for all  causes of death increased 1.7-fold in men and 1.3-
fold in women over the study period. 
 
Death from cardiovascular causes increased 4.7-fold in men & 
2.7-fold in women;  
Suicide increased 1.6-fold in men & 1.9-fold in women;  
Mortality from unspecified violence increased 3.8-fold in men 
& 3.4-fold in women 
Lawrence et 
al., 2003 
BMJ 
Population-based record-
linkage study of IHD 
mortality rates, hospital 
admission rates and rates 
of revascularisation 
procedures in MMI 
compared to the general 
population. 
210,129 users of 
mental health 
services in 
Western 
Australia during 
1980-1998. 
Mortality rate ratio (MRR) 
for IHD 
Poisson regression 
analysis of the 
mortality rates from 
1980-1998 
For the general population, the mortality rate has been 
decreasing by 1.9% per year (95% CI 1.7-2.1%) in males and 
by 0.7% per year in females (95% CI 0.5-1.0%).  
 
In contrast, in users of mental health services the mortality 
rate was not significantly changed in males (95% CI for annual 
increase -0.5% to 0.9%), and was increasing at a rate of 2.2% 
per year in females (95% CI 1.5-3.0%). 
Saha et al., 
2007 
JAMA 
Psychiatry 
Examination of the 
distribution of SMRs from 
37 papers.  Selected 
estimates using random-
effects meta-analysis 
were then pooled.  
37 papers drawn 
from 25 different 
nations 
All  cause Standardised 
mortality ratios (SMR). 
 
 
SMRs from studies in 
1970 (n=8), 1980 
(n=10) & 1990 (n=7) 
were compared. 
Meta-regression was 
used. 
Median all -cause SMR for all  persons was 2.58, with 10% and 
90% quintiles from 1.18 to 5.76.  
Median SMRs for 1970s, 1980s, and 1990s were 1.84, 2.98, 
and 3.20, respectively.  
 
There was a significant positive association between the 
follow-up period midpoint year and all -cause SMR. (Slope 
coefficient, 0.06; 95% CI, 0.01-0.11; z = 2.21; p =0 .03). 
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Author, Year 
& Journal 
Study methodology Sample Size Measurement of mortality 
used 
Measurement of 
change in mortality 
rates 
Main Findings 
Capasso et al., 
2008 
Schizophrenia 
Research 
Linkage study with 
median follow up of 23.5 
years 
319 Olmsted 
County residents 
meeting DSM-IV-
TR criteria for 
schizophrenia 
(n=242) or 
schizoaffective 
disorder (n=77) 
Cumulative survival 
probabilities were estimated 
using the Kaplan–Meier 
method and compared 
using a one-sample log-rank 
test with the general l ife 
expectancy for the 
Caucasian population of the 
United States and 
Minnesota for persons of 
l ike age, gender, and 
calendar year of birth. Log-
rank test was used to 
compare survival of groups 
of patients 
No formalised 
charting of survival 
over time 
Significant (p < 0.001) increase in mortality for patients with a 
diagnosis of schizophrenia and schizoaffective disorder 
compared both with the mortality of the Caucasian 
population of the United States and Minnesota for persons of 
the same age, gender, and calendar year of birth.  
Individual survival curves for schizophrenia and 
schizoaffective disorder were very similar, having the same 
level of significance.  
Coronary artery disease was the primary cause of death 
(20%), whereas cancers (including lung cancer) accounted for 
19% of deaths 
 
Given the improvement in l ife expectancy for the general 
population, concerns about access and availability of medical 
and psychiatric care in the United States and other countries, 
the study concluded that these factors are l ikely contributing 
to the widening gap between survival of those with serious 
mental i l lness compared to the general population 
Brown et al., 
2010, 
BJPsych 
Prospective record 
linkage study of the 25 
year mortality of those 
with schizophrenia, with 
focus on change over 
time 
A community 
cohort of 370 
people with 
schizophrenia 
All  cause Standardised 
mortality ratios (SMR), SMR 
by specific causes (suicide, 
lung cancer, breast cancer, 
diabetes, cardiovascular 
disease, pneumonia, COPD, 
accident and undetermined) 
and mean age at death 
Change in all  cause, 
change in natural, 
change in un-natural 
and change in 
cardiovascular SMR 
over time 
Mean age at death of males was significantly lower than that 
of the females (57.3 v. 65.5 years, p<0.001). This difference 
remained when unnatural deaths were excluded.  
All-cause SMR was 289 (95% CI 247-337). 
Most significant contributions to the overall  excess mortality 
came from circulatory diseases (33%) and respiratory 
diseases (19%). 
 
All-cause SMR showed small but non-significant changes 
between 1981 and 2006, fall ing in the first 5 years then rising 
slightly from 264 (95% CI 174–384) in 1986–1991 to 292 (95% 
CI 212–392) in 2001–2006 (p= 0.6).  
SMR for cardiovascular diseases increased over the study 
period from 129 (95% CI 27–377) in 1981–1986 to 350 (95% 
CI 186–598) in 2001–2006. (p= 0.053). 
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Author, Year 
& Journal 
Study methodology Sample Size Measurement of mortality 
used 
Measurement of 
change in mortality 
rates 
Main Findings 
Hoye et al., 
2011 
Schizophrenia 
Research 
Linkage study using data 
from the University 
Hospital of North 
Norway. Follow up 
period of 27 years 
1,111 patients 
with 
schizophrenia 
compared to the 
general 
population.  
Age adjusted SMRs for all  
cause, natural cause, 
unnatural cause and specific 
causes of mortality (namely 
suicide, cardiovascular 
disease & cancer) in men 
and women with 
schizophrenia compared to 
the general population.  
 
SMRs for 1980-1988, 
1989-1997 and 1998-
2006 were calculated 
and compared 
Male SMR was higher than female SMR (3.5 95%CI 3.1-4.1 vs. 
2.6 95%CI 2.1-3.2 p=0.01 respectively) 
 
SMR in 1998-2006 was higher than that in 1980-1988 for both 
men 3.8 (95% CI 3.0-4.1) vs. 2.8 (95% CI 2.1-3.6) and women 
2.6 (95% CI 1.9-3.7) vs. 2.1 (95% CI 1.2-4.4). 
 
Hoang et al., 
2011 
BMJ 
 
Linked dataset of English 
national hospital episode 
statistics and data from 
death certification. 
Follow up 7 years 
272,248 
discharges from 
hospital for 
schizophrenia in 
England for 
1999-2006 
Age and sex adjusted SMRs 
for deaths from unnatural 
and natural causes and 
SMRs for specific causes of 
death including 
cardiovascular disease, 
respiratory disease, cancer, 
accidents and 
suicide/deaths from 
undetermined intent  
Poisson test of trend 
was used to 
investigate whether 
there was a 
significant trend in 
standardised 
mortality ratios over 
time 
Age and sex SMR were double the population average. In 
2006 SMR was 2.2 in the population discharged with 
schizophrenia. 
SMR was higher in younger than in older people: in 2006 in 
those aged < 45 SMR was 6.2 (95% CI 4.9-7.5) vs. 2.0 (95% CI 
1.7-2.3) in those aged 65-84 
 
SMR increased from 1.6 (95% CI 1.5-1.8) in 1999 to 2.2 (95% 
CI 2.0-2.4) in 2006.  
Poisson test for trend confirmed that the trend in risk of 
mortality was significant (P<0.001). 
 
Morden et al., 
2012 
General 
Hospital 
Psychiatry  
Patients in the Veteran 
Affairs Health system 
with schizophrenia were 
linked to National Death 
Index and compared to 
individuals in the Veteran 
Affairs Health system 
without serious mental 
i l lness 
65,362 patients 
in the Veteran 
Affairs (VA) 
health system 
with 
schizophrenia 
and 65,362 VA 
patients without 
serious mental 
i l lness (non-SMI) 
All-cause and cause-specific 
mortality was compared for 
fiscal years 2000–2007.  
 
Mean years of potential l ife 
lost (YPLLs) were calculated 
annually. 
Comparison of all -
cause and cause-
specific mortality and 
years of potential l ife 
lost (YPLLs) between 
2000 -2007. 
All  cause annual mortality rate for those with schizophrenia 
was 257 in 2000 vs. 311 in 2007. This compared to an all  
cause annual mortality rate of 196 in those without SMI in 
2000 and 247 in 2007. 
 
Years of potential Life lost was 12.8 years in 2000 and 15.4 
years in 2007 for individuals with schizophrenia compared to 
11.8 years in 2000 and 14.0 years in 2007 for individuals 
without SMI    
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Author, Year 
& Journal 
Study methodology Sample Size Measurement of mortality 
used 
Measurement of 
change in mortality 
rates 
Main Findings 
Dutta et al., 
2012 
Psychological 
Medicine 
 
 
 
 
 
 
 
 
 
 
 
Patients with first 
episode psychosis in 
three catchment areas of 
the U.K. were traced 
after a mean of 11.5 
years follow-up and 
death certificates were 
obtained. Data analysis 
was by indirect 
standardization. 
2723 patients: 
London (1965-
2004, n=2056), 
Nottingham 
(1997-1999, 
n=203) and 
Dumfries and 
Galloway (1979-
1998, n=464) 
Overall  standardized 
mortality ratio (SMR) and 
specific cause SMR 
Poisson regression 
models were used to 
test the difference in 
SMRs (for all  causes 
of death) over 
calendar period of 
follow-up, using the 
expected number of 
deaths for each 
stratum as the offset 
and assuming 
multiplicative effects 
between the number 
of deaths and 
calendar period. 
Overall  SMR was 184 [95% CI 167-202]. Most deaths (84.2%,) 
were from natural causes. Suicide had the highest SMR (1165, 
95% CI 873-1524). Respiratory system and infectious diseases 
had the highest SMR of the natural causes of death (232, 95% 
CI 183-291). Risk of death from diseases of the circulatory 
system was also high (SMR 139, 95% CI 117-164). 
There was strong evidence that the mortality gap compared 
with the general population for all  causes of death (p<0.001) 
and all  natural causes (p=0.01) increased over the four 
decades of the study. There was weak evidence that 
cardiovascular deaths may be increasing relative to the 
general population (p=0.07). 
Nielsen et al., 
2013 
Schizophrenia 
Research 
Longitudinal l inkage 
study using the Danish 
Psychiatric Research 
Register and the Danish 
Cause of Death Register. 
Data were analysed using 
descriptive statistics and 
survival analysis.  
14,974 patients 
with 
schizophrenia 
were compared 
to 1,311,419 
controls 
Average age of death was 
constructed for the 
schizophrenia population 
and the general population  
for all  causes and with self-
harm excluded as cause of 
death. 
 
Change in age at 
death between 1980 
and 2010 were 
calculated as marker 
of increase in 
mortality over time. 
Matched control vs. 
schizophrenia 
survival analysis, 
with entry defined as 
time of birth and 
Kaplan–Meier plots 
were obtained. Log-
rank test and Cox 
regression were 
employed. 
 
Average age of death in the schizophrenia population was 
lower compared to the general population (62.2 years; 95%CI 
61.9-62.5 vs. 73.4 years; 95% CI, 73.4–73.4, p < 0.001). 
Individuals with schizophrenia had an increased mortality 
rate compared with the general population (hazard ratio, 
2.05; 95% CI, 2.01–2.09). 
 
In the general population there was an average increase in 
age of death of 0.28 years/calendar year in men (95% CI, 
0.27–0.28), and in women an increase of 0.31 years/calendar 
year (95% CI, 0.31–0.32) (both p < 0.001). 
 
Age of death decreased in the schizophrenia population:  
-0.04 years/calendar year for men (95% CI, − 0.09 to 0.00), 
and for women − 0.05 years/calendar year (95% CI, − 0.09 to 
0.01) (both p < 0.05).  
A similar pattern was seen after acts of self-harm as cause of 
death were excluded from the analyses.  
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Author, Year 
& Journal 
Study methodology Sample Size Measurement of mortality 
used 
Measurement of 
change in mortality 
rates 
Main Findings 
Walker et al., 
2015  
JAMA 
Psychiatry 
Meta-analysis of studies 
reporting a measure of 
mortality.  
146 studies  Pooled mortality ratios 
using 
DerSimonian-Laird random-
effects models to allow for 
heterogeneity 
across studies. Random-
effects meta regression 
models were used to 
determine which study 
characteristics 
could explain heterogeneity. 
Pooled Relative Risk 
from studies 
published before 
1970, 1970-1979, 
1980-1989, 1990-
1999 and after 2000 
Relative risk of death increased over time: 
before 1970: 1.79 (95% CI 1.49-2.15), 
1970-1979: 2.07 (95% CI 1.86-2.31),  
1980-1989: 2.28 (95% CI 2.07-2.50), 
1990-1999: 2.43 (95% CI 2.24-2.63) and  
after 2000: 2.47 (95% CI 2.17-2.79). 
NB this is for ALL mental disorders combined.  
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Table 1-2 Recent Studies in Schizophrenia suggesting that there is no change in the mortality gap or it is improving: 
 
Author, Year 
& Journal 
Study 
methodology 
Sample Size Measurement of 
mortality used 
Measurement of change 
in mortality rates 
Main Findings 
Heila et al., 
2005 
Psychological 
Medicine  
Individuals 
hospitalized for 
schizophrenia were 
identified via the 
National Hospital 
Discharge Register 
and linked to 
mortality data from 
the National Causes 
of Death Register. 
58,761 
individuals 
with 
schizophrenia 
were 
included. 
Relative risks (RR) of death 
adjusted for age for total 
mortality, mortality due to 
natural causes (cancer, 
ischaemic heart disease, 
respiratory disease) and 
unnatural causes 
(accident, homicide, 
suicide), and suicide were 
calculated 
Trend in mortality over the 
whole study period (1980–
1996) was tested using 
poisson regression 
models. 
Individuals with schizophrenia had an increased mortality 
both from natural causes (RR 2.59, 95% CI 2.55–2.63) and 
from suicide (RR 9.9, 95% CI 9.43–10.30).  
 
The RR for both natural and unnatural deaths was highest 
among patients with <5 years from onset.  
 
Among them all -cause mortality rose in the 1990s, but 
decreased among patients with >10 years from onset. 
 
Otherwise no major changes or l inear trends were found in 
mortality during deinstitutionalization. 
Colton et al., 
2006 
Preventing 
Chronic 
Disease 
Age-adjusted death 
rates, SMRs, & 
YPPL, for mental 
health clients in 8 
states compared 
with the mortality 
of their state 
general populations 
over 3 years (1997-
2000) 
8 US states 
(Arizona, 
Missouri, 
Oklahoma, 
Rhode Island, 
Texas, Utah, 
Vermont, and 
Virginia) 
Age-adjusted death rates 
(AADRs), Standardised 
mortality ratios (SMRs), 
and years of potential l ife 
lost (YPLL) 
SMR over time Public mental health clients in all eight states studied had a 
greater risk of dying than the general populations of their 
states. Individuals with schizophrenia had higher AADRs and 
SMRs during every year submitted than the general 
populations of their states. SMR was highest in Oklahoma 
at 4.9 in 1997. 
However l ittle evidence of change in SMR over time: 
Missouri SMR 2.0 in 1999 & 2.2 in 2000 
Oklahoma SMR 4.9 in 1997 & 2.9 in 1999 and  
Texas SMR 4.4 in 1997 & 1.6 in 1999   
 
Tiihonen et 
al., 2009 
The Lancet 
Finnish Nationwide 
registers to 
compare the cause-
specific mortality in 
patients with 
schizophrenia 
l inked to the use of 
antipsychotic drugs 
66,881 
patients with 
schizophrenia 
vs. the total 
population 
(5·2 mill ion) 
between 
1996-2006 
All-cause mortality during 
current & cumulative 
exposure to any 
antipsychotic drug vs. no 
antipsychotic, & exposure 
to the 6 most frequently 
used antipsychotic drugs 
vs. perphenazine use. 
Comparison of l ife 
expectancy in those with 
schizophrenia and the 
general population at 
different ages, 10 years 
apart. 
Although the proportional use of second-generation 
antipsychotic drugs rose from 13% to 64% during follow-up, 
the gap in l ife expectancy between patients with 
schizophrenia and the general population did not widen 
between 1996 (25 years), and 2006 (22·5 years) 
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Author, Year 
& Journal 
Study 
methodology 
Sample Size Measurement of 
mortality used 
Measurement of change 
in mortality rates 
Main Findings 
Rantanen et 
al., 2009 
Social 
Psychiatry 
and 
Psychiatric 
Epidemiology 
Finnish hospital 
discharge register 
(FHDR), for 
Individuals with 
first hospitalisation 
for schizophrenia 
during 1980-1998 
was linked to date 
& cause of death 
from Statistics 
Finland over 5 
years 
23,959 
individuals 
with 
schizophrenia 
were 
included. 
5 year mortality after 
discharge from hospital - 
for all  causes, due to 
malignancy, ischaemic 
disease, any somatic 
cause, alcohol related, 
suicide and other 
unnatural cause.  
5 year mortality was 
calculated for males and 
females.  
Changes in 5-year follow-
up mortality during the 
study period were 
explored for both genders 
and for different causes of 
death separately using 
multivariate logistic 
regression analyses 
Proportion of deaths was significantly higher in males 
(10.1%) than in females (5.7% p<0.001). 
 
A significant reduction in overall 5-year mortality was 
observed among persons hospitalized in 1995-1998 when 
compared to people hospitalized 1980-1984 (p=0.062). 
 
In males a significant reduction was seen in all  mortality (p= 
0.025) and deaths from suicide (p=0.007) but not in the 
case of natural deaths. In females no significant changes in 
mortality were found. 
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Table 1-3 Recent Studies in Bipolar Disorder suggesting that the mortality gap is widening: 
 
Author, Year 
& Journal 
Study 
methodology 
Sample Size Measurement of mortality 
used 
Measurement of change 
in mortality rates 
Main Findings 
Hoang et al., 
2011 
BMJ 
 
Linked dataset of 
English national 
hospital episode 
statistics and data 
from death 
certification 
100,851 
discharges 
from hospital 
for bipolar 
disorder in 
England for 
1999-2006 
Age and sex adjusted SMRs for 
deaths from unnatural and 
natural causes were calculated. 
 
SMRs for specific causes of 
death were also included 
namely from cardiovascular 
disease, respiratory disease, 
cancer, accidents and 
suicide/deaths from 
undetermined intent  
Poisson test of trend was 
used to investigate 
whether there was a 
significant trend in 
standardised mortality 
ratios over time 
Age and sex standardised mortality ratios were 
about double the population average- in 2006 
SMR was 1.9 in the population discharged with 
bipolar disorder.  
 
SMR was higher in younger than in older people: 
in 2006 in those aged < 45 SMR was 3.4 (95% CI 
1.7-5.1) vs. 1.8 (95% CI 1.4 - 2.2), in those aged 
65-84  
 
SMR increased from 1.3 (95% CI 1.1-1.6) in 1999 
to 1.9 (95% CI 1.6- 2.2) in 2006. 
 
Poisson test of trend had results of borderline 
significance (p=0.06). 
 
Walker et al., 
2015  
JAMA 
Psychiatry 
Meta-analysis of 
studies reporting a 
measure of 
mortality.  
146 studies  Pooled mortality ratios using 
DerSimonian-Laird random-
effects models to allow for 
heterogeneity 
across studies. Random-effects 
meta regression 
models were used to determine 
which study characteristics 
could explain heterogeneity. 
Pooled Relative Risk from 
studies published before 
1970, 1970-1979, 1980-
1989, 1990-1999 and after 
2000 
Relative risk of death increased over time: 
before 1970: 1.79 (95% CI 1.49-2.15), 
1970-1979: 2.07 (95% CI 1.86-2.31),  
1980-1989: 2.28 (95% CI 2.07-2.50), 
1990-1999: 2.43 (95% CI 2.24-2.63) and  
after 2000: 2.47 (95% CI 2.17-2.79). 
NB this is for ALL mental disorders combined.  
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The difference in mortality rate ratios and life expectancy experienced by 
individuals with MMI compared to individuals without MMI is evidence of 
potential health inequality. However, the possible reasons underpinning this 
are poorly understood. Better understanding of possible explanatory factors for 
this health inequality will allow the development of strategies to address this. 
These strategies may be at a primary and secondary care level as well as at an 
individual and societal level. 
Although differences in mortality between individuals with MMI and 
individuals without MMI have been explored, as outlined above, there remain 
significant gaps in our understanding of this complex relationship. Detailed 
exploration of the cause of death across the lifespan of individuals with MMI 
is required, along with investigation into the impact of socioeconomic 
deprivation on cause and rate of death. Systematic comparison of the patterns 
and cause of death in individuals with schizophrenia and bipolar disorder will 
also be helpful to better aid understanding of the prognosis and outcomes of 
these disorders. By undertaking a study locally, an additional cohort of 
individuals will be investigated, and this will add to current evidence which to 
date has largely been from Sweden, Denmark, Australia and London. 
Ultimately, this thesis will attempt to explore some of these gaps in greater 
detail with the aim of better informing the development of strategies and 
policies to address the mortality gap.  
1.5 Conclusion: 
While increased physical comorbidity in individuals with MMI is widely 
reported in the literature, it is often reported, for a narrow range of single 
diseases in restricted cohorts of the population. This therefore limits 
generalisability of findings. To date there have been few large, systematic 
investigations into the patterns of physical health comorbidities in individuals 
with MMI compared to the general population using primary care data and 
none have been undertaken in Scotland. Therefore further investigation of 
rates and patterns of physical health comorbidity in MMI is required and this 
thesis will describe these patterns in detail. The influence of age, sex and 
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socioeconomic status on rates of physical comorbidity will also be considered. 
To date the rate of multimorbidity in MMI has been poorly explored, and 
given the influence of deprivation on rates of multimorbidity, and the fact that 
multimorbidity is common and is often the norm rather than the exception in 
individuals with long-term conditions, this is an area which requires further 
investigation. This thesis will therefore attempt to explore patterns of 
multimorbidity in a systematic manner in individuals with MMI.  
Given that there is some preliminary evidence for inequality in prescribing of 
physical health medication in individuals with MMI, further exploration of 
possible prescribing inequalities within a large primary care database in 
Scotland would be of clinical and scientific merit. In particular rates of 
prescription of statins, antiplatelets and anti-hypertensives in individuals with 
MMI and hypertension and MMI and coronary heart disease will be compared 
to individuals with hypertension without MMI and individuals with coronary 
heart disease without MMI. Given the significant burden of smoking in 
individuals with MMI and the modifiable nature of this risk factor, 
investigation to determine if there are inequalities in access to smoking 
cessation advice and nicotine replacement therapy (NRT) prescription for 
individuals with MMI will also be undertaken. It is hoped that the findings 
reported in this thesis will provide novel insights into potential inequalities in 
access to healthcare advice and prescribing in primary care in Scotland. 
While health inequalities are reported in individuals with MMI, to date no 
studies have focused on whether there is evidence of inequality in access to the 
incentivised healthcare provision for individuals with MMI within Scotland; 
namely in the form of the Quality and Outcome framework (QOF). Given the 
high uptake of the QOF within primary care across the UK, investigation into 
potential inequalities using QOF data is likely a reflection of UK wide 
practice. Due to the limited investigation into this area, this thesis will provide 
a novel insight into potential inequalities in aspects of incentivised primary 
care in Scotland and across the UK.  
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Increased mortality of individuals with MMI has been described but there 
remain significant gaps in our understanding of not only the patterns of cause 
of mortality across the lifespan, but also the effect of socioeconomic status on 
mortality rates. The studies carried out to date, have largely been out with 
Scotland and so a local study will be of scientific and clinical merit and can 
add to the wider scientific evidence. A comparison of patterns of cause and 
rate of mortality between schizophrenia and bipolar disorder would also be 
advantageous to add to current understanding. This thesis will therefore 
attempt to address some of the gaps in these areas by using a locally linked 
dataset.  
Finally, this thesis will provide a synthesis of these findings and focus on their 
clinical and scientific implications. Areas for future research will be 
highlighted and potential modifications to current working models will also be 
discussed.   
 
 
 
Chapter 2: Aims and Research Questions:  
2.1 Aims: 
The aims of this thesis were:  
1.To conduct a review of: a) the literature on physical health comorbidity and 
multimorbidity in schizophrenia and bipolar disorder relative to the general population, b) 
to review research which has explored possible mechanisms for health inequalities in these 
groups and c) the literature on premature mortality in schizophrenia and bipolar disorder 
relative to the general population 
2. To gain a more detailed understanding of the patterns of multiple physical health 
comorbidities in individuals with schizophrenia and bipolar disorder. 
3. To better understand possible explanations for health inequalities in individuals with 
schizophrenia and bipolar disorder by examining a) prescribing data in primary care and b) 
Quality and Outcome Framework (QOF) data in Scotland, England, Northern Ireland and 
Wales. 
4. To gain a more detailed understanding of the causes of premature mortality in 
individuals with schizophrenia and bipolar disorder. 
2.2 Research Questions: 
1. What are the patterns of multiple physical health comorbidities in individuals with 
schizophrenia and bipolar disorder and how do these compare to the general population? 
2.  Do patterns of prescribing for hypertension and coronary heart disease (CHD) in 
individuals with schizophrenia and bipolar disorder differ from the patterns of prescribing 
for hypertension and coronary heart disease in individuals without schizophrenia and 
bipolar disorder? 
3.  Do rates of recording of smoking cessation advice and patterns of prescribing of 
Nicotine Replacement Therapy (NRT) in smokers with schizophrenia and bipolar disorder 
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differ from smokers with other chronic diseases (diabetes, coronary heart disease (CHD) or 
hypertension)? 
4.  Do rates of payment, population achievement and exception reporting for comparable 
QOF indicators differ in individuals with schizophrenia or bipolar disorder across 
Scotland, England, Wales and Northern Ireland compared to other chronic diseases? 
5. What are the primary causes of death across the adult life span in individuals with 
schizophrenia and bipolar disorder and how do these causes of death compare to the 
general population?  
6. Does the primary cause of death in individuals with schizophrenia differ from the 
primary cause of death in individuals with bipolar disorder?  
7. Does socioeconomic status impact on rate and primary cause of death in individuals 
with MMI relative to the local (Glasgow) and wider (Scottish) populations? 
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Chapter 3: General Methods: 
Chapter Overview 
This chapter is a general overview of the approach and methods used for the studies 
reported in this thesis. More detailed methodological information is reported within each 
chapter. In order to address the aims of this thesis, a narrative review of the literature was 
undertaken (its methodology and findings are reported above in Chapter 1). This allowed 
gaps in the literature to be identified and the subsequent generation of the research 
questions. From there a decision regarding the statistical analyses using data from primary 
care, secondary care and national datasets was made. The datasets included in this thesis 
are-  
1. The Scottish Programme for Improving Clinical Effectiveness in Primary Care 
(SPICE) dataset, 
2. The Quality and Outcome Framework (QOF) Data- a national dataset and 
3. The Glasgow Psychosis Clinical Information System (PsyCIS)- a secondary care 
dataset. 
3.1 The Scottish Programme for Improving Clinical 
Effectiveness in Primary Care (SPICE) dataset 
3.1.1 Overview of SPICE 
The SPICE dataset is a cross sectional primary care database which contains information 
on 1,751,841 registered patients who were alive and permanently registered with 314 
general practices on March 31, 2007. Due to its size, the dataset is a representative sample 
covering approximately one third of the Scottish population. Secondary analyses using the 
SPICE database are included in Chapters 4 and 5.  
3.1.2 Research methodology undertaken using the SPICE dataset:  
The SPICE dataset includes basic demographic information including age, sex and 
socioeconomic status. Information on socioeconomic status is measured by the Carstairs 
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Index (divided into quintiles) and is calculated based on the individual’s address. The 
presence or absence of certain physical and mental health conditions (schizophrenia or 
bipolar disorder) were based on GP diagnostic Read Codes and/or prescription data. For 
example individuals with migraine were identified if four or more prescription only anti-
migraine medications were prescribed in the last year. A full list of the thirty two physical 
health conditions included and their definitions are found in Appendix 2.  
3.1.3 Statistical Analyses carried out using the SPICE dataset: 
3.1.3.1 Statistical Analyses of patterns of comorbidity: 
Analyses of this dataset were restricted to individuals aged 18 and over and the sample was 
divided into the following age groups for analysis: 18-25, 25-34, 35-44, 45-54, 55-64 and 
65 and older.  
Differences between groups such as individuals with schizophrenia or bipolar disorder, all 
other individuals (controls) and between males and females were calculated by age, 
deprivation and number of physical conditions. T-tests were used to analyse differences 
between groups and Chi squared tests were used for differences across age groups and 
deprivation quintiles. Logistic regression was used to calculate odds ratio (ORs) for the 
prevalence of the thirty two physical conditions, as well as no physical disorder, one 
comorbid disorder, two comorbid disorders and three or more comorbid disorders. Odds 
ratios (ORs) are reported with 95% confidence intervals (CIs) in individuals with either 
schizophrenia or bipolar disorder compared with controls and were adjusted for age, 
gender and deprivation.  Further detail of the statistical methodology undertaken is 
available in Chapter 4.   
3.1.3.2 Statistical analyses of prescribing patterns:  
For differences in prescribing patterns standard British National Formulary (BNF) 
classifications of drugs such as anti-hypertensives, statins, aspirin and clopidogrel were 
obtained. Prescribing rates of none, one and two or more anti-hypertensives were 
compared in individuals with comorbid schizophrenia or bipolar disorder and hypertension 
with individuals with hypertension without schizophrenia or bipolar disorder. Prescribing 
rates of none, one and two or more anti-hypertensives, along with aspirin or clopidogrel 
and statin prescription rates were compared in individuals with comorbid schizophrenia or 
bipolar disorder and coronary heart disease (CHD) and individuals with CHD without 
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schizophrenia or bipolar disorder. To ensure only current prescriptions were captured, 
prescribing data from the 84 days prior to the date that the dataset was obtained were 
included. Further detail of the statistical methodology undertaken is included in Chapter 4. 
3.1.3.3 Statistical analyses of risk factors: 
For risk factor profiles, rates of uncontrolled Blood Pressure (BP) (defined as did not 
achieve target BP: where systolic BP ≥ 140mmHg and diastolic BP ≥ 90mmHg if < 80 
years old and systolic BP ≥ 150mmHg and diastolic BP ≥ 90mmHg if aged 80 and over) 
and uncontrolled cholesterol (defined as cholesterol ≥ 5mmo/L) were compared across 
groups: namely individuals with schizophrenia or bipolar disorder and hypertension or 
CHD versus individuals with hypertension or CHD without schizophrenia or bipolar 
disorder. Odds ratio calculations were adjusted for age, gender and deprivation score and 
are reported with 95% confidence intervals.   
3.1.3.4 Statistical analyses of recording of smoking status, smoking 
cessation advice and Nicotine Replacement Therapy (NRT) 
prescription: 
Recording of smoking status was reviewed and recoded into current smoker, ex-smoker 
and non-smoker based on the Read Codes detailed in Appendix 3. Individuals, in whom 
smoking status was not recorded, were excluded. Odds ratio of current smoking, ex-
smoking and non-smoking in individuals with MMI with/without diabetes, individuals 
with diabetes without MMI, individuals with MMI with/without hypertension, individuals 
with hypertension without MMI, individuals with MMI with/without CHD and individuals 
with CHD without MMI were calculated using logistic regression adjusted for age, sex and 
deprivation status. Odds Ratios are reported with 95% confidence intervals. 
In smokers, recording of smoking cessation advice was reviewed and recoded into having 
occurred on not occurred based on Read Codes, detailed in Appendix 4. For differences in 
prescribing rates: standard British National Formulary (BNF) classifications of Nicotine 
Replacement Therapy (NRT) which included patches, gum, lozenges, inhalator or nasal 
spray were obtained. Further details of the Read Codes included are detailed in Appendix 
5. To ensure only current prescriptions were captured, prescribing data from the 84 days 
prior to the date that the dataset was obtained were included. 
In smokers, rate of recording of smoking cessation advice and rate of prescription of 
Nicotine Replacement Therapy (NRT) were then calculated. Odds ratios with 95% 
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confidence intervals, for recording of smoking cessation advice and prescribing of NRT for 
the different groups were calculated using logistic regression adjusted for age, sex and 
deprivation status. 
A comparison of rates of smoking, ex-smoking and non-smoking, rates of recording of 
smoking cessation advice in smokers and rates of NRT prescription in smokers, in 
individuals with schizophrenia and bipolar disorder was also undertaken. Odds ratios with 
95% confidence intervals were calculated using logistic regression again adjusted for age, 
sex and deprivation status.  
All analyses were performed in STATA version 12. A further more detailed explanation of 
the statistical methodology undertaken is detailed in Chapter 5.   
3.1.4 Ethical considerations for SPICE: 
The analysis of SPICE data was conducted as part of the Living Well with Multimorbidity 
Programme (CSO Grant ARPG/07/1) with Professor Stewart W Mercer (Principal 
Investigator) and Professor Bruce Guthrie (Epidemiology Lead). Therefore individual 
ethical approval for each study was not required.  
3.2 Quality and Outcome Framework (QOF) Data. 
3.2.1 Overview of QOF Data 
The General Medical Services’ Quality and Outcomes Framework (QOF), was introduced 
into the UK in 2004, and is an annual contract for the provision of care delivered by 
General Practices. It was introduced to standardise the improvement in the delivery of 
primary care and largely forms the basis of supplementary payment for General Practioners 
(GPs). Work using QOF data is included in Chapters 6 and 7.  
The QOF is dynamic in nature and so in Scotland, England, Northern Ireland and Wales 
the indicators have changed since their inception in 2004. In 2012/2013 the QOF was made 
up of four main components, known as domains. These four domains; clinical, 
organisation, patient experience and additional services, contain indicators against which 
the primary care practice scores points according to their level of achievement. The clinical 
domain contains clinical indicators across a wide variety of conditions which are managed 
within primary care- including heart failure, coronary heart disease (CHD), stroke, asthma, 
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chronic obstructive pulmonary disease (COPD) and mental illnesses. Supplementary 
payment of General Practices is calculated based on indicator achievement rate. 
Throughout the UK, the number of General practices participating in the QOF is high and 
so analysis of QOF data is representative of UK wide practice. Although there are subtle 
differences in QOF indicators between countries within the UK, some indicators are the 
same and so direct comparison between consistent indicators across different countries can 
be made.  
Within a clinical domain (for example mental health or asthma), individuals may not be 
suitable for all indicator measurements, and so there is a facility within the QOF to exclude 
and to except individuals from certain indicators. This then removes these individuals from 
the indicator achievement and payment calculations. This process is explained in more 
detail in Chapter 6.  
Three measurements are therefore used to describe QOF data: indicator 
achievement/practice payment rate, exception rate and population achievement rate. These 
three measurements have been included in this thesis and are detailed below (Figure 3-1).  
 
Indicator 
achievement          = 
rate aka Practice 
Payment Rate             
 
 
 number of individuals w ho have successfully met the indicator criteria (numerator)  
number of individuals w ho could have achieved that indicator target (denominator) once exclusions 
and exceptions have been removed. 
 
 
Exception rate        = 
number of individuals w ho met the exception criteria 
number of patients w ho w ere eligible for the target w ith exceptions included (denominator + 
exceptions) 
 
Population              = 
achievement rate     
 number of individuals w ho have successfully met the indicator criteria (numerator)  
number of patients w ho w ere eligible for the target w ith exceptions included (denominator + 
exceptions) 
 
Figure 3-1 Payment rate, Exception rate and Population achievement rate calculations.  
3.2.2 Research methodology undertaken for cross-jurisdiction 
comparison of QOF Data: 
To undertake a cross-jurisdiction comparison of QOF data: payment, exception and 
population achievement rates for two of the Mental Health indicators along with two 
comparator non-mental health indicators across the UK was undertaken for the years 
2011/2012 and 2012/2013. Data was obtained, from the Health and Social Care 
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Information Service in England, the Quality and Outcome Frameworks Information 
Services Division (ISD) of NHS Scotland, the Department of Health, Social Service and 
Public Safety in Northern Ireland and the Welsh Government.  
3.2.3 Statistical Analyses undertaken for cross-jurisdiction 
comparison of QOF Data: 
Both Mental Health indicators were compared with their non-mental health comparator 
indicator within the same year and geographical location (i.e. within Scotland, England, 
Northern Ireland and Wales) and also for the UK as a whole for 2011/12 and 2012/13. As 
data were non-parametric and paired (within countries by practice identifier), differences in 
rates within the same country were compared using a sign test. Median population 
achievement rate, payment rate and exception rate are reported along with inter quartile 
range (IQR). For the UK wide figures, differences in rates were compared using a non-
parametric equality of medians test. Differences in median population achievement rate 
between countries were compared to England using a quantile regression analysis weighted 
for practice denominator. Results are reported as percentage point difference with 99% 
confidence intervals. Further detail surrounding the statistical methodology undertaken is 
detailed in Chapter 6. All analyses were performed using STATA version 12.  
3.2.4 Research methods undertaken using Scottish QOF data: 
A retrospective analysis of exception rate data for the years 2005/2006 until 2012/2013 
inclusive for all the Mental Health indicators was undertaken. Exception rate data is 
available on the Quality and Outcome Frameworks Information Services Division (ISD) of 
NHS Scotland website. Median rate of exception for each of the Mental Health indicators 
in the above timeframe was calculated and charted over time to determine trends in 
exception rate reporting.  
A number of proxy comparator indicators for other chronic diseases, deemed similar to the 
Mental Health indicators were selected. These proxy comparator indicators were chosen 
after careful review and consideration of all available indicators within the QOF. Although 
the indicators were not always exactly the same, there were of the same type (i.e. 
measurement or target indicator) and used the same timeframe (for example measurements 
to be recorded within 12 months). The rationale for choosing the comparator indicators 
was discussed at supervision and agreement regarding their suitability was obtained from 
both supervisors. This was felt to be the most pragmatic option available to allow 
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comparison of indicators across a wider range of chronic diseases. Median exception rates 
were calculated and rates were then compared. This process is further detailed in Chapter 
7. 
A number of composite indicator areas were generated by combining exception rates for 
individual indicators within a clinical area. The clinical areas where composite indicators 
were generated included: mental health (MH), atrial fibrillation (AF); asthma; coronary 
heart disease (CHD); cancer, chronic kidney disease (CKD), chronic obstructive 
pulmonary disease (COPD), epilepsy, heart failure (HF), diabetes, hypertension, 
hypothyroidism, osteoporosis, peripheral artery disease (PAD), stroke, dementia and 
depression. The generated composite indicators included a variable number of individual 
indicators, for example the mental health composite indicator contained exception rates for 
nine individual Mental Health indicators, while the composite indicator for diabetes 
contained exception rates for fourteen individual diabetes indicators.  Due to changes in the 
mental health indicators (detailed in Chapter 7) exception rate data for composite clinical 
indicator areas were generated for 2011/2012 and 2012/2013 only.  
It has been recognised that the use of  a single QOF indicator as a marker of quality of 
clinical care is limited and there is some evidence to suggest that composite models may be 
more helpful (Holmboe et al., 2010). The use of multiple QOF indicators within a 
composite model, has been done by others (for example de Wet and colleagues (2012)) and 
therefore the generation of composite indicators was felt to be useful to allow comparison 
of the mental health indicators with a wide range of other physical health composite 
indicators.  
3.2.5 Statistical Analyses using Scottish QOF data: 
As data was non-parametric, median exception rates were calculated and are reported with 
interquartile ranges (IQR) and 95% confidence intervals (95% CI). Differences between 
indicator exception rates and changes in median exception rates over time were compared 
using a non-parametric equality of medians test. Further detail surrounding the statistical 
methodology undertaken is included in Chapter 7. All analyses were performed using 
STATA version 12. 
72 
 
3.2.6 Ethical considerations for the QOF data: 
Publically available practice level data was used and formal Ethical approval was therefore 
not required. 
3.3 The Glasgow Psychosis Clinical Information System 
(PsyCIS)  
3.3.1 Overview of PsyCIS 
The Glasgow Psychosis Clinical Information System (PsyCIS) is an electronic database of 
all individuals with a psychotic illness who have been in contact with secondary care 
psychiatric services in NHS Greater Glasgow and Clyde (NHSGG&C). This covers a 
population of approximately 1.1 million (National Records of Scotland, 2013). The 
database initially began as a retrospective case note audit of adults aged 18-65 with an 
ICD10 diagnosis of a psychotic illness, diagnosed by a consultant psychiatrist. Data was 
initially collected retrospectively over 42 months (from February 2002 until August 2005) 
and demographic information was entered onto the database. The data was collected by 
two specifically trained research nurses. Over 8,000 case notes were audited. Work using 
the PsyCIS database is included in Chapter 8. 
The ICD 10 diagnoses included in the PsyCIS database were: F20-29 Schizophrenia, 
schizotypal and delusional disorder, F30-F31 Mania and Bipolar Disorder, F32.3 Severe 
Depression with psychotic symptoms, F06.0 Organic Hallucinosis, F06.2 Organic 
delusional (schizophrenia- like) disorder, F06.30 Organic mood (affective) disorders, 
F06.31 Organic depressive disorder with psychotic symptoms, F53 Mental and behavioural 
disorders associated with the puerperium, not elsewhere classified and F1(x) Mental and 
behavioural disorders due to psychoactive substance with psychotic symptoms.  
Detailed baseline information including ICD-10 diagnosis (as determined by a consultant 
psychiatrist), Community Health Index (CHI) number, ethnicity, marital status, 
employment status, educational attainment, accommodation status and postcode were 
obtained. Clinical data including family history of psychosis, current illness severity (as 
measured by Health of the Nation Outcome Scores (HoNOS) and Clinical Global 
Impression (CGI)), psychiatric admissions data, use of the Mental Health Act, psychiatric 
comorbidities, current and previous medications, adverse drug effects and psychosocial 
interventions received were also obtained.  
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Clinical consensus diagnostic coding was applied in cases where a diagnosis either had not 
been recorded by a consultant psychiatrist or where there was uncertainty over the primary 
diagnosis. Prospective addition of new cases to the database has occurred from August 
2005 onwards using existing patient information management systems (PIMS). There is a 
reciprocal working relationship between the PsyCIS team and the local clinicians. All 
patients provide annual follow up information and this facilitates the return to consultants 
of clinically relevant information at an individualised caseload level. Annual review to 
check the accuracy of information such as postcode and current medication is undertaken 
and the database has undergone internal validity checking to determine the diagnostic 
accuracy of ICD10 diagnoses. Updates from the Health board to ensure that the data 
guardian is aware of any deaths of patients registered on the PsyCIS system also occurs.  
Currently the database currently holds information on over 7,200 patients with a diagnosis 
of psychotic disorder, including: schizophrenia (n=4,787); bipolar disorder (n=1,784); 
organic psychosis (n=67); psychotic depression (n=452); and substance-induced psychosis 
(n=160) and is still being added to.   
3.3.2 Research Methodology Undertaken using PsyCIS: 
All individuals with schizophrenia (F20-F29) or bipolar disorder (F30-F31) aged between 
18 and 65 who had died between 2006 and 2010 and lived within the Greater Glasgow area 
served by PsyCIS were identified. Date and cause of death were obtained by linkage to the 
Scottish Morbidity Records (SMR) held by the Information Services Division (ISD) of 
NHS Scotland. The International Statistical Classification of Diseases and Related Health 
Problems (ICD) was used to code cause of deaths, into nine categories using information 
from the Scottish Government website. The nine categories were as follows: 1) 
cardiovascular disease, 2) cerebrovascular disease, 3) respiratory diseases, 4) cancer, 5) 
alcohol related deaths, 6) mental and behavioural disorder due to drugs, 7) accidental, 8) 
suicide as defined by the Scottish suicide information database  (which includes deaths of 
undetermined origin) and 9) other. 
Scottish Index of Multiple Deprivation (SIMD) score was used as a measure of social 
deprivation. The SIMD identifies small areas of multiple deprivation (datazones) across 
Scotland by combining 38 indicators across 7 domains which are weighted. The domains 
include: current income (28%), employment (28%), health (14%), education (14%), 
geographic access to services (9%), crime (5%), and housing (2%) and are weighted based 
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on evidence from Oxford University’s Social Disadvantage Research Centre. Each domain 
contains information gathered from multiple sources, for example the health domain 
contains information regarding: hospital episodes related to alcohol use, hospital episodes 
related to drug use, a measure of mortality (the comparative mortality factor (CMF)), a 
measure of morbidity (comparative illness factor), emergency admission to hospital, 
population proportion prescribed drugs for anxiety, depression or psychosis and proportion 
of singleton births of low birth weight (<2,500g).  Each individual was allocated to a 
datazone and subsequent SIMD category based on their postcode (where 1 = most affluent 
and 5 = most deprived). There are 6,505 datazones covering Scotland and the SIMD score 
provides a relative measure of deprivation. Further detail is included in Appendix 6. 
3.3.3 Statistical Analyses carried out using PsyCIS: 
Cause of death by 10 year age at death ranges, i.e. <25, 25-34, 35-44, 45-54 and 55-64, 
were calculated for individuals with schizophrenia and bipolar disorder and compared to 
the local Glasgow and the wider Scottish population using annual mortality statistic data 
available from the General Register Office (GRO) for Scotland. Standardised mortality 
ratios (SMR) were calculated in the 10 year age ranges for the whole deceased population 
and further analysed by ICD10 diagnosis and gender.  
Two SMRs were calculated; a local (Glasgow) SMR and a wider (Scotland) SMR. For the 
Glasgow SMR the expected rate of death was derived by applying the Glasgow death rate 
data stratified by age and cause, to the PsyCIS cohort. This is further detailed in Chapter 8. 
For the wider (Scotland) SMR the expected rate of death was derived by applying the 
Scottish death rate data stratified by age and cause to the PsyCIS cohort. Both background 
rates were available on request from the General Register Office for Scotland. Glasgow 
and Scotland SMRs for all causes of death, all causes excluding suicides, and causes due to 
cardiovascular disease, cerebrovascular disease and cancer, were then calculated. 
All statistical tests were performed using STATA version 12. 95% confidence intervals for 
SMRs were calculated assuming that the data was normally distributed. Differences in 
death rates between men and women  were compared using Chi squared tests. Rates of 
primary cause of death in schizophrenia and bipolar disorder were also compared using 
Chi squared tests. Difference in rate of death between the most and least affluent quintile 
was compared using a Chi squared test. 
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3.3.4 Ethical considerations for PsyCIS: 
Ethical Approval was via Caldicott Guardian approval for NHS Greater Glasgow and 
Clyde.  
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Chapter 4: Patterns of comorbidity and prescribing 
trends in individuals with Schizophrenia and 
Bipolar Disorder- Analysis of SPICE Data: 
Chapter Overview 
This chapter will detail the patterns of recording of physical health comorbidities and 
multimorbidity in individuals with schizophrenia and bipolar disorder compared to the 
general population using SPICE data. It will also compare prescribing patterns in 
individuals with schizophrenia and bipolar disorder and comorbid hypertension or 
coronary heart disease (CHD) with prescribing patterns in individuals with hypertension or 
CHD without schizophrenia and bipolar disorder.  
4.1 Background: 
As outlined in Chapter 1, individuals with schizophrenia have increased rates of a number 
of chronic physical health problems including: diabetes (Dixon et al., 2000), metabolic 
syndrome (Heiskanen et al., 2013), chronic obstructive pulmonary disease (COPD) (Hsu et 
al., 2013) and osteoporosis (Howard et al., 2007). Similarly for individuals with bipolar 
disorder increased rates of: obesity (Carney and Jones, 2006a), diabetes (McIntyre et al., 
2005), metabolic syndrome (Bly et al., 2013), thyroid disease (Crump et al., 2013) and 
renal disease (Carney and Jones, 2006a) are described. However to date, large scale 
epidemiological studies investigating patterns of single and multip le physical health 
comorbidities in these individuals within a primary care setting in Scotland are lacking.  
In addition to the increased burden of disease that occurs, there may also be differences in 
access to healthcare for these individuals. As detailed in Chapter 1, there is evidence for 
differences in access to screening (Carney and Jones, 2006b), access to guideline 
consistent treatment (Kisely et al., 2009) and prescribing differences (Redelmeier et al., 
1998).  
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4.2 Aims: 
1. To describe the patterns of physical health comorbidities and multiple health 
comorbidities (multimorbidity) in individuals with schizophrenia compared to the 
general population. 
2. To describe the patterns of physical health comorbidities and multiple health 
comorbidities (multimorbidity) in individuals with bipolar disorder compared to the 
general population. 
3. To determine if there are differences in prescribing patterns in individuals with 
schizophrenia and a comorbid chronic disease (coronary heart disease (CHD) or 
hypertension) compared to individuals with a chronic disease (CHD or 
hypertension) who do not have schizophrenia or bipolar disorder.  
4. To determine if there are differences in prescribing patterns in individuals with 
bipolar disorder and a comorbid chronic disease (coronary heart disease (CHD) or 
hypertension) compared to individuals with a chronic disease (CHD or 
hypertension) who do not have schizophrenia or bipolar disorder.  
5. To determine if there are differences in rates of smoking, uncontrolled blood 
pressure and elevated cholesterol in individuals with schizophrenia and a comorbid 
chronic disease (coronary heart disease (CHD) or hypertension) compared to 
individuals with a chronic disease (CHD or hypertension) without schizophrenia or 
bipolar disorder. 
6. To determine if there are differences in rates of smoking, uncontrolled blood 
pressure and elevated cholesterol in individuals with bipolar disorder and a 
comorbid chronic disease (coronary heart disease (CHD) or hypertension) 
compared to individuals with a chronic disease (CHD or hypertension) without 
schizophrenia or bipolar disorder. 
4.3 Methods: 
As detailed in Chapter 3, the Scottish Primary Care Clinical Informatics Unit dataset 
(SPICE) was used. The presence of thirty two of the most common chronic physical health 
conditions that were extracted are listed in Appendix 2.   
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Due to the extensive nature of the dataset, the underlying differences in the nature of the 
mental illnesses of interest and the opportunity to separate individuals with schizophrenia 
from individuals with bipolar disorder, separate analyses by mental illness for rates of 
physical health comorbidities, multimorbidity and prescribing patterns were undertaken.  
Individuals were identified as having ‘schizophrenia or related non-organic psychosis’ 
(from here referred to as ‘schizophrenia’) based on the recording ever of any of the 
following primary care read codes (where % is noted this means “this code and any below 
it in the code hierarchy”): E10% schizophrenic disorders; E121 chronic paranoid 
psychosis; E12z paranoid psychosis NOS; E13% other non-organic psychoses; E13z non-
organic psychosis/psychotic episode; NOS E1z non-organic psychosis NOS; Eu20% 
schizophrenia; Eu22% persistent delusional disorder; or the recording in the last 12 months 
of Eu23% acute/transient psychotic disorder.    
Individuals were identified as having bipolar disorder based on the recording at any point 
of any of the following primary care Read Codes: E110% Manic disorder, single 
episode/hypomanic psychosis; E111% Recurrent manic episodes; E114% Bipolar affective 
- now manic/manic depressive - now manic; E115% Manic-depression - now depressed; 
E116% Manic bipolar affective disorder; E117% Unspecified bipolar affect disorder; 
E11y; Other manic-depressive psychosis; E11y0 Unspecified manic-depressive psychosis; 
E11y1 Atypical manic disorder; Eu30% Manic episode; Eu31 Bipolar affective 
disorder/manic depressive illness/manic depressive psychosis; Eu323 Severe 
depressive + psychotic; and Eu333 Recurrent depression now severe + psychosis. 
Analyses of this dataset were restricted to individuals aged 18 and over and the sample was 
divided into the following age groups for analysis: 18-25, 25-34, 35-44, 45-54, 55-64 and 
65 and older. Deprivation status was measured using the ,deprivation score (divided into 
quintiles) (Carstairs VMR, 1991). 
Differences between individuals with schizophrenia or bipolar disorder (cases), all other 
individuals (controls) and between men and women with schizophrenia or bipolar disorder 
were calculated by age, deprivation and number of physical conditions.  T-tests were used 
to test differences between groups. Chi squared tests were used for differences across age 
groups and deprivation quintiles.  Logistic regression was used to calculate odds ratio 
(ORs) and 95% confidence intervals in individuals with schizophrenia or bipolar disorder 
compared to controls for the prevalence of all thirty two physical conditions, as well as no 
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physical disorder, one comorbid disorder, two comorbid disorders and three or more 
comorbid disorders. Odds ratios were adjusted for age, gender and deprivation.   
For differences in risk factor profile and prescribing, individuals with CHD or 
hypertension and schizophrenia were compared to individuals with CHD or hypertension 
without schizophrenia. For this analysis individuals with bipolar disorder and CHD or 
hypertension were removed from the control group: the rationale being that as the control 
group was smaller, it was important to remove the effect of bipolar disorder on risk factor 
profile and prescribing trends. The reciprocal was true when comparing individuals with 
CHD or hypertension and bipolar disorder and individuals with CHD or hypertension 
without bipolar disorder- individuals with schizophrenia were removed from the analysis.  
For risk factor profile, rates of current smoking, uncontrolled blood pressure (defined as 
did not achieve target BP: where systolic BP ≥ 140mmHg and diastolic BP ≥ 90mmHg in 
individuals aged < 80 and systolic BP ≥ 150mmHg and diastolic BP ≥ 90mmHg in 
individuals aged 80 and over) and uncontrolled cholesterol (defined as ≥ 5mmoll-1) were 
compared across groups. Differences in prescribing between groups were analysed by 
comparing the percentage of patients on aspirin/clopidogrel (for CHD only), a statin and an 
anti-hypertensive agent. Antihypertensive agent was defined as any angiotensin-converting 
enzyme inhibitor (ACE-I) (all drugs in the BNF issue 51 Chapter 2.5.5.1), any angiotensin 
II receptor blocker (ARB) (all drugs in BNF chapter 2.2.2.2), any beta blocker (all drugs in 
BNF Chapter 2.4), any calcium channel blocker (any drug in BNF chapter 2.6.2), any 
alpha blocker (all drugs in BNF chapter 2.5.4), spironolactone (selected drugs from BNF 
Chapter 2.2.3) and any other anti-hypertensive not otherwise classified (all drugs in BNF 
Chapter 2.5.1, 2.5.2, 2.5.3 or 2.5.4 not previously counted). To ensure only current 
prescriptions were captured, prescribing data from the 84 days prior to the date that the 
dataset was obtained were included.  
4.4 Results: 
4.4.1 Main Findings  
9,677 individuals with schizophrenia (0.7% of the entire sample) and 1,414,701 controls 
were identified (Table 4-1).  Individuals with schizophrenia were more likely to be male 
compared to controls (51.3% vs. 49.1%; p<0.001) and tended to be older than controls 
(mean age 51.6 years vs. 48.0 years in control; p<0.001). Individuals with schizophrenia 
80 
 
were more socially deprived: with 23.3% living in the most deprived quintile compared to 
17.8% of controls (p<0.001) (Table 4-1). 
For the bipolar disorder group, 2,582 individuals (0.2% of the entire sample) and 1,421,796 
controls were identified (Table 4-1). Individuals with bipolar disorder were less likely to be 
male compared to controls (39.5% vs. 49.1%; p<0.001) and were older than controls (mean 
age 54.5 years vs. 48.0 years in controls; p<0.001). Similarly to individuals with 
schizophrenia, individuals with bipolar disorder were more socially deprived: with 17.9% 
living in the most deprived quintile compared to 15.7% of controls (p=0.003) (Table 4-1). 
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Table 4-1 Age, gender and deprivation score, schizophrenia versus controls and bipolar disorder versus controls. 
Bold if significant (p<0.001) difference between groups Adjusted for age, sex and deprivation status
 Schizophrenia vs. Controls  Bipolar Disorder vs. Controls  
 
 Schizophrenia 
n=9,677 
Controls 
n=1,414,701   
p value Bipolar Disorder 
n=2,582        
Controls 
n= 1,421,796       
p value 
Male n, % 
 
4,961           (51.27) 694,468      (49.09)     <0.001 1,021     (39.54) 698,408     (49.12) <0.001 
Mean Age, sd 
 
51.58     (16.54) 47.97        (18.25) <0.001 54.46     (15.28) 47.98     (18.25) <0.001 
Age Group 
<25 
25-34 
35-44 
45-54 
55-64 
65+ 
 
298           (3.08)     
1,216        (12.57) 
2,140        (22.11)                  
2,079        (21.48) 
1,771        (18.30)               
2,173        (22.46)   
 
151,395       (10.70)        
228,180       (16.13)      
276,853       (19.57) 
251,715       (17.79) 
217,562       (15.38)                      
288,996       (20.43) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
45     (1.74)         
217     (8.40)        
445      (17.23)        
626      (24.24)       
547     (21.19)        
702     (27.19)       
 
151,648      (10.67)        
229,179     (16.12)       
278,548     (19.59)        
253,168     (17.81)        
218,786     (15.39)        
290,467     (20.43)       
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Deprivation Status 
Least deprived-1 
2 
3 
4 
Most deprived 5 
 
1,260          (13.02) 
1,714          (17.71) 
2,263          (23.39) 
2,190          (22.63) 
2,250          (23.25) 
 
270,769     (19.14) 
302,440     (21.38) 
319,984     (22.62) 
269,194     (19.03) 
252,314     (17.84) 
 
<0.001 
<0.001 
0.073 
<0.001 
<0.001 
 
513       (19.87)        
570       (22.08)        
581      (22.50)        
514      (19.91)        
404     (15.65) 
 
 
271,516     (19.10)        
303,584     (21.35)        
321,666     (22.62)        
270,870     (19.05)        
254,160     (17.88) 
 
0.316 
0.374 
0.906 
0.270 
0.003 
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Recorded physical health comorbidities were significantly more common in 
individuals with schizophrenia, even after adjusting for age, gender and deprivation. 
Compared to individuals without schizophrenia, individuals with schizophrenia were 
significantly less likely to have no recorded comorbidity (OR 0.61, 95% CI 0.58-0.64) 
and significantly more likely to have one comorbidity (OR 1.22, 95% CI 1.16-1.28), 
two comorbidities (OR 1.37, 95% CI 1.29-1.45) and three or more comorbidities (OR 
1.19, 95% CI 1.13-1.27) (Table 4-2). 
A similar pattern was seen for the individuals with bipolar disorder, who compared to 
individuals without bipolar disorder were: significantly less likely to have no recorded 
comorbidity (OR 0.54, 95% CI 0.49-0.59) and significantly more likely to have one 
comorbidity (OR 1.25, 95% CI 1.44-1.36), two comorbidities (OR 1.34, 95% CI 1.20-
1.49) and three or more comorbidities (OR 1.31, 95% CI 1.18-1.46) (Table 4-2). 
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 Schizophrenia vs. Controls  Bipolar Disorder vs. Controls  
 
 
 
Schizophrenia 
 
n                  (%) 
Controls 
 
n                       (%) 
Odds 
Ratio 
95% 
Confidence 
Interval 
p value Bipolar Disorder 
n                  % 
Controls 
 
n                      % 
Odds 
Ratio 
95% 
Confidence 
Interval 
p value 
 
No comorbidity 
 
4,069      (2.05) 796,039    (56.27) 0.61 0.58-0.64 <0.001 929   (35.98) 799,179 (56.21) 0.54 0.49-0.59 <0.001 
 
1 comorbidities 
 
2,363    (24.42) 290,950    (20.57) 1.22 1.16- 1.28 <0.001 662  (25.64) 292,651 (20.58) 1.25 1.14- 1.36 <0.001 
 
2 comorbidities 
 
1,493    (15.43) 148,231    (10.48) 1.37 1.29- 1.45 <0.001 427 (16.54) 149,297 (10.50) 1.34 1.20-1.49 <0.001 
 
3 comorbidities 
 
1,752    (18.10) 179,481    (12.69) 1.19 1.13- 1.27 <0.001 564  (21.84) 180,669 (12.71) 1.31 1.18- 1.46 <0.001 
Table 4-2 Odds Ratios of No, 1, 2 and 3 Comorbidities in Schizophrenia vs. Controls and Bipolar Disorder vs. Controls. Controlled for age, 
sex and deprivation  
Bold if significant (p<0.001) difference between groups Adjusted for age, sex and deprivation status 
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For each of the thirty two individual physical health conditions assessed, the reported 
prevalence was significantly higher in individuals with schizophrenia for sixteen 
conditions including: viral hepatitis, constipation, Parkinson’s disease, epilepsy, 
dyspepsia, liver disease, Irritable Bowel Syndrome (IBS), Diabetes, blindness, thyroid 
disease, chronic pain, psoriasis/eczema, bronchitis/COPD, migraine, asthma and 
hearing loss. Reported prevalence was lower for six conditions including: atrial 
fibrillation (AF), hypertension, coronary heart disease (CHD), cancer, peripheral 
vascular disease (PVD) and rheumatoid arthritis (RA). (Tables 4-3 and 4-4 and Figure 
4-1).  
Similarly for individuals with bipolar disorder fourteen conditions were reported more 
prevalently including: viral hepatitis, constipation, Parkinson’s disease, thyroid 
disease, CKD, epilepsy, multiple sclerosis (MS), chronic pain, psoriasis/eczema, 
prostate disease, IBS, bronchitis/COPD, dyspepsia and Diabetes. The reported 
prevalence was lower for four chronic conditions including: AF, glaucoma, 
hypertension and CHD. (Tables 4-3 and 4-4 and Figure 4-1).   
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  Schizophrenia  
(n, %) 
Controls   
(n ,%) 
Bipolar Disorder 
(n, %) 
Controls  
(n, %) 
Atrial Fibrillation (AF) 137      (1.42) 23,839        (1.69)   39 (1.51) 23,937 (1.68) 
Hypertension 1,551      (16.03) 232,763   (16.45)    462  (17.89) 233,852 (16.45) 
Coronary Heart Disease (CHD) 579       (5.98) 80,888        (5.72) 170   (6.58) 81,297 (5.72) 
Cancer 288  (2.98) 43,376        (3.07) 115      (4.45) 43,549 (3.06) 
Peripheral Vascular Disease 
(PVD) 
167  (1.73) 23,073        (1.63)    59      (2.29) 23,181 (1.63) 
Rheumatoid Arthritis (RA) 389 (4.02) 57,619        (4.07) 119    (4.61) 57,889 (4.07) 
Prostate Disease 114 (1.18) 15,119        (1.07)   46        (1.78) 15,187  (1.07) 
Glaucoma 123  (1.27)    15,796        (1.12)   28  (1.08) 15,891 (1.12) 
Multiple Sclerosis (MS)   23 (0.24) 3,824          (0.27) 16        (0.62) 3,831 (0.27) 
Chronic Kidney Disease (CKD)   291 (3.01) 33,275        (2.35) 189       (7.32) 33,377  (2.35) 
Diverticular Disease 283 (2.92) 33,530        (2.37)   89      (3.45) 33,724 (2.37) 
Bronchiectasis 23   (0.24)   2,791        (0.20) 5       (0.19) 2,809 ( 0.20) 
Crohn’s Disease 71  (0.73) 9,680          (0.68) 27          (1.05) 9,724 (0.68) 
Stroke 350  (3.62) 36,195        (2.56)   89      (3.45) 36,456 (2.56) 
Sinusitis 69  (0.71) 9,096          (0.64)   17      (0.66) 9,148 (0.64) 
Heart Failure 196 (2.03) 18,703        (1.32) 47     (1.82) 18,852 (1.33) 
Hearing Loss 495  (5.12) 54,239        (3.83)   134    (5.19) 54,600 (3.84) 
Asthma 696 (7.19)   83,809        (5.92) 179      (6.93) 84,326 (5.93) 
Migraine 79 (0.82) 9,172          (0.65) 18     (0.70) 9,233 (0.65) 
Bronchitis/Chronic Obstructive 
Pulmonary Disease (COPD) 
577  (5.96) 52,530        (3.71) 169       (6.55) 52,938   (3.72) 
Psoriasis or Eczema 101  (1.04) 10,268        (0.73) 31        (1.20) 10,338  (0.73) 
Pain 1,332      (13.76) 124,799     (8.82)    451      (17.47) 125,680  (8.84) 
Thyroid Disease 738  (7.63) 71,205        (5.03)   376     (14.56) 71,567  (5.03) 
Blindness 104  (1.07)   8,274        (0.58) 30        (1.16) 8,348 (0.59) 
Diabetes 870  (8.99) 73,961        (5.23)   218       (8.44) 74,613 (5.25) 
Irritable Bowel Syndrome (IBS) 540   (5.58) 51,597        (3.65) 148      (5.73) 51,989 (3.66) 
Liver Disease 36   (0.37) 2,578          (0.18) 6          (0.23) 2,608 (0.18) 
Dyspepsia 1,106      (11.43) 78,098        (5.52) 237        (9.18) 78,967 (5.55) 
Epilepsy 213 (2.20) 12,171        (0.86) 47       (1.82) 12,337 (0.87) 
Parkinson’s Disease 73  (0.75) 2,668          (0.19)    19        (0.74) 2,722   (0.19) 
Constipation 873 (9.02) 35,543        (2.51) 249       (9.64) 36,167   (2.54) 
Viral Hepatitis  33  (0.34) 1,142          (0.08)   10        (0.39) 1,165   (0.08) 
Table 4-3 Percentage reported prevalence of the 32 Common Physical Conditions 
in Schizophrenia Compared to Controls and Bipolar Disorder Compared to Controls 
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 Schizophrenia vs. Controls  Bipolar Disorder vs. Controls  
  Odds 
Ratio 
95% Confidence 
Interval 
p value Odds 
Ratio 
95% Confidence 
Interval  
p value 
Atrial Fibrillation (AF) 0.62 0.52-0.73 <0.001 0.56 0.41-0.78 <0.001 
Hypertension 0.71 0.67-0.76 <0.001 0.69 0.62- 0.77 <0.001 
Coronary Heart Disease (CHD) 0.76 0.69- 0.83 <0.001 0.77 0.66-0.91 0.002 
Cancer 0.81 0.72-0.92 0.001 1.09 0.90- 1.32 0.38 
Peripheral Vascular Disease 
(PVD) 
0.83 0.72- 0.97 0.021 1.03 0.80 -1.34 0.81 
Rheumatoid Arthritis  (RA) 0.83 0.75- 0.92 <0.001 0.85 0.71-1.03 0.1 
Prostate Disease 0.86 0.71- 1.04 0.11 1.44 1.07-1.94 0.02 
Glaucoma 0.88 0.73-1.05 0.15 0.63 0.43-0.92 0.02 
Multiple Sclerosis (MS) 0.89 0.59-1.34 0.564 2.02 1.23- 3.31 0.005 
Chronic Kidney Disease (CKD) 0.96 0.85-1.08 0.484 2.12 1.81-2.48 <0.001 
Diverticular Disease 0.97 0.86- 1.09 0.605 0.94 0.76-1.17 0.59 
Bronchiectasis 1.00 0.66- 1.51 0.992   0.71 0.30-1.72 0.45 
Crohn’s Disease 1.03 0.81 - 1.30 0.803 1.38 0.94-2.01 0.1 
Stroke 1.08 0.96- 1.20 0.196 0.89 0.72- 1.11 0.29 
Sinusitis 1.10 0.87-1.40 0.422 0.92 0.57- 1.48 0.72 
Heart Failure 1.15 1.00-1.33 0.057 0.90 0.67-1.21 0.48 
Hearing Loss 1.14 1.04- 1.26 0.004 1.06 0.89- 1.27 0.49 
Asthma 1.22 1.13-1.31 <0.001 1.13 0.97- 1.32 0.111 
Migraine 1.28 1.02- 1.60 0.031 0.94 0.59-  1.50 0.8 
Bronchitis/Chronic Obstructive 
Pulmonary Disease (COPD) 
1.31 1.20- 1.43 <0.001 1.38 1.18-1.62 <0.001 
Psoriasis or Eczema 1.35 1.11-1.64 0.003 1.56 1.09-2.22 0.02 
Pain 1.39 1.30- 1.47 <0.001 1.72 1.55- 1.91 <0.001 
Thyroid Disease 1.43 1.32- 1.55 <0.001 2.40 2.14- 2.70 <0.001 
Blindness 1.44 1.18- 1.75 <0.001 1.35 0.94-1.94 0.1 
Diabetes 1.49 1.39- 1.61 <0.001 1.30 1.13- 1.50 <0.001 
Irritable Bowel Syndrome (IBS) 1.58 1.45-1.72 <0.001 1.41 1.19- 1.66 <0.001 
Liver Disease 1.67 1.20-2.32 0.002 1.18 0.53- 2.62 0.69 
Dyspepsia 1.93 1.81- 2.06 <0.001 1.35 1.18- 1.55 <0.001 
Epilepsy 2.42 2.11-2.77 <0.001 2.05 1.53- 2.7 <0.001 
Parkinson’s Disease 3.07 2.43-3.89 <0.001 2.52 1.60-3.97 <0.001 
Constipation 3.24 3.01 -3.49 <0.001 2.84 2.47-3.26 <0.001 
Viral Hepatitis 3.99 2.82-5.64 <0.001 5.90 3.16- 11.03 <0.001 
Table 4-4 Odds Ratios of the 32 Common Physical Conditions in Schizophrenia 
Compared to Controls and Bipolar Disorder Compared to Controls 
Italic- statistically less prevalent, normal font- no difference, bold statistically more 
prevalent Adjusted for age, sex and deprivation 
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 Figure 4-1 ORs for physical health comorbidities: Schizophrenia vs. Controls & Bipolar Disorder vs. Controls. Adjusted for age, gender & deprivation status. 
 Odds Ratio Schizophrenia vs. Controls 
 
 Odds Ratio Schizophrenia vs. Controls 
 
Odds Ratio Bipolar Disorder vs. Controls  
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The most recorded chronic physical health conditions in both individuals with 
schizophrenia and bipolar disorder were: viral hepatitis (OR 3.90 95% CI 2.82-5.64 
and OR 5.90 95% CI 3.16-11.03 respectively), constipation (OR 3.24 95% CI 3.01-
3.49 and OR 2.84 95% CI 2.47-3.26 respectively) and Parkinson’s disease (OR 3.07 
95% CI 2.43-3.89 and OR 2.52 95% CI 1.60-3.97 respectively) (Table 4-4).  
Both groups had higher recorded rates of other chronic health conditions including: 
diabetes (9.0% vs. 5.2% p<0.001 and 8.4% vs. 5.3% p<0.001), bronchitis/COPD 
(6.0% vs. 3.7%, p<0.001 and 6.6% vs. 3.7%, p<0.001) and chronic pain (13.8% vs. 
8.8%, p<0.001 and 17.5% vs. 8.8%, p=0.001). For individuals with bipolar disorder, 
Chronic Kidney Disease (CKD) was recorded much more frequently compared to 
controls (7.3% vs. 2.4%, p<0.001) (Table 4-3).  
For the six conditions in which the relative reported prevalence in individuals with 
schizophrenia was lower, four were cardiovascular-related: AF (OR 0.62 95% CI 
0.52-0.73), hypertension (OR 0.71 95% CI 0.67-0.76), CHD (OR 0.76 95% CI 0.69-
0.83) and peripheral vascular disease (PVD) (OR 0.83 95% CI 0.72-0.97). Similarly 
in bipolar disorder of the four conditions where the relative reported prevalence was 
lower, three were cardiovascular-related: namely AF (OR 0.56 95% CI 0.41-0.78), 
hypertension (OR 0.69 95% CI 0.62-0.77) and CHD (OR 0.77 95% CI 0.66-0.91) 
(Table 4-3).   
4.4.2 Gender Differences: 
Differences between men and women with schizophrenia and bipolar disorder in 
terms of the number of recorded physical health comorbidities as well as age and 
deprivation status were assessed.  
In the both groups on average women were older than men (55.6 vs. 47.8 years, 
p<0.001 schizophrenia group and 55.8 vs. 52.4 years, p<0.001 bipolar disorder 
group).  
Recorded physical comorbidity was particularly common in women with 
schizophrenia, with over two thirds of women having at least one recorded comorbid 
physical condition, compared to half of men (Table 4-5). Women with schizophrenia 
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were significantly more likely to have two and three or more recorded physical health 
conditions than men with schizophrenia (18.1% vs. 12.9%, p<0.001 for two physical 
health conditions and 23.9% vs. 12.6%, p<0.001 for three or more physical health 
conditions) (Table 4-5).  
Recorded physical comorbidity was also common in the bipolar disorder group, with 
over half of men and women having at least one recorded comorbid physical 
condition (Table 4-5). Women with bipolar disorder were significantly more likely to 
have three or more physical conditions recorded than men with bipolar disorder 
(25.0% vs. 17.0%, p<0.001) (Table 4-5).  
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Table 4-5 Differences between men and women with schizophrenia and bipolar disorder Bold if significant (p<0.001) difference between groups 
Adjusted for age, sex and deprivation status
 Schizophrenia Group Bipolar Disorder Group 
 
 Male Female 
 
 Male Female  
Number, (%) 
 
4,961  (51.27) 4,716  (48.73)  1,021  (39.54) 1,561  (60.46)  
Mean Age, sd 
 
47.78  (15.17) 55.59  (16.97) Diff 7.80  
(95%CI 7.16 to 8.44) 
p<0.001 
52.43  (15.08) 55.79  (15.28) Diff 3.36  
(95% CI 2.16 to 4.56) 
p=<0.001 
Deprivation Mean  0.77  (3.53) 0.29  (3.36) Diff -0.48  
(95% CI -0.62 to -0.34) 
p<0.001 
-0.40  (3.2) -0.25  (3.33) Diff 0.15 
(95% CI -0.11 to 0.40) 
p=0.2687 
Age Group (n,%) 
<25 
25-34 
35-44 
45-54 
55-64 
65+ 
 
196  (3.95) 
816  (16.45) 
1,275  (25.70) 
1,111  (22.39) 
836  (16.85) 
727  (14.65) 
 
102  (2.16) 
400  (8.48) 
865  (18.34) 
968  (20.53) 
935  (19.83) 
1,446  (30.66) 
 
p<0.001 
p<0.001 
p<0.001 
p=0.025 
p<0.001 
p<0.001 
 
20  (1.96) 
111  (10.87) 
195  (19.10) 
253  (24.78) 
214  (20.96) 
228  (22.33) 
 
25  (1.6) 
106  (6.79) 
250  (16.02) 
373  (23.89) 
333  (21.33) 
474  (30.37) 
 
p=0.498 
p<0.001 
p<0.001 
p=0.608 
p=0.821 
p<0.001 
 
Deprivation Status (n,%) 
Least deprived-1 
2 
3 
4 
Most deprived 5 
 
582  (11.73) 
852  (17.17) 
1,117  (22.52) 
1,130  (22.78) 
1,280  (25.80) 
 
678  (14.38) 
862  (18.28) 
1,146  (24.30) 
1,060  (22.48) 
970  (20.57) 
 
p<0.001 
p=0.155 
p=0.038 
p=0.723 
p<0.001 
 
207  (20.27) 
228  (22.33) 
230  (22.53) 
213  (20.86) 
143  (14.01) 
 
306  (19.60) 
342  (21.91) 
351  (22.49) 
301  (19.28) 
261  (16.72) 
 
p=0.676 
p=0.846 
p=0.980 
p=0.326 
p=0.063 
Multimorbidity (n,%) 
None 
1 
2 
3 or more 
 
2,492  (50.23) 
1,208  (24.35) 
638  (12.86) 
623  (12.56) 
 
1,577  (33.44) 
1,155  (24.49) 
855  (18.13) 
1,129  (23.94) 
 
p<0.001 
p=0.872 
p<0.001 
p<0.001 
 
430  (42.12) 
263  (25.76) 
154  (15.08) 
174  (17.04) 
 
499  (31.97) 
399  (25.56) 
273  (17.49) 
390  (24.98) 
 
p<0.001 
p=0.910 
p=0.0108 
p<0.001 
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4.4.3 Risk factor and prescribing differences  
4.4.3.1  Coronary Heart Disease (CHD)  
579 individuals with recorded comorbid schizophrenia and CHD, 170 individuals 
with recorded comorbid bipolar disorder and CHD and 80,718 individuals with 
recorded CHD without schizophrenia or bipolar disorder were identified. Mean age of 
individuals with recorded comorbid schizophrenia and CHD and recorded comorbid 
bipolar disorder and CHD was lower than the mean age of individuals with recorded 
CHD only (69.3 years vs. 71.4 years, p<0.001 and 68.8 years vs. 71.4 years, p=0.002 
respectively). Rate of smoking was higher in individuals with recorded schizophrenia 
and CHD (OR 1.92 95% CI 1.59-2.31, p<0.001) and in individuals with recorded 
bipolar disorder and CHD (OR 1.74 95% CI 1.24-2.45, p<0.002) compared to 
individuals with recorded CHD without MMI. Rates of recording of uncontrolled 
blood pressure and cholesterol were similar (Table 4-6).  
There was no difference in rates of prescribing of aspirin or clopidogrel between 
individuals with recorded comorbid schizophrenia and CHD, individuals with 
recorded comorbid CHD and bipolar disorder and individuals with recorded CHD 
without MMI. Rate of prescribing of statins for individuals with recorded 
schizophrenia and CHD occurred significantly less frequently than in individuals with 
recorded CHD without MMI (OR 0.67 95% CI 0.56-0.80, p<0.001). Although 
prescribing of statins, tended to occur less frequently in individuals with recorded 
comorbid bipolar disorder and CHD compared to individuals with recorded CHD 
without MMI, the difference did not reach statistical significance (OR 0.72 95% CI 
0.52-1.10, p=0.059) (Table 4-6). 
Rates of prescribing of no anti-hypertensive were higher in individuals with recorded 
CHD and schizophrenia and recorded CHD and bipolar disorder compared to 
individuals with recorded CHD without MMI, when adjusted for age, sex and 
deprivation (OR 1.98 95% CI 1.63-2.40, p<0.001 and OR 2.53 95% CI 1.81-3.54, 
p<0.001 respectively). Rates of prescribing of 2 or more anti-hypertensives were 
lower in individuals with recorded CHD and schizophrenia and recorded CHD and 
bipolar disorder compared to individuals with recorded CHD without MMI, again 
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when adjusted for age, sex and deprivation (OR 0.66 95% CI 0.56-0.78, p<0.001 and 
OR 0.55 95% CI 0.46-0.67, p<0.001 respectively (Table 4-6).
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Table 4-6 Differences between individuals with CHD & schizophrenia, Bipolar Disorder & CHD and individuals with CHD without MMI 
ORs adjusted for Age, Sex and Socioeconomic Deprivation Status, Bold if significant. 
 Schizophrenia & 
CHD 
(n=579) 
CHD no MMI 
(n=80,718) 
Odds Ratio  
(95% CI) 
p value Bipolar Disorder 
& CHD 
(n=170) 
CHD no MMI 
(n=80,718) 
Odds Ratio  
(95% CI) 
p value 
Male n, % 
 
288 (49.7) 46,101 (57.1)  <0.001 84 (49.4) 46,101 (57.1)  0.043 
Mean Age, sd 
 
69.3 (0.52) 71.4 (0.04)  <0.001 68.8 (0.87) 71.4 (0.04) 
 
0.002 
Smoking 204 (35.2) 16,809 (20.8) 1.92 
(1.59-2.31) 
<0.001 55 (32.3) 16,809 (20.8) 1.74 
(1.24-2.45) 
0.002 
Mean Carstairs Score, sd 
 
0.19 (0.15) 0.07 (0.01) 
 
0.3825 -0.38 (0.24) 0.07 (0.01) 
 
0.073 
Cholesterol  >5 mmoll
-1
 123 (24.6) 
(n=501) 
15,683 (19.4) 
(n=73,034) 
1.11 
(0.90-1.36) 
0.326 32 (18.8) 15,683 (19.4) 0.93 
(0.63-1.38) 
0.720 
Uncontrolled BP 27 (4.7) 3,927 (4.9) 0.92 
(0.62-1.366) 
0.673 7 (4.1) 3,927 (4.9) 0.80 
(0.37-1.71) 
0.563 
Aspirin/clopidogrel 435 (75.1) 59,275 (73.4) 1.09 
(0.90-1.32) 
0.359 119 (70.0) 59,275 (73.4) 0.85 
(0.62-1.19) 
0.350 
Statin 393 (67.9) 60,364 (74.8) 0.67 
(0.56-0.80) 
<0.001 119 (70.0) 60,364 (74.8) 0.72 
(0.52-1.01) 
0.059 
No Antihypertensive 135 (23.3) 10,877 (13.5) 1.98 
(1.63-2.40) 
<0.001 48 (28.2) 10,772 (13.3) 2.53 
(1.81-3.54) 
<0.001 
1 Antihypertensive 155 (26.8) 21,294 (26.4) 1.01 
(0.84-1.21) 
0.953 50 (29.4) 21,294 (26.4) 1.14 
(0.82-1.58) 
0.444 
2 or more 
Antihypertensive 
289 (49.9) 48,547 (60.1) 0.66 
(0.56-0.78) 
<0.001 72 (42.4) 48,547 (60.1) 0.49 
(0.36-0.67) 
<0.001 
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4.4.3.2 Hypertension  
1,551 individuals with recorded comorbid schizophrenia and hypertension, 462 
individuals with recorded comorbid bipolar disorder and hypertension and 232,301 
individuals with recorded hypertension without MMI were identified. There was no 
difference in mean age of individuals with recorded schizophrenia and hypertension 
or recorded bipolar disorder and hypertension compared to the mean age of 
individuals with recorded hypertension without MMI (66.0 years vs. 66.9 years, 
p=0.005 and 65.5 years vs. 66.9 years, p=0.016 respectively) (Table 4-7). Rate of 
smoking was higher in individuals with recorded schizophrenia and hypertension and 
recorded bipolar disorder and hypertension (OR 1.80 95% CI 1.60-2.02, p<0.001 and 
OR 2.04 95% CI 1.66-2.50, p<0.001 respectively). Rates of uncontrolled blood 
pressure were similar between the three groups (Table 4-7).  
There was no difference in rates of prescribing of statins between individuals with 
recorded schizophrenia or bipolar disorder and hypertension and individuals with 
recorded hypertension without MMI. Rates of prescribing of no anti-hypertensive 
were higher in individuals with recorded hypertension and schizophrenia and recorded 
hypertension and bipolar disorder compared to individuals with recorded hypertension 
without MMI, when adjusted for age, sex and deprivation (OR 1.60 95% CI 1.41-
1.82, p<0.001 and OR 1.59 95%CI 1.26-2.01, p<0.001 respectively).  Rates of 
prescribing of two or more anti-hypertensives were lower in individuals with recorded 
hypertension and schizophrenia and recorded hypertension and bipolar disorder 
compared to individuals with recorded hypertension without MMI, when adjusted for 
age, sex and deprivation (OR 0.71 95% CI 0.64-0.78, p<0.001 and OR 0.55 95% CI 
0.46-0.67, p<0.001 respectively) (Table 4-7). 
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Table 4-7 Differences in individuals with Hypertension and Schizophrenia, Hypertension and Bipolar Disorder and individuals with Hypertension 
without MMI 
Odds ratios adjusted for Age, Sex and Socioeconomic Deprivation Status. Bold if significant 
 Schizophrenia & 
Hypertension 
(n=1,551) 
Hypertension 
no MMI 
(n=232,301) 
Odds Ratio  
(95% CI) 
p value Bipolar Disorder 
& Hypertension 
(n=462) 
Hypertension 
no MMI 
(n=232,301) 
Odds Ratio  
(95% CI) 
p value 
Male n, % 
 
581 (37.5) 102,713 (44.2)  <0.001 168 (36.4) 102,713 (44.2)  0.0007 
Mean Age, sd 
 
66.0 (0.34) 66.9 (0.03)  0.0046 65.5 (0.55) 66.9 (0.03)  0.0156 
Smoking 433 (27.9) 39,755 (17.1) 1.80 
(1.60-2.02) 
<0.001 133 (28.8) 39,755   (44.2) 2.04 
(1.66-2.50) 
<0.001 
Mean Carstairs Score, sd 
 
0.18 (0.09) -0.22 (0.01) 
 
<0.001 -0.61 (0.14) -0.22 (0.01) 
 
0.009 
Uncontrolled BP 180 (11.6) 25,826 (11.1) 1.01  
(0.87-1.19) 
0.805 50 (10.8) 25,826 (11.1) 0.94 
(0.70-1.27) 
0.704 
Statin 651 (42.0) 96,284 (41.4) 1.06 
(0.96-1.18) 
0.257 168 (36.4) 96,284 (41.4) 0.87 
(0.72-1.06) 
0.160 
No Antihypertensive 304 (19.6) 30,183 (13.0) 1.60 
(1.41-1.82) 
<0.001 91 (19.7) 30,183 (13.0) 1.59 
(1.26-2.01) 
<0.001 
1 Antihypertensive 504 (32.5) 70,089 (30.2) 1.10 
(0.99-1.23) 
0.073 180 (39.0) 70,089 (30.2) 1.44 
(1.19-1.74) 
<0.001 
2 or more 
Antihypertensive 
743 (47.9) 132,029 (56.8) 0.71 
(0.64-0.78) 
<0.001 191 (41.3) 132,029 (56.8) 0.55 
(0.46-0.67) 
<0.001 
 
 
4.5 Discussion: 
4.5.1 General Findings: 
In keeping with several other reports (Laursen et al., 2011; Crump et al., 2013; Carney et 
al., 2016; De Hert et al., 2011a) multiple physical health comorbidity was common in 
individuals with schizophrenia and bipolar disorder. Almost half (43.7%) of individuals 
with recorded schizophrenia had at least one recorded chronic physical comorbidity and 
one third had two or more. Almost two thirds (64.0%) of individuals with bipolar disorder 
had a least one recorded chronic physical health comorbidity. The finding of increased 
recorded comorbidity in individuals with bipolar disorder compared to individuals with 
schizophrenia has been reported elsewhere (Oreški et al., 2012), although in a small cohort 
(197 individuals with schizophrenia and 92 individuals with bipolar disorder). Our findings 
therefore added to the limited studies in this area.    
4.5.2 Specific Conditions: 
Three chronic physical health conditions were found to be particularly more commonly 
recorded in individuals with schizophrenia and bipolar disorder (viral hepatitis, 
constipation and Parkinson’s disease). High recording rates of epilepsy, chronic pain, IBS 
and dyspepsia in individuals with schizophrenia and bipolar disorder were also found. 
Individuals with schizophrenia and bipolar disorder often have higher rates of drug misuse 
compared to the general population (Tohen et al., 1998) and so may be at higher risk of 
viral hepatitis through drug taking behaviours. This may partly explain the higher recorded 
rates of viral hepatitis. Constipation is an important though often under-recognised side-
effect of antipsychotic medication (Nielsen and Meyer, 2012; De Hert et al., 2011b) and 
lithium treatment and was more commonly recorded in individuals with schizophrenia and 
bipolar disorder compared to controls. It is estimated that between 20 and 30% of all 
individuals taking antipsychotic medications will have constipation and so these findings 
may be an under-estimate. Recording of Parkinson’s disease (which included 
Parkinsonism) was also significantly more common in the schizophrenia and bipolar 
disorder groups than in controls. This may partially be explained by an increase in Read 
Codes of Parkinsonism due to extra-pyramidal side-effects of antipsychotic medication.   
Recorded rates of diabetes, chronic pain and bronchitis in individuals with bipolar disorder 
and schizophrenia were also found to be higher compared to controls even when 
controlling for age, sex and deprivation status. This is perhaps not unexpected, partly due 
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to the high rates of obesity and high rates of smoking that is often reported in individuals 
with bipolar disorder and schizophrenia (Myles et al., 2012). High recorded rates of 
chronic kidney disease (CKD) and thyroid disease were also found in the bipolar disorder 
cohort and may be partly as a consequence of known treatment side effects. For example 
lithium is known to cause both thyroid and renal dysfunction.  
4.5.3 Cardiovascular comorbidity: 
Of the six conditions which were recorded less frequently in individuals with 
schizophrenia four were for cardiovascular disorders: namely AF, hypertension, CHD and 
PVD. Similarly in the bipolar disorder cohort recorded rates of AF, hypertension and CHD 
were significantly lower compared to the control population. This was somewhat 
unexpected, especially in the context of several studies reporting high rates of 
cardiovascular morbidity and mortality in individuals with schizophrenia and bipolar 
disorder (Laursen et al., 2011; Crump et al., 2013).  
However a population-based study of administrative claims data in the United States had 
similar findings: they found that rates of hypertension and ischaemic heart disease were 
lower than expected in individuals with schizophrenia compared to controls (Carney et al., 
2006). Similarly, a recent meta-analysis of prescribing data for individuals with and 
without major mental illness (including schizophrenia) found that individuals with severe 
mental illness had lower than expected rates of being prescribed medications for 
cardiovascular disease (Mitchell et al., 2012). Furthermore, in a recent Swedish national 
cohort study, although individuals with schizophrenia were more likely to die prematurely 
than the general population and the leading causes of death were cardiovascular disease 
and cancer, rates of recording of cardiovascular disease and cancer were not particularly 
elevated in individuals with schizophrenia (Crump et al., 2013). This was despite an 
increase in healthcare system contacts, suggesting that cardiovascular disease and cancer 
were significantly under-diagnosed and/or under-recorded in this population. This may 
also be true for the SPICE cohort and may partly explain the findings.  
However there may be several other possible explanations for these findings. Although 
rates of consultation in individuals with MMI are generally comparable to the general 
population (Dickerson et al., 2003) information on number of healthcare contacts was not 
available for this dataset. It is possible that in this cohort, individuals with schizophrenia or 
bipolar disorder may not consult their GP as frequently as the general population, due to an 
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expectation that their physical health needs will be met by their community mental health 
team (CMHT). Some individuals may also have low awareness of symptoms of cardiac or 
vascular disease and so may not present to their GP, leading to under-recording and under-
diagnosis of physical health problems (De Hert, 2011c).  
It is also possible that relatively asymptomatic conditions such as hypertension and AF are 
less likely to be identified than constipation, IBS, Parkinson’s disease, dyspepsia and 
epilepsy and this too may partly explain these findings. It is also possible that, even when 
these individuals attend, GPs may not be assessing and/or recording cardiac problems as 
often as they might (Mackell et al., 2005). It has been recognised that individuals with 
mental illness and comorbid physical health problems do not receive the same level of 
assessment and treatment for their physical problems as individuals without mental illness 
(Thornicroft et al., 2009; Druss et al., 2001). There is also the additional difficulty of 
diagnostic over-shadowing- whereby symptoms of physical illnesses may be attributed to 
the individual’s mental illness (Nash, 2013). These factors may all contribute to the lower 
than expected recording rates of AF, hypertension and CHD in this cohort.    
Hypertension was the most commonly recorded comorbidity in individuals with 
schizophrenia and bipolar disorder, but it was significantly less commonly recorded than in 
the control group. This may be due to the use of antihypertensive agents for symptoms 
such as anxiety or akathisia in individuals with schizophrenia and bipolar disorder or the 
hypotensive effect of some antipsychotic medications. However it may also be due to the 
occurrence of less frequent monitoring of blood pressure (BP) in primary care for 
individuals with schizophrenia and bipolar disorder relative to controls. This would be of 
concern given the NICE guidelines which recommend BP monitoring for individuals with 
schizophrenia who are prescribed antipsychotic medication (NICE Clinical Guideline 82, 
2009). 
4.5.4 Risk factors and Prescribing Differences: 
Rates of smoking in individuals with comorbid schizophrenia and hypertension, comorbid 
schizophrenia and CHD, comorbid bipolar disorder and hypertension and comorbid bipolar 
disorder and CHD were significantly higher than in individuals with hypertension and 
CHD without schizophrenia and bipolar disorder. The finding of high smoking rates in 
individuals with schizophrenia and bipolar disorder compared to the general population has 
been reported elsewhere (Myles et al., 2012). However this specific finding of higher 
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smoking rates in individuals with schizophrenia or bipolar disorder and comorbid physical 
health problems is of clinical concern given the adverse effects on health smoking is 
known to have.  
For the prescribing data, a significantly lower rate of statin prescribing in individuals with 
comorbid CHD and schizophrenia compared to individuals with CHD without 
schizophrenia and bipolar disorder was found. A trend towards lower rates of statin 
prescribing in individuals with comorbid CHD and bipolar disorder compared to 
individuals with CHD without schizophrenia and bipolar disorder was also found. This is 
of clinical significance as for individuals with CHD; statins are recommended for all 
individuals regardless of their pre-treatment cholesterol. Therefore a reduction in statin 
prescription is indicative of a missed opportunity to deliver a specific evidence based 
intervention.  
For individuals with CHD and schizophrenia and CHD and bipolar disorder, significantly 
higher rates of no anti-hypertensive prescription and significantly lower rates of two or 
more anti-hypertensives being prescribed were found; this potentially points towards less 
intensive treatment of blood pressure in individuals with schizophrenia and bipolar 
disorder. This finding of possible reduced intensity of treatment was replicated in the 
hypertensive cohort: where individuals with schizophrenia and hypertension and bipolar 
disorder and hypertension had higher rates of none and one anti-hypertensive being 
prescribed but lower rates of two or more anti-hypertensives being prescribed compared to 
individuals with hypertension without schizophrenia and bipolar disorder.   
The findings of disparities in prescribing patterns have been reported elsewhere (Mitchell 
et al., 2012) and possible reasons for this are complex, multifactorial and may arise at both 
a primary and secondary care level. GPs, who initiate most pharmacological treatments for 
cardiovascular disease, may not feel confident in managing potential drug interactions 
between psychotropic medications and pharmacological treatments for cardiovascular 
disease. Concerns about suicide risk and the potential toxicity of some of the anti-
hypertensive medications should they be taken in overdose may also contribute to over-
cautious prescribing.  
GPs may not feel confident in their interactions with individuals with MMI and so may be 
less likely to follow up individuals with comorbid MMI and physical health problems 
(Fleury et al., 2009). Physical health problems (such as hyperlipidaemia) may occur at a 
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young age in individuals with MMI, and GPs may be unsure about the necessity to treat 
given the current cardiovascular risk algorithms that are used to estimate cardiovascular 
risk. Cardiovascular risk in individuals with schizophrenia and bipolar disorder may be 
under-estimated by existing cardiovascular risk estimation tools (which include 
Framingham, ASSIGN and QRISK and are weighted heavily by age). These tools have not 
been validated in individuals with MMI (Holt, 2014) and so under-estimation of risk, may 
add to the difficulties of under-recognition and under-treatment of these conditions. 
Mental health professionals also may not be confident in prescribing medications for 
primary and secondary prevention and may not appropriately diagnose physical health 
problems in their patients (Koranyi 1979; Felker et al., 1996) potentially due to incomplete 
physical examinations (Koran et al., 1989).  
The issue of rates of attendance at GP appointments and outpatient clinics in order to 
initiate medications to treat physical illness in individuals with MMI is also unclear. Some 
studies report that individuals with MMI have a higher frequency of healthcare visits and 
so are more likely to experience guideline recommended care for their comorbid physical 
health condition (Kurdyak and Gnam, 2004) while other reports suggest that attendance at 
such appointments and concordance with treatment may be reduced. Nonetheless it is 
likely that adherence to the cardiovascular medications prescribed may be even less than 
this data suggests and so the disparity in health care provision may be even wider than is 
reported here.   
4.6 Strengths and limitations: 
Strengths include the large sample size and so it is likely to be representative of the wider 
Scottish population. The rate of a recorded diagnosis of schizophrenia or related psychotic 
disorder of 0.7% is similar to most estimates of the prevalence of schizophrenia of around 
1% (Saha et al., 2008). Estimates of the incidence and prevalence of schizophrenia varies 
widely by geographical location, largely due to differences in population characteristics 
and diagnostic assessment. However it is probable that some individuals with 
schizophrenia or a related psychotic disorder are known only to secondary care services 
(and so are not recorded within primary care) and therefore are not recorded in this dataset. 
It is also possible that a small additional proportion may not be in contact with either 
primary or secondary care and thus are missing from the study population. Both 
possibilities represent a limitation of this data.  
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The rate of a recorded diagnosis of bipolar disorder was 0.2%. Most estimates of the 
prevalence of bipolar disorder are 1% (Ferrari et al., 2011) and so this is lower than 
predicted. Possible reasons for this may include the under-diagnosis of bipolar disorder 
within primary care, which may potentially reflect the considerable debate and variation in 
the definition of this condition. As is the case with schizophrenia, it is also possible that 
some individuals with bipolar disorder are known only to secondary care services and are 
not recorded within primary care and additionally a small proportion may not be in contact 
with either primary or secondary care. Data from 314 primary care practices was included 
in the SPICE dataset and it is likely that there is variation in the diagnostic coding for 
bipolar disorder within the practices. Given the relatively low prevalence of bipolar 
disorder, in this sample, it is likely that the individuals included represent the more severe 
end of the bipolar spectrum. However it must also be acknowledged that the lower than 
expected rates of recording of Bipolar Disorder, may introduce a potential risk of bias, 
perhaps due to increased illness severity. It is also possible that a small number of 
individuals on lithium, may have been coded as Bipolar Disorder without the consideration 
of a diagnosis of possible treatment resistant depression. This may also be reflected in the 
increased recorded prevalence of Chronic Kidney Disease (CKD) in the Bipolar group.    
Within the Read Code definitions used, a number of individuals in the bipolar disorder 
group had a Read code of ‘severe/psychotic depression’. Severe or psychotic depression 
may be an early manifestation of bipolar disorder (Joseph et al., 2001) however psychotic 
features are present in a minority of cases of major unipolar depression (Johnston et al., 
1991). Due to limitations in the way data was extracted it was not possible to separate out 
the individuals with psychotic depression from the bipolar disorder group. However given 
that 11 out of the 13 Read Codes were for definite bipolar disorder diagnoses, it is 
estimated that the proportion of individuals in this sample with psychotic unipolar 
depression as opposed to bipolar disorder would have been very low. However this does 
represent a further limitation of this data. 
The data utilised, is routine primary care data from 314 practices and there is likely to be 
variability of diagnostic coding for the thirty two conditions of interest. While routine data 
is reflective of ‘real world’ practice, there are some limitations associated with this type of 
study. The use of primary care Read Codes to identify bipolar disorder, schizophrenia and 
a combination of Read Codes and where relevant prescribing data to identify the thirty two 
medical comorbidities also has limitations. While this method represents a balance 
between diagnostic accuracy and real-world representativeness, some of the Read Code 
 
 
102 
estimates for certain conditions may have been prone to bias: for example, higher recorded 
rates of thyroid disease for bipolar individuals may be related to more frequent 
venepuncture associated with medication (lithium) monitoring. It is also possible that in 
addition to the under-recognition and under-recording of cardiovascular disease in 
individuals with schizophrenia and bipolar disorder, some of the prevalence rates for the 
other physical health comorbidities included may be underestimates. This is a limitation of 
the design of the study in general, whereby Read Codes and/or prescribing data without 
confirmatory interviews were used to define diagnoses.  
4.7 Conclusions:  
Overall, these data suggest that individuals with schizophrenia and bipolar disorder in a 
Scottish Primary Care setting have high rates of recorded multiple comorbid physical 
health problems but lower rates of recording of certain cardiovascular diseases. The data 
also suggests that individuals with schizophrenia and bipolar disorder are less likely to 
have their cardiovascular illnesses treated as intensively as individuals without MMI. 
Further investigation of possible reasons for the differences in healthcare provision is 
required. Further training for GPs, Psychiatrists and Physicians to build confidence in 
prescribing and addressing the lifestyle risk factors of these individuals is recommended to 
ensure that a multidisciplinary focus on improving physical health investigation, diagnosis, 
treatment and monitoring occurs. This may then help to address the inequality in life 
expectancy experienced by individuals with MMI. 
Given the interaction between physical and mental health problems leading to prolonged 
hospitalisation, treatment failure, poor quality of life (de Hert, 2011a) and premature 
mortality, these findings highlight the need for an integrated approach to care (Leucht et 
al., 2007; Truyers et al., 2011). The current separation between specialist physical and 
mental health services, and between primary and secondary care services in the UK and in 
other countries, makes the care of the physical health of individuals with schizophrenia and 
bipolar disorder difficult to co-ordinate. This can lead to fragmented, disjointed care. 
Several reports have highlighted that more integrated services are needed but the best way 
to achieve this remains unclear (The Kings Fund, 2012: Department of Health, 2011: 
London School of Economics, 2012: Schizophrenia Commission, 2012).  
Integrated care, defined as the delivery of preventive and curative health services which 
vary according to the individual’s needs over time and across different levels of the 
 
 
103 
healthcare system, can be difficult to achieve. Given that cardiovascular risk assessment is 
acceptable to many people with psychosis (Osborn et al., 2003), potentially a more 
systematic use of such screening in both primary and secondary care may improve early 
detection and treatment of hypertension and CHD.  However further research is needed to 
evaluate the effectiveness of such approaches. 
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Chapter 5: Smoking Status, cessation advice and 
prescribing of Nicotine Replacement Therapy 
(NRT) in individuals with Major Mental Illness 
(MMI):  
Chapter Overview: 
This chapter uses the SPICE dataset to describe in detail recorded rates of current smoking, 
ex-smoking and non-smoking in individuals with: Major Mental Illness (MMI), individuals 
with MMI and comorbid diabetes, coronary heart disease (CHD) or hypertension and 
individuals with diabetes, coronary heart disease (CHD) or hypertension without MMI. 
Rates of current smoking, ex-smoking and non-smoking in individuals with bipolar 
disorder and schizophrenia are also compared. Within these groups, rates of recording of 
smoking cessation advice and prescribing of nicotine replacement therapy (NRT) are 
compared as a marker of potential inequality in access to healthcare advice and treatment.  
5.1 Background: 
As highlighted in Chapter 1, tobacco use remains the single leading cause of preventable 
disease and premature death in the world (WHO Report, 2011). Despite a considerable 
reduction in tobacco use in developed countries, over the past few decades it remains 
particularly common in individuals with MMI, with estimates that 70% of individuals with 
schizophrenia and 45% of individuals with bipolar disorder smoke compared to 20% of the 
general population (Myles et al., 2012). Additionally there is evidence that individuals with 
MMI smoke more cigarettes compared to the general population and individuals with 
schizophrenia extract more nicotine from each cigarette compared to the general 
population (Olincy et al., 1997). Given the fact that individuals with MMI have increased 
standardised mortality rates (SMR) compared to the general population (Hoang et al., 
2011; Wahlbeck et al., 2011; Laursen et al., 2011; Crump et al., 2013) and approximately 
two-thirds of this premature mortality is due to cardiovascular disease, smoking-related 
lung disease and type II diabetes (Tiihonen et al., 2009; Saha et al., 2007; Laursen et al., 
2007; Heila et al., 2005) strategies to improve the health of this cohort of individuals is 
imperative.   
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In the UK, where cigarette smoking accounts for over 100,000 deaths annually (Doll et al., 
2004), cessation of smoking is thought to be the single most important and cost effective 
method for improving an individual’s health and wellbeing (Peto et al., 2005). Primary 
care health professionals in particular have an important role in helping smokers stop 
smoking. Recording of smoking status is important as it is recognised that in cases where 
smoking is recorded prominently in medical records, physicians are more likely to address 
issues regarding smoking (Boyle et al., 2010). Moreover, brief advice against smoking is 
recognised as not only a simple intervention to deliver, but also as an effective intervention 
in promoting abstinence (Stead et al., 2008a).   
Prescribing of Nicotine Replacement Therapy (NRT) in the form of patches, lozenges, 
gum, tablets, nasal or mouth spray in primary care, is an important and effective lifestyle 
modification intervention which is known to increase the chance of smoking cessation 
compared to placebo or no NRT use (Stead et al., 2008b; Silagy et al., 2002). Anti-craving 
medications including varenicline and bupropion are also effective strategies in smoking 
cessation (Cahill et al., 2007) but their use is limited in individuals with a history of mental 
illness, due to the risk of mood disturbance and suicidal behaviour particularly with 
varenicline (BNF, 2014). Given the particularly high rates of smoking and high nicotine 
load in individuals with MMI, NRT may be particularly helpful in promoting abstinence.  
There is evidence to suggest that despite the increased physical health problems 
experienced by individuals with MMI, there are inequalities for both the access to and the 
quality of a range of physical healthcare services as detailed in Chapter 1. However it is 
unknown if these inequalities occur in either the recording of smoking cessation advice or 
in NRT prescribing trends within primary care in Scotland. These questions are therefore 
the focus of this chapter. 
5.2 Aims: 
1. To describe the rates of recording of smoking, ex-smoking and non-smoking in 
individuals with MMI compared to other chronic diseases (namely diabetes, coronary heart 
disease (CHD) and hypertension) in primary care.  
2. To determine whether rates of recording of smoking cessation advice in individuals with 
MMI differ from the rates of recording of smoking cessation advice in individuals with 
other chronic diseases (diabetes, CHD and hypertension).   
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3. To determine whether rates of Nicotine Replacement Therapy (NRT) prescription in 
individuals with MMI differ from the rates of NRT prescription in individuals with other 
chronic diseases (diabetes, CHD and hypertension).   
4. To determine if there are differences in: rates of smoking, ex-smoking and non-smoking, 
rates of recording of smoking cessation advice and rates of Nicotine Replacement Therapy 
(NRT) prescription in individuals with schizophrenia compared to bipolar disorder.    
5.3 Methodology: 
The dataset from the Scottish Primary Care Clinical Informatics Unit at the University Of 
Aberdeen (SPICE), detailed in Chapter 3 was used. As in the previous studies, individuals 
were identified as having Major Mental Illness (MMI) based on the recording ever of the 
schizophrenia and bipolar disorder Read Codes listed in Chapter 4.  
Individuals with diabetes, without MMI were identified from the Read Codes C10E.% and 
C10F.% (with C10F8 excluded). Individuals with coronary heart disease, without MMI 
were identified from Read codes G3... - G330z, G33z. - G3401, G342. - G366., G38.. – 
G3z..and Gyu3 and individuals with hypertension without MMI were identified using their 
appropriate Read Codes (G2..., G20..%, G24.. - G2z.. (Excluding G24z1)). Individuals 
with comorbid MMI and diabetes, comorbid MMI and CHD and comorbid MMI and 
hypertension were analysed as a separate group. Within the MMI cohort individuals with 
schizophrenia and bipolar disorder were compared as a separate analysis.  
As before, analyses of this data were restricted to individuals aged 18 and over and the 
sample was divided into the following age groups for analysis: <25, 25-34, 35-44, 45-54, 
55-64 and 65 and older. Deprivation status was measured using the Carstairs deprivation 
score. Rates of multimorbidity were also noted. Smoking status was coded as current 
smoker, ex-smoker or non-smoker using the Read Codes included in Appendix 3. Where 
tobacco consumption was unknown or not recorded, smoking status was coded as missing. 
Smoking cessation advice was coded as being given if the Read Codes included in 
Appendix 4 were recorded in the primary care record.  Prescription of NRT was coded if 
there was a recording of prescribing of NRT in the form of patches, gum, lozenges, 
inhalator or nasal spray included in an individual’s primary care record. These are detailed 
in Appendix 5. To ensure only current prescriptions were captured, prescribing data from 
the 84 days prior to the date that the dataset was obtained were included. 
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Logistic regression was used to calculate odds ratio (ORs) and 95% confidence intervals 
(CI) of smoking, ex-smoking and non-smoking in individuals with MMI with and without 
the comorbid chronic disease (diabetes, CHD and hypertension) compared to individuals 
with the chronic disease without MMI. Differences in individuals with MMI without the 
chronic disease, individuals with comorbid MMI and the chronic disease and individuals 
with the chronic disease without MMI were calculated by age, deprivation and number of 
physical health conditions. T tests were used to analyse differences between groups and 
Chi squared tests for differences across age groups and deprivation quintiles. Odds ratios 
(ORs) with 95% confidence intervals for recording of smoking cessation advice and NRT 
prescription for smokers with MMI with and without the chronic disease of note compared 
to individuals with the chronic disease without MMI were also calculated. Odds ratio 
calculations were adjusted for age, gender and deprivation.  
The analyses were then repeated comparing rates of smoking, ex-smoking and non-
smoking along with rates of recording of smoking cessation advice and NRT prescription 
in individuals with schizophrenia and bipolar disorder.    
5.4 Results:  
5.4.1 Rates of Smoking in MMI compared to the Controls 
From 1,426,670 individuals aged over 18: 12,259 individuals with MMI (0.9%) and 
1,414,411 individuals without MMI (99.1%) were identified. Recording of smoking status 
was available in the majority of cases, however missing data occurred significantly more 
frequently in individuals without MMI (controls) (10.0%) compared to individuals with 
MMI (3.8%) (Table 5-1). 
 MMI  
(n=12,259) 
Controls  
(n=1,414,411) 
Smoking recorded 11,788 (96.2) 1,272,289        (90.0) 
Missing data on smoking 471 (3.8) 142,122  (10.0) 
 Table 5-1 Rates of recording of smoking status in individuals with/without MMI  
Bold if significant (p<0.001)  
When smoking status was recorded, rates of smoking were higher in individuals with MMI 
compared to the individuals without MMI (47.5% vs. 27.0% p<0.001). Rates of ex-
smoking and non-smoking were significantly lower in individuals with MMI compared to 
individuals without MMI (18.8% vs. 21.4%, p<0.001 and 33.7% vs. 51.6%, p<0.001 
respectively) (Table 5-2).  
 
 
108 
The odds ratio for smoking, was higher in individuals with MMI (2.53 95% CI 2.44-2.63) 
compared to individuals without MMI and was particularly increased in men (2.83 95% CI 
2.68-2.98). Odds ratio for ex-smoking and non-smoking were lower for individuals with 
MMI compared to individuals without MMI (0.79 95% CI 0.75-0.83 and 0.50 95% CI 
0.48-0.52) (Table 5-2). 
 
 
 
 
 
 
Table 5-2 Odds Ratio of smoking, ex-smoking and non-smoking in individuals 
with/without MMI  
Bold if significant (p<0.001) 
1
Adjusted for age, sex and deprivation status 
2 
Adjusted for age 
and deprivation status 
 
5.4.2  MMI compared to Diabetes: 
From 1,426,670 individuals aged over 18: 73,743 individuals with diabetes without MMI 
(5.2%), 11,171 individuals with MMI without diabetes (0.8%) and 1,088 individuals with 
MMI and diabetes (0.08%) were identified. Recording of smoking status was available in 
the majority of cases, however missing data occurred significantly more frequently in 
individuals with MMI (4.1%) compared to individuals with MMI and diabetes (0.7%) and 
individuals with diabetes without MMI (0.6%) (Table 5-3).   
 
 
 
Table 5-3 Rates of recording of smoking status in individuals with/without MMI 
with/without diabetes 
Bold if significant (p<0.001) compared to those with Diabetes without MMI 
 MMI  
(n=11,788) (%) 
 
Controls  
(n=1,272,289) (%) 
 
Odd Ratio 
MMI vs. Controls  
 
Sm
o
ke
r 5,604 
(47.5) 
343,804 
(27.0) 
 
All
1
  2.53 (2.44-2.63) 
Males
2
 2.83 (2.68-2.98) 
Females
2
 2.28 (2.16-2.40) 
Ex
-S
m
o
ke
r 
2,213 
(18.8) 
271,957 
(21.4) 
 
All
1
 0.79 (0.75-0.83) 
Males
2
 0.76 (0.71-0.81) 
Females
2
0.87 (0.81-0.92) 
N
o
n
 
Sm
o
ke
r 3,971 
(33.7) 
656,528 
(51.6) 
 
All
1
  0.50 (0.48-0.52) 
Males
2
  0.42 (0.40-0.45) 
Females
2
0.55 (0.53-0.58) 
 MMI No 
Diabetes 
(n=11,171) (%) 
MMI & Diabetes 
(n=1,088) (%) 
Diabetes No 
MMI 
(n=73,743) (%) 
Missing data on smoking 463 (4.1) 8             (0.7) 423 (0.6) 
Smoking recorded 10,708 (95.9) 1,080 (99.3) 73,311 (99.4) 
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In individuals who had their smoking status recorded, men with diabetes made up a greater 
proportion compared to individuals with MMI without diabetes (53.1% vs. 48.9%, 
p<0.001) and MMI and diabetes (53.1% vs. 41.1%, p<0.001). Mean age of individuals 
with diabetes who had their smoking status recorded was higher than the mean age of 
individuals with MMI without diabetes (63.5 vs. 51.5 years, p<0.001) and MMI and 
diabetes (63.5 vs. 60.6 years, p<0.001). Rate of having three or more additional physical 
health problems was most common in individuals with MMI and diabetes (60.3%) (Table 
5-4). 
 
Table 5-4 Demographics of individuals with/without MMI with/without diabetes who 
have had their smoking status recorded  
Bold if significant (p<0.001) compared to those with Diabetes without MMI 
5.4.2.1 Rate of Smoking in MMI vs. Diabetes: 
When smoking was recorded, rates of smoking were highest in individuals with MMI 
without diabetes (48.6%) followed by MMI and diabetes (37.1%). Rates of ex-smoking 
were highest in individuals with diabetes without MMI (35.8%) as were rates of non-
smoking (44.3%) (Table 5-5).   
All  MMI No 
Diabetes 
(n=10,708) 
p value  MMI & Diabetes 
(n=1,080) 
p value Diabetes No 
MMI 
(n=73,311) 
Male n, % 
 
5,231 (48.9) <0.001 444 (41.1) <0.001 38,917 (53.1) 
Mean Age, sd 
 
51.5 (0.16) <0.001 60.6 (0.43) <0.001 63.5 (0.05) 
Age Group 
<25 
25-34 
35-44 
45-54 
55-64 
65+ 
 
294 (2.7) 
1,315 (12.3) 
2,371 (22.1) 
2,398 (22.4) 
1,997 (18.6) 
2,333 (21.8) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
14 (1.3) 
63 (5.8) 
183 (16.9) 
240 (22.2) 
163 (24.4) 
317 (29.4) 
 
0.719 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
1,046 (1.4) 
2,133 (2.9) 
5,154 (7.0) 
10,001 (13.6) 
16,840 (23.0) 
38,137 (52.0) 
Mean Carstairs Score, sd 0.35 (0.03) <0.001 0.43 (0.11) <0.001 0.05 (0.01) 
Deprivation Status 
Least deprived-1 
2 
3 
4 
Most deprived 5 
 
1,554 (14.5) 
2,006 (18.7) 
2,499 (23.3) 
2,339 (21.8) 
2,310 (21.6) 
 
0.009 
<0.001 
0.118 
<0.001 
<0.001 
 
157 (14.5) 
187 (17.3) 
251 (23.2) 
252 (23.3) 
253 (21.6) 
 
0.393 
0.003 
0.548 
0.004 
0.002 
 
11,351 (15.5) 
15,437 (21.1) 
17,615 (24.0) 
14,510 (19.8) 
14,398 (19.6) 
Additional morbidities  
0 
1 
2 
3+ 
 
2,084 (19.5) 
2,790 (26.1) 
2,266 (21.2) 
3,568 (33.3) 
 
<0.001 
<0.001 
<0.001 
<0.001 
 
74 (6.9) 
146 (13.5) 
209 (19.4) 
651 (60.3) 
 
<0.001 
<0.001 
0.885 
<0.001 
 
9,760 (13.3) 
14,934 (20.2) 
14,316 (19.5) 
34,401 (46.9) 
 
 
110 
In individuals with comorbid MMI and diabetes, rates of smoking were significantly lower 
and rates of ex-smoking significantly higher compared to individuals with MMI without 
diabetes. There was no difference in non-smoking rates between individuals with MMI 
without diabetes and individuals with comorbid MMI and diabetes (Table 5-5). 
The odds ratio for smoking, was highest in individuals with MMI without diabetes (2.68 
95% CI 2.5-2.80). In individuals with MMI and diabetes OR for smoking was 2.23 (95% 
CI 1.96-2.53). In both cohorts OR for smoking was higher in men (3.10 95% CI 2.91-3.30 
and 2.42 95% CI 2.00-2.94) (Table 5-5).  
Odds ratio for ex-smoking, was lowest in individuals with MMI without diabetes (0.53 
95% CI 0.50-0.55) and was particularly low in men (0.46 95% CI 0.43-0.50). Odds ratio 
for non-smoking, was lowest in individuals with MMI without diabetes (0.56 95% CI 0.53-
0.58) and was particularly low for men (0.46 95% CI 0.43-0.49) (Table 5-5). 
 MMI  No 
diabetes 
(n=10,708) 
MMI & 
Diabetes 
(n=1,080) 
Diabetes 
No MMI 
(n=73,311) 
Odd Ratio 
MMI no DM vs. DM no 
MMI 
Odds ratio 
MMI & DM vs. DM no 
MMI 
Sm
o
ki
n
g 5,203 
(48.6) 
401 
(37.1) 
14,570 
(19.9) 
 
All
1
  2.68 (2.56-2.80) 
Males
2
 3.10 (2.91-3.30) 
Females
2
 2.33 (2.19-2.48) 
 
All
1
 2.23 (1.96-2.53) 
Males
2
 2.42 (2.00-2.94) 
Females
2
2.11 (1.77-2.50) 
Ex
-S
m
o
ke
r 
1,927 
(18.0) 
286 
(26.5) 
26,278 
(35.8) 
 
All
1
 0.53 (0.50-0.55) 
Males
2
 0.46 (0.43-0.50) 
Females
2
0.63 (0.59-0.68) 
 
All
1
 0.76 (0.66-0.87) 
Males
2
 0.77 (0.63-0.95) 
Females
2
0.77 (0.64-0.92) 
 
N
o
n
 
Sm
o
ke
r 3,578 
(33.4) 
393 
(35.5) 
32,463 
(44.3) 
 
All
1
  0.56 (0.53-0.58) 
Males
2
  0.46 (0.43-0.49) 
Females
2
0.62 (0.59-0.66) 
 
All
1
  0.66 (0.58-0.75) 
Males
2
  0.54 (0.44-0.67) 
Females
2
 0.71 (0.61-0.84) 
Table 5-5 Odds Ratio of smoking, ex-smoking and non-smoking in individuals 
with/without MMI with/without diabetes 
Bold if significant (p<0.001) compared to those with Diabetes without MMI 
1
Adjusted for age, 
sex and deprivation status 
2 
Adjusted for age and deprivation status 
For individuals who had diabetes and were identified as smokers, the majority were male 
(54.8%). Mean age was 58.6 years (sd 0.12) which was similar to individuals who smoked 
and had comorbid MMI and diabetes (56.4 years).  There was no significant difference in 
deprivation distribution between the three groups. Rates of comorbidity were high in all 
three cohorts, but were highest in individuals with MMI and diabetes (94.3%) followed by 
individuals with diabetes without MMI (83.6%) (Table 5-6). 
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Table 5-6 Demographics of smokers with/without MMI with/without diabetes  
Bold if significant (p<0.001) compared to those with Diabetes no MMI 
5.4.2.2 Rates of Smoking Cessation Advice in Smokers in MMI vs. Diabetes 
In smokers with MMI, rate of recording of smoking cessation advice was significantly 
lower compared to smokers with diabetes without MMI (88.7% vs. 98.0%, OR 0.22 95% 
CI 0.19-0.25, p<0.001). Smokers with comorbid MMI and diabetes had the highest 
recorded rates of smoking cessation advice, although when compared to smokers with 
diabetes without MMI- the OR did not reach significance (98.5% vs. 98.0%, OR 1.37 95% 
CI 0.61-3.11) (Table 5-7).  
 
 
 
 
All Smokers MMI No Diabetes 
(n=5,203) 
p value MMI & 
Diabetes 
(n=401) 
p value Diabetes No 
MMI 
(n=14,570) 
Male n, % 
 
2,923 (56.2) 0.077 189 (47.1) 0.002 7,978 (54.8) 
Mean Age, sd 47.1 (0.19) <0.001 56.4 (0.65) 0.002 58.6  (0.12) 
Age Group 
<25 
25-34 
35-44 
45-54 
55-64 
65+ 
 
172 (3.3) 
828 (15.9) 
1,412 (27.1) 
1,278 (24.6) 
906  (17.4) 
606 (11.6) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
1 (0.2) 
15 (3.7) 
57 (14.2) 
114         (28.4) 
99           (24.7) 
115 (28.7) 
 
0.023 
0.438 
0.026 
<0.001 
0.231 
<0.001 
 
 
252 (1.7) 
664 (4.6) 
1,562 (10.7) 
2,721 (18.7) 
3,991 (27.4) 
5,380 (36.9) 
Mean Carstairs Score, sd 0.97 (0.05) 0.043 0.95 (0.18) 0.614 0.86 (0.03) 
 
Deprivation Status 
Least deprived-1 
2 
3 
4 
Most deprived 5 
 
525 (10.1) 
861 (16.6) 
1,188 (22.8) 
1,225 (23.5) 
1,404 (27.0) 
 
0.445 
0.454 
0.007 
0.060 
0.972 
 
44 (12.0) 
63 (15.7) 
86 (21.5) 
98 (24.4) 
106 (26.4) 
 
0.744 
0.497 
0.386 
0.304 
0.815 
 
1,525 (10.5) 
2,477 (17.0) 
3,395 (23.3) 
3,245 (22.3) 
3,928 (27.0) 
Additional 
Multimorbidities 
0 
1 
2 
3+ 
 
1,007 (19.4) 
1,420 (27.3) 
1,134 (21.8) 
1,642 (31.6) 
 
<0.001 
<0.001 
<0.001 
<0.001 
 
23 (5.7) 
69           (17.2) 
88           (22.0) 
221         (55.1) 
 
<0.001 
0.087 
0.089 
<0.001 
 
2,273 (15.6) 
3,018 (20.7) 
2,708 (18.6) 
6,571 (45.1) 
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 MMI No 
Diabetes 
(n=5,203)  
MMI & 
Diabetes 
(n=401) 
Diabetes 
No MMI 
(n=14,570)     
Odd Ratio 
MMI no DM vs. DM no 
MMI 
Odds ratio 
MMI & DM vs. DM no 
MMI 
Offered 
Smoking 
cessation 
4,616 
(88.7) 
395 
(98.5) 
14,275  
(98.0) 
All
1
 0.22 (0.19-0.25) 
Males
2
 0.22 (0.18-0.27) 
Females
2
0.22 (0.17-0.27) 
All
1
 1.37 (0.61-3.11) 
Males
2
 1.17 (0.41-3.08) 
Females
2
1.94 (0.48-7.93) 
Not 
Offered  
Smoking 
cessation 
587 
(11.3) 
6 
(1.5) 
295 
(2.0) 
Table 5-7 Rates of recording of smoking cessation advice in individuals with/without 
MMI with/without Diabetes  
Bold if significant (p<0.001) compared to diabetes no MMI 
1
Adjusted for age, sex and 
deprivation status 
2 
Adjusted for age and deprivation status 
 
5.4.2.3 Rates of NRT Prescription in Smokers in MMI vs. Diabetes: 
In smokers with MMI without diabetes rate of NRT prescription was lower (25.4%) 
compared to smokers with diabetes without MMI (29.1%) and smokers with comorbid 
MMI and diabetes (27.4%) (Table 5-8). 
The odds ratio of NRT prescription was significantly lower in smokers with MMI without 
diabetes compared to smokers with diabetes without MMI (OR 0.75 95% CI 0.69-0.81). 
There was no significant difference in the odds ratio of NRT prescription in smokers with 
comorbid MMI and diabetes compared to smokers with diabetes without MMI (OR 0.87 
95% CI 0.70-1.09) (Table 5-8).  
Table 5-8 Rates of Nicotine Replacement Therapy (NRT) in smokers with/without MMI 
with/without Diabetes 
Bold if significant (p<0.001) compared to diabetes no MMI 
1
Adjusted for age, sex and 
deprivation status 
2 
Adjusted for age and deprivation status 
 MMI No 
Diabetes 
(n=5,203)  
MMI & 
DM 
(n=401) 
Diabetes 
No MMI 
(n=14,570)     
Odd Ratio 
MMI no DM vs. DM no 
MMI 
Odds ratio 
MMI & DM vs. DM no 
MMI 
Prescribed 
NRT 
 
1,323 
(25.4) 
110 
(27.4) 
4,234 
(29.1) 
All
1
 0.75(0.69-0.81) 
Males
2
 0.67 (0.60-0.75) 
Females
2
 0.83 (0.75-0.93) 
All
1
 0.87 (0.70-1.09) 
Males
2
 0.77 (0.54-1.10) 
Females
2
0.95 (0.71-1.28) 
Not 
Prescribed 
NRT 
 
3,880 
(74.6) 
291 
(72.6) 
10,336 
(70.9) 
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5.4.3 MMI compared to Coronary Heart Disease (CHD):  
From 1,426,670 individuals aged over 18: 80,718 individuals with CHD without MMI 
(5.7%), 11,510 individuals with MMI without CHD (0.8%) and 749 individuals with MMI 
and CHD (0.05%) were identified (Table 5-9).  
Recording of smoking status occurred in the majority of cases. Missing data was more 
frequent in individuals with MMI without CHD (4.0%) compared to individuals with MMI 
and CHD (0.7%) and individuals with CHD without MMI (0.5%) (Table 5-9).   
 
 
 
 
Table 5-9  Rates of recording of smoking status in individuals with/without MMI 
with/without Coronary Heart Disease (CHD) 
Bold if significant (p<0.001) compared to those with CHD no MMI 
Mean age of individuals with CHD without MMI who had their smoking status recorded 
was higher than the mean age of individuals with MMI without CHD (71.3 vs. 51.2 years, 
p<0.001) and MMI and comorbid CHD (71.3 vs. 69.1 years, p<0.001). Mean Carstairs 
score for individuals with MMI without CHD was highest (0.37) compared to individuals 
with MMI and CHD (0.06) and CHD without MMI (0.08). Rate of additional 
multimorbidity was common. Having three or more additional physical health problems 
was most common in individuals with MMI and CHD (71.9%) (Table 5-10).  
 
 
 
 
 
 
 
 
 MMI No CHD 
(n=11,510)  
MMI & CHD  
(n=752) 
CHD No MMI 
(n=80,718) 
Smoking Recorded 11,044 (96.0) 744 (98.9) 80,309 (99.5) 
Missing 466 (4.0) 8 (1.1) 409 (0.5) 
 
 
114 
Table 5-10 Demographics of individuals with/without MMI with/without CHD who have 
had their smoking status recorded  
Bold if significant (p<0.001) compared to individuals with CHD no MMI 
5.4.3.1 Rate of Smoking in MMI vs. CHD: 
When smoking status was recorded there were higher rates of smoking in individuals with 
MMI without CHD (48.4%) and individuals with MMI and CHD (34.8%) compared to 
individuals with CHD without MMI (20.9%). Highest rates of ex-smoking occurred in 
individuals with CHD without MMI (44.3%) compared to individuals with MMI and CHD 
(34.3%, p<0.001) and individuals with MMI without CHD (17.7%, p<0.001) (Table 5-11).  
No significant difference in rate of non-smoking was seen across the three cohorts (33.9% 
MMI no CHD vs. 30.8% MMI and CHD and 34.8% CHD no MMI) (Table 5-11).  
The OR of smoking, when adjusted for age, sex and deprivation status was highest in 
individuals with comorbid MMI and CHD (1.88 95% CI 1.59-2.21) (Table 5-11).  
The OR of ex-smoking, when adjusted for age, sex and deprivation status was lowest in 
individuals with MMI without CHD (0.53 95% CI 0.33-0.37), and was particularly low in 
men (0.31 95% CI 0.28-0.33) (Table 6-13). When adjusted for age, sex and deprivation 
All  MMI  No CHD 
(n=11,044) 
p 
value 
MMI & CHD 
(n=744) 
p value CHD no MMI 
(n=80,309) 
Male n, % 5,305 (49.7) <0.001 370 (49.7) <0.001 45,898 (57.2) 
 
Mean Age, sd 51.2 (0.15) <0.001 69.1 (0.45) <0.001 71.3 (0.04) 
 
Age Group 
<25 
25-34 
35-44 
45-54 
55-64 
65+ 
 
296 (2.7) 
1,347 (12.2) 
2,459 (22.3) 
2,549 (23.1) 
2,096 (19.0) 
2,297 (20.8) 
 
<0.001 
<0.001 
<0.001 
<0.001 
0.330 
<0.001 
 
0 (0) 
1 (0.1) 
15 (2.0) 
80 (10.8) 
177 (23.0) 
477 (64.1) 
 
0.773 
0.654 
0.003 
<0.001 
0.002 
<0.001 
 
9 (0.01) 
69 (0.09) 
759 (0.9) 
5,048 (6.3) 
15,555 (19.4) 
58,869 (73.3) 
Mean Carstairs Score, sd 0.37 (0.03) <0.001 0.06 (0.13) 0.8841 0.08 (0.01) 
 
Deprivation Status 
Least deprived-1 
2 
3 
4 
Most deprived 5 
 
1,589 (14.4) 
2,053 (18.6) 
2,553 (23.1) 
2,443 (22.1) 
2,406 (21.8) 
 
0.001 
<0.001 
0.508 
<0.001 
<0.001 
 
122 (16.4) 
140 (18.8) 
197 (26.5) 
148 (19.9) 
137 (18.4) 
 
0.528 
0.125 
0.049 
0.747 
0.435 
 
12,492 (15.5) 
16,961 (21.1) 
18,793 (23.4) 
16,360 (20.4) 
15,70 (73.3) 
Additional Multimorbidities 
0 
1 
2 
3+ 
 
2,084 (18.9) 
2,837 (25.7) 
2,340 (21.2) 
3,783 (34.3) 
 
<0.001 
<0.001 
<0.001 
<0.001 
 
27 (3.6) 
72 (9.7) 
110 (14.8) 
535 (71.9) 
 
<0.001 
<0.001 
0.003 
<0.001 
 
7,024 (8.8) 
13,198 (16.4) 
15,296 (19.1) 
44,791 (55.8) 
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status the odds ratio of non-smoking, was 1.44 (95% CI 1.38-1.52) in individuals with 
MMI without CHD and 0.82 (95% CI 0.70-0.96) in individuals with MMI and CHD (Table 
5-11).  
 MMI No 
CHD 
(n=11,044)  
MMI & CHD 
(n=744) 
CHD no MMI 
(n=80,309) 
Odd Ratio 
MMI no CHD vs. CHD no 
MMI 
Odds ratio 
MMI & CHD vs. CHD no 
MMI 
Sm
o
ki
n
g 5,345 
(48.4) 
259 
(34.8) 
16,809 
(20.9) 
 
All
1
 1.27 (1.20-1.33) 
Males
2
 1.51 (1.41-1.63) 
Females
2
1.03 (0.96-1.11) 
 
All
1
 1.88 (1.59-2.21) 
Males
2
 1.84 (1.47-2.30) 
Females
2
1.94 (1.53-2.46) 
Ex
-S
m
o
ke
r 
1,958 
(17.7) 
255 
(34.3) 
35,554 
(44.3) 
 
All
1
 0.53 (0.33-0.37) 
Males
2
 0.31 (0.28-0.33) 
Females
2
0.40 (0.37-0.43) 
 
All
1
 0.70 (0.60-0.82) 
Males
2
 0.73 (0.59-0.90) 
Females
2
0.69 (0.55-0.87) 
N
o
n
-
Sm
o
ke
r 3,741 
(33.9) 
230 
(30.9) 
27,946 
(34.8) 
 
All
1
 1.44 (1.38-1.52) 
Males
2
 1.33 (1.24-1.43) 
Females
2
1.58 (1.48-1.69) 
 
All
1
 0.82 (0.70-0.96) 
Males
2
 0.76 (0.59-0.98) 
Females
2
0.85 (0.68-1.05) 
Table 5-11 Odds Ratio of smoking, ex-smoking and non-smoking in individuals 
with/without MMI with/without CHD 
 Bold if significant (p<0.001) compared to CHD no MMI 
1
Adjusted for age, sex and 
deprivation status 
2
Adjusted for age and deprivation status 
Of individuals with CHD without MMI identified as smokers, the majority were male 
(59.7%). Mean age was 65.7 (sd 0.08) which was significantly older than individuals with 
MMI without CHD (47.0 sd 0.19, p<0.001).  Deprivation distribution of smokers with 
CHD without MMI, smokers with MMI without CHD and smokers with MMI and 
comorbid CHD was similar. Rates of comorbidity were high in all three cohorts, but were 
highest in individuals with MMI and CHD (94.6%) followed by individuals with CHD 
without MMI (89.4%) (Table 5-12).  
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Table 5-12 Demographics of smokers with/without MMI with/without CHD  
Bold if significant (p<0.001) compared to CHD No MMI 
 
5.4.3.2 Rates of recording of smoking cessation advice in smokers in MMI 
vs. CHD: 
In smokers with MMI without CHD rates of recording of smoking cessation advice were 
significantly lower compared to smokers with CHD without MMI (88.9% vs. 98.7%, 
p<0.001, OR 0.12 95% CI 0.10-0.15). Although rates of recording of smoking cessation 
advice were lower in smokers with comorbid MMI and CHD (97.7%) the OR was not 
significant (OR 0.52 95% CI 0.23-1.19) (Table 5-13). 
 MMI No 
CHD 
(n=5,345) 
MMI & 
CHD 
(n=259) 
CHD No 
MMI 
(n=16,809) 
Odd Ratio 
MMI no CHD vs. CHD No 
MMI 
Odds ratio 
MMI & CHD vs. CHD No 
MMI
 
Offered 
Smoking 
cessation 
4,754 
(88.9) 
253 
(97.7) 
16,589 
(98.7) 
All
1
 0.12 (0.10-0.15) 
Males
2
 0.12 (0.09-0.15) 
Females
2
0.14 (0.10-0.19) 
All
1
 0.52 (0.23-1.19) 
Males
2
 0.42 (0.15-1.16) 
Females
2
0.74 (0.18-3.08) 
Not 
offered 
Smoking 
cessation 
591 
(11.1) 
6 
(2.3) 
220 
(1.3) 
Table 5-13 Rates of recording of smoking cessation advice in individuals with/without 
MMI with/without CHD Bold if significant (p<0.001) compared to CHD No MMI 
1
Adjusted for 
age, sex and deprivation status 
2
Adjusted for age and deprivation status 
All smokers MMI  No CHD  
(n=5,345) 
p value MMI & CHD 
(n=259) 
p value CHD No MMI 
(n=16,809) 
Male n, % 
 
2,972 (55.6) <0.001 
 
140 (54.1) 0.064 10,041 (59.7) 
Mean Age, sd 
 
47.0 (0.19) <0.001 63.6 (0.69) 0.002 65.7 (0.08) 
Age Group 
<25 
25-34 
35-44 
45-54 
55-64 
65+ 
 
173 (3.2) 
843 (15.8) 
1,458 (27.3) 
1,350 (25.3) 
918 (17.2) 
603 (11.3) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
0 (0) 
0 (0) 
11 (4.2) 
42 (16.2) 
88 (34.0) 
118 (45.6) 
 
0.781 
0.496 
0.023 
0.096 
0.168 
0.003 
 
5 (0.03) 
30 (0.2) 
365 (2.2) 
2,141 (12.7) 
5,045 (30.0) 
9,223 (54.9) 
Mean Carstairs Score, sd 0.97 (0.05) <0.001 1.04 (0.24) 0.519 1.18 (0.03) 
Deprivation Status 
Least deprived-1 
2 
3 
4 
Most deprived- 5 
 
549 (10.3) 
876 (16.4) 
1,210 (22.6) 
1,278 (23.9) 
1,432 (26.8) 
 
<0.001 
0.428 
0.406 
0.978 
0.004 
 
24 (9.3) 
48 (18.5) 
64 (24.7) 
45 (17.4) 
78 (30.1) 
 
0.782 
0.257 
0.314 
0.015 
0.776 
 
1,475 (8.8) 
2,678 (15.9) 
3,714 (22.1) 
4,016 (23.9) 
4,926 (29.3) 
Additional Multimorbidities  
0 
1 
2 
3+ 
 
2,601 (48.7) 
1,370 (25.6) 
750 (14.0) 
624 (11.7) 
 
<0.001 
<0.001 
<0.001 
<0.001 
 
14 (5.4) 
30 (11.6) 
41 (15.8) 
174 (67.2) 
 
0.007 
0.013 
0.231 
<0.001 
 
1,788 (10.6) 
2,936 (17.5) 
3,153 (18.8) 
8,932 (53.1) 
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5.4.3.3 Rate of NRT prescription in smokers in MMI vs. CHD: 
Rate of NRT prescription was lowest in smokers with MMI without CHD (25.3%) 
compared to smokers with CHD without MMI (33.4%) and smokers with comorbid MMI 
and CHD (31.7%) (Table 5-14). 
Odds ratio of NRT prescription was significantly lower in smokers with MMI without 
CHD compared to smokers with CHD without MMI (OR 0.34 95% CI 0.31-0.38). There 
was no significant difference in the OR of NRT prescription in smokers with MMI and 
CHD compared to smokers with CHD without MMI (Table 5-14).  
 MMI No 
CHD 
(n=5,345)  
CHD & 
MMI 
(n=259) 
CHD No 
MMI 
(n=16,809) 
Odd Ratio 
MMI no CHD vs. CHD No 
MMI 
Odds ratio 
MMI & CHD vs. CHD No 
MMI
 
Prescribed  
NRT 
1,351  
(25.3) 
82  
(31.7) 
5,614  
(33.4) All
1
 0.34 (0.31-0.38) 
Males
2
 0.30 (0.26-0.34) 
Females
2
0.40 (0.35-0.45) 
All
1
 0.91 (0.62-1.07) 
Males
2
 0.69 (0.47-1.02) 
Females
2
0.97 (0.66-1.42) 
Not 
Prescribed 
NRT 
3,994  
(74.7) 
177  
(68.3) 
11,195  
(66.0) 
Table 5-14 Rates of Nicotine Replacement Therapy (NRT) in smokers with/without MMI 
with/without CHD 
 Bold if significant (p<0.001) compared to CHD No MMI 
1
Adjusted for age, sex and 
deprivation status 
2
Adjusted for age and deprivation status 
5.4.4 MMI compared to Hypertension: 
From 1,426,670 individuals aged over 18: 232,201 individuals with hypertension without 
MMI (16.3%), 10,246 individuals with MMI without hypertension (0.7%) and 2,013 
individuals with MMI and hypertension (0.14%) were identified. 
Recording of smoking status was available in the majority of cases, however missing data 
occurred significantly more frequently in individuals with MMI without hypertension 
(4.5%) compared to individuals with MMI and hypertension (0.7%) and individuals with 
hypertension without MMI (0.4%) (Table 5-15).   
 
 
 
 
 
118 
 
 
 
Table 5-15 Rates of recording of smoking status in individuals with MMI with/without 
hypertension 
Bold if significant (p<0.001) compared to hypertension 
Mean age of individuals with hypertension who had their smoking status recorded was 
higher than the mean age of individuals with MMI without hypertension (66.9 vs. 49.6 
years, p<0.001) and MMI and hypertension (66.9 vs. 65.8 years, p<0.001). Rate of 
additional multimorbidity was common. Having three or more additional physical health 
comorbidities was most common in individuals with MMI and hypertension (54.1%) 
(Table 5-16).  
Table 5-16 Demographics of individuals with/without MMI with/without hypertension 
who have had their smoking status recorded  
Bold if significant (p<0.001) compared to hypertension No MMI 
5.4.4.1 Rate of Smoking in MMI vs. Hypertension: 
When smoking status was recorded there were higher rates of smoking in individuals with 
MMI without hypertension (51.5%) and in individuals with MMI and hypertension 
(28.3%) compared to individuals with hypertension without MMI (17.2%) (Table 5-19). 
There were higher rates of ex-smoking in individuals with hypertension without MMI 
 MMI No 
Hypertension 
(n=10,246)  
Hypertension & 
MMI 
(n=2,013) 
Hypertension No 
MMI 
(n=232,221) 
Smoking recorded 9,789 (95.5) 1,999 (99.3) 231,329 (99.6) 
Missing  457 (4.5) 14 (0.7) 892 (0.4) 
All  MMI No 
Hypertension 
(n=9,789) 
p value MMI & 
Hypertension 
(n=1,999) 
p value Hypertension 
No MMI 
(n=231,329) 
Male n, % 
 
4,929 (50.4) <0.001 746 (37.3) <0.001 102,312 (44.2) 
Mean Age, sd 
 
49.6 (0.16) <0.001 65.8 (0.29) <0.001 66.9 (0.03) 
Mean Carstairs Score, sd 0.42 (0.04) <0.001 0.003 (0.07) 0.003 -0.22 (0.01) 
Deprivation Status 
Least deprived-1 
2 
3 
4 
Most deprived 5 
 
1,380 (14.1) 
1,810 (18.5) 
2,241 (22.9) 
2,163 (22.1) 
2,195 (22.4) 
 
<0.001 
<0.001 
0.098 
<0.001 
<0.001 
 
 
331 (16.6) 
383 (19.2) 
509 (25.5) 
428 (21.4) 
348 (17.4) 
 
0.073 
0.002 
0.053 
0.008 
0.743 
 
41,889 (18.1) 
51,067 (22.1) 
54,634 (23.6) 
44,109 (19.1) 
39,630 (17.1) 
Additional Multimorbidities  
0 
1 
2 
3+ 
 
2,084 (21.3) 
2,683 (27.4) 
2,045 (20.9) 
2,977 (30.4) 
 
0.115 
<0.001 
<0.001 
<0.001 
 
181 (9.1) 
367 (18.4) 
370 (18.5) 
1,081 (54.1) 
 
<0.001 
<0.001 
0.376 
<0.001 
 
50,803 (22.0) 
55,509 (24.0) 
44,634 (19.3) 
80,383 (34.7) 
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(33.3%) and in individuals with MMI and hypertension (28.4%) compared to individuals 
with MMI without hypertension (16.8%). Rate of non-smoking was highest in individuals 
with hypertension without MMI (49.5%) (Table 5-17).  
The odds ratio of smoking was highest in individuals with MMI without hypertension 
(2.91 95% CI 2.78-3.04) and was particularly high in men (3.50 95% CI 3.30-3.73) (Table 
5-19). Odds ratio of ex-smoking was lower in individuals with MMI without hypertension 
(0.52 95% CI 0.49-0.55) and was particularly low in men (0.49 95% CI 0.45-0.53). Odds 
ratio of non-smoking was also lower in individuals with MMI without hypertension (0.46 
95% CI 0.44-0.48) (Table 5-17). 
 
MMI without 
Hypertension 
(n=9,789) 
Hypertension 
&  MMI 
(n=1,999) 
Hypertension 
No MMI 
(n=231,329) 
Odd Ratio 
MMI no Hypertension 
vs. Hypertension No MMI 
 
Odds ratio 
MMI & Hypertension 
vs. Hypertension No MMI 
 
Sm
o
ki
n
g 5,038 
(51.5) 
566 
(28.3) 
39,775 
(17.2) 
 
All
1
 2.91 (2.78-3.04) 
Males
2
 3.50 (3.30-3.73) 
Females
2 
2.47 (2.32-2.63) 
 
All
1
 1.85 (1.67-2.05) 
Males
2
 2.11 (1.81-2.47) 
Females
2
1.72 (1.50-1.96) 
Ex
-S
m
o
ke
r 
1,645 
(16.8) 
568 
(28.4) 
77,118 
(33.3) 
 
All
1
 0.52 (0.49-0.55) 
Males
2
 0.49 (0.45-0.53) 
Females
2 
0.62 (0.57-0.67) 
 
All
1
 0.85 (0.77-0.94) 
Males
2
 0.75 (0.64-0.88) 
Females
2
0.95 (0.83-1.07) 
N
o
n
 
Sm
o
ke
r 3,106 
(31.7) 
865 
(43.3) 
114,436 
(49.5) 
 
All
1
 0.46 (0.44-0.48) 
Males
2
 0.34 (0.31-0.36) 
Females
2
0.54 (0.51-0.57) 
 
All
1
 0.74 (0.68-0.81) 
Males
2
 0.71 (0.61-0.82) 
Females
2
0.73 (0.66-0.82) 
Table 5-17 Odds Ratio of smoking, ex-smoking and non-smoking in individuals 
with/without MMI with/without hypertension 
 Bold if significant (p<0.001) compared to hypertension No MMI
 1
Adjusted for age, sex and 
deprivation status 
2
Adjusted for age and deprivation status 
Of the individuals with hypertension without MMI identified as smokers, 47.1% were 
male, compared to 56.7% of individuals with MMI without hypertension who smoked and 
44.9% of individuals with MMI and hypertension who smoked. Mean age of individuals 
with hypertension without MMI who smoked was 62.9 years (sd 0.60), which was 
significantly older than individuals with MMI without hypertension (46.3 years, p<0.001) 
and individuals with MMI and hypertension (61.0 years, p<0.001).  Deprivation 
distribution of all three groups was similar. Rates of comorbidity were high in all three 
cohorts; rate of three or more additional physical health comorbidities was highest in MMI 
and hypertension (53.2%) (Table 5-18). 
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Table 5-18 Demographics of smokers with/without MMI with/without hypertension  
Bold if significant (p<0.001) compared to hypertension No MMI 
5.4.4.2 Rates of recording of smoking cessation advice in smokers in MMI 
vs. Hypertension: 
Rates of recording of smoking cessation advice were significantly lower in smokers with 
MMI without hypertension (88.3%) compared to smokers with hypertension without MMI 
(98.5%) and smokers with comorbid hypertension and MMI (98.6%). Although OR of 
recording of smoking cessation advice in smokers with MMI without hypertension was 
lower than for smokers with hypertension without MMI (0.15 95% CI 0.13-0.18), it was 
similar for smokers with comorbid MMI and hypertension (OR 1.08 95% CI 0.53-2.18, 
p=0.830) (Table 5-19). 
 
 
 
Smokers MMI No 
Hypertension  
(n=5,038) 
p value MMI & 
Hypertension 
(n=566) 
p value Hypertension 
No MMI 
(n=39,775) 
Male n, % 2,858 (56.7) 
 
<0.001 254 (44.9) <0.001 18,747 (47.1) 
Mean Age, sd 46.3 (0.19) 
 
<0.001 61.0 (0.51) <0.001 62.9 (0.60) 
Age Group 
<25 
25-34 
35-44 
45-54 
55-64 
65+ 
 
173 (3.4) 
833 (16.5) 
1,422 (28.2) 
1,289 (25.6) 
811 (16.1) 
510 (10.1) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
0 (0) 
10 (1.8) 
47 (8.3) 
103 (18.2) 
195 (34.5) 
211 (37.3) 
 
0.372 
0.111 
0.002 
0.405 
0.148 
<0.001 
 
56 (0.1) 
425 (1.1) 
2,139 (5.4) 
6,709 (16.9) 
12,564 (31.6) 
17,881 (45.0) 
Mean Carstairs Score, sd 1.01 (0.05) <0.001 0.61 (0.15) 0.467 0.71 (0.02) 
Deprivation Status 
Least deprived-1 
2 
3 
4 
Most deprived 5 
 
496 (9.9) 
835 (16.6) 
1,137 (22.6) 
1,192 (23.7) 
1,378 (27.4) 
 
 
<0.001 
0.002 
0.484 
0.027 
<0.001 
 
77 (13.6) 
89 (15.7) 
137 (24.2) 
131 (23.1) 
132 (28.3) 
 
0.106 
0.112 
0.502 
0.624 
0.357 
 
4,542 (11.4) 
7,285 (18.3) 
9,147 (23.0) 
8,858 (22.3) 
9,943 (25.0) 
Additional Multimorbidities  
0 
1 
2 
3+ 
 
1,007 (20.0) 
1,386 (27.5) 
1,107 (22.0) 
1,538 (30.5) 
 
0.016 
<0.001 
<0.001 
<0.001 
 
57 (10.1) 
96 (17.0) 
112 (19.8) 
301 (53.2) 
 
<0.001 
<0.001 
0.782 
<0.001 
 
8,533 (21.5) 
9,260 (23.3) 
7,683 (19.3) 
14,299 (35.9) 
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 MMI no 
Hypertension 
(n=5,038)  
Hypertension 
& MMI 
(n=566) 
Hypertension 
No MMI 
(n=39,775) 
Odd Ratio 
MMI no Hypertension 
vs . Hypertension No MMI 
Odds  ratio 
MMI & Hypertension 
vs . Hypertension No MMI  
Offered 
Smoking 
Cessation 
4,449 
(88.3) 
558 
(98.6) 
39,186 
(98.5) 
All10.15 (0.13-0.18) 
Males
2
0.18 (0.15-0.22) 
Females2 0.13 (0.10-0.16) 
Al l 11.08 (0.53-2.18) 
Males
2
0.99 (0.41-2.43) 
Females 21.33 (0.42-4.18) 
Not 
offered 
Smoking 
Cessation 
589 
(11.7) 
8 
(1.4) 
589 
(1.5) 
Table 5-19 Rates of recording of smoking cessation advice in individuals with/without 
MMI with/without Hypertension 
 Bold if significant (p<0.001) compared to Hypertension No MMI
 1
Adjusted for age, sex and 
deprivation status 
2
Adjusted for age and deprivation status 
5.4.4.3 Rates of NRT Prescription in smokers in MMI vs. Hypertension: 
There was no difference in rate of NRT prescription in smokers with MMI (25.4%) 
compared to smokers with hypertension without MMI  (26.4%) and smokers with 
comorbid MMI and hypertension (27.4%) (Table 5-20). 
When adjusted for age, sex and deprivation, the OR of NRT prescription in smokers with 
MMI without hypertension was significantly lower compared to smokers with 
hypertension without MMI (OR 0.71 95% CI 0.66-0.76) (Table 5-20). However there was 
no difference in OR of NRT prescription in smokers with comorbid MMI and hypertension 
compared to smokers with hypertension without MMI (OR 1.01 95%CI 0.84-1.22) (Table 
5-20).  
 
 
MMI no 
Hypertension 
(n=5,038)  
Hypertension 
& MMI 
(n=566) 
Hypertension 
No MMI 
(n=39,775) 
Odd Ratio 
MMI no Hypertension 
vs . Hypertension No MMI 
Odds  ratio 
MMI & Hypertension 
vs . Hypertension No MMI 
Prescribed 
NRT 
1,278 
(25.4) 
155 
(27.4) 
10,495 
(26.4) All10.71 (0.66-0.76) 
Males20.67 (0.37-0.71) 
Females2 0.80 (0.72-0.89) 
Al l 11.01 (0.84-1.22) 
Males 20.85 (0.63-1.15) 
Females 21.15 (0.90-1.46) 
Not 
Prescribed 
NRT 
3,760 
(74.6) 
411 
(72.6) 
29,280 
(73.6) 
Table 5-20 Rates of Nicotine Replacement Therapy (NRT) in smokers with/without MMI 
with/without Hypertension 
 Bold if significant (p<0.001) compared to Hypertension No MMI
 1
Adjusted for age, sex and 
deprivation status 
2
Adjusted for age and deprivation status 
5.4.5 Comparison of Schizophrenia with bipolar disorder:  
From 1,426,670 individuals aged over 18, 9,677 individuals with schizophrenia (0.7%) and 
2,582 individuals with bipolar disorder (0.2%) were identified.  
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Recording of smoking status was available in the majority of cases. There was no 
difference in the rate of missing data between individuals with schizophrenia and 
individuals with bipolar disorder (4.1% vs. 2.8%; p=0.002) (Table 5-21).  
 Schizophrenia 
(n=9,677) 
Bipolar Disorder 
(n=2,582) 
p value 
Missing data on smoking 399 (4.1) 72        (2.8) 
0.002 
Smoking recorded 9,278 (95.9) 2,510 (97.2) 
Table 5-21 Rates of recording of smoking status in individuals with Schizophrenia vs. 
Bipolar Disorder 
There was also no significant difference in rates of diabetes, CHD and hypertension 
between both groups (Table 5-22). 
 Schizophrenia 
(n=9,677) 
Bipolar Disorder 
(n=2,582) 
p value 
Diabetes 870 (9.0) 218 (8.4) 0.386 
CHD 579 (6.0) 170 (6.6) 0.257 
Hypertension 1,551 (16.0) 462 (17.9) 0.023 
Table 5-22 Rates of comorbid diabetes, CHD and hypertension in individuals with 
Schizophrenia vs. Bipolar Disorder 
When smoking was recorded, rates of smoking were higher in individuals with 
schizophrenia (48.8%) compared to individuals with bipolar disorder (42.8%, p<0.001). 
Rates of ex-smoking were higher in the bipolar disorder group compared to the 
schizophrenia group (21.2% vs. 48.8%, p<0.001). Rates of non-smoking were similar 
(33.1% vs. 36.0%). There was no difference in rates of smoking, ex-smoking and non-
smoking between the two groups when adjusted for age, sex and deprivation (Table 5-23).  
 Schizophrenia 
(n=9,278) 
Bipolar Disorder 
(n=2,510) 
Odd Ratio All  Schizophrenia vs. 
 Bipolar Disorder 
Sm
o
ki
n
g 4,529 
(48.8) 
1,075 
(42.8) 
All
1 
1.03 (0.94-1.13)
 
Males
2
 1.19 (1.03-1.37) 
Females
2
0.93 (0.82-1.05)
 
Ex
-S
m
o
ke
r 
1,681 
(18.1) 
532 
(21.2) 
All
1
 0.86 (0.77-0.96) 
Males
2
 0.83 (0.70-0.99) 
Females
3
0.92 (0.80-1.07) 
N
o
n
-
Sm
o
ke
r 3,068 
(33.1) 
903 
(36.0) 
All
1
 1.01 (0.92-1.11) 
Males
2
 0.92 (0.79-1.07) 
Females
3
1.06 (0.94-1.20) 
 Table 5-23 Odds Ratio of smoking, ex-smoking and non-smoking in individuals with 
schizophrenia vs. bipolar disorder 
 Bold if significant (p<0.001) difference between groups
1
Adjusted for age, sex and 
deprivation status 
2
Adjusted for age and deprivation status 
 
 
123 
Of the individuals with schizophrenia identified as smokers, 58.6% were male, compared 
to 42.4% of individuals with bipolar disorder (p<0.001). Mean age of the schizophrenia 
cohort was 47.1 years (sd 0.21) which was significantly younger than the bipolar disorder 
group (50.7 years, p<0.001). There were some differences in distribution of deprivation of 
smokers with schizophrenia compared to smokers with bipolar disorder: whereby 
individuals with schizophrenia were more likely to come from the most deprived area and 
less likely to come from the least deprived area compared to smokers with bipolar disorder.  
Rates of comorbidity were similar in smokers with schizophrenia and bipolar disorder  
(Table 5-24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-24 Demographics of smokers with schizophrenia and bipolar disorder  
Bold if significant (p<0.001) difference between schizophrenia and bipolar disorder 
5.4.5.1 Rates of recording of smoking cessation advice in smokers in 
schizophrenia vs. bipolar disorder: 
There was no difference in rates of recording of smoking cessation advice in smokers with 
schizophrenia compared to smokers with bipolar disorder (89.2% vs. 90.1%, p=0.349) and 
 Schizophrenia 
(n=4,529) 
Bipolar Disorder 
(n=1,075) 
p value 
Male n, % 
 
2,656 (58.6) 456 (42.4) <0.001 
 
Mean Age, sd 
 
47.1 (0.21) 50.7 (0.42) <0.001 
 
Age Group 
<25 
25-34 
35-44 
45-54 
55-64 
65+ 
 
158 (3.5) 
723 (16.0) 
1,231 (27.2) 
1,091 (24.1) 
785 (17.3) 
541 (11.9) 
 
15 (1.4) 
120 (11.2) 
238 (22.1) 
301 (28.0) 
221 (20.6) 
180 (16.7) 
 
<0.001 
<0.001 
0.001 
0.008 
0.013 
<0.001 
 
Mean Carstairs Score, sd 
 
1.14 (0.53) 
 
0.26 (0.11) 
 
<0.001 
 
Deprivation Status 
Least deprived-1 
2 
3 
4 
Most deprived 5 
 
409 (9.0) 
711 (15.7) 
1,030 (22.7) 
1,083 (23.9) 
1,296 (28.6) 
 
164 (15.3) 
213 (19.8) 
244 (22.7 
240 (22.3) 
214 (19.9) 
 
<0.001 
0.001 
0.975 
0.271 
<0.001 
 
Additional Multimorbidities  
0 
1 
2 
3+ 
 
816 (18.0) 
1,183 (26.1) 
984 (21.7) 
1,546 (34.1) 
 
191 (17.8) 
260 (24.2) 
219 (20.4) 
405 (37.7) 
 
0.848 
0.192 
0.331 
0.029 
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there was no difference in the odds ratio calculated when adjusted for age, sex and 
deprivation (OR 1.00 95% CI 0.80-1.26) (Table 5-25).  
 Schizophrenia 
(n=4,529) 
Bipolar Disorder 
(n=1,075) 
Odd Ratio All  Schizophrenia vs.  Bipolar 
Disorder 
Offered 
Smoking Cessation 
4,038 
(89.2) 
969 
(90.1) 
All
1 
1.00 (0.80-1.26) 
Males
2
 1.10 (0.81-1.50) 
Females
2
0.91 (0.65-1.27)
 Not offered 
Smoking Cessation 
491 
(10.8) 
106 
(9.9) 
Table 5-25 Rates of recording of smoking cessation advice in individuals with 
schizophrenia vs. bipolar disorder. 
Bold if significant (p<0.001) difference between groups
1
Adjusted for age, sex and 
deprivation status 
2
Adjusted for age and deprivation status 
5.4.5.2 Rates of NRT Prescribing in smokers in schizophrenia vs. bipolar 
disorder: 
There was no difference in rates of NRT prescribing in smokers with schizophrenia 
compared to smokers with bipolar disorder (25.2% vs. 27.4%, p=0.137) and no difference 
in the odds ratio when adjusted for age, sex and deprivation (OR 0.95 95% CI 0.82-1.11) 
(Table 5-26).  
 Schizophrenia 
(n=4,529) 
Bipolar Disorder 
(n=1,075) 
Odd Ratio All  Schizophrenia vs.  Bipolar 
Disorder 
Prescribed  NRT 1,139 
(25.2) 
294 
(27.4) 
All
1 
0.95 (0.82-1.11) 
Males
2 
1.10 (0.85-1.42) 
Females
2
0.87 (0.72-1.06)
 Not Prescribed NRT 3,390 
(74.8) 
781 
(72.6) 
Table 5-26 Rates of Nicotine Replacement Therapy (NRT) in smokers with schizophrenia 
and bipolar disorder 
Bold if significant (p<0.001) difference between groups
1
Adjusted for age, sex and 
deprivation status 
2
Adjusted for age and deprivation status 
5.5 Discussion: 
5.5.1 Increased smoking rates in individuals with MMI: 
Rates of smoking were significantly higher in individuals with a record of MMI compared 
to individuals without MMI who had diabetes, CHD or hypertension. Rates of smoking 
were also significantly higher in individuals with MMI and comorbid diabetes, CHD and 
hypertension compared to individuals who had diabetes, CHD and hypertension without 
MMI. Males with MMI had particularly elevated odd ratios of smoking compared to 
females, across most of the comparator groups.  
 
 
125 
The high rates of smoking seen in our cohort are in keeping with other studies, with one 
meta-analysis reporting that individuals with schizophrenia have more than five times the 
odds of current smoking than the general population (Tsoi et al., 2013). While other studies 
have reported higher rates of smoking in men with MMI compared to women (Ma et al., 
2009), to date, there have been no studies calculating odds ratios by sex, for rates of 
smoking, ex-smoking and non-smoking in MMI compared to other chronic diseases. These 
findings are therefore novel and of clinical note.  
In this cohort odds ratios (adjusted for age, sex and deprivation status) for non-smoking 
and ex-smoking were lower in individuals with MMI compared to individuals with 
diabetes and hypertension without MMI. This was an expected finding, given the evidence 
for the impact of smoking cessation on vascular risk (Price et al., 1999) and the high 
priority level given to smoking cessation promotion for individuals with a diagnosis of 
diabetes or hypertension. However in this cohort the odds ratio of non-smoking was higher 
in individuals with MMI without CHD compared to individuals with CHD without MMI. 
This unexpected finding may be explained by the differences in age profile of the groups 
(individuals with CHD without MMI were significantly older compared to individuals with 
MMI without CHD).  
5.5.2 Smoking rates in individuals with schizophrenia and bipolar 
disorder: 
Although absolute rates of smoking were higher and absolute rates of ex-smoking were 
lower in individuals with schizophrenia compared to bipolar disorder there was no 
difference in adjusted odds ratios for smoking, ex-smoking and non-smoking in individuals 
with schizophrenia compared to individuals with bipolar disorder. This was a surprising 
finding as other studies have reported higher rates of smoking in schizophrenia compared 
to bipolar disorder (Myles et al., 2012). This finding may in part, be explained by the 
smaller than expected cohort of individuals with bipolar disorder. 
5.5.3 Reduced rates of smoking cessation advice and reduced 
NRT prescription rates in individuals with MMI: 
We found that recorded rates of smoking cessation advice in smokers with MMI were 
significantly lower than the recorded rates of smoking cessation advice in smokers with 
diabetes (88.7% vs. 98.0%, p<0.001), smokers with CHD (88.9% vs. 98.7%, p<0.001) and 
smokers with hypertension (88.3% vs. 98.5%, p<0.001). This is similar to de Leon and 
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colleagues (2005) who found lower rates of smoking cessation advice in smokers with 
schizophrenia compared to controls who smoked (ORs 0.19 CI, 0.14–0.24) (de Leon and 
Diaz, 2005) and similar to the findings of Szatkowski and McNeill, (2013), who reported 
lower rates of smoking cessation advice per consultation in individuals with a mental 
illness or prescription of a psychoactive medication, compared to individuals without 
mental illness or psychoactive medication prescription.      
Individuals who smoked with comorbid MMI and diabetes, comorbid MMI and CHD and 
comorbid MMI and hypertension had comparable recorded rates of smoking cessation 
advice compared to smokers without MMI and the comparator chronic disease. To date, 
there have been no similar comparisons between recorded rates of smoking cessation 
advice in individuals with comorbid MMI and physical health problems with recorded 
rates of smoking cessation advice in individuals with chronic physical health problems 
without MMI. These findings are therefore novel.   
Although the recording of smoking cessation advice for certain chronic diseases is 
incentivised through the Quality and Outcome Framework (QOF), prescribing of NRT is 
not incentivised for any chronic disease. The impact of the QOF on rates of recording of 
smoking cessation in primary care has been investigated. For example Taggar and 
colleagues reported that since the introduction of the QOF in 2004, there had been a 
substantial increase in the recording of smoking status and cessation advice in primary 
care, which was sustained over time (Taggar et al., 2012). They also reported that factors 
such as: greater social deprivation, being female and having a chronic medical condition, 
were associated with an increased likelihood of having a recent recording of smoking 
status or have smoking cessation advice recorded. They also found that since the 
introduction of the QOF, the strongest characteristic associated with recording of smoking 
status and cessation advice was the presence of comorbidity. The findings in this cohort 
appear to echo this: as the presence of comorbidity (MMI and diabetes, MMI and CHD and 
MMI and hypertension) was associated with an increased likelihood of smoking cessation 
advice being recorded.  
In this study, the odds ratio of prescription of NRT in smokers with MMI without a 
comorbid chronic physical disease (diabetes, CHD or hypertension) was lower than NRT 
prescription rates in smokers without MMI with the comparable comorbid chronic physical 
disease (diabetes, CHD and hypertension). This finding is in keeping with that of 
Szatkowski and McNeill, (2013), who reported lower rates of NRT prescription per 
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consultation in individuals with a mental illness or prescription of a psychoactive 
medication, compared to individuals without mental illness or psychoactive medication 
prescription.  
In this cohort when NRT prescription rates for smokers with MMI and a comorbid chronic 
physical disease (diabetes, CHD and hypertension) were compared to individuals who 
smoked with a chronic physical disease (diabetes, CHD and hypertension) without MMI, 
there was no significant difference in NRT prescription rates. To my knowledge studies 
comparing rates of NRT prescription in individuals with comorbid MMI and a physical 
health disorder with rates of NRT prescription in individuals with a physical health 
disorder without MMI have not been done. This finding again suggests that physical health 
comorbidity is associated with higher rates of NRT prescription in individuals with MMI.  
5.5.4 Rates of smoking cessation advice and NRT prescription in 
individuals with schizophrenia compared to bipolar 
disorder: 
In this cohort, there was no difference in recorded rates of smoking cessation advice or 
prescription of NRT in smokers with schizophrenia compared to smokers with bipolar 
disorder. While there have been studies comparing rates of NRT use in individuals with 
severe mental illness and “general mental illness” (Bowden et al., 2011), NRT use was 
self-reported retrospectively in a small sample size. Therefore this study is novel in its 
comparison of recording of rates of cessation advice and NRT prescription in a large 
epidemiological cohort of individuals with major mental illness within primary care.  
5.5.5 Possible Reasons for the study findings: 
Heavy smoking in individuals with schizophrenia has been associated with increased 
positive symptoms and it is hypothesised that individuals may self-medicate with tobacco 
and nicotine in an attempt to alleviate distressing and troubling symptoms (Goff et al., 
1992). Nicotine is known to act on various neurotransmitters and may be associated with 
increased positive reinforcement in individuals with MMI (Picciotto and Corrigall, 2002). 
Smoking is also known to increase the metabolism of some antipsychotic drugs (Desai et 
al., 2001) and some individuals may smoke heavily to reduce the adverse effects of 
antipsychotic medication.   
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It is also recognised that individuals with schizophrenia often have difficulty in filtering 
out unnecessary information, thought to be secondary to abnormalities in sensorimotor 
gating (Kumari and Sharma, 2002), and it has been reported that cigarette smoking can 
improve sensory gating in individuals with schizophrenia (Adler et al., 1998). This may 
potentially partly explain the increased smoking rates in individuals with schizophrenia. 
Additionally, many individuals with MMI who consume tobacco, may spend time in 
settings that tolerate smoking and so may experience less stigma associated with smoking 
and less pressure to quit than the general population (Bayer and Stuber, 2006). As 
highlighted in Chapter 1, smoking has been seen as part of psychiatry’s culture, and so 
these factors in combination, may in part explain the high smoking rates seen in this cohort 
of individuals.   
While it is recognised that successful smoking cessation in all individuals is challenging, a 
number of factors which predict success in the general population are the same as those 
which predict success in individuals with MMI. These factors include; pharmacotherapy 
for nicotine dependence, confidence in ability to quit and age at initiation of smoking 
(Culhane et al., 2008). Therefore it is clear that in order to reduce the high smoking rates in 
individuals with MMI, appropriate access to NRT is essential. Reasons as to why in this 
cohort, rates of recording of smoking cessation advice and NRT prescription were less in 
individuals with MMI are multifactorial and likely include patient and clinician factors.  
It has been hypothesised that the cognitive deficits in frontal executive function in 
particular in attention among individuals with schizophrenia, may contribute to the low 
success rates of smoking cessation (Moss et al., 2009). There is also some evidence to 
suggest that the perceived health risks associated with smoking may be lower in 
individuals with schizophrenia (Kelly et al., 2012). Individuals with MMI may also be 
ambivalent to stopping smoking due to the absence of positive role models of ex-smokers, 
tolerance of smoking in mental health environments despite smoking bans in the wider 
society (The Scottish Government, 2008) and previous experience of cigarettes being used 
as positive reinforcement in token economies (Gustafson, 1992). These factors may 
contribute to lower rates of individuals with MMI seeking out opportunities to stop 
smoking.  
Possible clinician factors leading to reduced smoking cessation advice recording and NRT 
prescription may include: clinician smoking status, clinician attitude to smoking (Stead et 
al., 2009), stigma, lack of specific information regarding prescribing of smoking cessation 
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therapies in individuals with MMI and potentially perceived hopelessness in achieving 
abstinence by the clinician (Williams and Ziedonis, 2006). 
However despite the combination of high smoking rates, potential perceived beneficial 
effects of smoking (in terms of positive symptoms, medication side effect management and 
cognitive improvement) and possible ambivalence to smoking cessation, there is evidence 
that individuals with severe mental illness (SMI) are able to successfully quit smoking, 
despite extensive histories of heavy smoking. Dickerson and colleagues, (2011) 
interviewed 78 individuals with SMI who had successfully quit smoking for an average of 
7.4 years (± 8.6) after smoking for a mean of 25.3 years (± 11.4). In their cohort, the 
primary reasons for quitting smoking were health concerns and cost of cigarettes and the 
main contributing factors to achieving abstinence were; social support from friends/family, 
direction from a doctor, use of NRT and the advice of friends who had previously quit. 
This study therefore reinforces the importance of providing adequate smoking cessation 
advice and appropriate prescription of NRT for smokers with MMI. With the 
implementation of changes to smoking laws within mental health institutions later this 
year, acute admission units, may present a route to discussing smoking cessation and 
indeed NRT prescription.    
5.6 Strengths and limitations: 
Strengths of this study include the large sample size (almost 1.8 million individuals) and so 
it is likely to be representative of the wider Scottish population.  The rate of a recorded 
diagnosis of diabetes of 5.2% is similar to the Scottish estimate of 4.3% (Diabetes.org, 
2012) and the rate of a recorded diagnosis of CHD of 5.7% is also similar to the British 
Heart Foundation (BHF) estimates of male prevalence of CHD of 7.5% and female 
prevalence of 5.2% (Coronary Heart Disease Statistics, 2012). Although the rate of a 
recorded diagnosis of hypertension in this cohort was 16.3%, which is lower than the 
Scottish estimates of around one third (ScotPHO High Blood Pressure Prevalence, 2012). 
It is well recognised that under-diagnosis and under-treatment of hypertension is a major 
problem- with estimates of between 11-14% of individuals with hypertension receiving no 
treatment (HSCIS Hypertension 2012). The estimated prevalence in this cohort is similar 
to the OQF hypertension prevalence rate of 12.5% for the same contract year (QOF 
Scotland 2006/2007).  
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The rate of a recorded diagnosis of MMI (namely bipolar disorder and schizophrenia 
combined) in this cohort of 0.9% is lower than population estimates of 2% (when the 
disorders are combined) (Saha et al., 2008; Ferrari et al., 2011). This may reflect both 
under-diagnosis compared to epidemiological estimates and under-recording of MMI in 
primary care. In particular there is considerable debate and variation in the definitions and 
prevalence of bipolar disorder and this has likely impacted on the estimated prevalence 
rates in this cohort. Other possible reasons for the lower than expected recorded prevalence 
rate of MMI, is that although individuals with MMI are known to secondary care services 
they may not be recorded within primary care. Additionally some individuals may not be 
in contact with either primary or secondary care and so would be missing from this study 
population. These factors represent limitations of these data.  
The data used in this study is from 314 primary care practices and is routine clinical data. 
As such there may be variability of diagnostic coding for all the conditions included in this 
study. This is a limitation of the design of this analysis whereby Read Codes without 
confirmatory interviews were used to define diagnoses. A further limitation is the potential 
for smoking status to be noted and where appropriate smoking cessation advice given, but 
for this advice not to be recorded on the primary care clinical record. It was also 
impossible to determine from our data if there had been previous attempts at smoking 
cessation and if there was historical NRT prescription use. This is again a limitation of the 
design of this study and could only be overcome by detailed review of individual electronic 
records and where appropriate paper case notes.  
A further limitation of this study is with regard the exclusion of individuals with missing 
data. Missing data occurred more frequently in individuals with MMI. Although reasons 
for this are unclear. Missing data may be: missing completely at random (MCAR), missing 
at random (MAR) or not missing at random (NMAR) and possible reasons for missing data 
need to be considered. It is possible that in the SPICE dataset the presence of MMI may 
have impacted on the likelihood of data on smoking status being missing, although this 
was impossible to determine. As the data was cross-sectional, individuals with missing 
data were excluded from the analysis. Although this in itself has limitations and 
consequences for data interpretation it was felt that given the large sample size, this was 
the most suitable action. 
The impact of the Quality and Outcome Framework (QOF) incentivising the recording of 
smoking status and the recording of smoking cessation advice in certain chronic diseases 
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also has to be considered.  Since the introduction of the QOF in 2004, recording of 
smoking status in individuals aged 15-75 with a physical comorbidity has been 
incentivised. From 2004 until 2008, individuals with a chronic disease (namely diabetes, 
CHD, hypertension, asthma, COPD, TIA or stroke) had both smoking status and smoking 
cessation advice incentivised. For the smoking status indicator target to be achieved, it was 
required that for any individual with one or any combination of the aforementioned chronic 
diseases, smoking status should be recorded in the past 15 months. For those who smoked, 
smoking cessation advice or referral to a specialist service, where available, within the 
previous 15 months was also incentivised. In 2008 the list of chronic diseases incentivised 
was expanded to include CKD, schizophrenia, bipolar disorder and related psychoses. 
Therefore smoking cessation advice for individuals with MMI was not specifically 
incentivised by the QOF until 2008. As this data was captured in March 2007 this may 
partly explain the differences in smoking cessation advice in those with MMI. Of note 
however is that NRT prescription is not (and indeed has never been) incentivised in the 
QOF.  
5.7 Conclusions: 
Smoking rates were significantly higher in individuals with a record of MMI compared to 
individuals in the primary care cohort without MMI and with the other chronic diseases 
investigated: diabetes, CHD and hypertension. Despite this, rate of recording of smoking 
cessation advice was significantly lower in individuals with MMI compared to the rate in 
individuals with a chronic disease without MMI and individuals with MMI and comorbid 
diabetes, CHD and hypertension. NRT prescribing also occurred less frequently in smokers 
with MMI compared to smokers with comorbid diabetes and MMI and smokers with 
diabetes without MMI. These findings are suggestive of inequalities in access to health 
care advice and prescribing in individuals with MMI compared to individuals without 
MMI within primary care.  
Cigarette smoking remains a major modifiable risk factor for many chronic diseases and as 
such smoking cessation is recognised as being one of the most cost effective methods for 
improving an individual’s health and wellbeing. Given the particularly high rates of 
smoking and evidence of higher levels of nicotine dependence in individuals with MMI, 
smoking cessation represents an important and essential public health intervention for this 
cohort of patients. Given the effectiveness of smoking cessation advice and NRT 
prescribing in achieving abstinence from smoking and the evidence to suggest that 
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individuals with MMI are motivated to stop smoking, more needs to be done to promote 
these interventions for individuals with MMI.   
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Chapter 6 Possible mechanisms for inequality: 
Data from the Quality and Outcomes Framework 
(QOF) across the UK. 
Chapter Overview: 
This chapter describes in detail data from the primary care Quality and Outcomes 
Framework (QOF). Here access to healthcare is measured by comparing payment, 
population achievement and exception rates of two specific Mental Health (MH) indicators 
with two similar indicators for Diabetes and Chronic Kidney Disease (CKD). A 
comparison of these indicators across the whole of the United Kingdom (UK), with data 
from England, Scotland, Northern Ireland and Wales is used and a cross jurisdiction 
analysis is undertaken. Differences in rates of payment, population achievement and 
exception between indicators are described and possible reasons for the findings are 
explored. These measures are used as a proxy indicator of access to healthcare within 
primary care. 
6.1 Background to the Quality and Outcomes Framework 
(QOF): 
The General Medical Services’ Quality and Outcomes Framework (QOF), which was 
introduced into the UK in 2004, is an annual contract for the provision of care delivered by 
General Practices. It was introduced to standardise the improvement in the delivery of 
primary care and largely forms the basis of supplementary payment for General Practioners 
(GPs). Since Healthcare devolution in 1998 which gave the Scottish Parliament, the 
Northern Ireland Assembly and the National Assembly for Wales, greater power over 
health services and public health matters, the NHS, in terms of its management, structure 
and trajectory have continued to diverge (Greer, 2004). Although some QOF indicators 
differ between Scotland, England, Northern Ireland and Wales, many are consistent across 
the four countries and so QOF data analysis allows a unique opportunity for a cross 
jurisdiction comparison of health care and quality.  
The QOF is dynamic in nature and so in Scotland, England, Northern Ireland and Wales 
many indicators have changed since their inception in 2004. From 2006 onwards, any 
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changes made to the QOF occur after consensus decision by an expert panel, made up of a 
consortium of academic bodies, who review new evidence. Any changes suggested by this 
panel are then discussed, negotiated and a joint decision is made involving coordination 
between NHS Employers and the General Practitioners Committee (GPC) which are part 
of the British Medical Association (BMA). The National Institute for Health and Clinical 
Excellence (NICE) also provide independent expertise surrounding developing further 
clinical and health improvement indicators and this has been ongoing since April 2009.  
The QOF Advisory Board along with NHS Employers and the General Practitioners 
Committee (GPC) have developed a number of principles which are enshrined within the 
QOF. These principles include- 
 Indicators should, where possible, be based on the best available evidence, 
 The number of indicators in each clinical condition should be kept to the 
minimum number compatible with an accurate assessment of patient care, 
 Data should never be collected purely for audit purposes, 
 Only data which is useful in patient care should be collected. The basis of the 
consultation should not be distorted by an over emphasis on data collection. 
An appropriate balance has to be struck between excess data collection and 
inadequate sampling and 
 Data should never be collected twice for example data required for audit 
purposes should be data routinely collected for patient care and obtained from 
existing practice clinical systems. 
In the 2012/2013 Scottish, English, Northern Irish and Welsh QOF there were four main 
components, known as domains.  The four domains; clinical, organisation, patient 
experience and additional services, contain indicators against which the primary care 
practice scores points according to their level of achievement. In 2012/2013 practices 
could score up to a maximum of 1,000 points across 148 indicators.  
6.2 Clinical Domains: 
These are clinical indicators which exist across a wide variety of clinical conditions which 
are largely managed within primary care. The clinical conditions which are included in the 
QOF are common, associated with significant morbidity and are diagnostically 
unambiguous. The indicators that are set are evidence based, achievable by the primary 
care team, clearly defined and are able to be consistently extracted from the computerised 
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records of the general practices which participate in the QOF.  Since the inception of the 
QOF the clinical indicators have evolved and developed over time; for example in 
Scotland in 2004/2005 there were 76 indicators from 10 clinical domains however in 
2012/2013 there were 96 indicators from 22 clinical domains (Table 6-1). Similar changes 
to the QOF have occurred throughout the UK.  
 
 
Table 6-1  Clinical domains and indicators included in the Scottish QOF by year 2004/2005 to 2012/2013  
 
Clinical indicator area 
2004/05 - 2005/06 2006/07 - 2007/08 2008/09 2009/10 - 2010/11 2011/12 2012/13 
Number of 
indicators  
Total points 
available  
Number of 
indicators  
Total points 
available  
Number of 
indicators  
Total points 
available  
Number of 
indicators 
Total points 
Available 
Number of 
indicators  
Total points 
Available 
Number of 
indicators 
Total points 
Available 
Asthma 7 72 4 45 4 45 4 45 4 45 4 45 
Atrial Fibrillation - - 3 30 3 30 3 27 3 27 4 27 
Cancer 2 12 2 11 2 11 2 11 2 11 2 11 
CHD (Coronary Heart Disease) 15 121 10 89 10 89 8 76 10 87 7 69 
CKD (Chronic Kidney Disease) - - 4 27 4 27 5 38 5 38 5 36 
COPD 8 45 5 33 5 28 5 30 5 30 5 30 
Cardiovascular Disease - 
Primary Prevention 
- - - - - - 2 13 2 13 2 13 
Dementia - - 2 20 2 20 3 26 2 20 3 26 
Depression - - 2 33 2 33 3 31 3 53 3 31 
Diabetes Mellitus 18 99 16 93 16 93 15 92 17 100 15 88 
Epilepsy 4 16 4 15 4 15 4 14 4 15 4 14 
Heart Failure - - 3 20 3 20 4 29 4 29 4 29 
Hypertension 5 105 3 83 3 83 3 79 3 81 3 69 
Hypothyroidism 2 8 2 7 2 7 2 7 2 7 2 7 
Learning Disabilities - - 1 4 1 4 2 7 1 4 2 7 
Mental Health 5 41 6 39 6 39 10 40 6 39 10 40 
Obesity - - 1 8 1 8 1 8 1 8 1 8 
Osteoporosis - - - - - - - - - - 3 9 
(PAD)Peripheral Artery Disease - - - - - - - - - - 4 9 
Palliative Care - - 2 6 2 6 2 6 2 6 2 6 
Conditions assessed 
for smoking 
- - 2 68 2 68 2 60 2 60 4 73 
Stroke & Transient 
Ischaemic Attack 
10 31 8 24 8 24 7 22 8 24 7 22 
Totals  76  550  80  655  80  650  87 661 86  697 96 669 
 
 
6.3 Health care system changes since devolution: 
Since health care devolution, the NHS, in Scotland, England, Northern Ireland and Wales, 
has undergone significant change. In Scotland, integration of healthcare occurred, with the 
formation of fourteen geographical health boards and a “flat” organisational structure 
where the power previously associated with trusts was reduced (McLean et al., 2007). In 
England, the NHS took a “top down” approach to management and became focused on 
meeting targets- especially focusing on waiting times. This led to the formation of 
independent sector treatment centres, foundation trusts and private polyclinics (Bevan and 
Hood, 2006). However of late, focus has shifted towards providing a healthcare service 
based on patient choice resulting in more healthcare providers and increased privatisation 
especially within primary care. In Wales, after devolution, a relatively radical change to the 
NHS occurred. A strong public health focus resulted in local health boards working in 
partnership with local commissioning authorities (National Assembly for Wales, 2001). 
While in Northern Ireland difficulties in the peace process meant that changes to healthcare 
policy have been limited with periods of “direct rule” from UK ministers even after 
devolution (Greer, 2004).   
Given these changes, comparing quality of care across the UK has been challenging. 
However some QOF indicators are consistent across the UK and given the high uptake of 
the QOF amongst UK GPs, analysis of QOF data allows a unique opportunity for the 
comparison of the quality of care between the four countries to occur.  This cross- 
jurisdiction comparison is helpful to determine possible trends, potential areas of concern 
and possible patterns in performance that occur within primary care. 
6.3.1 QOF in Scotland: 
In 2012/2013, 988 practices out of 996 practices participated in the QOF (99.2%). The 
average number of points obtained by the GP practices was 979 out of a possible 1000 
(QOF Scotland, 2013). Ten Mental Health (MH) indicators for individuals with 
schizophrenia, bipolar disorder and other psychoses contributed a maximum of 40 points 
from the available 1,000 points in 2012/2013. QOF data is published by ISD Scotland and 
is readily available on their website.  
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6.3.2 QOF in England: 
As was seen in Scotland, the English QOF had a high uptake amongst GP practices, with 
8,020 practices covering over 99% of registered patients participating in the 2012/2013 
QOF. The average number of points achieved was 960.8 (QOF England, 2013). As with 
the Scottish 2012/2013 QOF, there were 148 indicators across four domains, making up a 
possible 1,000 points. In parallel with Scotland there were ten Mental Health indicators 
contributing to a maximum of 40 points. English QOF data is published by the Health and 
Social Care Information Centre (HSCIC) and again is readily available.  
6.3.3 QOF in Northern Ireland:  
In Northern Ireland in 2012/2013, every single GP practice (353) participated in the QOF. 
The average total number of points achieved was 981 (QOF Northern Ireland, 2013). As 
with Scotland and England, 148 indicators were measured across the four domains 
contributing to a maximum of 1,000 points. QOF data is published by the Department of 
Health, Social Service and Public Safety (DHSSPSNI) and is readily available on their 
website. In parallel with Scotland and England, in the 2012/2013 QOF there were ten 
Mental Health indicators contributing to a maximum of 40 points.  
6.3.4 QOF in Wales: 
In Wales in 2012/2013, every single GP practice (471) participated in the QOF. Again 148 
indicators were measured across the four domains contributing to a maximum of 1,000 
points. The average number of points achieved was 970 (QOF Wales, 2013). QOF data is 
published by the Welsh Government and is readily available on their website. In the 
2012/2013 Welsh QOF there were ten Mental Health indicators contributing to a maximum 
of 40 points.  
6.4 Concerns about the QOF: 
Although the QOF was introduced as a way of incentivising practices and improving the 
delivery of care, it has been recognised that it has a number of limitations. Despite the high 
rates of GP participation and high level of point attainment over a number of years (Sutton 
and McLean, 2006; Doran et al., 2008; Fischbacher et al., 2009; Kiran et al., 2010), the 
evidence for improvement in patient outcome has been inconsistent. For example Sermuga 
and colleagues, (2011) found that “good quality of care for hypertension was stable or 
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improving before pay for performance was introduced” and “(pay for performance) had no 
discernible effects on processes of care or on hypertension related clinical outcomes” 
(Sermuga et al., 2011). Similar findings have been found by Purdy and colleagues, (2011) 
who investigated emergency respiratory admissions and by Bottle and colleagues, (2008) 
who reported on rates of hospitalisation for coronary heart disease. These reports have all 
led to concerns about the effectiveness of the QOF in improving patient care.  
There is also recognition that the use of individual measures of care delivery (such as a 
single QOF indicator) as a marker of quality of clinical care is limited and that composite 
models (Holmboe et al., 2010) may be more helpful. It is thought that composite models 
highlight opportunities for further improvement in care provision even when the individual 
measures already indicate that care quality is high. Additionally there have been concerns, 
that the maximum payment thresholds for QOF indicators are too low- which may lead to 
some high performing practices wrongly assuming that their quality of care does not 
require further improvement (Fleetcroft et al., 2008; Ashworth and Kordowicz, 2010) and 
so further compromising patient care. The use of multiple QOF indicators within a 
composite model, as an alternative method of describing the quality of clinical care 
processes and outcome may be helpful in the future when evaluating quality of care 
delivered and is an area of recent interest. In a provisional study, de Wet and colleagues 
(2012), combined QOF indicators to generate a care bundle to measure the quality of 
evidence based care provision in nine practices in Scotland. They found that while 
compliance with individual QOF-based care bundle components was high, overall (‘all or 
nothing’) compliance with QOF-based care bundles was substantially lower. They 
therefore concluded that “care bundles may provide a more informed measure of care 
quality than existing methods” (de Wet et al., 2012). Their work has highlighted some 
further limitations of measuring and interpreting single indicator QOF rates.  
It has also been recognised that by financially rewarding practices for meeting a range of 
clinical, organisational and patient experience indicators a number of unintended adverse 
consequences may arise. The risks to the quality of care delivered, if payment is linked to 
delivery of care have long been recognised. A systematic review by Choix- Couturier and 
colleagues, (2000) identified a number of risks including: 
 Limited continuity of care, 
 Reduced range of services available, especially preventative and psychological 
support, 
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 Under use or improper use of emergency services resulting in delayed treatment, 
 Reduced confidence of patients, 
 Risk of ethical conflicts, 
 Reduced time for teaching and research, 
 Multiplicity of guidelines from different sources and  
 Conflicts of interest between physicians and patients.  
In particular there have also been concerns that patients may be coerced or refused care if 
they are non-compliant with the indicator QOF (Casalino and Elster, 2007; McDonald and 
Roland, 2009). In order to protect against this, a number of mechanisms have been built 
into the QOF system. In particular the setting of the target of the upper payment thresholds 
for indicators at under 100% and the facility to “except” patients from QOF indicator 
targets, if felt to be clinically appropriate.  
6.5 Exception Codes: 
Exception codes can be applied to individuals within certain indicators included in the 
QOF if felt to be clinically appropriate. These individuals are then excepted from the 
indicator denominator and therefore the payment calculation. Reasons for exception coding 
include: 
 patient refusal to attend; for this to occur, patients have to be recorded as refusing 
to attend for review after being invited to attend on at least three occasions during 
the financial year to which achievement payments relate (except in the case of 
indicator CS002(S), where the patient should have received the nationally agreed 
invitations from the recall system),  
 patients for whom it is not appropriate to review the chronic disease parameters 
due to particular circumstances, for example, a patient who has a terminal illness 
or is extremely frail, 
 patients newly diagnosed or who have recently registered with the contractor who 
should have measurements made within three months and delivery of clinical 
standards within nine months e.g. blood pressure or cholesterol measurements 
within target levels, 
 patients who are on maximum tolerated doses of medication whose levels remain 
sub-optimal, 
 patients for whom prescribing a medication is not clinically appropriate e.g. those 
who have an allergy, contraindication or have experienced an adverse reaction, 
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 where a patient has not tolerated medication, 
 where a patient does not agree to investigation or treatment (informed dissent) 
and this has been recorded in their patient record following a discussion with the 
patient, 
 where the patient has a supervening condition which makes treatment of their 
condition inappropriate e.g. cholesterol reduction where the patient has liver 
disease or 
 where an investigative service or secondary care service is unavailable. 
Although an individual may meet more than one reason for exception, only one exception 
code is recorded. The exact reason for exception coding is often not recorded by the GP 
surgery and data regarding exception rate by exception type is extremely limited.  
Since 2011/2012 there have been three clinical indicator groups where exception reporting 
is not applicable- Obesity, Learning Difficulties and Palliative Care. In obesity and 
learning difficulties the QOF indicator refers only to a register- with no numerator or 
denominator and so no exceptions are possible. In Palliative Care, the indicators are 
structured in such a way that neither a numerator nor denominator exists, therefore 
exception reporting does not apply. 
6.5.1 Exception coding across Scotland, England, Northern 
Ireland and Wales 
Reasons for exception reporting are fairly consistent across all four countries, except in 
Scotland, where failure to attend for a review after three invitations is classified as 
informed dissent (along with patient choice to not engage with a treatment and/or 
investigation). However this failure to attend after three invitations is considered as a 
separate exception code in England, Northern Ireland and Wales.  
6.5.2 Exception coding in MMI 
For individuals on the Mental Health register, exception reporting may additionally occur 
if the individual has an exception code for a similar indicator for another chronic disease - 
for example if an individual with diabetes and schizophrenia is excepted from the HbA1c 
diabetes target indicator, then they too will be excepted from the mental health blood 
glucose indicator. This does not occur across other comorbid chronic diseases (for example 
diabetes and coronary heart disease) even if the indicators are similar. 
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6.5.3 Concerns about exception reporting: 
Although exception reporting was introduced as a way of safe guarding patient care, it has 
been recognised that it has potential drawbacks. Exception reporting allows practices to 
receive the maximum renumeration without necessarily providing the required care for all 
eligible patients and so it is recognised that if exception rules are applied too readily or 
indeed inappropriately, high achievement scores may mask suboptimal care (Roland 2004). 
There are also concerns that exception coding can be used for financial exploitation- 
whereby patients in whom the target has been missed are falsely excluded, a practice 
known as “gaming”. In the UK however, there is little evidence of this practice occurring. 
Since the introduction of the QOF in 2004, there have also been concerns expressed by the 
Royal College of General Practioners (RCGP) that exception reporting may be 
disproportionately elevated in certain cohorts of the population- namely individuals with 
multiple chronic physical health problems, individuals living in more deprived areas and 
individuals with mental illness (NHS Alliance, 2004). These individuals are often the most 
vulnerable and most in need of high quality clinical care. This has led to concerns that 
individuals who are excepted may paradoxically experience a lower standard of treatment 
and care, due to increased focus on target attainment. Given the profile of individuals at 
most risk of being excepted, clinicians and academics have argued that this may contribute 
to a worsening of health inequalities (NHS Alliance, 2004). 
Exception rates are generally low (less than 6%) (Doran et al., 2008), with little evidence 
of widespread fraud or gaming (Simpson et al., 2007), but there are concerns about some 
practices achieving high scores by excepting or excluding unusually large numbers of 
patients (Doran et al., 2008; Gravelle et al., 2010). There is also wide variation in 
exception rates by clinical indicator, potentially indicating variation in prioritisation of care 
and subsequent inequality in level of care and delivery of treatment provided for certain 
QOF indicators.  
Despite there being concerns about the inappropriate use of exception reporting with 
subsequent calls for changes to be made (Audit Commission, 2011), General Practioners 
perceive exception reporting as an important and defensible safeguard against 
inappropriate or over treatment of patients (Campbell et al., 2011). To date little work has 
been done, comparing rates of exception coding by QOF indicator over time, exploring the 
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characteristics of low achievement indicators and exploring the characteristics of practices 
with high exception rates.  
6.6 Exclusion Criteria: 
Given the range of clinical indicators within a clinical domain, not all individuals on a 
clinical domain register, will be suitable for every indicator. Some individuals will 
therefore require to be excluded from a certain indicator for definitional reasons. For 
example for attainment of mental health indicator 16 at least 40% of patients aged 20 to 60 
in Scotland with schizophrenia, bipolar affective disorder and other psychoses should have 
a cervical screening test performed in the preceding 5 years, all males of any age and all 
females aged <20 and >60 require to be excluded from the QOF denominator as they are 
unable to participate in cervical screening.  
Similarly other indicators (and therefore the indicator denominator) may refer only to 
patients of a specific age group (e.g. 14 to 19 years old), patients with a specific status (e.g. 
those who smoke), or patients with a specific length of diagnosis (e.g. greater than 1 year). 
A further example of reasons for exclusion would be for the 2011/2012 QOF Asthma 3 
indicator (40% of patients with asthma between the ages of 14 and 19 should have a record 
of smoking status in the previous 15 months). Asthma patients who do not fit into this age 
bracket (i.e. individuals who are <14 and >19) are excluded from the denominator on the 
basis of the indicator definition. Exclusions are important considerations when calculating 
target attainment rates and in the generation of supplementary payment for GPs. 
6.7 QOF Data Collection and analysis: 
Although the QOF data that is collected is not primarily a research data set, the information 
gathered can be utilised for clinical audit purposes. Due to the level of detail obtained from 
each practice it can be used to help gauge healthcare equality. Information regarding 
exception reporting across many clinical domains can also be obtained and comparisons of 
exception rates within countries and between indicators can be reported.   
Given the consistency of some QOF indicators between Scotland, England, Northern 
Ireland and Wales, QOF data analysis allows a unique opportunity to compare health care 
data and aspects of quality of care across the four countries. In particular the ten Mental 
Health indicators were consistent across all four countries until 2013/2014.  
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6.8 Exception Rate Reporting Work to date: 
Studies on QOF data and in particular QOF exception reporting are infrequent and much of 
the literature surrounding exception reporting arise from English General Practices and as 
such are not directly comparable to the Scottish, Welsh and Northern Irish populations. 
While there have been studies investigating the relationship between remoteness and 
quality of care (McLean et al., 2007), practice size and QOF attainment (Wany et al., 2006) 
and the relationship between choice of clinical computing system and QOF attainment 
(Kontopantelis et al., 2013) studies investigating exception rates are infrequent.  
One recent paper, focused on rates of informed dissent as a particular reason for exception 
coding across clinical indicators (including three Mental Health Indicators). It found that 
higher rates of informed dissent were associated with: higher numbers of registered 
patients, higher levels of local area deprivation, and failure of the practice to secure 
maximum remuneration in the previous year (Doran et al., 2012). The relationship of 
higher exception coding rates and deprivation has been reported elsewhere; where one 
study found that “practices with a more deprived patient population were more likely to 
report ‘exceptions’ for Diabetes indicators.” Interestingly no such relationship was 
reported with the achievement of QOF targets (Sigfrid et al., 2006). However clearly more 
work regarding exception rates could be undertaken, especially within a Scottish primary 
care setting.  
6.9 Cross Jurisdiction QOF Work to Date: 
Studies comparing QOF data between the four UK countries are extremely limited. One 
study by Saxena and colleagues, (2007) investigated the relationship between practice size, 
caseload, deprivation and quality of care of patients with coronary heart disease, 
hypertension and stroke using primary care data from Scotland and England- however this 
study did not compare data between the countries during their analysis. To date only one 
study has directly compared indicator achievement rates, across Scotland, England, 
Northern Ireland and Wales. McLean and colleagues, (2007) compared achievement rate 
data across a number of indictors in coronary heart disease (CHD), hypertension, stroke 
and diabetes. They found that the quality of care in CHD, stroke, hypertension and diabetes 
in Wales was significantly lower than elsewhere in the UK particularly for the complex 
care process, intermediate outcomes and treatment QOF indicators (McLean et al., 2007).   
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There has also been one qualitative study investigating GPs attitudes to exception reporting 
across all four UK countries (Campbell et al., 2011). This qualitative analysis of practice 
staffs’ views on exception reporting in 27 practices recruited from Scotland (2), England 
(21), Northern Ireland (2) and Wales (2) found that practice staff viewed exception 
reporting as “an important and clinically necessary part of the QOF.” They justified 
exceptions on the basis of “practicing patient-centred care within a framework of 
population-based health measures”, or “because of the poor face validity of the indicators 
themselves for individual patients”. Practices generally reported that excepting patients 
was the “exception to the rule” and that it was an important and defensible safeguard 
against inappropriate treatment or over-treatment of patients. When directly questioned 
about inappropriate excepting they stated that this may occur in “other practices”. However 
some participants did acknowledge that exception reporting was used, particularly at the 
end of the financial year, to help meet unmet targets and to prevent the practice being 
penalised financially. Nonetheless the authors concluded that “most practices value and use 
exception reporting as a clinical safeguard to quality individual patient care within an 
evidence-based but largely population- level and inflexible framework” (Campbell et al., 
2011). Unfortunately in the study, no comment in potential differences in attitudes between 
the four countries was made. This would likely have been limited by the small numbers of 
non-English practices included in the study.  
To date little work has specifically focused on rates of payment, rates of population 
achievement and exception rates of Mental Health indicators compared to other physical 
health indicators. There have also been no studies which have specifically explored 
exception and achievement rates for Mental Health indicators as a potential marker of 
inequalities in health care provision across all four UK countries. 
6.10 Aims: 
1. To describe and compare indicator payment, population achievement and exception 
rates for Body Mass Index (BMI) and Blood Pressure (BP) recording for 
individuals with Major Mental Illness (schizophrenia, bipolar disorder and other 
psychoses) relative to Diabetes and Chronic Kidney Disease (CKD) across the UK 
in 2011/2012 and 2012/2013.   
2. To compare population achievement rates of these indicators across Scotland, 
England, Northern Ireland and Wales for 2011/2012 and 2012/2013.  
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6.11 Scientific rationale: 
The QOF incentivises Body Mass Index (BMI) and Blood Pressure (BP) recording for 
individuals with Major Mental Illness (schizophrenia, bipolar disorder and other 
psychoses). It also incentivises BMI recording in Diabetes and BP recording in Chronic 
Kidney Disease (CKD). As these indicators were defined in the same way and were 
consistent across the four UK countries, they were chosen for further study and 
comparison.   
6.12  Methodology: 
To explore the potential inequality in access to care, a detailed comparison of payment, 
population achievement and exception rates for two of the ten Mental Health (MH) 
indicators was undertaken for the two most recent QOF years (2011/2012 and 2012/2013). 
The indicators (Blood Pressure (BP) recording and Body Mass Index (BMI) recording in 
MMI) were chosen as both are clinically important and are consistent across the whole of 
the UK.  
For comparison, BP recording in Chronic Kidney Disease (CKD) and BMI recording in 
diabetes were chosen as proxy comparator indicators. Again both indicators are clinically 
important and were consistent across the whole of the UK.  
High blood pressure is an important cardiovascular risk factor. The health benefits gained 
from successful BP control (defined as systolic BP<140mmHg) are marked- with a 
predicted reduction in 28-44% of strokes and 20-35% of ischaemic heart disease (He and 
MacGregor, 2003). Frequent, accurate recording and monitoring of BP is also associated 
with reductions in systolic and diastolic BP (Glynn et al., 2010) and so is recognised as an 
important intervention.  BP recording in individuals with CKD and MMI has been included 
in the QOF since 2006 and 2011 respectively and given its consistency across the four 
countries within the UK, it was chosen for more detailed study.  
While it is recognised that poor diet and sedentary lifestyle has contributed to increased 
rates of obesity (Healthy Lives, Healthy People, 2011), Scotland in particular has one of 
the highest prevalence’s of obesity in Europe (28.2% of all adults have a BMI > 30kg/m2) 
(Grieve et al., 2013). In individuals with MMI, obesity occurs at an even higher rate 
(Ratliff et al., 2013; Allison et al., 1999) and there is evidence to suggest that obesity in 
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individuals with schizophrenia, has a profound influence on cardiometabolic risk compared 
to age, gender, race and BMI matched controls without MMI (Bailey et al., 2012). Reasons 
for the increased risk are unclear but may be partly explained by poor diet, physical 
inactivity and psychotropic medications. Across Europe a drive towards increased 
screening and preventative interventions, particularly for cardiovascular disease (European 
Guidelines on CVD Prevention, 2012) has led to a subsequent reduction in mortality (The 
Scottish Government Better Heart Disease and Stroke Care Action Plan, 2009). It is 
recognised that BMI recording in individuals with diabetes and MMI is an important 
public health issue. As such it has been included in the QOF since 2004 and 2011. Given 
its importance and its consistency across the UK it was chosen for more detailed study.  
These two pairs of indicators were the only directly comparable, consistent indicators 
which occurred across the UK in the QOF. 
Exception rate and payment rate data for recording of Body Mass Index (BMI) in 
individuals with Major Mental Illness (MMI) and Diabetes and BP recording in individuals 
with MMI and Chronic Kidney Disease (CKD) for 2012/2013 and 2011/2012 was 
obtained, from the Health and Social Care Information Service in England (HSCIS), 
Information Services Division (ISD) in Scotland, the Department of Health, Social Service 
and Public Safety in Northern Ireland (DHSSPSNI) and the Welsh Government Website.  
Practice performance and payment was calculated based on indicator achievement rate; 
whereby achievement rate equalled the number of individuals who had successfully met 
the indicator criteria (numerator) divided by the total number of individuals who could 
have achieved that indicator target (denominator) once exclusions and exceptions had been 
removed. However given that high exception rates may artificially inflate achievement 
(payment) rate and mask suboptimal care, population achievement rate can be calculated 
for individual practices by dividing the number of patients who achieved the target by the 
number of patients who were eligible for the target with exceptions included back into the 
denominator (Figure 6-1). This is felt to be a more useful measurement of quality of care.  
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Figure 6-1 Practice Payment and Population Achievement Rate Calculations 
 
For some practices exception rate data was not available. This was due to either 
inconsistencies with the exception and achievement rate data or due to the exception data 
not being definitive (ISD Scotland). Only practices with an indicator denominator >5 were 
included in this study.  
For both blood pressure and BMI, the Mental Health (MH) indicator was compared with 
the non-MH indicator within the same year and geographical location (i.e. within Scotland, 
England, Northern Ireland and Wales and also for the UK as a whole). As data were non-
parametric and paired (within countries by GP practice identifier), differences in rates 
within the same country were compared using a sign test. Median population achievement 
rate, payment rate and exception rate were calculated along with inter quartile range (IQR). 
For the UK wide figures, differences in rates were compared using a non-parametric 
equality of medians test. Differences in median population achievement rate between 
countries were compared to England using a quantile regression analysis weighted for 
practice denominator. Results are reported as percentage point difference with 99% 
confidence intervals (CI).  
6.13 Results:  
6.13.1 2012/2013: 
In Scotland, indicator payment and exception rate data were available for a maximum of 
97.3% GP practices (n=969). In England data was available for 99% of practices (n=7,938) 
and in Northern Ireland and Wales, QOF data was available for all (100%) GP practices 
(Northern Ireland n=353 and Wales n= 471).  
 
Practice Payment/                  = 
Indicator achievement rate   
 
number of individuals who have successfully met the indicator cri teria (numerator) 
number of individuals who could have achieved that indicator target (denominator)  
once exclus ions  and exceptions  have bee n removed. 
 
Population a chievement rate = number of patients  who achieved the target (numerator)  
number of patients  who were el igible for the target 
with exceptions  included (denominator + exceptions)  
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The percentage of the practice population on each disease register differed across the four 
countries to a significant extent; with higher prevalence found for Mental Health in 
Scotland and Wales (0.87% and 0.86%), for diabetes in England (4.83%) and for CKD in 
Wales (3.58%) (Table 6-2). 
 
 
 
 
 
 
Table 6-2 Raw prevalence rate of QOF Registers, with comparison to England 
2012/2013 
All significant difference in prevalence rate from England are shown in bold 
6.13.2 Body Mass Index (BMI) recording in Mental Health versus 
Diabetes:  
Unweighted indicator payment and population achievement rate for BMI recording in 
Major Mental Illness was significantly lower than the payment and population 
achievement rates for BMI recording in diabetes throughout the whole of the UK 
combined; payment rate 92.7% vs. 95.5%, p<0.001, population achievement rate: 84.0% 
vs. 92.5%,p<0.001 and for each country individually; payment rate 92.4% vs. 95.4%, 
p<0.001 and population achievement rate: 84.0% vs. 92.5%, p<0.001 in England; payment 
rate 94.0% vs. 96.3%, p<0.001 and population achievement rate: 82.2% vs. 92.1%, 
p<0.001 in Scotland; payment rate 93.3% vs. 95.2%, p<0.001 and population achievement 
rate 88.0% vs. 93.1%, p<0.001 in Northern Ireland and payment rate 92.2% vs. 95.6%, 
p<0.001 and population achievement rate: 82.1% vs. 91.8%, p<0.001 in Wales (Table 6-3).  
Although payment rates were consistently higher in Scotland for each of the indicators 
studied, higher exception rates led to the lower population achievement rates reported. 
Exception rate, for BMI recording in MMI was significantly higher than the exception rate 
for BMI recording in diabetes; for the UK combined; 7.4% vs. 2.3%, p<0.001 and for each 
country individually; 6.5% vs. 2.2%, p<0.001 in England; 11.8% vs. 3.5%, p<0.001 in 
Scotland; 4.3% vs. 1.6%, p<0.001 in Northern Ireland and 9.5% vs. 3.4%, p<0.001 in 
Wales. (Table 6-3) 
 England Scotland Northern Ireland Wales 
Mental Health 
Raw proportion (%) 
Ratio to England 
 
0.84 
1 
 
0.87 
1.04 
 
0.84 
1 
 
0.86 
1.02 
Diabetes 
Raw proportion (%) 
Ratio to England 
 
4.83 
1 
 
4.62 
0.96 
 
4.14 
0.86 
 
5.44 
1.13 
Chronic Kidney Disease 
Raw proportion (%) 
Ratio to England 
 
3.36 
1 
 
3.25 
0.97 
 
3.52 
1.05 
 
3.58 
1.07 
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Table 6-3 Payment, exception and population achievement rates for recording of BMI 
in MMI and diabetes across the UK 2012/2013 
Unweighted results All differences between payment, exception and population achievement rates 
for MMI vs. CKD for all countries individually and UK combined,  bold if statistically significant 
p<0.001 
6.13.3 Blood Pressure (BP) recording in Mental Health versus 
Chronic Kidney Disease:  
Unweighted indicator payment and population achievement rates for Blood Pressure (BP) 
recording in Major Mental Illness were also significantly lower than payment and 
population achievement rates for Chronic Kidney Disease (CKD) across the whole of the 
UK combined; payment rate: 94.1% vs.97.8%, p<0.001 and population achievement rate: 
87.0% vs. 97.1%, p<0.001; and for each country individually; payment rate: 93.8% vs. 
97.7%, p<0.001 and population achievement rate: 87.0% vs. 97.2%, p<0.001 in England; 
payment rate: 95.9% vs. 98.4%, p<0.001 and population achievement rate: 85.7% vs. 
97.2%, p<0.001 in Scotland; payment rate 94.9% vs. 97.9% and population achievement 
rate: 91.1% vs. 97.4%, p<0.001 in Northern Ireland and payment rate 94.0% vs. 97.8%, 
p<0.001 and population achievement rate 85.5% vs. 97.0%, p<0.001 in Wales (Table 6-4).  
Although payment rates were consistently higher in Scotland for each of the indicators 
studied, higher exception rates led to the lower population achievement rates reported. 
Exception rate was also significantly higher in MMI compared to CKD; 6.4% vs. 0.3%, 
p<0.001 for the UK combined, 5.6% vs. 0.0%, p<0.001 in England, 9.7% vs. 0.6%, 
 
 
 Payment Rate 
Median (IQR) 
Exception Rate 
Median (IQR) 
Population Achievement 
Rate Median (IQR) 
UK 
(n=9645) 
MMI  
 
92.7  (89.3-95.8) 
 
7.4  (3.3-15.9) 
 
84.0  (76.3-90.0) 
 
Diabetes 
 
95.5  (93.3-97.2) 
 
2.3  (0.9-4.7) 
 
92.5  (89.7-94.9) 
 
England 
(n=7856) 
MMI  
 
92.4  (88.5-95.5) 
 
6.5  (2.2-13.0) 
 
84.0  (76.4-90.0) 
 
Diabetes 
 
95.4  (93.2-97.1) 
 
2.2  (1.0-4.0) 
 
92.5  (89.8-94.9) 
 
Scotland 
(n=965) 
MMI  94.0  (91.4-97.2) 
 
11.8  (5.4 - 19.3) 
 
82.2  (74.4 – 88.9) 
 
Diabetes 96.3  (94.3-97.8) 
 
3.5  (1.9 -6.1) 
 
92.1  (89.4-94.6) 
 
Northern 
Ireland 
(n=353) 
 
MMI  93.3  (90.9-95.7) 
 
4.3  (0.0-8.1) 
 
88.0  (84.1-92.7) 
 
Diabetes 95.2 (93.3 – 97.1) 
 
1.6  (0.5-3.4) 
 
93.1  (91.2-95.0) 
 
Wales 
(n=471) 
MMI  92.2  (89.8-94.7) 
 
9.5  (4.2-15.4) 
 
82.1  (75.0-88.5) 
 
Diabetes 95.6  (93.4-97.3) 
 
3.4  (1.8-5.7) 
 
91.8  (88.9-94.0) 
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p<0.001 in Scotland, 3.4% vs. 1.6%, p<0.001 in Northern Ireland and 7.7% vs. 0.4%, 
p<0.001 in Wales (Table 6-4).  
  Payment Rate 
Median (IQR) 
Exception Rate 
Median (IQR) 
Population Achievement 
Rate Median (IQR) 
UK 
(n=9725) 
MMI 94.1  (90.9-97.1) 
 
6.4  (3.0-13.1) 
 
87.0  (81.3-91.7) 
 
CKD 97.8  (96.3-98.9) 
 
0.3  (0.0-1.0) 97.1  (95.5-98.4) 
England 
(n=7942) 
MMI 93.8  (90.5-96.8) 
 
5.6  (1.7-10.6) 
 
87.0  (81.3-91.7) 
 
CKD 97.7  (96.2-98.9) 
 
0.0  (0.0-0.8) 97.2  (95.5 – 98.4) 
Scotland 
(n=962) 
MMI 95.9  (93.1-100.0) 
 
9.7  (4.4- 15.7) 
 
85.7  (80.0 -  91.2) 
 
CKD 98.4  (97.0-99.5) 
 
0.6 (0.0-1.7) 97.2  (95.6 - 98.6) 
Northern 
Ireland 
(n=353) 
 
MMI 94.9  (92.4-97.5) 
 
3.4  (0.0-6.9) 
 
91.1  (86.7-94.3) 
 
CKD 97.9  (96.5-99.0) 
 
1.6  (0.5-3.4) 97.4  (96.2-98.9) 
Wales 
(n=468) 
MMI 94.0  (91.1-97.2) 
 
7.7  (3.5-13.2) 
 
85.5  (80.4-90.0) 
CKD 97.8  (96.3-98.8) 
 
0.4  (0.0-1.2) 97.0  (95.4-98.2) 
Table 6-4  Payment, exception and population achievement rates for recording of BP in 
MMI and CKD across the UK 2012/2013 
Unweighted results All differences between payment, exception and population achievement rates 
for MMI vs. CKD for all countries individually and UK combined,  bold if statistically significant 
p<0.001 
6.13.4 Differences between countries: 
The weighted median population achievement rates for BMI and BP recording in MMI  
were significantly lower in Scotland compared to England (BMI:-1.5% 99% CI -2.7 to -
0.3%, p<0.001 and BP: -1.8% 99% CI -2.7 to -0.9%, p<0.001). Population achievement 
rates were also lower in Wales compared to England (Table 6-5). Rates in Northern Ireland 
for both Mental Health indicators were significantly higher compared to England (BMI: 
2.1% 99%CI 1.1 to 3.0, p<0.001 and BP: 2.1% 99% CI 1.4-2.8%, p<0.001) (Table 6-5).  
Differences in weighted median population achievement rates for BMI recording in 
Diabetes and BP recording in CKD in Scotland, Northern Ireland and Wales were less 
marked compared to weighted median population achievement rates in England (Table 6-
5).  
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Table 6-5 Weighted Median Population Achievement Rate Percentage Point Difference from 
England by indicator for 2012/2013 with 99% Confidence Intervals weighted by practice denominator. 
All significant differences in percentage point from England are shown in bold 
 
6.13.5 2011/2012 
In Scotland, indicator achievement and exception rate data were available for a maximum 
of 97.3% of GP practices (n=969). In England data was available for 99% of practices 
(n=7,938) and in Northern Ireland and Wales, QOF data was available for all (100%) GP 
practices (Northern Ireland n=353 and Wales n= 471).  
Prevalence rates for the Mental Health, Diabetes and Chronic Kidney Disease (CKD) 
registers differed across the four countries to a significant extent; with higher prevalence 
rates for Mental Health found in Scotland and Wales (0.85% and 0.84%) for diabetes in 
England and Wales (4.62% and 5.26%) and for Chronic Kidney Disease in Wales (3.45%) 
(Table 6-6).  
  
 
 
 
 
 
 
 
 
  
England 
 
Scotland 
 
 
Northern Ireland 
 
Wales  
B
M
I R
ec
or
di
ng
 
Menta l Health (MH12) 
% point difference (99% CI) 
 
82.9 (76.0-88.5) 
 
-1.5 (-2.7 to -0.3) 
p<0.001 
2.1 (1.1 to 3.0) 
p<0.001 
-0.5 (-1.0 to -0.01) 
p=0.025 
Diabetes (DM02) 
% point difference (99% CI) 
 
92.2 (89.6-94.5) 
 
-0.5 (-1.0 to -0.05) 
p=0.004 
0.3 (-0.1 to 0.7) 
p=0.028 
-0.2 (-0.4 to -0.04) 
p=0.002 
B
P 
R
ec
or
di
ng
 
Menta l Health (MH13)  
% point difference (99% CI) 
 
86.1 (81.0-90.3) 
 
-1.8 (-2.7 to - 0.9) 
p<0.001 
2.1 (1.4 to 2.8) 
p<0.001 
-0.4 (-0.7 to 0.01) 
p = 0.013 
CKD (CKD02)  
% point difference (99% CI) 
 
97.0 (95.4-98.1) 
 
0.02 (-0.2 to 0.3) 
p=0.797 
0.2(0.01 to 0.4) 
p= 0.012 
-0.07 (-0.17 to 0.03) 
p=0.058 
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Table 6-6 Raw prevalence rate of QOF Registers, with comparison to England 
2011/2012 
All significant difference in prevalence rate from England are shown in bold 
6.13.6 Body Mass Index (BMI) recording in Mental Health versus 
Diabetes:  
Unweighted indicator payment and population achievement rate for BMI recording in 
Major Mental Illness was significantly lower than the payment and population 
achievement rates for BMI recording in diabetes throughout the whole of the UK 
combined: payment rate 92.3% vs. 95.7%, p<0.001 and population achievement rate: 
82.4% vs. 92.8%, p<0.001 and for each country individually; payment rate 92.2% vs. 
95.7%, p<0.001 and population achievement rate: 82.6% vs. 92.9%, p<0.001 in England; 
payment rate 93.5% vs. 96.0%, p<0.001 and population achievement rate 78.1% vs. 
92.1%, p<0.001 in Scotland; payment rate 92.5% vs. 95.5%, p<0.001 and population 
achievement rate: 86.7% vs. 93.2%, p<0.001 in Northern Ireland and payment rate 92.5% 
vs. 95.8%, p<0.001 and population achievement rate 80.0% vs. 91.9%, p<0.001 in Wales 
(Table 6-7).  
Although payment rates were consistently higher in Scotland for each of the indicators 
studied, higher exception rates led to the lower population achievement rates reported. 
Exception rate, for BMI recording in MMI was significantly higher than the exception rate 
for BMI recording in diabetes; for the UK combined; 8.9% vs. 2.8%, p<0.001 and for each 
country individually; 7.5% vs. 2.1%, p<0.001 in England; 14.3% vs. 3.5%, p<0.001 in 
Scotland; 4.8% vs. 1.7%, p<0.001 in Northern Ireland and 10.5% vs. 3.4%, p<0.001 in 
Wales. (Table 6-7) 
 
 
England Scotland 
 
Northern Ireland 
 
Wales 
Mental Health 
Raw prevalence rate (%) 
Ratio to England 
 
0.82 
1 
 
0.85 
1.04 
 
0.83 
1.01 
 
0.84 
1.02 
Diabetes 
Raw prevalence rate (%) 
Ratio to England 
 
4.62 
1 
 
4.43 
0.96 
 
4.00 
0.87 
 
5.26 
1.14 
Chronic Kidney Disease 
Raw prevalence rate (%) 
Ratio to England 
 
3.37 
1 
 
3.27 
0.97 
 
3.28 
0.97 
 
3.45 
1.02 
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  Payment Rate 
Median (IQR) 
Exception Rate 
Median (IQR) 
Population 
Achievement Rate 
Median (IQR) 
UK 
(n=9645) 
MMI  92.3  (87.5-95.7) 
 
8.9  (3.0-17.8) 82.4  (74.2-89.0) 
Diabetes 95.7  (93.6-97.4) 
 
2.8  (1.1-6.8) 92.8  (90.0-95.1) 
England 
(n=7998) 
MMI  92.2  (86.7-95.7) 
 
7.5  (2.5-14.3) 82.6  (74.5-89.2) 
Diabetes 95.7  (93.5-97.4) 
 
2.1  (0.9-4.0) 92.9  (90.2-95.2) 
Scotland 
(n=942) 
MMI  93.5  (90.7-96.8) 
 
14.3  (7.1 - 22.6) 78.1  (70.1-86.4) 
Diabetes 96.0  (94.0-97.7) 
 
3.5  (1.8-6.0) 92.1  (88.8-94.6) 
Northern 
Ireland 
(n=349) 
MMI  92.5  (90.0-95.2) 
 
4.8  (0.0-9.1) 86.7  (80.6-91.5) 
Diabetes 95.5  (93.5-97.1) 
 
1.7  (0.6-3.1) 93.2  (91.0-95.3) 
Wales 
(n=469) 
MMI  92.5  (88.2-95.5) 
 
10.5  (5.1-17.7) 80.0  (72.7-87.3) 
Diabetes 95.8  (93.6-97.5) 
 
3.4  (1.8-5.2) 91.9  (89.2-94.4) 
Table 6-7 Payment, exception and population achievement rates for recording of BMI 
in MMI and diabetes across the UK 2011/2012 
Unweighted results Differences between payment, exception and population achievement rates for 
MMI vs. CKD for all countries individually and UK combined, bold if statistically significant 
p<0.001 
6.13.7 Blood Pressure (BP) recording in Mental Health versus 
Chronic Kidney Disease:  
Unweighted indicator payment and population achievement rates for Blood Pressure (BP) 
recording in Major Mental Illness were also significantly lower than payment and 
population achievement rates for Chronic Kidney Disease (CKD) across the whole of the 
UK combined; payment rate 94.1% vs. 97.8%, p<0.001 and population achievement rate: 
86.3% vs. 97.2%, p<0.001; and for each country individually; payment rate 93.9% vs. 
97.7%, p<0.001 and population achievement rate 86.4% vs. 97.2%, p<0.001 in England; 
payment rate 95.9% vs. 98.3% and population achievement rate: 84.1% vs. 97.5%, 
p<0.001 in Scotland; payment rate 94.7% vs. 98.0%, p<0.001 and population achievement 
rate: 90.0% vs. 97.5%, p<0.001 in Northern Ireland and payment rate 94.4% vs. 97.8%, 
p<0.001 and population achievement rate: 84.8% vs. 97.1%, p<0.001 in Wales (Table 6-8).  
Although payment rates were consistently higher in Scotland for each of the indicators 
studied, higher exception rates led to the lower population achievement rates reported. 
Exception rate was also significantly higher in MMI compared to CKD; 6.4% vs. 0.3%, 
p<0.001 for the UK combined, 5.9% vs. 0.0%, p<0.001 in England, 10.9% vs. 0.6%, 
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p<0.001 in Scotland, 3.7% vs. 0.0%, p<0.001 in Northern Ireland and 8.3% vs. 0.3%, 
p<0.001 in Wales (Table 6-8).  
  Payment Rate 
Median (IQR) 
Exception Rate 
Median (IQR) 
Population 
Achievement Rate 
Median (IQR) 
UK 
(n=9725) 
MMI 94.1  (90.6-97.4) 
 
7.4  (2.5-17.8) 86.3  (80.0-91.3) 
CKD 97.8 (96.3-99.1) 
 
0.3  (0.0-1.8) 97.2  (95.5-98.6) 
England 
(n=8019) 
MMI 93.9  (90.3-97.2) 
 
5.9  (1.9-11.4) 86.4  (80.4-91.4) 
CKD 97.7  (96.2-99.0) 
 
0.0  (0.0-0.7) 97.2  (95.5-98.5) 
Scotland 
(n=902) 
MMI 95.9  (92.9-100.0) 
 
10.9  (5.6 -17.2) 84.1  (77.4 – 89.8) 
CKD 98.3  (97.0-99.5) 
 
0.6  (0.0-1.6) 97.5  (95.5-98.7) 
Northern 
Ireland 
(n=349) 
MMI 94.7  (91.7-97.3) 
 
3.7  (0.0-7.7) 90.0  (84.5-93.8) 
CKD 98.0  (96.8-99.0) 
 
0.0  (0.0-0.6) 97.5  (96.0-98.8) 
Wales 
(n=471) 
MMI 94.4  (91.2-97.7) 
 
8.3  (3.9-14.1) 84.8  (77.6-90.0) 
CKD 97.8  (96.2-99.0) 
 
0.3  (0.0-1.0) 97.1  (95.2-98.4) 
Table 6-8  Payment, exception and population achievement rates for recording of BP in 
MMI and CKD across the UK 2011/2012 
Unweighted results Differences between payment, exception and population achievement rates for 
MMI vs. CKD for all countries individually and UK combined, bold if statistically significant 
p<0.001 
6.13.8 Differences between countries: 
Weighted median population achievement rates for BMI and BP recording in MMI  were 
significantly lower in Scotland compared to England (BMI:-3.6% 99% CI -4.8 to -2.5%, 
p<0.001 and BP: -2.1% 99% CI -3.0 to -1.3%, p<0.001). Rates were also lower in Wales 
compared to England (Table 6-9). Rates in Northern Ireland for both Mental Health 
indicators were significantly higher compared to England (BMI: 2.5% 99%CI 1.6 to 3.4, 
p<0.001 and BP: 2.0% 99% CI 1.4 to 2.6%, p<0.001) (Table 6-9).  
Differences in weighted median population achievement rates for BMI recording in 
Diabetes and BP recording in CKD in Scotland, Northern Ireland and Wales were less 
marked compared to weighted median population achievement rates in England (Table 6-
9). 
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 Table 6-9 Weighted Median Population Achievement Rate Percentage Point Difference 
from England by indicator for 2011/2012 
 99% Confidence Intervals weighted by practice denominator. All significant differences in 
percentage point from England are shown in bold 
6.13.9 Summary of Main Findings: 
Throughout the UK, population achievement and payment rates for recording of BMI and 
Blood Pressure in MMI were significantly lower than population achievement and 
payment rates for recording of BMI and Blood Pressure in diabetes and CKD.  In general 
mental health population achievement rates were lower in Scotland and Wales compared to 
England but were higher in Northern Ireland compared to England. When directly 
comparing indicators which were of the same type, higher exception rates and lower 
population achievement and payment rates in MMI compared to diabetes and CKD were 
found across the whole of the UK. This is the first study to directly compare similar 
measurement indicator population achievement rates for different chronic diseases across 
Scotland, England, Northern Ireland and Wales. While the full reasons for these findings 
are unclear, the clinical, societal and financial implications of undetected, raised BMI and 
Blood Pressure would be significant. 
6.14  Discussion:  
6.14.1 Comparison with existing literature: 
Almost ten years after the introduction of the QOF, there have been few studies comparing 
indicator achievement rates across the different countries. Changes in healthcare policy 
since devolution, with increased integration in Scotland (McLean et al., 2007), a “top 
  
England  
 
Scotland 
 
 
Northern Ireland 
 
Wales  
 
B
M
I R
ec
or
di
ng
 
 
Mental Health (MH12) 
% point difference (99% CI) 
 
 
82.6 (74.5-89.2) 
 
 
 
-3.6 (-4.8 to -2.5) 
p<0.001 
 
2.5 (1.6 to 3.4) 
p<0.001 
 
-0.4 (-0.9 to -0.1) 
p=0.025 
 
Diabetes (DM02) 
% point difference (99% CI) 
 
92.9 (90.2-95.2) 
 
 
 
-0.8 (-1.2 to -0.3) 
p<0.001 
 
0.3 (0.04 to 0.7) 
p=0.025 
 
-0.3 (-0.4 to -0.9) 
p<0.001 
B
P 
R
ec
or
di
ng
 
 
Mental Health (MH13) 
% point difference (99% CI) 
 
86.4 (80.4-91.4) 
 
 
 
-2.1 (-3.0 to -1.3) 
p<0.001 
 
2.0 (1.4 to 2.6) 
p<0.001 
 
-0.4 (-0.8 to -0.1) 
p=0.002 
 
CKD (CKD02) 
% point difference (99% CI) 
 
 
97.2 (95.5-98.5) 
 
0.002 (-0.2 to 0.2) 
p=0.979 
 
0.2(0.01 to 0.4) 
p=0.006 
 
-0.009 (-0.11 to 0.09) 
p=0.803 
157 
 
down,” “target meeting” approach in England (Bevan and Hood, 2006), a strong public 
health focus in Wales (National Assembly for Wales, 2001) and limited change in 
Northern Ireland due to a protracted peace process (Greer, 2004) has led to difficulties in 
cross-national comparisons of healthcare systems and outcomes. However the consistency 
across the UK of the QOF indicators included in this study, has allowed a comparison of 
the quality of care between the four countries.  This cross- jurisdiction comparison is 
helpful to determine trends, potential areas of concern and possible patterns in performance 
that occur within primary care. The finding of lower population achievement rates and 
higher exception rates for both mental health indicators across all four countries improves 
not only the generalisability of these results but also suggests that this is a UK wide 
pattern.  
Difference in prevalence rates of the registers included in this study across the four 
countries is of note. In particular the finding of the relatively high prevalence rate of the 
diabetes register in England compared to Scotland and Northern Ireland. This finding was 
unexpected, and represents a marked increase in the English estimated prevalence of 
diabetes from the 2004/2005 QOF data. This finding may in part be explained by 
differences in disease prioritisation since devolution within the four countries.  
The finding of higher population achievement rates in Northern Ireland, and lower 
population achievement rates in Scotland and Wales compared to England has been 
reported elsewhere, although for intermediate outcome and treatment indicators for CHD, 
stroke, hypertension and diabetes (McLean et al., 2007). Potential reasons for the higher 
population achievement rates in Northern Ireland may include better health, improved 
population stability or a younger population compared to the rest of the UK. There is 
evidence from England that practices with a higher proportions of patients over the age of 
65 have lower achievement rates (Doran et al., 2006).   
6.14.2 Differences between BMI Recording in Mental Health 
versus Diabetes: 
The findings of significantly lower population achievement rates for BMI recording in 
MMI compared to Diabetes, is of clinical concern. Given the move towards primary 
prevention, a population achievement rate of 78%, for recording of BMI in MMI in 
Scotland suggests that although the majority are receiving QOF level care, there is room 
for improvement as the remaining proportion may be missing out on opportunities for 
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screening and subsequent intervention to address cardiometabolic risk. Whether this 
improvement is possible, given that the onus is on individuals to attend their practice, 
would be best explored through subsequent studies.  
Reasons for the lower achievement rates observed in the MMI indicators may be best 
considered in relation to the patient, the practice and the indicator itself. The QOF does not 
incentivise home visits and so, if individuals do not attend, they are more likely to be 
excepted: this may account for higher levels of exceptions in individuals with MMI, who at 
times can be difficult to engage with. It is also recognised that individuals who are 
housebound (which is a reason for exception) have higher rates of mental illness (Joan et 
al., 2011). While obesity is recognised as a major public health problem, there are many 
barriers to its management including- lack of motivation on the patient’s part (Mercer and 
Tessier, 2001). These reasons may contribute to the lower population achievement rates 
and higher exception rates reported in this study.  
Practice factors contributing to lower achievement rates may include GPs or practice 
nurses perceiving a lack of training, inadequate facilities and poor success rates within 
obesity management (Mercer and Tessier, 2001). The primary care clinician may also 
perceive that obesity should be addressed within secondary care and so they may focus 
their consultation on adherence to antipsychotic medications and assessing suicide risk 
(which are not QOF incentive outcomes). However given the high rates of obesity within 
the UK and the planned retirement of the BMI indicator for the 2014/2015 QOF in 
England this finding is of concern (QOF England, 2015),  as it may lead to further losses in 
opportunity to intervene and improve the physical health of this group of individuals.  
6.14.3 Differences in BP Recording in Mental Health versus 
Chronic Kidney Disease: 
The findings of significantly lower population achievement rates for BP recording in MMI 
is also of clinical concern. While it is unclear from this data what proportion of those with 
a recorded BP had normal or elevated BP, it is recognised that frequent, accurate recording 
and monitoring of BP is associated with reductions in systolic and diastolic BP and 
therefore better control. BP monitoring for individuals with schizophrenia on antipsychotic 
medication, has also been recommended in the NICE guideline for schizophrenia since 
2009 (NICE Clinical Guideline 82, 2009). Although the drive towards a more integrated 
approach to the management of the physical health of individuals with MMI, has been 
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relatively recent (London School of Economics, 2012: Schizophrenia Commission, 2012), 
the evidence for poor cardiometabolic health in this cohort of patients has been apparent 
since the late 1990s and early 2000s (Harris and Barraclough, 1998; Brown et al., 2000) 
and has been reflected within clinical guidelines over the past 5 years. This disparity in 
recording of BP in individuals with MMI compared to individuals with CKD is of concern 
and highlights possible inequalities in access to incentivised healthcare.    
6.14.4 Other possible reasons for the differences observed: 
While it is recognised that individuals with MMI experience many barriers to care, one 
possible reason for the lower population achievement and payment rates observed may 
include the stigma associated with mental illness, as well as the perceived separation of 
physical and mental healthcare by the patient, their carer, GPs and psychiatrists. Although 
individuals with MMI have more physical health problems than the general population, 
inequalities such as those outlined in Chapter 1 are persistently reported for both the access 
to and the quality of a range of physical healthcare services (Lambert and Newcomer, 
2009; de Hert 2011a).  
However, there are likely to be several other factors which interact to contribute to the 
lower population achievement and payment rates observed in the MMI indicators. Firstly, 
the Mental Health BMI and BP indicators were introduced into the QOF in 2011/2012, 
while the BMI measurement indicator for Diabetes has been part of the QOF since its 
inception in 2004/2005 and, similarly, the BP measurement indicator QOF for CKD was 
introduced in 2006/2007. It is recognised that indicator payment rates improve with time 
and then plateau (Reeves et al., 2010) and so the disparity in length of time that the 
indicators have existed may contribute to the differences in population achievement and 
payment rate observed.  
Another possible explanation may be that while Blood Pressure recording and BMI 
calculation have long been recognised as important aspects of the management of CKD 
and Diabetes - as evidenced by guidelines dating back many years - this aspect of 
monitoring and treatment for individuals with MMI has been highlighted only relatively 
recently. A further important factor that may contribute to the lower population 
achievement and payment rates observed in the MMI indicators is that of multimorbidity 
and the inadequacy of a single-disease focused practice and organisation that currently 
dominates clinical work in the NHS. This often leads not only to the separation of the 
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physical and mental health needs of patients, but also the separation of the multiple 
physical health needs of a complex multimorbid patient into single organ or single disease 
focused specialists.   
6.15 Strengths and Limitations: 
This is the first study to directly compare population achievement, payment and exception 
rates for individual mental health indicators with other individual chronic disease 
indicators across the whole of the UK. These results may act as a starting point for a more 
detailed examination of the possible reasons for these findings. The national scope of this 
study, with data from England, Scotland, Wales and Northern Ireland and the high level of 
uptake of the QOF within UK practices represents strengths of this study, but some 
limitations are acknowledged.  
The QOF data used is a payment rather than quality monitoring system and was obtained at 
a practice rather than a patient level basis- this meant that patient level case mix adjustment 
was not possible. Given that individuals with a chronic disease are likely to have more than 
one (Barnett et al., 2012), it was not possible to assess the effect of multimorbidity on 
achievement and exception rates and is a limitation to this work. As individual patients can 
appear in more than one chronic disease indicator denominator, the level of patient overlap 
between the three chronic diseases (MMI, CKD and diabetes) investigated was not 
ascertained.  
A further limitation is that due to exception reporting being under individual practice 
control, there may be some variation in practice policy, both locally and between countries. 
For example some practices in certain parts of the country may not directly record all rates 
of exception if they have exceeded the upper payment threshold for the indicator however 
this may not be the case in other parts of the country. Differences in practice performance 
are also associated with choice of clinical computing system (Kontopantelis et al., 2013) 
and given that data were obtained from the whole of the UK, variation in clinical 
computing software likely occurred and may be a confounder. While data from two 
contractual years has been reviewed, further longitudinal work is required to determine if 
these differences are sustained over a prolonged time frame.  
161 
 
6.16 Conclusions: 
Although rates of population achievement, payment and exception reporting vary across 
clinical indicators, this study has found evidence of: lower population achievement rates, 
lower payment rates and higher rates of exception reporting for BMI and BP recording in 
MMI compared to Diabetes and CKD, throughout the whole of the UK. Variation in 
population achievement rate of the mental health indicators across the UK, with generally 
lower rates in Scotland and Wales relative to England and higher rates in Northern Ireland 
was also found. Explanations for these findings are multifactorial and include patient, 
clinician and wider organisational factors. However, they may represent an element of 
inequality in access to healthcare for individuals with MMI compared to individuals 
without MMI. Given these findings, further investigation, for example through detailed 
auditing of patient level data, and monitoring of patterns of exception coding, along with 
continued monitoring of population achievement rate data, is required to ensure that the 
QOF indicators and indeed exception reporting is appropriately used within primary care. 
Continued efforts must also be made to reduce barriers and improve integration of primary 
and secondary care to provide higher quality healthcare for individuals with Major Mental 
Illness. 
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Chapter 7 Possible mechanisms for inequality:  
longitudinal data from the Scottish Quality and 
Outcomes Framework (QOF) 
 Chapter Overview: 
Further to the findings in Chapter 6, this chapter focuses on the QOF in Scotland and 
compares access to health care for individuals with MMI to a number of other chronic 
physical diseases using data from 2005/2006 until 2012/2013. Access to health care and 
potential inequalities are assessed using exception reporting data. Individual mental health 
indicators, single chronic disease indicators and composite indicator exception rates are 
compared to measure access to care and to determine possible inequalities in healthcare.  
7.1 Aims: 
1. To describe rates of exception reporting across different Mental Health indicators 
in Scotland compared to rates of exception reporting for other chronic physical 
health conditions. 
2. To determine if specific mental health indicators in Scotland have significantly 
different rates of exception reporting compared to specific indicators for asthma, 
epilepsy, diabetes, dementia, chronic kidney disease (CKD), chronic obstructive 
pulmonary disease (COPD) and hypertension. 
3. To determine if composite Mental Health indicators have significantly different 
rates of exception reporting compared to other composite clinical indicators, for the 
two most recent QOF years (2012/2013 and 20112/2012). 
4. To describe patterns of exception rates for each of the mental health indicators and 
their proxy comparator indicators over time (i.e. 2005/2006 to 2012/2013) within 
Scotland. 
7.2 Methodology: 
A retrospective survey of exception rate data available on the Quality and Outcome 
Frameworks (QOF) Information Services Division (ISD) of NHS Scotland, website for 
2005/2006 until 2012/2013 for all the Mental Health indicators was carried out. This data 
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is freely available and contains information on nearly all the 988 GP practices in Scotland 
which utilise the QOF scheme. 
Median rate of exception reporting for each Mental Health indicator and comparator 
physical health indicator, along with the 95% confidence interval (CI) and the inter-
quartile range (IQR) were calculated. Median rates were charted over time to determine 
trends in exception rate reporting.  
A number of proxy indicators for other chronic physical health conditions, deemed 
comparable to the Mental Health (MH) indicators were identified. As data was non-
parametric medians across different indicators over different years were calculated using a 
non-parametric equality of medians test. All statistical analysis were carried out in STATA 
version 12.  
7.2.1 Mental Health Indicators in the Scottish QOF over time: 
Mental health (MH) has been represented in the QOF since its inception in 2004/2005. 
Initially there were 5 indicators (Table 7-1).  
Short 
QOF 
Code 
Descriptor of Code 
No of 
points 
M inimum 
Threshold  
attainment 
Maximum 
Threshold 
attainment 
MH01 
 
The practice can produce a register of people with severe  long 
term-mental health problems who require and have agreed to 
regular follow-up 
7   
MH02 
 
The percentage of patients with severe long-term mental 
health problems with a review recorded in the preceding 15 
months. This review includes a check on the accuracy of 
prescribed medication, a review of physical health and a 
review of co-ordination arrangements with secondary care 
23 25 90 
MH03 
 
The percentage of patients on lithium therapy with a record of 
lithium levels checked within the previous 6 months 
3 25 90 
MH04 
 
The percentage of patients on lithium therapy with a record of 
serum creatinine and TSH in the previous 15 months 
3 25 90 
MH05 
 
The percentage of patients on lithium therapy with a record of 
lithium levels in a therapeutic range within the previous 6 
months 
3 25 90 
Table 7-1 Mental Health (MH) Indicators 2004/2005 
 
However in the 2006/2007 QOF a number of changes occurred; MH01 was reworded from 
“severe long term mental health problems” to specifically mentioning mental health 
disorders- namely schizophrenia, bipolar affective disorder and other psychoses;  MH03 
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was removed; MH06 and MH07 were added and MH02 was reworded and recoded as 
MH09.  These remained in place until 2010/2011 (Table 7-2). 
Short 
QOF 
Code 
Descriptor of Code 
No of 
points 
M inimum 
Threshold 
attainment 
Maximum 
Threshold 
attainment 
MH04 
 
The percentage of patients on lithium therapy with a record of 
serum creatinine and TSH in the previous 15 months  
1 40 90 
MH05 
 
The percentage of patients on lithium therapy with a record of 
lithium levels in a therapeutic range within the previous 6 
months  
2 40 90 
MH06 
 
The percentage of patients on the register who have a 
comprehensive care plan documented in the records agreed 
between individuals, their family and/or carers as appropriate  
6 25 50 
MH07 
 
The percentage of patients with schizophrenia, bipolar 
affective disorder and other psychoses who do not attend the 
practice for their annual review who are identified and 
followed up by practice team within 14 days of non-attendance 
3 40 90 
MH08 
 
The practice can produce a register of people with 
schizophrenia, bipolar affective disorder and other psychoses 
4   
MH09 
 
The percentage of patients with schizophrenia and bipolar 
affective disorder and other psychoses with a review recorded 
in the previous 15 months.  In the review there is evidence that 
the patient has participated in routine health promotion and 
prevention advice appropriate to their age and health status 
23 40 90 
Table -7-2 Mental Health (MH) Indicators 2006/2007 until 2010/2011 
 
In 2011/2012 the mental health QOF underwent further substantial revision; MH04 and 
MH05 were reworded and recoded to MH17 and MH18; MH06 was re-coded as MH10; 
MH09 was expanded with specific targeting of alcohol consumption (MH11), body mass 
index (BMI) (MH12), blood pressure (BP) (MH13), cholesterol:hdl ratio (MH14) and 
blood glucose (MH15). Finally MH16 was added to incentivise cervical screening for 
women with MMI (Table 7-3).  
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Short 
QOF 
Code 
Descriptor of Code 
No of 
points 
M inimum 
Threshold 
attainment 
Maximum 
Threshold 
attainment 
MH08 
 
The practice can produce a register of people with 
schizophrenia, bipolar affective disorder and other psychoses  
4   
MH10 
 
The percentage of patients on the register who have a 
comprehensive care plan documented in the records agreed 
between individuals, their family and/or carers as appropriate 
6 25 50 
MH11 
 
The percentage of patients with schizophrenia, bipolar affective 
disorder and other psychoses who have a record of alcohol 
consumption in the preceding 15 months  
4 40 90 
MH12 
 
The percentage of patients with schizophrenia, bipolar affective 
disorder and other psychoses who have a record of BMI in the 
preceding 15 months 
4 40 90 
MH13 
 
The percentage of patients with schizophrenia, bipolar affective 
disorder and other psychoses who have a record of blood 
pressure in the preceding 15 months 
4 40 90 
MH14 
 
The percentage of patients aged 40 years and over with 
schizophrenia, bipolar affective disorder and other psychoses 
who have a record of total cholesterol:hdl ratio in the preceding 
15 months  
5 40 80 
MH15 
 
The percentage of patients aged 40 years and over with 
schizophrenia, bipolar affective disorder and other psychoses 
who have a record of blood glucose level in the preceding 15 
months 
5 40 80 
MH16 
 
The percentage of patients (aged from 25 to 64 in England and 
Northern Ireland, from 20 to 60 in Scotland and from 20 to 64 in 
Wales) with schizophrenia, bipolar affective disorder and other 
psychoses whose notes record that a cervical screening test has 
been performed in the preceding 5 years 
5 40 80 
MH17 
 
The percentage of patients on lithium therapy with a record of 
serum creatinine and TSH in the preceding 9 months 
1 40 90 
MH18 
 
The percentage of patients on lithium therapy with a record of 
lithium levels in the therapeutic range within the preceding 4 
months 
2 40 90 
Table 7-3 Mental Health (MH) Indicators 2011/2012 
 
In 2012/2013 the mental health indicators underwent further revision. MH14 was 
renumbered as MH19 (due to changes in the minimum threshold for attainment) and 
MH15 was replaced by MH20 (whereby HbA1c was added as an alternative to blood 
glucose level obtainment for individuals aged 40 years and over with schizophrenia, 
bipolar affective disorder and other psychoses). MH08, MH10, MH11, MH12, MH13, 
MH16, MH17 and MH18 remained unchanged from the previous year (Table 7-4). 
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Table 7-4 Mental Health (MH) Indicators 2012/2013 
 
For each indicator, information technology systems hold the number of patients in each 
practice on every single clinical register. For the indicator target to be met and for payment 
to occur, each indicator has a minimum threshold for attainment. For example in 
2012/2013, for MH10, a minimum of 30% of individuals on the mental health register 
should have a comprehensive care plan documented in their records in order for the 
practice to receive any payment for this indicator. Provided the minimum attainment figure 
is met, payment will occur. 
 
Short 
QOF 
Code 
Descriptor of Code 
No of 
points 
M inimum 
Threshold 
attainment 
Maximum 
Threshold 
attainment 
MH08 
 
The practice can produce a register of people with 
schizophrenia, bipolar affective disorder and other psychoses  
4   
MH10 
 
The percentage of patients on the register who have a 
comprehensive care plan documented in the records agreed 
between individuals  their family and/or carers as 
appropriate 
6 30 55 
MH11 
 
The percentage of patients with schizophrenia  bipolar 
affective disorder and other psychoses who have a record of 
alcohol consumption in the preceding 15 months 
4 50 90 
MH12 
 
The percentage of patients with schizophrenia  bipolar 
affective disorder and other psychoses who have a record of 
BMI in the preceding 15 months 
4 50 90 
MH13 
 
The percentage of patients with schizophrenia  bipolar 
affective disorder and other psychoses who have a record of 
blood pressure in the preceding 15 months 
4 50 90 
MH16 
 
The percentage of patients (aged from 25 to 64 in England 
and Northern Ireland  from 20 to 60 in Scotland and from 20 
to 64 in Wales) with schizophrenia  bipolar affective disorder 
and other psychoses whose notes record that a cervical 
screening test has been performed in the preceding 5 years 
5 45 80 
MH17 
 
The percentage of patients on lithium therapy with a record 
of serum creatinine and TSH in the preceding 9 months 
1 50 90 
MH18 
 
The percentage of patients on lithium therapy with a record 
of lithium levels in the therapeutic range within the 
preceding 4 months 
2 50 90 
MH19 
 
The percentage of patients aged 40 years and over with 
schizophrenia; bipolar affective disorder and other psychoses 
who have a record of total cholesterol:hdl ratio in the 
preceding 15 months 
5 45 80 
MH20 
 
The percentage of patients aged 40 years and over with 
schizophrenia; bipolar affective disorder and other psychoses 
who have a record of blood glucose or HbA1c in the preceding 
15 months 
5 45 80 
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7.2.2 Identification of Comparator Indicators: 
As detailed in Table 6-1 in Chapter 6, many chronic physical diseases such as asthma, 
diabetes, epilepsy, COPD, chronic kidney disease (CKD) and dementia are included within 
the QOF. If there is equal access to care across all chronic diseases (both physical and 
mental illnesses), rates of exception should be similar across QOF indicators. Therefore 
indicators across a range of chronic physical health conditions deemed similar to the 
Mental Health Indicators were identified for each year of interest and exception rates were 
compared. Given the dynamic nature of the QOF, care was taken to ensure that indicators 
matched on a year to year basis.  
Unfortunately an exact comparator for all mental health indicators across all years was not 
possible. Therefore comparable indicators from other chronic physical health conditions 
were selected as proxy comparators to the mental health indicators. These proxy indicators 
were also dynamic over time, with some being phased out and replaced by others.  
For MH04: The percentage of patients on lithium therapy with a record of serum creatinine 
and TSH in the previous 15 months, DM22: The percentage of patients with diabetes who 
have a record of estimated glomerular filtration rate (eGFR) or serum creatinine testing in 
the previous 15 months was the best comparator indicator identified for years 2006/2007 
until 2010/2011. MH04 was superseded by MH17, (the percentage of patients on lithium 
therapy with a record of serum creatinine and TSH in the preceding 9 months) in 
2011/2012 and due to the change in timeframe for recording of estimated glomerular 
filtration rate (eGFR) or serum creatinine from 15 months to 9 months, no indicator from 
2011/2012 onwards was deemed suitable as a comparator. 
For MH05: The percentage of patients on lithium therapy with a record of lithium levels in 
a therapeutic range within the previous 6 months. No indicator was deemed suitable for 
comparison- as there is no other indicator for therapeutic drug level monitoring. 
For MH06: The percentage of patients on the mental health register who have a 
comprehensive care plan documented in the records agreed between individuals, their 
family and/or carers as appropriate, it was deemed that EPILEPSY07: The percentage of 
patients aged 18 years and over on drug treatment for epilepsy who have a record of 
medication review involving the patient or carer in the previous 15 months,  
DEMENTIA02: The percentage of patients diagnosed with dementia whose care has been 
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reviewed in the previous 15 months, COPD13: The percentage of patients with COPD who 
have had a review, undertaken by a healthcare professional, including an assessment of 
breathlessness using the Medical Resource Council (MRC) dyspnoea score in the 
preceding 15 months and ASTHMA06: The percentage of patients with asthma who have 
had an asthma review in the previous 15 months were the best indicators to use for 
comparison.  
The indicators EPILEPSY07, DEMENTIA02 and ASTHMA06 were available for 
comparison for 2006/2007 until 2010/2011 while the COPD13 indicator was available for 
comparison after its introduction in 2009/2010. EPILEPSY07 was withdrawn in 2010/2011 
and so data for comparison after this time was not available. In 2011/2012 MH06 was 
recoded as MH10 and so in 2011/2012 MH10 was compared to DEMENTIA02, 
ASTHMA06 and COPD13. In 2012/2013 ASTHMA06 was replaced by ASTHMA09 (The 
percentage of patients with asthma who have had an asthma review in the preceding 15 
months that includes an assessment of asthma control using the 3 Royal College of 
Physicians (RCP) questions). This was still deemed a comparable indicator to MH10. 
Therefore in 2012/2013 MH10 was compared to DEMENTIA02, ASTHMA09 and 
COPD13.  
For MH07: The percentage of patients with schizophrenia, bipolar affective disorder and 
other psychoses who do not attend the practice for their annual review who are identified 
and followed up by practice team within 14 days of non-attendance, no comparable 
indicators for any of the years reviewed was identified.  
For MH09: The percentage of patients with schizophrenia and bipolar affective disorder 
and other psychoses with a review (namely routine health promotion and prevention advice 
appropriate to their age and health status) recorded in the previous 15 months, indicator 
CVD02: The percentage of people diagnosed with hypertension who are given lifestyle 
advice in the last 15 months for: increasing physical activity, smoking cessation, safe 
alcohol consumption and healthy diet exception rate was deemed suitable as a comparator 
indicator. Exception rates for the indicator CVD02 was available for 2010/2011, allowing 
comparison for this year only. MH09 was then superseded and expanded in 2011/2012 and 
so data for comparison is available for 1 year only (2010/2011). 
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For MH11: The percentage of patients with schizophrenia, bipolar affective disorder and 
other psychoses who have a record of alcohol consumption in the preceding 15 months, no 
direct comparator indicator was identified.  
For MH12: The percentage of patients with schizophrenia, bipolar affective disorder and 
other psychoses who have a record of BMI in the preceding 15 months which was 
introduced in 2011/2012, DM02: The percentage of patients with diabetes whose notes 
record BMI in the previous 15 months was identified as a comparator indicator and 
available from 2011/2012 onwards. 
For MH13: The percentage of patients with schizophrenia, bipolar affective disorder and 
other psychoses who have a record of blood pressure in the preceding 15 months which 
was introduced in 2011/2012, CKD02: The percentage of patients on the CKD register 
whose notes have a record of blood pressure in the previous 15 months was identified as a 
comparator indicator and available from 2011/2012 onwards.  
For MH14: The percentage of patients aged 40 years and over with schizophrenia, bipolar 
affective disorder and other psychoses who have a record of total cholesterol: High Density 
Lipoprotein (HDL) ratio in the preceding 15 months, no comparator indicator was 
identified. Although indicators in other chronic physical health conditions, involve the 
recording of cholesterol: HDL ratio, they all state that the ratio of cholesterol: HDL should 
be below a certain target in the preceding 15 months. Given this difference, no comparator 
proxy indicator was identified.  
For MH15: The percentage of patients aged 40 years and over with schizophrenia, bipolar 
affective disorder and other psychoses who have a record of blood glucose level in the 
preceding 15 months, no comparator indicator was found.  
For MH16: The percentage of patients aged 20 to 60 in Scotland with schizophrenia, 
bipolar affective disorder and other psychoses whose notes record that a cervical screening 
(CS) test has been performed in the preceding five years no comparator indicator exception 
data were available. Although indicator CS01: (the percentage of patients aged from 21 to 
60 whose notes record that a cervical smear has been performed in the last five years) 
exists, no exception rate data were available.   
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For MH17: The percentage of patients on lithium therapy with a record of serum creatinine 
and (Thyroid Stimulating Hormone) (TSH) in the preceding 9 months introduced in 
2011/2012, no comparator indicator was identified.  
For MH18: The percentage of patients on lithium therapy with a record of lithium levels in 
the therapeutic range within the preceding 4 months, no comparator indicator was 
identified.  
For MH19: The percentage of patients aged 40 years and over with schizophrenia; bipolar 
affective disorder and other psychoses who have a record of total cholesterol: HDL ratio in 
the preceding 15 months no comparator indicator was identified. 
For MH20: The percentage of patients aged 40 years and over with schizophrenia; bipolar 
affective disorder and other psychoses that have a record of blood glucose or HbA1c 
recording in the preceding 15 months, no comparator indicator was identified. 
Table 7-5 describes the years for which exception rate data and comparator indicator data 
were available.  
 
 
 
 
 
171 
 
Table 7-5 Mental Health (MH) Indicator and Physical Health Indicator Comparators over time  
  2004/2005 2005/2006 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011 2011/2012  2012/2013 
MH01 √Exception data  √√Exception data               
MH02 √Exception data  √Exception data                
MH03 √Exception data  √Exception data                
MH04   
MH17 * 
√Exception data  √Exception data  √Exception data   
 
√DIABETES22 
√Exception data   
 
√DIABETES22 
√Exception data   
 
√DIABETES22 
√Exception data   
 
√DIABETES22 
√Exception data   
 
√DIABETES22 
* 
√Exception data  
* 
√Exception data  
MH05  
MH18 * 
√Exception data  √Exception data  √Exception data  √Exception data  √Exception data  √Exception data  √Exception data  * 
√Exception data  
* 
√Exception data  
MH06  
 
MH10 * 
    √ Exception data  
 
√EPILEPSY07 
√ASTHMA06 
√DEMENTIA02 
√ Exception data   
 
√EPILEPSY07 
√ASTHMA06 
√DEMENTIA02 
√ Exception data   
 
√EPILEPSY07 
√ASTHMA06 
√DEMENTIA02 
√ Exception data   
 
√EPILEPSY07 
√ASTHMA06 
√DEMENTIA02 
√COPD13 
√ Exception data   
 
√EPILEPSY07 
√ASTHMA06 
√DEMENTIA02 
√COPD13 
* 
 √ Exception data   
 
√ASTHMA06 
√DEMENTIA02 
√COPD13 
 * 
√ Exception data   
 
√ASTHMA09 
√DEMENTIA02 
√COPD13 
MH07     √Exception data  √Exception data  √Exception data  √Exception data  √Exception data  √Exception data  √Exception data  
MH08     √Exception data  √Exception data  √Exception data  √Exception data  √Exception data  √Exception data  √Exception data  
MH09     √Exception data  √Exception data  √Exception data  √Exception data  √Exception data  
 
√ CVD02 
    
MH11               √Exception data  √Exception data  
MH12               √Exception data 
 
√ DM02 
√Exception data 
 
√DM02 
MH13               √Exception data 
 
√CKD02 
√Exception data 
 
√CKD02 
MH14  
MH19 * 
              √Exception data   * 
√Exception data 
MH15 
MH20* 
              √Exception data  *  
√Exception data 
MH16               √Exception data  √Exception data  
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7.2.3 Generation of Composite Indicators: 
Exception rate data for sixteen clinical indicator areas (in addition to the mental health 
indicators) were obtained from ISD Scotland for 2011/2012 and 2012/2013. These 
indicator areas comprised: atrial fibrillation (AF); asthma; coronary heart disease (CHD); 
cancer; chronic kidney disease (CKD); chronic obstructive pulmonary disease (COPD); 
epilepsy, heart failure (HF);  diabetes; hypertension; hypothyroidism; osteoporosis; 
peripheral artery disease (PAD); stroke; dementia and depression. Composite indicators 
were generated by combining exception rates for all indicators within a clinical area; for 
example the mental health composite indicator contained exception rates for nine 
individual indicators, while the composite indicator for diabetes contained exception rates 
for fourteen individual indicators.  
Composite indicators for the two most recent QOF years only were generated (2011/2012 
and 2012/2013); this was due to the significant changes in the Mental Health indicators 
which were introduced in 2011/2012 (Tables 7-3 & 7-4).    
7.3 Results: 
7.3.1 2012/2013 Median Exception Rates: 
Median rate of exception varied widely by clinical indicator (Table 7-6); MH17 (creatinine 
and TSH monitoring for lithium prescription) and MH18 (lithium level being within the 
therapeutic range) had the lowest rates of exception (both 0.0%) while MH20 (blood 
glucose/HbA1c recording) and MH16 (cervical smears) had the highest rate of exception 
reporting (25.5% and 17.8% respectively) (Table 7-6).   
Of the comparator indicators: COPD13 (COPD review) and ASTHMA09 (asthma review) 
had the highest rate of exception reporting (11.9% and 11.6% respectively) while CKD02 
(BP recording in Chronic Kidney Disease) had the lowest exception rate (0.6%) (Table 7-
6).  
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QOF Variable Median Exception 
Rate (%) 
95% Confidence 
Interval 
Inter-Quartile 
Range (IQR) 
MH10  Comprehensive Care Plan 
(n=966) 
6.3 5.7- 6.9 2.0-12.2 
MH11  Recording of alcohol 
consumption  (n=965) 
11.1 10.2- 11.9 5.0-19.3 
MH12  BMI recording (n=965) 11.8 11.0-12.5 5.0-19.6 
MH13  BP recording (n=965) 9.5 8.7- 10.3 4.0-15.8 
MH16  Cervical Smears (n=948) 17.8 16.7- 20.0 7.3-28.6 
MH17  Creatinine & TSH monitoring on 
lithium (n=905) 
0.0 0.0-0.0 0.0-5.9 
MH18  Therapeutic lithium level 
(n=901) 
0.0 0.0- 6.0 0.0-18.2 
MH19  Cholesterol:HDL ratio recording 
(n=959) 
16.0 14.3 -17.6 6.7-27.3 
MH20 blood glucose/HbA1c recording 
(n=965) 
25.5 23.1- 24.1 16.7-31.6 
ASTHMA09 Asthma review (n=968) 11.6 9.9- 12.9 2.7-23.4 
DEM02 Dementia Review (n=963) 5.9 5.4- 6.3 2.1-11.0 
COPD13 COPD Review (n=967) 11.9 11.3- 12.7 6.4-19.0 
CKD02 BP recording in Chronic Kidney 
Disease (n=969) 
0.6 0.5-0.7 1.9-6.1 
DM02  BMI recording in Diabetes  
(n=968) 
3.5 3.2- 3.6 0.0-1.7 
Table 7-6 Indicator Exception Rates 2012/2013 
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Figure 7-1 Indicator Exception Rates 2012/2013 
Where line is median, box is the interquartile range (25
th
 to 75
th
 centile) and whiskers show the 
upper and lower adjacent values (furthest observation within 1.5 times the interquartile range of the 
upper and lower 
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7.3.1.1 Comprehensive Care Plan (MH10): 
Median exception rate of documentation of a comprehensive care plan in MMI, was 
compared with rate of documentation of a care plan in dementia, (MH10 vs. DEM02), 
there was no significant difference in exception rate identified (6.3% vs. 5.9%, p=0.194). 
When median exception rates of documentation of a comprehensive care plan in MMI, 
were compared directly with the rates of a review for Asthma and COPD, (MH10 vs. 
ASTHMA09 and MH10 vs. COPD13), exception rates were significantly lower for 
comprehensive care plan reviews in MMI (6.3% vs. 11.6%, p<0.001 and 6.3% vs. 11.9%, 
p<0.001) (Table 7-7). 
7.3.1.2 Blood Pressure (MH12) and Body Mass Index Recording (MH13): 
Median exception rate of BMI recording in MMI, was compared directly with rate of BMI 
recording in diabetes, (MH12 vs. DM02): exception rate was found to be significantly 
higher in MMI compared to diabetes (11.8% vs. 3.5%, p<0.001) (Table 7-7).  
Median exception rate of Blood Pressure recording in MMI, was compared with BP 
recording in Chronic Kidney Disease (CKD), (MH13 vs. CKD02), exception rate was 
found to be significantly higher in MMI (9.5% vs. 0.6%, p<0.001) (Table 7-7).  
 Median Exception Rate 
(%) 
p value 
MH10 Comprehensive Care Plan vs. 
ASTHMA09 asthma review 
6.3  vs.  11.6 <0.001 
MH10 Comprehensive Care Plan vs. DEM02 
Dementia review 
6.3  vs.  5.9 0.194 
MH10 Comprehensive Care Plan vs. COPD13 
COPD review 
6.3  vs.  11.9 <0.001 
MH12 BMI recording vs. DM02 BMI recording 
in Diabetes 
11.8  vs.  3.5 <0.001 
MH13 BP recording vs. CKD02 BP recording in 
Chronic Kidney Disease 
9.5  vs.  0.6 <0.001 
Table 7-7 Comparison of Indicator Exception rates 2012/2013 Bold if significantly 
higher, italic if significantly lower  
7.3.1.3 Composite Indicators: 
In 2012/2013 sixteen composite physical health indicators were identified. The median 
exception rate for the Mental Health composite indicator was 11.1% (IQR 0.0-21.4%). 
This was significantly higher than the median exception rate for thirteen of the composite 
chronic disease indicators; atrial fibrillation (AF) (3.5% IQR 0.0-16.7%, p<0.001); 
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hypertension (3.4% IQR 1.4-6.6%, p<0.001); asthma (5.9% IQR 1.1-14.3%, p<0.001); 
coronary heart disease (CHD) (9.9% IQR 3.6-18.4%, p<0.001); cancer (0.0% IQR 0.0-
0.0%, p<0.001); chronic kidney disease (CKD) (4.3% IQR 0.3-12.0%, p<0.001); diabetes 
(8.4% IQR 4.3-14.0%, p<0.001); depression (7.7% IQR 1.8-20.0%, p<0.001); dementia 
(10.0% IQR 2.6-25.0%, p=0.022); hypothyroidism (0.5% IQR 0.0-1.6%, p<0.001); 
osteoporosis (0.0% IQR 0.0-28.6%, p<0.001); peripheral artery disease (PAD) (7.3% IQR 
2.6-15.0%, p<0.001) and stroke (6.6% IQR 2.8-12.5%, p<0.001) (Figure 7-2).  
The Mental Health composite median exception rate was significantly lower than that of 
the epilepsy composite indicator (17.4% IQR 4.5-37.1%, p<0.001) and the COPD 
composite indicator (12.8% IQR 7.1-19.34%, p<0.001). No difference in exception rate 
was found compared to the composite heart failure indicator (11.1% IQR 3.0-26.5%, 
p=0.890) (Figure 7-2).  
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Figure 7-2 Median Exception Rates for Composite Indicators 2012/2013 
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7.3.2 2011/2012 Median Exception Rates: 
In 2011/2012 median rate of exception varied widely by clinical indicator (Table 7-8); 
MH17 (creatinine and TSH monitoring in lithium prescription) and MH18 (lithium level 
being within the therapeutic range) had the lowest rates of exception (both 0.0%) while 
MH14 (cholesterol: HDL recording) and MH15 (blood glucose recording) had the highest 
median rate of exception reporting (16.0% and 25.0% respectively) (Table 7-8).   
Of the comparator indicators COPD13 (COPD review) and ASTHMA06 (Asthma review) 
had the highest median rate of exception reporting (12.6% and 6.7% respectively) while 
CKD02 (BP recording in Chronic Kidney Disease) had the lowest median exception rate 
(0.6%) (Table 7-8 and Figure 7-3). 
QOF Variable Median Exception 
Rate (%) 
95% Confidence 
Interval 
Inter-Quartile 
Range (IQR) 
MH10  Comprehensive Care Plan 
(n=942) 
7.8 7.1 - 8.3 2.9-14.3 
MH11  recording of alcohol 
consumption  (n=941) 
13.7 12.8-14.7 6.7-22.4 
MH12 BMI recording (n=941) 14.3 13.5-15.0 7.0-22.6 
MH13  BP recording (n=942) 10.7 10.0- 11.7 5.1-17.2 
MH14 Cholesterol:HDL ratio 
recording (n=942) 
16.0 15.0-16.7 7.9-25.0 
MH15 blood glucose recording 
(n=942) 
25.0 23.7- 25.6 16.7-33.3 
MH16  Cervical Smears (n=923) 17.8 16.7- 19.1 6.3-28.6 
MH17  Creatinine & TSH 
monitoring on lithium (n=890) 
0.0 0.0- 0.0 0.0-5.6 
MH18  Therapeutic lithium level 
(n=887) 
0.0 0.0- 0.0 0.0-16.7 
ASTHMA09 Asthma review (n=943) 6.7 5.8- 8.1 2.2-18.4 
DEM02 Dementia Review (n=938) 5.0 4.6- 5.6 0.0-10.2 
COPD13 COPD Review (n=942) 12.6 11.8- 13.3 6.8-19.8 
CKD02 BP recording  in Chronic 
Kidney Disease(n=941) 
0.6 0.5-0 .7 0.0-1.6 
DM02 BMI recording In Diabetes  
(n=943) 
3.5 3.3-3.7 1.6-6.0 
Table 7-8 Indicator exception Rates 2011/2012 
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Figure 7-3 Indicator Exception Rates 2011/2012 
7.3.2.1 Comprehensive Care Plan (MH10): 
When median exception rate of documentation of a comprehensive care plan in MMI, was 
compared with the rate of documentation of a care plan in dementia (MH10 vs. DEM02), 
median exception rate in MMI was found to be significantly higher (7.8% vs. 5.0%, 
p<0.001) (Table 7-9).   
Median exception rate of documentation of a comprehensive care plan in MMI, was 
compared with the exception rate for Asthma Review, (MH10 vs. ASTHMA06). No 
significant difference in exception rates was found (7.8% vs. 6.7%, p=0.160). Rate of 
exception for COPD review (COPD13) was significantly higher than for the 
comprehensive care plan review in MMI (12.6% vs. 7.8%, p<0.001) (Table 7-9). 
7.3.2.2 Blood Pressure (MH12) and Body Mass Index Recording (MH13): 
Median exception rate of recording of BMI in MMI (MH12), was significantly higher 
compared with median exception rate of BMI recording in diabetes (DM02), (14.3% vs. 
3.5%, p<0.001) (Table 7-9).  
Median exception rate of Blood Pressure recording in MMI (MH13) was also significantly 
higher than median exception rate for BP recording in Chronic Kidney Disease (CKD02), 
(10.7% vs. 0.6%, p<0.001) (Table 7-9).  
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 Median Exception 
Rate (%) 
p value 
MH10 Comprehensive Care Plan vs. ASTHMA09 
asthma review 
7.8  vs.  6.7 0.160 
MH10 Comprehensive Care Plan vs. DEM02 
Dementia review 
7.8  vs.  5.0 <0.001 
MH10 Comprehensive Care Plan vs. COPD13 
COPD review 
7.8  vs. 12.6  <0.001 
MH12 (BMI recording) vs. DM02 (BMI recording) 14.3  vs.  3.5 <0.001 
MH13 (BP recording) vs. CKD02 (BP recording) 10.7  vs.  0.6 <0.001 
Table 7-9 Comparisons of Median Exception Rates 2011/2012 Bold if significantly 
higher, italic if significantly lower 
7.3.2.3 Composite Indicators: 
In 2011/2012 fourteen composite physical health indicators were identified. The median 
exception rate for the Mental Health composite indicator was 12.5% (IQR 2.4-22.2%), this 
was significantly higher than ten composite chronic disease indicators; atrial fibrillation 
(AF) (2.8% IQR 0.0-6.1%, p<0.001); hypertension (3.0% IQR 1.3-5.9%, p<0.001); asthma 
(4.7% IQR 0.59-11.3%, p<0.001); coronary heart disease (CHD) (4.2% IQR 0.9-11.2%, 
p<0.001); cancer (0.0% IQR 0.0-0.0%, p<0.001); chronic kidney disease  (CKD) (4.2% 
IQR 0.9-11.2%, p<0.001); diabetes (8.1%, IQR 4.1-13.6% p<0.001); depression (8.7% 
IQR 2.2-23.1%, p<0.001); hypothyroidism (0.5% IQR 0.0-1.5%, p<0.001) and stroke 
(6.9% IQR 3.0-12.9%, p<0.001) (Figure 7-4).  
As with 2012/2013 the Mental Health composite median exception rate was significantly 
lower than the epilepsy composite indicator (16.7% IQR 4.1-37.2%, p<0.001) and the 
COPD composite indicator (14.3% IQR 8.2-22.2%, p<0.001). No difference was found for 
the composite heart failure indicator (12.1% IQR 3.0-27.3%, p=0.330) and the dementia 
indicator (12.1% IQR 2.6-42.8%, p=0.853) (Figure 7-4). 
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Figure 7-4 Median Exception Rates for Composite Indicators 2011/2012 
7.3.3 2010/2011 Median Exception Rates: 
In 2010/2011 median rate of exception varied widely by clinical indicator (Table 7-10); 
MH04 (Creatinine and TSH monitoring in lithium prescription), MH05 (Therapeutic 
lithium level) and MH07 (Mental Health Annual review) had the lowest rates of exception 
(all 0.0%) while MH06 (comprehensive care plan) and MH09 (routine health promotion) 
had the highest median rate of exception reporting (8.7% and 13.3% respectively) (Table 
7-10) (Figure 7-5).   
Of the comparator indicators; COPD13 (COPD Review) and ASTHMA06 (Asthma 
Review) had the highest median rate of exception reporting (11.7% and 6.7% respectively) 
while DM22 (estimated glomerular filtration rate (eGFR) or serum creatinine reported in 
Diabetes) had the lowest median exception rate (2.2%) (Table 7-10) (Figure 7-5). 
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Variable Median Exception 
Rate (%) 
95% Confidence 
Interval 
Inter-Quartile 
Range (IQR) 
MH04 Creatinine & TSH monitoring 
on lithium (n=890) 
0.0 0.0-0.0 0.0-0.0 
MH05 Therapeutic lithium level 
(n=889) 
0.0 0.0-0.0 0.0-16.7 
MH06  Comprehensive Care Plan 
(n=950) 
8.7 7.7- 9.5 2.6-15.9 
MH07 Annual MH review (n=778) 0.0 0.0-0.0 0.0-0.0 
MH09 Routine Health Promotion 
(n=949) 
13.3 12.5- 14.3 5.7-23.8 
ASTHMA06 Asthma review  (n=955) 6.7 5.7-7.7 1.8-17.2 
DEMENTIA02 Dementia review  
(n=946) 
5.1 4.7- 5.8 0.0-10.2 
DM22  eGFR or serum creatinine 
reported in Diabetes (n=954) 
2.2 2.1-2.4 1.1-4.0 
EPILEPSY07 Medication Review 
(n=947) 
2.9 2.3 - 3.3 0.0-9.6 
COPD13 COPD Review (n=953) 11.7 11.0-12.5 6.2-19.3 
CVD02 Lifestyle Advice  (n=952) 6.5 5.9- 7.1 2.5-11.8 
Table 7-10 Indicator Exception rates2010/2011 
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Figure 7-5 Indicator Exception Rates 2010/2011 
7.3.3.1 Renal Function Monitoring (MH04): 
Median exception rate of creatinine and TSH monitoring in lithium prescription, was 
compared with the rate of eGFR/creatinine measurement in diabetes, (MH04 vs. DM22). 
Exception rate was significantly lower for creatinine and TSH monitoring in lithium 
prescription compared to diabetes (0.0% vs. 2.2%, p<0.001) (Table 7-11).  
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7.3.3.2 Comprehensive Care Plan (MH06): 
Median exception rate of documentation of a comprehensive care plan in MMI was 
compared with the rate of documentation of a care plan in dementia and epilepsy, (MH10 
vs. DEM02 and MH10 vs. EPILEPSY07). Median exception rates in MMI were 
significantly higher compared to dementia and epilepsy (8.7% vs. 5.1%, p<0.001 and 8.7% 
vs. 2.9%, p<0.001 respectively) (Table 7-11).   
Median exception rate of documentation of a comprehensive care plan in MMI was also 
compared with the exception rate in Asthma Review. No difference in exception rate 
between asthma and MMI was found (6.7% vs. 8.7%, p=0.7757 respectively). Rate of 
exception for COPD Review was significantly higher than for comprehensive care plan 
reviews in MMI (11.7% vs. 8.7%, p<0.001) (Table 7-11).   
7.3.3.3 Health Promotion (MH09): 
Median exception rate of health promotion in MMI was compared with exception rate of 
lifestyle education in hypertension, (MH09 vs. CVD02). Median exception rate was 
significantly higher in MMI compared to hypertension (13.3% vs. 6.5%, p<0.001) (Table 
7-11). 
  Median Exception 
Rate (%)  
p value 
MH04 Creatinine & TSH monitoring on lithium vs. 
DM22 Creatinine or eGFR measurement in 
Diabetes 
0.0  vs.  2.2 <0.001 
MH06 Comprehensive Care Plan vs. EPILEPSY07 
Medication  review 
8.7  vs.  2.9 <0.001 
MH06 Comprehensive Care Plan vs. ASTHMA06 
Asthma review 
8.7  vs.  6.7 0.7757 
MH06 Comprehensive Care Plan vs. COPD13 COPD 
review 
8.7  vs.  11.7 <0.001 
MH06 Comprehensive Care Plan vs. DEMENTIA02 
Dementia Review 
8.7  vs.  5.3 <0.001 
MH09 Health Promotion vs. CVD02 Lifestyle Advice 13.3  vs.  6.5 <0.001 
Table 7-11 Comparison of Median Exception rates 2010/2011 Bold if significantly higher, 
italic if significantly lower 
7.3.4 2009/2010 Median exception rates:  
In 2009/2010 median rate of exception varied widely by clinical indicator (Table 7-12); 
MH04 (Creatinine and TSH monitoring in lithium prescription), MH05 (Therapeutic 
lithium level) and MH07 (Mental Health Annual review) had the lowest median rates of 
exception (all 0.0%) while MH06 (comprehensive care plan) and MH09 (routine health 
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promotion) had the highest median rate of exception reporting (9.4% and 12.8% 
respectively) (Table 7-12 and Figure 7-6).   
Of the comparator indicators COPD13 (COPD review) and ASTHMA06 (Asthma Review) 
had the highest median rate of exception reporting (12.8% and 6.1% respectively) while 
DM22 (eGFR or serum creatinine reported in Diabetes) had the lowest median exception 
rate (2.3%) (Table 7-12 and Figure 7-6). 
Variable Median Exception 
Rate (%) 
95% Confidence 
Interval 
Inter-Quartile 
Range (IQR) 
MH04 Creatinine & TSH monitoring on 
lithium (n=936) 
0.0 0.0-0.0 0.0-0.0 
MH05 Therapeutic lithium level 
(n=936) 
0.0 0.0-0.0 0.0-14.3 
MH06  Comprehensive Care Plan 
(n=993) 
9.4 8.5- 1 3.6-18.4 
MH07 Annual MH review (n=805) 0.0 0.0-0.0 0.0-0.0 
MH09 Routine Health Promotion 
(n=991) 
12.8 11.9- 13.8 5.1-23.8 
ASTHMA06 Asthma review  (n=995) 6.1 5.2-7.1 1.6-15.1 
DEMENTIA02 Dementia review  
(n=985) 
4.2 3.8- 4.8 0.0-9.3 
DM22  eGFR or serum creatinine 
reported (n=997) 
2.3 2.1- 2.5 1.0-4.0 
EPILEPSY07 Medication Review 
(n=993) 
2.9 2.4- 3.4 0.0-8.3 
COPD13 COPD Review (n=993) 12.8 12.0- 13.6 6.7-20.0 
CVD02 Lifestyle Advice  (n=986) 9.8 8.7- 11.1 1.8-19.1 
Table 7-12 Indicator Exception rates 2009/2010 
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Figure 7-6 Indicator exception rates 2009/2010 
7.3.4.1 Renal Function Monitoring (MH04): 
Median exception rate of creatinine and TSH monitoring in lithium prescription, was 
compared with the exception rate of creatinine or eGFR measurement in diabetes, (MH04 
vs. DM22). Exception rate was significantly lower in lithium prescription monitoring 
compared to diabetes monitoring (0.0% vs. 2.3%, p<0.001) (Table 7-13). 
7.3.4.2 Comprehensive Care Plan (MH06): 
Median exception rate of documentation of a comprehensive care plan in MMI, was 
compared with the exception rate of documentation of a care plan in dementia, epilepsy 
and asthma, (MH10 vs. DEM02, MH10 vs. EPILEPSY07 and MH10 vs. ASTHMA06). 
Median exception rates in MMI were significantly higher compared to dementia, epilepsy 
and asthma (9.4% vs. 4.2%, p<0.001, 9.4% vs. 2.9%, p<0.001 and 9.4% vs. 6.1%, p<0.001 
respectively) (Table 7-13).   
Median exception rate of documentation of a comprehensive care plan in MMI, was 
compared with the exception rate of a COPD review, (COPD13 vs. ASTHMA06). 
Exception rate was significantly higher in COPD (12.8% vs. 9.4%, p<0.001) (Table 7-13).   
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 Median Exception 
Rates (%)   
p value 
MH04 Creatinine & TSH monitoring on lithium vs. 
DM22 Creatinine or eGFR measurement in 
Diabetes 
0.0 vs. 2.3 <0.001 
MH06 Comprehensive Care Plan vs. EPILEPSY07 
Medication review 
9.4 vs. 2.9 <0.001 
MH06 Comprehensive Care Plan vs. ASTHMA06 
Asthma review 
9.4 vs. 6.1 <0.001 
MH06 Comprehensive Care Plan vs. COPD13 COPD 
review 
9.4 vs. 12.8 <0.001 
MH06 Comprehensive Care Plan vs. DEMENTIA02 
Dementia Review 
9.4 vs. 4.2 <0.001 
Table 7-13 Comparison of Median Exception Rates 2009/2010 Bold if significantly 
higher, italic if significantly lower 
7.3.5 2008/2009 Median exception rates:  
In 2008/2009, median rate of exception varied widely by clinical indicator (Table 7-14 and 
Figure 7-7); MH04 (Creatinine & TSH monitoring on lithium), MH05 (Therapeutic lithium 
level) and MH07 (Mental Health Annual review) had the lowest median rates of exception 
(all 0.0%) while MH06 (comprehensive care plan) and MH09 (routine health promotion) 
had the highest median rate of exception reporting (13.1% and 14.6% respectively) (Table 
7-14 and Figure 7-7).   
Of the comparator indicators ASTHMA06 (Asthma review) had the highest median rate of 
exception reporting (6.6%) while DM22 (eGFR or serum creatinine measurement in 
Diabetes) had the lowest median exception rate (2.2%) (Table 7-14 and Figure 7-7). 
Variable Median Exception 
Rate (%) 
95% Confidence 
Interval 
Inter-Quartile 
Range (IQR) 
MH04 Creatinine & TSH monitoring on 
lithium (n=942) 
0.0 0.0-0.0 0.0-0.0 
MH05 Therapeutic lithium level (n=935) 0.0 0.0-0.0 0.0-0.0 
MH06 Comprehensive Care Plan (n=996) 13.1 12.0-14.1 5.7-22.8 
MH07 Annual MH review (n=786) 0.0 0.0-0.0 0.0-0.0 
MH09 Routine Health Promotion (n=987) 14.6 14.0-15.6 6.7-25.4 
ASTHMA06 Asthma review  (n=997) 6.6 5.8-7.5 1.6-15.7 
DEMENTIA02 Dementia review  (n=989) 5.0 4.4-5.6 1.3-5.0 
DM22 eGFR or serum creatinine reported 
(n=998) 
2.2 2.0-2.3 0.9-3.8 
EPILEPSY07 Medication Review (n=994) 3.8 3.2-4.4 0.0-10.5 
Table 7-14 Indicator Exception Rates 2008/2009 
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Figure 7-7 Indicator exception rates 2008/2009 
7.3.5.1 Renal Function Monitoring (MH04): 
Median exception rate of creatinine and TSH monitoring in lithium prescription, was 
compared with the exception rate of eGFR estimation and creatinine measurement in 
diabetes, (MH04 vs. DM22). Exception rate was significantly lower in lithium prescription 
compared to diabetes (0.0% vs. 2.2%, p<0.001) (Table 7-15). 
7.3.5.2 Comprehensive Care Plan (MH10): 
Median exception rate of documentation of a comprehensive care plan in MMI, was 
compared with the rate of documentation of a care plan in dementia, epilepsy and asthma, 
(MH10 vs. DEM02, MH10 vs. EPILEPSY07 and MH10 vs. ASTHMA06). Median 
exception rates in MMI were significantly higher compared to dementia, epilepsy and 
asthma (13.1% vs. 5.0%, p<0.001, 13.1% vs. 3.8%, p<0.001 and 13.1% vs. 6.6%, p<0.001) 
(Table 7-15).   
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Median Exception 
Rates (%) 
p value 
MH04 Creatinine & TSH monitoring on lithium vs. 
DM22 Creatinine or eGFR measurement in 
Diabetes 
0.0  vs.  2.2 <0.001 
MH06 Comprehensive Care Plan vs. EPILEPSY07 
Medication review 
13.1  vs.  3.8 <0.001 
MH06 Comprehensive Care Plan vs.ASTHMA06 
Asthma review 
13.1  vs.  6.6 <0.001 
MH06 Comprehensive Care Plan vs. DEMENTIA02 
Dementia Review 
13.1  vs.  5.0 <0.001 
Table 7-15 Comparison of Median Exception rates 2008/2009 Bold if significantly higher, 
italic if significantly lower 
7.3.6 2007/2008 Median exception rates: 
In 2007/2008 median rate of exception varied widely by clinical indicator (Table 7-16 and 
Figure 7-8); MH04 (Creatinine and TSH monitoring in lithium prescription), MH05 
(Therapeutic lithium level) and MH07 (Mental Health Annual review) had the lowest 
median rates of exception (all 0.0%) while MH06 (comprehensive care plan) and MH09 
(routine health promotion) had the highest median rate of exception reporting (16.7% and 
15.0% respectively) (Table 7-16 and Figure 7-8).   
Of the comparator indicators DEMENTIA02 (Dementia Review) had the highest median 
rate of exception reporting (5.7%) while DM22 (eGFR or serum creatinine recording in 
Diabetes) had the lowest median exception rate (2.2%) (Table 7-16 and Figure 7-8). 
Variable Median Exception 
Rate (%) 
95% Confidence 
Interval 
Inter-Quartile 
Range (IQR) 
MH04 Creatinine & TSH monitoring on 
lithium (n=947) 
0.0 0.0-0.0 0.0-0.0 
MH05 Therapeutic lithium level (n=944) 0.0 0.0 -5.6 0.0-20.0 
MH06 Comprehensive Care Plan (n=993) 16.7 15.4 - 18.2 8.1-28.1 
MH07 Annual MH review (n=761) 0.0 0.0-0.0 0.0-39.6 
MH09 Routine Health Promotion (n=983) 15.0 14.3- 16.4 6.6-26.8 
ASTHMA06 Asthma review  (n=998) 3.4 5.5- 7.3 1.7-15.7 
DEMENTIA02 Dementia review  (n=991) 5.7 5.1- 6.2 0.0-11.1 
DM22 eGFR or serum creatinine reported 
(n=999) 
2.2 2.1- 2.4 0.9-3.8 
EPILEPSY07 Medication Review (n=994) 3.7 3.1-  4.4 0.0-9.5 
Table 7-16 Indicator Exception Rates 2007/2008 
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Figure 7-8 Indicator exception rates 2007/2008: 
7.3.6.1 Renal Function Monitoring (MH04): 
Median exception rate of creatinine and TSH monitoring in lithium prescription, was 
compared with the rates of eGFR estimation or creatinine measurement in diabetes, (MH04 
vs. DM22). Exception rate was lower in lithium prescription compared to diabetes (0.0% 
vs. 2.2%, p<0.001) (Table 7-17). 
7.3.6.2 Comprehensive Care Plan (MH06): 
Median exception rate of documentation of a comprehensive care plan in MMI was 
compared with the exception rate of documentation of a care plan in dementia, epilepsy 
and asthma, (MH10 vs. DEM02, MH10 vs. EPILEPSY07 and MH10 vs. ASTHMA06). 
Median exception rates in MMI were significantly higher compared to dementia, epilepsy 
and asthma (16.7% vs. 5.7%, p<0.001, 16.7% vs. 3.7%, p<0.001 and 16.7% vs. 3.4%, 
p<0.001 respectively) (Table 7-17).   
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 Median Exception 
Rates (%) 
p value 
MH04 Creatinine & TSH monitoring on lithium vs. 
DM22 Creatinine or eGFR measurement in Diabetes 
0.00  vs.  2.22 <0.001 
MH06 Comprehensive Care Plan vs. EPILEPSY07 
Medication Review 
16.7  vs.  3.7 <0.001 
MH06 Comprehensive Care Plan vs. ASTHMA06 
Asthma review 
16.7  vs.  3.4 <0.001 
MH06 Comprehensive Care Plan vs. DEMENTIA02 
Dementia Review 
16.7  vs.  5.7 <0.001 
Table 7-17 Comparison of Median Exception Rates 2007/2008 Bold if significantly 
higher, italic if significantly lower 
7.3.7 2006/2007 Median exception rates: 
In 2006/2007, median rate of exception varied widely by clinical indicator (Table 7-18 and 
Figure 7-9); MH04 (Creatinine and TSH monitoring in lithium prescription), MH05 
(Therapeutic lithium level) and MH07 (Mental Health Annual review) had the lowest 
median rates of exception (all 0.0%) while MH06 (comprehensive care plan) and MH09 
(routine health promotion) had the highest median rate of exception reporting (18.9% and 
14.8% respectively) (Table 7-18 and Figure 7-9).   
Of the comparator indicators ASTHMA06 (Asthma Review) had the highest median rate 
of exception reporting (6.0%) while DM22 (eGFR or serum creatinine reported in 
Diabetes) had the lowest median exception rate (2.2%) (Table 7-18 and Figure 7-9). 
Variable Median Exception 
Rate (%) 
95% Confidence 
Interval 
Inter-Quartile 
Range (IQR) 
MH04 Creatinine & TSH monitoring on 
lithium (n=928) 
0.0 0.0-0.0 0.0-4.9 
MH05 Therapeutic lithium level (n=927) 0.0 0.0-0.0 0.0-15.0 
MH06 Comprehensive Care Plan 
(n=984) 
18.9 17.2- 20.4 8.3-33.3 
MH07 Annual MH review (n=669) 0.0 0.0-0.0 0.0-0.0 
MH09 Routine Health Promotion 
(n=982) 
14.8 13.3-16.4 5.6-27.4 
ASTHMA06 Asthma review  (n=987) 6.0 5.2-6.8 1.8-15.2 
DEMENTIA02 Dementia review  (n=983) 5.5 4.9-5.9 0.0-11.1 
DM22 eGFR or serum creatinine 
reported (n=990) 
2.2 2.1-2.4 1.0-3.9 
EPILEPSY07 Medication Review (n=981) 3.4 3.0-4.0 0.0-9.1 
Table 7-18 Indicator Exception rates 2006/2007 
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Figure 7-9 Indicator exception rates 2006/2007: 
7.3.7.1 Renal Function Monitoring (MH04): 
Median exception rate of creatinine and TSH monitoring in lithium prescription, was 
compared with the rates of eGFR estimation and creatinine measurement in diabetes, 
(MH04 vs. DM22). Exception rate was significantly lower in lithium prescription 
compared to diabetes (0.0% vs. 2.2%, p<0.001) (Table 7-19). 
7.3.7.2 Comprehensive Care Plan (MH10): 
Median exception rates of documentation of a comprehensive care plan in MMI were 
significantly higher compared to documentation of a care plan in dementia, epilepsy and 
asthma (18.9% vs. 6.0%, p<0.001, 18.9% vs. 3.4%, p<0.001 and 18.9% vs. 6.0%, p<0.001 
respectively) (Table 7-19).   
 
 
Median Exception 
Rate (%) 
p value 
MH04 Creatinine & TSH monitoring on lithium vs.DM22 
Creatinine or eGFR measurement in Diabetes 
0.0  vs.  2.2 <0.001 
MH06 Comprehensive Care Plan vs. EPILEPSY07 
Medication review 
18.9  vs.  3.4 <0.001 
MH06 Comprehensive Care Plan vs. ASTHMA06 Asthma 
review 
18.9  vs.  6.0  <0.001 
MH06 Comprehensive Care Plan vs. DEMENTIA02 
Dementia Review 
18.9  vs.  6.0 <0.001 
Table 7-19 Comparison of Median Exception rates 2006/2007 Bold if significantly higher, 
italic if significantly lower 
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7.3.8 2005/2006 Median exception rates: 
In 2005/2006 median rate of exception for MH04 (Creatinine and TSH monitoring in 
lithium prescription) and MH05 (Therapeutic lithium level) were low (both 0.0%). 
ASTHMA06 (Asthma Review) had the highest median rate of exception reporting (4.5%) 
(Table 7-20 and Figure 7-10).  
No direct comparison between proxy indicators was possible for this QOF year.  
Variable Median Exception 
Rate (%)  
95% 
Confidence 
Interval 
Inter-
Quartile 
Range (IQR) 
MH04 Creatinine & TSH monitoring on 
lithium (n=924) 
0.0 0.0-0.0 0.0-4.8 
MH05 Therapeutic lithium level (n=920) 0.0 0.0-0.0 0.0-14.3 
ASTHMA06 Asthma review  (n=973) 4.5 3.9-5.3 1.3-12.4 
Table 7-20 Indicator Exception rates 2005/2006 Bold if significantly higher, italic if 
significantly lower 
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Figure 7-10 Indicator exception rates 2005/2006: 
7.3.9 Patterns of Mental Health Indicator median exception rates 
over time: 
For the Mental Health indicators related to lithium therapy (MH04/MH17 measurement of 
creatinine and TSH and MH05/MH18 therapeutic level of lithium) exception rates were 
low and remained static throughout the duration of the study (Table 7-21 and Figure 7-11). 
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Exception rate of non-attendance at a Mental Health annual review (MH07), was also low 
(0.0%). It too remained at this level, until it was removed as an indicator in 2010/2011 
(Table 7-21 and Figure 7-11).  
The median exception rate for the Comprehensive Care Plan Indicator (MH06/MH10) 
decreased over the study timeframe; from 18.9% IQR 9.3-32.7% in 2006/2007 to 8.8% 
IQR3.1-15.4% in 2010/2011, p<0.001 and then from 7.9% IQR 3.2–14.0% in 2011/2012 to 
6.4% IQR 2.4-11.8% in 2012/2013, p<0.001 as MH10 (Table 7-21 and Figure 7-11).  
For the health promotion indicator (MH09), median exception rates fell during the study 
timeframe: from 14.8% IQR 5.6-27.4% in 2006/2007 to 13.3% IQR 5.7-23.8% in 
2010/2011, p<0.001. (Table 7-21 and Figure 7-11). 
For the recording of alcohol consumption (MH11) median exception reporting rate also fell 
from 13.7% IQR 6.7-22.4% in 2011/2012 to 11.1% IQR 5.0-19.3% in 2012/2013, p<0.001. 
(Table 7-21 and Figure 7-11). 
For BMI recording (MH12), median exception reporting rate fell from 14.3% IQR 7.0-
22.6% in 2011/2012 to 11.8% IQR 5.0-19.6% in 2012/2013, p<0.001. (Table 7-21 and 
Figure 7-11). 
For blood pressure recording (MH13) median exception reporting rate fell marginally from 
10.7% IQR 5.1-17.2% in 2011/2012 to 9.5% IQR 4.0-15.8% in 2012/2013, p=0.005 (Table 
7-21 and Figure 7-11). 
For recording of total cholesterol:hdl ratio ( MH14/MH19), blood glucose or HbA1c 
(MH15/MH20) and recording of cervical smear (MH16), median exception reporting rates 
were relatively stable over the study timeframe (Table 7-21 and Figure 7-11).   
7.3.10 Patterns of Chronic Disease Comparator Indicator median 
exception rates over time: 
There was a mixed pattern in exception rate reporting trends for the comparator chronic 
disease indicators during this study timeframe; with some rates falling, some increasing 
and others remaining relatively stable throughout.  
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There was a significant reduction in median exception rate from 9.8% IQR 1.8-19.1% in 
2009/2010 to 6.5% IQR 2.5-11.8% in 2010/2011, p<0.001, for the lifestyle advice in 
hypertension indicator (CVD02). However median exception rate for the asthma review 
indicator (ASTHMA06) increased from 4.5% IQR 1.3-12.4% in 2005/2006 to 6.7% IQR 
2.2-18.4% in 2011/2012, p<0.001 (Table 7-21 and Figure 7-12). 
There was no significant change in median exception rate for the: epilepsy care plan 
indicator (EPILEPSY07), COPD review indicator (COPD13), dementia indicator 
(DEMENTIA02), monitoring of eGFR or creatinine in diabetes (DM 22), Blood Pressure 
monitoring in CKD (CKD02) and BMI recording in Diabetes (DM02) throughout the study 
timeframe (Table 7-21 and Figure 7-12). 
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Table 7-21 Mental Health and Comparator Indicators changes over time 2005/2006 – 2012/2013 P
1
 sign rank test between years marked with * Bold if 
significantly reduction in exception rate over time 
 
Variable 2005/2006 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011 2011/2012 2012/2013 P
1 value 
MH04/MH17 Creatinine & TSH check on lithium *0.0 0.0 0.0 0.00 0.0 0.0 0.0 *0.0 0.6947 
MH05/MH18  Therapeutic lithium level  *0.0 0.0 0.0 0.00 0.0 0.0 0.0 *0.0 0.0025 
MH06/MH10 Comprehensive Care Plan   *18.9 16.7 13.1 9.4 8.7 7.8 *6.3 <0.001 
MH07  Annual MH review   0.0 0.0 0.0 0.0 0.0    
MH09 Routine Health promotion   *14.8 15.0 14.6 12.8 *13.3   <0.001 
MH11 recording of alcohol consumption         *13.7 *11.1 <0.001 
MH12 BMI recording        *14.3 *11.8 <0.001 
MH13 BP recording        *10.7 *9.5 0.005 
MH14/MH19  Cholesterol:HDL ratio recording        *16.0 *16.0 0.3886 
MH15/MH20 Blood glucose (HbA1c) recording        *25.0 *25.5 0.0336 
MH16 Cervical Screening        *17.8 *17.8 0.553 
ASTHMA06 Asthma Review  *4.5 6.0 3.4 6.6 6.1 6.7 *6.7  <0.001 
ASTHMA09 Asthma Review        11.6  
DEM02 Dementia Review   *5.5 5.7 5.0 4.2 5.1 5.0 *5.9 0.7653 
DM22  Creatinine/eGFR check in diabetes   *2.2 2.2 2.2 2.3 *2.2   0.9010 
EPILEPSY07 Epilepsy Review   *3.4 3.7 3.8 2.9 *2.9   0.6690 
COPD13 COPD Review       *12.8 11.7 12.6 *11.9 0.0662 
CVD02  Lifestyle Advice      *9.8 *6.5   <0.001 
CKD02 BP recording         *0.6 *0.6 0.4157 
DM02 BMI recording         *3.5 *3.5 0.5400 
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*  
Figure 7-11 Mental Health Indicators over time 2005/2006 – 2012/2013 
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Figure 7-12 Comparators Indicators over time 2005/2006 – 2012/2013 
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7.3.11 Summary of Main Findings: 
7.3.11.1 Composite Indicators:   
Median rates of exception reporting for the composite mental health indicators were 
significantly higher in thirteen out of sixteen comparable composite chronic disease 
indicators for the 2012/2013 QOF year. For example median exception rate was for the 
composite MH indicator was 11.1% IQR 0.0-21.4% compared to 3.4% IQR 1.4-6.6%, 
p<0.001 for the hypertension composite indicator. A similar pattern was seen in 
2011/2012; where exception reporting for the composite mental health indicators was 
significantly higher in ten out of fourteen of the comparable composite chronic disease 
indicators. 
7.3.11.2 Individual Indicators:  
7.3.11.2.1 Body Mass Index (BMI) recording (MH12):  
 
There was a higher rate of median exception reporting for BMI recording in MMI 
compared to diabetes in 2012/2013 and 2011/2012.  
7.3.11.2.2 Blood Pressure (BP) monitoring (MH13):  
 
The median exception rate for BP recording in MMI was also significantly higher than the 
median exception rate for BP recording in chronic kidney disease in 2012/2013 and 
2011/2012.  
7.3.11.2.3 Routine health promotion & prevention advice (MH09): 
 
The median exception rates for routine health promotion in MMI was significantly higher 
than the median exception rate for the documentation of lifestyle advice in hypertension in 
both 2010/2011 and 2009/2010.  
7.3.11.2.4 Creatinine and TSH monitoring (MH04): 
 
Lower rates of exception reporting for creatinine and TSH monitoring in lithium 
prescription compared to eGFR and creatinine monitoring in diabetes occurred throughout 
this study from 2006/2007 until 2011/2012.  
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7.3.11.2.5 Comparison of Comprehensive Care Plans (MH06/MH10) with similar 
reviews: 
 
Exception reporting rates were significantly higher for the mental health care plan indicator 
compared to the dementia, asthma and epilepsy review indicators for each year from 
2006/2007 until 2009/2010. In 2010/2011 there was no difference in exception rates 
between the mental health care plan indicator and the asthma review indicator but 
exception rates for the mental health indicator remained higher than that of the dementia 
and epilepsy reviews. By 2012/2013, there was no difference in exception rates between 
the mental health care plans and dementia reviews.  
Notably median exception rates for the metal health care plan were significantly lower for 
all comparator years, than the median exception rates for COPD reviews. 
7.4 Discussion: 
7.4.1 Composite Indicator Exception Rates: 
In Scotland rates of exception reporting for the composite mental health indicators were 
significantly higher compared to the majority of the other composite chronic disease 
indicators within the two most recent QOF years. This finding is in keeping with Doran 
and colleagues (Doran et al., 2006), who found overall median exception rates for mental 
health indicators to be higher than that for asthma and COPD in English practices (median 
exception rate 9.5% for mental health, 2.7% for asthma and 8.2% for COPD). While it is 
recognised that individuals with MMI experience many barriers to care, possible reasons 
underlying the higher exception rates observed in this study are likely to include; the 
stigma associated with mental illness, as well as the perceived separation of physical and 
mental healthcare. The latter issue may be of particular significance given that many of the 
indicators included in the mental health QOF are related to physical healthcare measures.   
While it is recognised that exception rates may vary widely by indicator (Doran et al., 
2008; Sigfrid et al., 2006) - often partly due to whether the indicator of interest is a 
measurement indicator (e.g. BP measurement), treatment indicator (e.g. prescribing ACE 
inhibitors in certain populations) or an outcome indicator (e.g. cholesterol level <5mmoll-1) 
–this study has found that when directly comparing individual indicators which were of the 
same type, higher exception rates in MMI persisted across a range of indicators over a 
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number of years. This suggests possible inequalities in access to certain aspects of 
incentivised healthcare in Scotland which have persisted over at least 2 QOF years. 
7.4.2 Lower Exception rates in the Lithium Indicators 
However higher exception rates were not universally reported across all Mental Health 
indicators. For example exception rates for the creatinine and TSH monitoring in lithium 
prescription indicator were lower than exception rates for the comparable eGFR and 
creatinine monitoring indicator in diabetes. This was persistent across the duration of the 
study. Given the importance of lithium monitoring not only due to its narrow therapeutic 
window, its potential for side effects and its risk of toxicity, it would appear that in 
Scotland, there are extremely low levels of exception reporting for this indicator in primary 
care. Reasons may be due in part to a high level of awareness of the potential risks of 
lithium, along with clinically cautious prescribing by secondary care. Improved prescribing 
guidance along with possible high levels of patient involvement in their care, may in part 
explain this low exception rate. The need for adherence to therapeutic monitoring before 
the dispensing of medication may also occur (as is seen with clozapine) and this may also 
help explain the low exception rates observed for this indicator. 
7.4.3 Comprehensive Care Plan Documentation Exception Rates:  
Median rates of exception reporting for the comprehensive care plan documentation 
indicator (MH06/MH10) improved during this study timeframe. Although the median 
exception rates were significantly higher than that for dementia care plans, asthma reviews 
and medication reviews in epilepsy, at the start of this study, by 2012/2013 exception rates 
either showed no difference or were lower than comparator indicators, suggesting 
improvement with time. This finding of a decrease in exception rate over time for this 
Mental Health indicator may be in keeping with general trends of improved achievement 
rates and reduced exception rates which occur as the age of the indicator increases (Reeves 
et al., 2010). The finding of higher exception rate for the COPD indicator may be due in 
part to increased rates of being housebound (Gore et al., 2000) or increased rates of 
comorbid mental health problems which are known to be relatively common in individuals 
with COPD (Gore et al., 2000).  
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7.4.4 Health Promotion, BMI and BP Recording Exception Rates:  
Higher median exception rates for the health promotion review (MH09), BMI recording 
(MH12) and Blood Pressure measurement (MH13) indicators in MMI compared to their 
respective comparator indicators in hypertension (CVD02), Diabetes (DM02) and Chronic 
Kidney Disease (CKD02) were reported in this study. These findings are of significant 
clinical concern. It is recognised that the increased morbidity and mortality experienced by 
individuals with MMI is largely due to a higher prevalence of modifiable risk factors, 
many of which are due to lifestyle choices (Parks et al., 2006). Therefore health promotion 
combined with the recording and monitoring of cardiovascular risk factors (such as BMI 
and BP) are important interventions in order to begin to address the gap in morbidity and 
mortality experienced by individuals with MMI.    
In particular the finding of increased median rates of exception reporting for BMI 
recording is of particular clinical concern not only due to the high rates of obesity that are 
seen in patients with MMI (Ratliff et al., 2013: Allison et al., 1999) but also because of 
recent evidence to suggest that obesity in individuals with schizophrenia has a profound 
influence on cardiometabolic risk. Reasons for this increased risk associated with obesity 
are unclear but may in part be explained by poor diet and physical inactivity. Given the 
move towards primary prevention, higher median exception reporting for the recording of 
BMI and BP in MMI is of significant clinical concern as it suggests that opportunities for 
screening and for subsequent intervention to address cardiometabolic risk are being missed 
in this vulnerable patient group. The retirement of the BMI measurement indicator in MMI 
for the 2014/2015 QOF in England is also of concern (QOF England 2014/2015). These 
concerns have been further detailed in Chapter 6. 
Although it is recognised that individuals with MMI have more physical health problems 
than the general population, inequalities are persistently reported for both the access to and 
the quality of a range of physical healthcare services (Lambert and Newcomer, 2009; de 
Hert 2011a). This study’s findings of high rates of median exception reporting in Mental 
Health measurement indicators compared to measurement indicators in other chronic 
diseases supports the evidence of inequalities in access to some aspects of incentivised 
QOF care in Scotland.  
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7.5 Strengths and Limitations: 
This is the first study to directly compare median exception rates for individual and 
composite mental health indicators with other individual and composite chronic disease 
indicators over time and so adds to previous work in this area. The national scope of this 
study represents a major strength but some potential limitations similar to those detailed in 
Chapter 6 are acknowledged. Firstly, some practices may not directly record all exceptions 
(if for example, the maximum payment threshold has been obtained) and so exception 
codes may be under-recorded. Secondly not all practices had exception rate data available. 
This is likely due to limitations in data extraction. However this meant that the number of 
practices whose data was available varied by indicator. While it may be the case that 
availability of exception rate data may be influenced by the indicator itself, due to the fact 
that most practices had exception rate data available (i.e. greater than 900 practices) it is 
likely that the effect of this was small. Thirdly, while it is recognised that individuals with 
a chronic disease are likely to have more than one (Barnett et al., 2012), it was not possible 
to assess the effect of multimorbidity on exception rates. Detailed auditing within 
practices, where reasons for exception could be examined across multiple indicator areas 
for the same person would allow this to be investigated further. 
A further limitation of this work is that of the individual non-Mental Health indicators 
chosen for comparison with the comprehensive care plan indicator (MH06/MH10). 
Exception rates for the asthma review, COPD review, medication review in epilepsy and 
dementia care review indicators were chosen as proxy comparators: with the rationale 
being that these components (symptom review and medication review) should be included 
within a comprehensive care plan. While the skills, expertise and time required to complete 
the individual indicators may not be directly comparable, they represented the closest 
comparator indicators available within the QOF and were therefore felt to be a useful 
proxy measurement of equity in care across different chronic illnesses. Although the 
differences in the indicator definitions is a limitation to the design of this study.  
The composite indicators generated in this study were also made up of different types of 
indicators (measurement and target indicators) and often contained different numbers of 
individual indicators (for example the Mental Health composite indicator contained nine 
individual indicators, while the CKD composite indicator contained four individual 
indicators). These factors may have influenced the median composite exception rate that 
was calculated for each chronic disease composite indicator. However the generation of a 
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median composite indicator exception rate for each chronic disease allowed a broad 
comparison over many chronic diseases and allowed general trends in median exception 
rates to be described. Although this technique has limitations, it has been detailed by others 
in this field (de Wet et al., 2012).  
A further limitation to this study is that the different indicators investigated have been 
present in the QOF for different lengths of time. It is generally accepted that indicator 
exception rates decrease with time and then plateau (Reeves et al., 2010), and so 
differences in the exception rates observed in this study, may in part be explained by 
variations in the age of indicators. However by undertaking a longitudinal approach to 
exception rates, namely back to the inception of the QOF, this effect has been minimised.  
7.6 Conclusions: 
Although median rates of exception reporting varied across clinical indicators, there was 
evidence of higher rates of median exception reporting for composite and individual 
mental health indicators relative to a number of composite and individual comparator 
indicators for other chronic physical health problems. Although reductions in the gap 
between rates of median exception reporting in comprehensive care planning in mental 
health versus its comparator indicators have improved over time, the gap in median 
exception rates for health promotion indicators (including recording of BMI and BP) 
remain wide.  
Despite the risk of increased exception rates in MMI being a concern highlighted by the 
Royal College of General Practioners (RCGP) at the inception of the QOF in 2004, higher 
exception rates and as such potential inequalities in healthcare provision appear to have 
continued over the following 9-10 years that the QOF has been in place. Further 
investigation, for example through detailed auditing of patient level data and monitoring of 
patterns of exception reporting over time, is required to ensure that the QOF indicators and 
exception reporting are appropriately used within primary care. Continued efforts must 
also be made to reduce barriers to care and improve integration of health services in order 
to provide higher quality healthcare for individuals with MMI. This will then act to help 
reduce inequalities in care. 
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Chapter 8: Increased mortality in Major Mental 
Illness (MMI): findings from The Glasgow 
Psychosis Clinical Information System (PsyCIS) 
 Chapter Overview: 
This chapter describes and compares rate, age and primary cause of death of individuals 
with Major Mental Illness (MMI) within The Glasgow Psychosis Clinical Information 
System (PsyCIS) with the rate, age and primary cause of death of individuals living in the 
local (Glasgow) and wider (Scottish) areas. Rate of death was compared using 
Standardised Mortality Ratios (SMR). The impact of socioeconomic status on rate and 
primary cause of death between groups was also investigated. Finally a comparison of 
primary cause of death across the lifespan of individuals with schizophrenia and bipolar 
disorder was also undertaken.    
8.1 Scottish Mortality within a European Setting: 
As outlined in Chapter 1, individuals with MMI die 15-20 years younger than individuals 
without MMI; however work detailing mortality rates of individuals with MMI exclusively 
in Scotland has been limited. Scotland is often dubbed the “sick man of Europe” and the 
Glasgow Centre for Population Health (GCPH) has produced a 60 year overview of 
Scottish Mortality Rates in a European context (GCPH Still the Sick Man of Europe? 
2012). They found that Scotland has had the highest mortality in Western Europe among 
working age (15-74 years old) men and women since the late 1970s. The GCPH also 
recognised that although mortality rates for Scottish men of working age have been falling 
at a similar rate to other Western European countries; they have remained consistently 
elevated compared to the Western European average. For women, although there has also 
been a reduction in mortality rates in Scotland, when compared to other Western European 
countries the reduction has been less than the European average; which has resulted in an 
increased gap in mortality rates with Scottish women experiencing higher mortality rates 
than their European counterparts. In 2010 it was estimated that Scottish male mortality 
rates were around 20% higher and female working age mortality rates were 30% higher 
than the Western European mean (GCPH Still the Sick Man of Europe? 2012).  
The GCPH also highlighted another area potentially of greater concern: that of a plateauing 
mortality rate in younger working age adults (15-44 years). They reported that although 
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mortality rates have reduced from the 1950s until the mid-1980s, further reduction in 
mortality rate from the mid-1980s onwards has “stalled”. This has been particularly 
evident in Scottish men since 1982 and in Scottish women since 1987. Additionally this 
plateauing of Scottish mortality rate, is unusual compared to other European Countries: 
where in all but one of the other nineteen European Countries (namely Northern Ireland) 
included in their overview, a reduction in mortality in men and women has continued to 
occur in recent years; albeit to varying extents. Subsequent to Scotland’s plateau in 
mortality rate, its relative ranking for younger working age mortality has progressively 
worsened for both sexes over the last 55 years; in fact it was reported as the highest among 
the sixteen Western European countries in the study by the GCPH (GCPH Still the Sick 
Man of Europe? 2012).  
More locally, when the Scottish younger working age mortality is compared to the younger 
working age mortality in England and Wales it was reported to be 46% higher for women 
and 54% higher for men in 2009 (GCPH Still the Sick Man of Europe? 2012). These 
findings highlight the unique challenges which face the healthcare system in Scotland.  
8.2 Glasgow Mortality Rates: 
Within Glasgow mortality rates are higher and age of death lower than that of Scottish 
averages (Scot PHO Public Health Information for Scotland, 2015). Although it is 
recognised that certain factors which impact on health; such as obesity, diabetes and diet, 
are not significantly different in Glasgow than elsewhere in Scotland, many health 
outcomes are worse. A substantial proportion of these differences can be explained by the 
socio-economic profile seen in Glasgow however it is recognised that this does not fully 
explain the differences seen.    
The impact of deprivation on health outcomes has been recognised since health records 
began (Equally Well: Report of the Ministerial Task Force on Health Inequalities, 2008). 
As early as 1842 Edwin Chadwick reported this relationship in Aberdeen and it is 
recognised globally that mortality rates, life expectancy, rates of comorbidity and health 
related behaviour all vary between social group; with individuals from more deprived areas 
commonly experiencing more adverse outcomes and reduced life expectancy compared to 
individuals from more affluent areas (Hosseinpoor at al., 2012; MacIntyre and Ellaway, 
2003).  
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Inequalities in socioeconomic status may arise in a number of different ways and interact 
with each other in a complex manner to affect both health related behaviour and health 
outcomes. Physical factors such as damp housing, air pollution and living in a threatening 
environment, along with individual psychological factors such as personal strengths and 
coping abilities will impact on health related behaviours such as smoking, diet and 
exercise. The relationship between these factors is complex and likely bidirectional; for 
example an individual with poor coping skills, may smoke and drink excessively while 
avoiding exercise in order to cope with living in a damp house where they feel threatened. 
Wider systems in place within the society that an individual lives; for example education 
systems, health care systems, working opportunities and taxation policies, will also impact 
on socioeconomic inequalities.  
Although life expectancy and health behaviours have improved in Glasgow over the past 
50 years, the rates of improvement have differed depending on an individuals’ 
socioeconomic status. As Scotland’s ranking in terms of European mortality rates have 
worsened over time, so too has the gap in life expectancy between the most affluent and 
most deprived areas (SPHSU, 2007). For example life expectancy at birth in Glasgow 
improved by 2.2 years (from 75.8 years in 1998-2000 to 78.0 years in 2008-2010) but in 
Edinburgh, life expectancy improved by 2.8 years (from 79.0 years in 1998-2000 to 81.8 
years in 2008-2010) (GRO for Scotland Table 9, 2010). This highlights the particular 
challenges which face the healthcare system in Glasgow. 
8.3 More than deprivation: 
While it is known that the impact of deprivation on health and mortality is significant, the 
differences in life expectancy in Scotland compared to the rest of Europe and in Glasgow 
compared to the rest of Scotland cannot be fully explained by deprivation alone (Hanlon et 
al., 2001; McCartney et al., 2011). When all-cause mortality in Scotland was compared to 
all-cause mortality in England and Wales in 1981, it was 12% higher in Scotland, while in 
2001, the Scottish all-cause mortality was 15% higher. When the Carstairs Deprivation 
Index was used to try and explain the rise in excess all-cause mortality over the 20 year 
period, the proportion that could be explained by differences in deprivation fell from 62% 
in 1981 to 47% in 2001 (McCartney et al., 2012). The gap in mortality (between Scotland 
and the rest of Europe) which cannot be explained by deprivation has been termed the 
“Scottish Effect”.  
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This phenomenon has been replicated more locally on a city basis- namely in Glasgow. 
When premature mortality (deaths in those < 65 years) in Glasgow was compared to the 
similarly deprived English cities of Liverpool and Manchester, it was found that premature 
deaths were 30% higher in Glasgow than in Liverpool and Manchester and deaths at all 
ages were almost 15% higher. This excess has been shown for all adult age groups, for 
both sexes and across different neighbourhood types (both deprived and non-deprived). Of 
more concern is that the excess mortality appears to be greatest in the working-age groups 
(15-44 and 45-64), where it was 45% and 30% higher respectively. The gap in mortality 
seen in Glasgow that cannot be explained by deprivation alone has been termed the 
“Glasgow Effect.” (GCPH Still the Sick Man of Europe? 2012). 
As a consequence of these findings, much work has been undertaken by the GCPH 
comparing Glasgow, with Liverpool and Manchester in greater detail, to determine 
possible explanations for the “Glasgow Effect”. Work is on-going within this field, but 
differences in Standardised Mortality Ratios (SMR) for certain causes of death between the 
three cities are consistently reported. For example when SMR are calculated for specific 
causes of death, such as lung cancer, suicide, alcohol and drug related deaths, deaths were 
27% higher in relation to lung cancer, almost 70% higher for suicide, 2.3 times higher for 
alcohol-related causes, and almost 2.5 times higher for drug-related deaths in individuals 
living in Glasgow relative to individuals living in Liverpool and Manchester (GCPH Still 
the Sick Man of Europe? 2012). Clearly more detailed work is required to develop a better 
understanding of possible explanations for this.  
Of note, and of potential hope, is that when analysis of long term trends in premature 
mortality for the three cities is dated back to the 1920s, the current trend of higher 
mortality rates in Glasgow compared to Liverpool and Manchester has not always been 
observed. This widening gap in mortality began to appear at the start of the 1980s and has 
continued over the past 25-30 years. This observation has led researchers to consider that 
the excess mortality and “Glasgow Effect” may be a relatively recent phenomenon. It is 
hypothesised that with the correct intervention this trend could be slowed and even 
reversed. 
Given the unique mortality patterns and profile of the general population within Glasgow 
and Scotland, exploration of age and cause of death in individuals with MMI within a 
Glasgow and Scottish setting is of clinical interest and importance. This combined with the 
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paucity of research to date has led to the further investigation of the patterns of mortality 
included in this thesis. 
8.4 Aims: 
1. To describe the age and primary cause of death of individuals with major mental 
illness (MMI) within the Glasgow Psychosis Clinical Information System (PsyCIS) 
relative to the local (Glasgow) and wider (Scottish) populations. 
2. To assess the impact of socioeconomic status on rate and primary cause of death in 
individuals with MMI (schizophrenia and bipolar disorder) relative to the local 
(Glasgow) and wider (Scottish) populations. 
3. To compare calculated standardised mortality ratios (SMR), for individuals with 
MMI to the local (Glasgow) and wider (Scottish) populations.   
4. To compare primary cause of death by ICD 10 diagnosis (schizophrenia and bipolar 
affective disorder), across the life-span. 
8.5 Scientific Rationale: 
While the increase in standardised mortality rates (SMR) for individuals with MMI 
compared to the general population is substantial (Crump et al., 2013; Hoang et al., 2011; 
Laursen et al., 2011; Wahlbeck et al., 2011), and reasonably well described, little work has 
assessed whether causes of mortality vary across the life-span.  Although the relationship 
between age and suicide has been investigated (Gunnell and Middleton, 2003), with the 
recognition that suicide is a particularly important contributor to excess mortality in young 
males, little work has been done detailing other causes of death across the lifespan of 
individuals with MMI.   
While it is recognised that socioeconomic status has a significant impact on health and 
wellbeing and, with only a few exceptions, health outcomes are generally worse in 
deprived communities (Strickland et al., 1998), little work has specifically focused on the 
relationship between mortality and socioeconomic deprivation for individuals with MMI. 
This is therefore worthy of further exploration.   
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Historically it has been considered that bipolar disorder had a better prognosis than 
schizophrenia (Falret, 1854), however recent studies are increasingly recognising that the 
level of the increased mortality experienced by individuals with schizophrenia and bipolar 
disorder may be similar. Despite this, detailed comparisons of primary cause of death 
across the life span of individuals with schizophrenia and bipolar disorder are limited and 
again worthy of further exploration especially in a Scottish setting. These areas of 
investigation are the focus of this chapter.  
8.6 Methods: 
8.6.1 Sample: 
All individuals with schizophrenia (F20-F29) or bipolar disorder (F30-F31) aged between 
18 and 65 who had died between 2006 and 2010 and lived within the Greater Glasgow area 
covered by PsyCIS were identified. Date and cause of death were obtained by linkage to 
the Scottish Morbidity Records held by the Information Services Division (ISD) of NHS 
Scotland using patient Community Health Index (CHI) number. The International 
Statistical Classification of Diseases and Related Health Problems (ICD) was used to code 
cause of deaths, grouped into nine categories using information from the Scottish 
Government website: 1) cardiovascular disease, 2) cerebrovascular disease, 3) respiratory 
disease, 4) cancer, 5) alcohol related deaths, 6) mental and behavioural disorder due to 
drugs, 7) accidental, 8) suicide as defined by the Scottish suicide information database 
(which includes deaths of undetermined origin) and 9) other (GRO Website and GRO 
Suicide Definitions) (Table 8-1). 
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Main categories of 
cause of death  
ICD 10 Codes 
1) cardiovascular 
disease 
I20-I25- including acute MI I219 & atherosclerotic heart disease I251 & I259  
2) cerebrovascular 
disease 
I60-I69-  including subarachnoid haemorrhage I600, I609, brain stem intra cerebr al 
haemorrhage I613, subdural haemorrhage I620, other unspecified stroke I64 & 
cerebral infarction I639, I693 & I679 
3) respiratory 
disease 
J00-J99-  including, COPD J441 & J449, pneumonia J189, J22 & J690, emphysema 
J439, asthma J459 & bronchiectasis J459 
4) cancer C00-C97- including oral C069 & C329, GI tract C159, C169,19 & C20, lung C349, 
cervix C539, brain C719, skin C446, bladder C679 & lymphoma C819 & C851  
5) alcohol related 
deaths 
including mental and behavioural disorder due to use of alcohol F1 0, degeneration 
of nervous system due to alcohol G31.2, alcoholic polyneuropathy G62.1, alcoholic 
cardiomyopathy I42.6, alcoholic gastritis K29.2, alcoholic l iver disease K70, chronic 
hepatitis, not elsewhere classified K73, fibrosis and cirrhosis of l iver  K74 (excluding 
K74.3-K74.5 – bil iary cirrhosis), alcohol induced chronic pancreatitis K86.0, 
accidental poisoning by, and exposure to, alcohol X45  
6) mental and 
behavioural disorder 
due to drugs 
F11-F16 & F18-F19 
7) accidental  Including transport accidents V01-V99, falls W00-W19, death due to fire X00, 
accidental poisoning X40-X49 (excluding X45), assault  X04 & X59-Y09 and other 
accidents  Y85 & Y86 
8) suicide As defined by the Scottish suicide information database (X60-X84 & Y87.0 and  
deaths of undetermined origin Y10-Y34) including- intentional self-poisoning X61 
& X62, intentional hanging X70, intentional drowning X71, intentional jump from 
height X80, intentional jump before moving object X81, intentional death by fire 
X76, poisoning of undetermined intent Y11 & Y12, fall  or jump from height of 
undetermined intent Y30 & undetermined cause of death Y34 
9) other Including all other codes not included in above 1-8.  A00-B99, E00-E99, G00-G30, 
G32-G61, G62-G99, H00-H95, I00-I19, I26-I41, I43-I59, I70-I99, K00-K28, K30-KK69, 
K70-K85, K87-K93, L00-L99. M00-M99, N00-N99, O00-O99, Q00-Q99, R00-R99, in 
particular  left ventricular failure I501, hypertensive disease I119, aortic aneurysm 
I711 & I713, peripheral vascular disease E145, ischaemic gut K550, cardiomegaly 
I517, cardiomyopathy I426 & I429, valvular disease I080, sarcoidosis D869, PE 
I269, obesity E668 & E669, unspecified cardiac arrest I469, unspecified diabetes 
E149, diabetic coma E140, diabetic ketoacidosis E141 and diabetes with renal 
complications E122, UTI N390, septicaemia A419, hypo-osmolality E871, phlebitis 
I803, GI haemorrhage K922, gastrointestinal ulcer K221, K254 & K264, appendicitis 
K37, intestinal obstruction K566 and renal failure N19.   
Table 8-1 ICD 10 Codes for Cause of death 
Scottish Index of Multiple Deprivation (SIMD) score was used as a measure of social 
deprivation (more detail is included in Appendix 1). Each individual was allocated to a 
SIMD category based on their postcode: where 1 is most deprived and 5 is most affluent.  
8.6.2 Analyses: 
Cause of death by 10 year age ranges, i.e. <25, 25-34, 35-44, 45-54 and 55-64, were 
calculated for the total deceased MMI population (schizophrenia and bipolar disorder 
combined) and compared to the local (Glasgow) population and the wider (Scottish) 
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population using annual mortality statistic data available from the General Register Office 
(GRO) for Scotland (GRO Scotland).  
Cause of death by SIMD quintile for the total deceased MMI population (schizophrenia 
and bipolar disorder combined) was also calculated and compared with cause of death in 
the local (Glasgow) and wider (Scottish) population, using annual mortality statistic data. 
Rates and patterns in cause of death by deprivation quintile were compared in individ uals 
with MMI to the local Glasgow and wider Scottish populations. Both all-cause mortality 
rate and mortality rate excluding suicide in the MMI population were calculated. The 
rationale being that as suicide is a major contributor to premature death in MMI it may in 
itself be influenced by socioeconomic status.   
Standardised mortality ratios (SMR) were calculated in the 10 year age ranges for the 
whole deceased MMI population and further analysed by schizophrenia and bipolar 
disorder diagnosis and gender. SMR for all causes of death, all causes excluding suicides, 
and causes due to cardiovascular disease, cerebrovascular disease and cancer, were 
calculated.  
For local (Glasgow) SMR calculations, the expected rate of death was derived by applying 
the Glasgow death rate stratified by age, sex and cause to the PsyCIS cohort. For the wider 
(Scotland) SMR calculations, the expected rate of death was derived by applying the 
Scotland death rate stratified by age, sex and cause to the PsyCIS cohort (Figure 8-1).   
 
 
 
 
 
 
 
 
 
 
 
Figure 8-1 Standardised Mortality Ratio (SMR) Calculations 
 
Glasgow expected number of deaths   = Glasgow death rate x number in PsyCIS cohort 
         1000 
 
Glasgow Standardised Mortality Ratio (SMR)   =       actual number of deaths in the PsyCIS cohort 
              Glasgow expected number of deaths  
 
Scotland expected number of deaths   =  Scotland death rate x number in PsyCIS cohort 
         1000 
 
Scotland Standardised Mortality Ratio (SMR)    =  actual number of deaths in PsyCIS cohort              
              Scotland expected number of deaths  
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8.7 Results: 
8.7.1 Age and primary cause of death in individuals with MMI:  
The primary cause of death in individuals with MMI differed from that in the local 
Glasgow and wider Scottish populations (Table 8-2). When age at death was considered, a 
higher proportion of individuals with MMI who had died were aged 25-34 and 35-44 
compared to individuals who had died in Scotland (7.8% vs. 5.8%, p<0.001 and 16.5% vs. 
12.5%, p<0.001) (Table 8-2). The proportion of deaths by age group in individuals with 
MMI was more similar to the pattern observed locally in Glasgow (Table 8-2).  
The proportion of men that died in each group was similar: 67.8% of deaths in those with 
MMI were in men, 64.5% of deaths in Glasgow were in men (p=0.298) and 61.9% of 
deaths in Scotland were in men (p=0.063) (Table 8-2). 
Cause of death differed between the three groups: for example, death due to cancer 
occurred less frequently in individuals with MMI compared to the local Glasgow and 
wider Scottish populations (14.3% vs. 27.3%, p<0.001 and 33.2%, p<0.001) (Table 8-2). 
Alcohol related deaths were also lower (6.5% (MMI) vs. 12.8% (Glasgow), p=0.005 and 
9.7% (Scotland), p=0.099) (Table 8-2). The proportion of deaths due to suicide was higher 
in individuals with MMI compared to that of the local Glasgow and wider Scottish 
populations (14.8% vs. 7.0%, p<0.001 and 6.5%, p<0.001), as were drug related deaths 
(7.8% vs. 5.1%, p=0.065 and 3.2%, p<0.001) (Table 8-2). The proportion of deaths due to 
cardiovascular disease were similar across the three groups (14.8% in those with MMI, 
13.2% in those living in Glasgow (p=0.546) and 13.7% in those living in Scotland 
(p=0.626) (Table 8-2). 
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Table 8-2 Cause of Death of the Deceased PsyCIS Cohort compared to Glasgow and 
Scottish Populations 
Bold if significant (p<0.001) p
1 
Chi squared combined MMI group vs. Glasgow City, p
2 
Chi 
squared combined MMI group vs. Scotland 
Compared to the local Glasgow and wider Scottish population, individuals with MMI had a 
different pattern of cause of death across the life span (Table 8-3 & Figure 8-2). Suicide 
was the single leading cause of death in individuals with MMI aged <25 (100%), 25-34 
(27.8%) and 35-44 (26.3%). For individuals with MMI aged 45-54, suicide and 
cardiovascular disease were the leading causes of death (both 12.5%), while in the 55-64 
age group cardiovascular disease was the single most common cause of death (21.2%), 
followed by cancer (20.2%).  
In the Scottish population, accidental deaths were the leading cause of death in the <25 
(35.5%) and 25-34 age groups (21.5%), whereas in the 35-44, 45-54 and 55-64 age groups, 
cancer was the single leading cause of death (18.7%, 31.4% and 41.1% respectively).  
  
Combined 
MMI Group 
(n=230) 
 
Glasgow City 
(n=8,094) 
P
1 Scotland 
(n=54,590) 
P
2 
Cause of death (n, %) 
Cerebrovascular
 
Disease 
Cardiovascular Disease 
Cancer 
Respiratory disease
 
Alcohol Related  
Accidental Deaths 
Suicide  
Other
 
Mental & behavioural disorder 
due to drugs  
 
8 (3.5) 
34 (14.8) 
33 (14.3) 
24 (10.4) 
15 (6.5) 
11 (4.8) 
34 (14.8) 
53 (23.0) 
18 (7.8) 
 
304 (3.8) 
1069 (13.2) 
2211 (27.3) 
606 (7.5) 
1032 (12.8) 
400 (4.9) 
568 (7.0) 
1492 (18.4) 
412 (5.1) 
 
0.833 
0.546 
<0.001 
0.096 
0.005 
0.912 
<0.001 
0.076 
0.065 
 
2186 (4.0) 
7465 (13.7) 
18129 (33.2) 
3451 (6.3) 
5319 (9.7) 
2882 (5.3) 
3533 (6.5) 
9869 (18.1) 
1756 (3.2) 
 
0.685 
0.626 
<0.001 
0.001 
0.099 
0.734 
<0.001 
0.05 
<0.001 
 
 
Male (n, %) 
 
156 (67.8%) 5218 (64.5%) 0.298 33772 (61.9%) 0.063 
Rate of death/age group (n,%) 
<25 
25-34 
35-44 
45-54 
55-64 
 
3 (1.3) 
18 (7.8) 
38 (16.5) 
72 (31.3) 
99 (43.0) 
 
238 (2.9) 
559 (6.9) 
1250 (15.4) 
2171 (26.8) 
3876 (47.9) 
 
0.144 
0.588 
0.656 
0.131 
0.147 
 
1902 (3.5) 
3186 (5.8) 
6841 (12.5) 
13841 (25.4) 
28820 (52.8) 
 
0.07 
<0.001 
<0.001 
0.039 
0.003 
Death Rate/Quintile (n, %) 
5      Most affluent 
4 
3 
2 
1- Most deprived  
 
 
11 (4.8) 
15 (6.5) 
34 (14.8) 
64 (27.8) 
106(46.1) 
 
 
257 (3.2) 
450 (5.6) 
732 (9.0) 
1286 (15.9) 
5369 (66.3) 
 
 
0.173 
0.531 
0.003 
<0.001 
<0.001 
 
 
5974 (10.9) 
8244 (15.1) 
10338 (18.9) 
12643 (23.2) 
17391 (31.9) 
 
 
0.003 
0.0003 
0.108 
0.09 
<0.001 
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In the Glasgow population suicide and accidental deaths were the most common causes of 
death in the <25s (29.4% and 24.8% respectively) while in the 25-34 age group drug 
related deaths and suicide were the most common causes of death (both 27.8%). In the 35-
44 age group alcohol related deaths were the leading cause of death (20.3%) while in the 
45-54 and 55-64 age groups cancer was the leading cause of death (26.5% and 36.4% 
respectively) (Table 8-3 & Figure 8-2).
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Table 8-3 Cause of death in PsyCIS Population compared to the Glasgow and Scottish Population by age group Bold if significant (p<0.05) 
 <25 25-34 35-44 45-54 55-64 
Cardiovascular disease 
MMI vs. Glasgow n, (%) 
 
MMI vs. Scotland n, (%) 
 
0 (0) vs. 1 (0.4) 
p=0.91 
0 (0) vs. 8 (0.4) 
p=0.910 
 
1 (5.6) vs. 14 (2.5) 
p=0.423 
1 (5.6) vs. 77 (2.4) 
p=0.389 
 
3 (7.9) vs. 99 (7.9) 
p=0.909 
3 (7.9) vs. 609 (8.9) 
p=0.811 
 
9 (12.5) vs. 310 (14.3)  
p=0.671 
9 (12.5) vs. 2042 (14.8) 
 p=0.591 
 
21 (21.2) vs. 645 (16.6) 
p=0.229 
21 (21.2) vs. 4729 (16.4) 
p=0.198 
Cerebrovascular disease 
MMI vs. Glasgow n, (%) 
 
MMI vs. Scotland n, (%) 
 
0 (0) vs. 5 (2.1) 
p=0.80 
0 (0) vs. 20 (1.1) 
p=0.856 
 
0 (0) vs. 7 (1.3) 
p=0.633  
0 (0) vs. 49 (1.5) 
p=0.596 
 
1(2.6) vs. 31 (2.5) 
p=0.999 
1(2.6) vs. 230 (3.4) 
p=0.803 
 
4(5.6) vs. 100 (4.6) 
p=0.706 
4(5.6) vs. 613 (4.4) 
p=0.643 
 
3 (3.0) vs. 161 (4.2) 
p=0.579 
3 (3.0) vs. 1274 (4.4) 
p=0.501 
Respiratory disease 
MMI vs. Glasgow n, (%) 
 
MMI vs. Scotland n, (%) 
 
0 (0) vs. 9 (3.8) 
p=0.73 
0 (0) vs. 45 (2.4) 
p=0.787 
 
0 (0) vs. 8 (1.4) 
p=0.609 
0 (0) vs. 75 (2.4) 
p=0.510 
 
3 (7.9) vs. 52 (4.2) 
p=0.2953  
 3 (7.9)vs.233 (3.4)  
p=0.130 
 
7(9.7) vs. 138 (6.4) 
p=0.253 
7(9.7) vs. 676 (4.9) 
p=0.058 
 
14 (14.1) vs. 399 (10.3) 
p=0.215 
14 (14.1) vs.2422 (8.4)  
p=0.04 
Cancer  
MMI vs. Glasgow n, (%) 
 
MMI vs. Scotland n, (%) 
 
0 (0) vs. 19 (8.0) 
p=0.61 
0(0) vs. 139 (7.3)  
p=0.627 
 
2 (11.1) vs. 48 (8.6) 
p=0.708  
2(11.1) vs. 301 (9.4)  
p=0.810 
 
3(7.9)vs. 157 (12.6) 
p=0.287 
3(7.9)vs1286 (18.8) 
p=0.086 
 
8 (11.1) vs.576 (26.5)  
p=0.003 
8 (11.1)vs. 4455(32.2) 
p<0.001 
 
20 (20.2) vs.1411(36.4) 
p<0.001 
20 (20.2) vs.11948 (41.5) 
p<0.001 
Alcohol Related Deaths 
MMI vs. Glasgow n, (%) 
 
MMI vs. Scotland n, (%) 
 
0 (0) vs. 4 (1.7) 
p=0.82 
0 (0) vs. 19 (1.0) 
p=0.862 
 
1 (5.6) vs. 46 (8.2) 
p=0.683 
1 (5.6) vs. 210 (6.6) 
p=0.860 
 
1 (2.6) vs. 254 (20.3)  
p=0.008 
1 (2.6) vs. 980 (14.3)  
p=0.039 
 
8(11.1) vs.358 (16.5)  
p=0.224 
8(11.1) vs. 1947 (14.1)  
p=0.472 
 
5 (5.1) vs. 370 (9.5) 
p=0.131 
5 (5.1) vs. 2163 (7.5) 
p=0.355 
Mental & behavioural disorder due to drugs  
MMI vs. Glasgow n, (%) 
 
MMI vs. Scotland n, (%) 
 
0 (0) vs. 29 (12.2) 
p=0.519 
0 (0) vs. 263 (13.8)  
p=0.488 
 
5 (27.8) vs.143 (25.6) 
 p=0.834 
(27.8) vs. 666 (20.9)  
p=0.475 
 
5(13.2) vs.179 (14.3) 
 p=0.704 
(13.2) vs.608 (8.9) 
 p=0.357 
 
7 (9.7) vs. 49 (2.3) 
p<0.001 
7 (9.7) vs. 188 (1.4) 
p<0.001 
 
1(1.0) vs. 12 (0.3) 
p=0.228 
1 (1.0) vs. 31 (0.1) 
p=0.007 
Accidental Deaths 
MMI vs. Glasgow n, (%) 
 
MMI vs. Scotland n, (%) 
 
0 (0) vs. 59 (24.8) 
p=0.321 
0 (0) vs. 584 (30.78)  
p=0.249 
 
1 (5.6) vs. 63 (11.3) 
p=0.447 
1 (5.6) vs. 502 (15.8) 
 p=0.236 
 
1(2.6) vs. 94 (7.5) 
p=0.205 
1(2.6) vs. 586 (8.6) 
p=0.192 
 
7(9.7) vs. 90 (4.1) 
p=0.022 
7(9.7) vs. 604 (4.4) 
p=0.027 
 
2 (2.0) vs. 94 (2.4) 
p=0.495 
2 (2.0) vs. 606 (2.1) 
p=0.954 
Suicide  
MMI vs. Glasgow n, (%) 
 
MMI vs. Scotland n, (%) 
 
 
3 (100) vs. 70 (29.4) 
p=0.008 
3 (100)vs. 474 (24.9) 
p=0.31 
 
5(27.8) vs. 139(24.9)  
p=0.779 
5(27.8) vs. 751(23.6) 
 p=0.675  
 
10(26.3)vs.161 (12.9) 
p=0.014 
10(26.3)vs986 (14.4) 
p=0.038 
 
9 (12.5)vs.123 (5.7)  
p=0.015 
9 (12.5)vs.815 (5.9) 
 p=0.018 
 
7 (7.1) vs. 75 (1.93) 
p<0.001 
7 (7.1) vs. 507 (1.8) 
p<0.001 
Other  
MMI vs. Glasgow n, (%) 
 
MMI vs. Scotland n, (%) 
 
 
0 (0) vs. 42 (17.6) 
p=0.423 
0 (0) vs. 350 (18.4)  
p=0.411 
 
3 (16.7) vs. 91 (16.3)  
p=0.965 
3 (16.7) vs. 555(17.4)  
p=0.93 
  
11(28.9) vs. 223 (17.8) 
 p=0.071 
11 (28.9) vs. 1323(19.3)  
p=0.135 
 
13 (18.1) vs. 427 (19.7) 
 p=0.735 
13(18.1) vs. 2501 (18.1) 
 p=0.998  
 
26 (26.3) vs.709 (18.3) 
 p=0.044 
26 (26.3) vs.5140 (17.8) 
p=0.029 
All Cause of death  
MMI vs. Glasgow 
MMI vs. Scotland 
 
3 vs. 238 
3 vs. 1902 
 
18 vs. 559 
18 vs. 3186 
 
38 vs. 1250 
38 vs. 6841 
 
72 vs. 2171 
72 vs. 13841 
 
99 vs. 3876 
99 vs. 28820 
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Figure 8-2 Cause of death by Age Group in individuals with MMI compared to the wider Scottish and local Glasgow population by age group 
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8.7.2 Impact of socioeconomic status on rate and primary cause 
of death:  
The rate of death per 10,000 population over the 5 years for MMI compared to the local 
Glasgow and wider Scottish populations was higher across all socioeconomic quintiles and 
persisted even when suicide was excluded as a cause of death (Figure 8-3). For example, in 
the most deprived cohort, the rate of death (excluding suicide) in individuals with MMI 
was 697.2 per 10,000 population compared to a rate of 252.4 per 10,000 population for 
Scotland and 274.7 per 10,000 population for Glasgow.  
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Figure 8-3 Death Rate/10,000 population per 5 years for those with MMI and for the 
general population living in Glasgow and Scotland by deprivation quintile  
 
There appeared to be a graded relationship between increasing level of deprivation and 
death rate in MMI, mirroring that seen in the local Glasgow and wider Scottish general 
population. When suicide was excluded as a cause of death for individuals with MMI, this 
graded relationship appeared most prominent.  
When the primary cause of death for individuals with MMI was reported in more detail by 
deprivation quintile, and compared to the local Glasgow and wider Scottish populations, a 
number of differences were identified. For individuals living in the most deprived cohort, 
higher drug-related deaths occurred in MMI compared to the local Glasgow and wider 
Scottish population rates (12.3% vs. 5.9%, p<0.001 and 5.1% p=0.002 respectively). A 
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lower proportion of deaths due to cancer in individuals with MMI living in the most 
deprived quintile were also observed, relative to the local Glasgow and wider Scottish 
populations (12.3% vs. 25.1% p=0.013 and 26.3% p<0.001) (Table 8-4).   
The proportion of suicide was significantly higher in individuals with MMI living in the 
most affluent quintile relative to the local Glasgow and wider Scottish populations (54.6% 
vs. 5.8%, p<0.001 and 5.5%, p<0.001). Similarly, an increase in proportion of suicide was 
observed for individuals with MMI living in the most deprived quintile compared to the 
local Glasgow and wider Scottish population (12.3% vs. 6.9%, p=0.05 and 6.9%, p=0.05) 
(Table 8-4)
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Table 8-4 Cause of death in individuals with MMI compared to Glasgow and Scotland by SIMD Quintile  
Bold if significant (p<0.05) 
 Cause of Death 
 n, (%) 
SIMD Category  
Most Affluent                                                                                                                                                             Most deprived 
Accidental MMI vs . Glasgow 
 
MMI vs . Scotland 
 
0 (0) vs . 9 (3.5) 
p=0.535 
0 (0) vs . 273 (4.7) 
p=0.45 
0 (0) vs . 21 (4.7) 
p=0.40 
0 (0) vs . 6491(6.0) 
p=0.345 
1 (2.9  vs . 23 (3.1) 
p=0.94 
1 (2.9 ) vs . 601 (5.8) 
p=0.49 
5 (7.8) vs . 59 (4.6) 
p= 0.265 
5 (7.8) vs . 618 (4.9) 
p=0.31 
5 (4.7) vs . 88 (5.4) 
p= 0.02 
5 (4.7) vs .899(5.2) 
p=0.84 
Alcohol 
 
MMI vs . Glasgow 
 
MMI vs . Scotland 
 
 
1 (9.1) vs . 18 (7.0) 
p=0.693 
1 (9.1) vs .336  (5.8) 
p=0.64 
0(0) vs . 38 (8.4) 
p=0.26 
0(0) vs . 530 (6.4) 
p=0.326 
1(2.9) vs .78 (10.7) 
p= 0.178 
1 (2.9) vs . 864 (8.4) 
p=0.282 
10 (15.6) vs .152 (11.8) 
p= 0.425 
10 (15.6) vs .1275 (10.1) 
p= 0.196 
8 (2.8) vs. 746 (13.9) 
p= 0.003 
8 (2.8) vs.2314 (13.3)  
p=0.004  
Cancer 
 
MMI vs . Glasgow 
 
MMI vs . Scotland 
 
0 (0) vs. 109 (42.4) 
p=0.03 
0 (0) vs. 2726  (47.0) 
p=0.025 
1(6.7) vs .163 (36.2) 
p=0.067 
 1(6.7) vs.3287 (39.9) 
p=0.050 
1 (32.4) vs .236 (32.2) 
p= 0.992 
11 (32.4) vs . 3606 (34.9) 
p=0.829  
8 (12.5) vs.357 (27.8) 
p= 0.0312  
8 (12.5) vs.3942 (31.2) 
p=0.011  
13(12.3) vs. 1346.(25.1) 
p= 0.013 
1 (12.3) vs.4568 (26.3) 
p=0.008 
Cardiovascular 
 
MMI vs . Glasgow 
 
MMI vs . Scotland 
 
2 (18.2) vs . 33 (12.8) 
p=0.44 
2 (18.2) vs . 734 (12.7) 
p=0.608 
1 (6.7) vs . 47 (10.4) 
p=0.66 
1(6.7)vs .1048(12.7) 
p=0.525 
2 (5.9)  vs . 109 (14.9) 
p=0.191 
2 (5.9) vs . 1463 (14.2) 
p=0.213 
8 (12.5) vs .171 (13.1) 
p= 0.872 
8 (12.5) vs .1802 (19.3) 
p=0.727  
21 (19.8) vs . 709 (13.2) 
p= 0.09 
21(19.8) vs .2418 (13.9) 
p=0.138  
Cerebrovascular MMI vs . Glasgow 
 
MMI vs . Scotland 
 
1(9.1)  vs . 13 (5.1) 
p=0.58 
1(9.1) vs .  253 (4.4) 
p=0.455 
2(13.3) vs .20 (4.4) 
p=0.14 
2(13.3) vs .378 (4.6) 
p=0.138 
1 (2.9) vs . 27 (3.7) 
p=0.826 
1 (2.9) vs . 390 (3.8) 
p=0.806 
0 (0) vs .3.4 (44)  
p= 0.139 
0 (0) vs . 478 (3.8)  
p=0.120  
4 (3.8)  vs . 200 (3.7) 
p= 0.979 
4 (3.8) vs . 687 (4.0) 
p=0.929  
Mental & 
behavioural 
disorder due to 
drugs 
MMI vs . Glasgow 
 
MMI vs . Scotland 
 
0(0) vs . 4 (1.6) 
p=0.68 
0(0) vs . 72(1.2) 
p=0.716 
2(13.3) vs. 12 (2.7) 
p=0.028 
2 (13.3) vs.1.7(138) 
p=0.001 
2 (5.9)vs . 23 (3.1) 
p= 0.40 
2 (5.9) vs . 238 (2.3) 
p=0.183  
1 (1.6) vs .58 (4.5)  
p= 0.275 
1 (1.6) vs . 422 (3.3)  
p=0.44  
13 (12.3) vs. 315 (5.9) 
p <0.001 
13 (12.3) vs. 886 (5.1) 
p=0.002 
Other 
 
MMI vs . Glasgow 
 
MMI vs . Scotland 
 
1 (9.1) vs . 4.5 (17.5)  
p= 0.52 
1 (9.1) vs .1043 (18.0)  
p=0.525  
5(33.3) vs .91 (20.2) 
p=0.34 
5 (33.3) vs . 1447 (17.6) 
p=0.207 
8 (23.5)vs . 133 (18.2) 
p=0.521 
8(23.5) vs .1899 (18.4) 
p=0.528 
16(25.0) vs .258 (20.1)  
p= 0.44 
16(25.0 vs .2381(1838)  
p=0.310  
23 (21.2)) vs . 965 (18.0) 
p= 0.418 
23 (21.2) vs . 3099 (17.8) 
p=0.393 
Respiratory 
 
MMI vs . Glasgow 
 
MMI vs . Scotland 
 
0 (0) vs . 11 (4.3) 
p= 0.49 
0 (0) vs .217  (3.7) 
p=0.527  
2(13.3) vs . 25 (5.6) 
p=0.257 
 2(13.3) vs .406 (4.9) 
p=0.169 
3(8.8)  vs . 45 (6.1) 
p= 0.287 
3(8.8) vs . 621 (6.0) 
p=0.522  
8 (12.5) vs .98 (7.6)  
p=0.199 
8 (12.5) vs . 888 (7.0)  
p=0.121 
11 (10.4) vs . 427 (8.0) 
p= 0.405 
11 (10.4) vs . 1319 (7.6) 
p=0.322  
Suicide MMI vs . Glasgow 
 
MMI vs . Scotland 
 
6 (54.6) vs. 15 (5.8) 
p<0.001 
6 (54.6) vs. 320 (5.5) 
p<0.001  
2 (13.3) vs . 33 (7.3) 
p= 0.433 
2(13.3) vs .519 (16.3) 
p=0.308  
5 (14.7)  vs . 58 (7.9) 
p=0.208 
5 (14.7) vs .656 (6.3) 
p=0.07 
8 (12.5) vs . 82 (6.9) 
p= 0.08 
8 (12.5) vs . 837 (6.6) 
p=0.086 
13 (12.3) vs. 373 (6.9) 
p= 0.054 
13(12.3) vs. 1201 (6.9) 
p=0.05  
Al l  Cause of death MMI vs . Glasgow 
MMI vs . Scotland 
11 vs . 257  
11 vs . 5947 
15 vs .450 
15vs .8244 
34  vs . 732 
34  vs . 10388 
64 vs . 1286 
64 vs . 12643 
106 vs .5369  
106 vs .17391 
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8.7.3 Standardised Mortality Ratios (SMR): 
Scotland Standardised mortality ratios (Scotland SMR) and Glasgow Standardised 
mortality ratios (Glasgow SMR) were elevated in all age ranges for the combined 
schizophrenia/bipolar (MMI) group (Table 8-5), with an overall Scotland SMR across all 
age ranges of 2.7 (95% CI 2.4-3.1) and Glasgow SMR of 1.8 (95% CI 1.6-2.0). When 
suicide was excluded as a cause of death, the overall Scotland SMR remained elevated at 
2.3 (95% CI 2.0-2.7) and the Glasgow SMR was 1.5 (95% CI 1.3-1.8). In the younger age 
groups (<25, 25-34 and 35-44), Scotland SMR and Glasgow SMR were markedly elevated 
for individuals with MMI (Table 8-5). 
Deaths due to cardiovascular disease were higher in individuals with MMI over the age of 
25 and were particularly elevated in the 25-34 age group (Scotland SMR 9.6 (95% CI 0.2-
53.2), Glasgow SMR 16.7 (95% CI 0.4-93.1)) although confidence intervals were wide. 
Similarly, cancer deaths for MMI were significantly elevated in the 25-34 age group 
(Scotland SMR 4.8 (95% CI 0.6-17.4), Glasgow SMR 9.7 (95% CI 1.2-35.2)) but were 
lower in the 45-54 and 55-64 age groups (Scotland SMR 0.5 (95% CI 0.2-0.9), Glasgow 
SMR 0.8 (95% CI 0.3-1.5) and Scotland SMR 0.5 (95% CI 0.3-0.8), Glasgow SMR 0.8 
(95% CI 0.5-1.2) respectively) (Table 8-5). 
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Table 8-5 SMRs for all individuals with MMI (Schizophrenia and Bipolar Disorder) by cause of death and age group 
SMR (95% CI) <25 25-34 35-44 45-54 55-64 All ages 
All cause Male & Female  
Scotland SMR  
Glasgow SMR  
 
38.3 (7.9-111.8) 
40.8 (8.4-119.4) 
(n=3) 
 
8.3 (4.9-13.0) 
7.5 (4.4-11.9) 
(n=18) 
 
4.1 (2.9-5.6) 
2.6 (1.8-3.5) 
(n=38) 
 
2.7 (2.1-3.4) 
1.8 (1.4-2.3) 
(n=72) 
 
2.1 (1.7-2.6) 
1.4 (1.1-1.7) 
(n=99) 
 
2.7 (2.4-3.1) 
1.8 (1.6-2.0) 
(n=230) 
All cause Male  
Scotland SMR  
Glasgow SMR   
 
30.5 (0.4-11.0) 
47.7 (5.8-172.2) 
(n=2) 
 
6.9 (3.8-11.3) 
9.1 (5.1-15.0) 
(n=15) 
 
3.5 (2.3-5.0) 
2.9 (2.0-4.2) 
(n=29) 
 
2.4 (1.8-3.2) 
2.0 (1.5-2.6) 
(n=47) 
 
2.1 (1.6-2.7) 
1.7 (1.3-2.1) 
(n=63) 
 
2.6 (2.2-3.0) 
3.3 (2.8-3.9) 
(n=156) 
All cause Female  
Scotland SMR   
Glasgow SMR  
 
52.1 (1.3-290.2) 
31.7 (0.8-177.0) 
(n=1) 
 
8.1 (1.7-23.7) 
4.0 (0.8-11.6) 
(n=3) 
 
4.3 (1.9-8.1) 
1.8 (0.8-3.4) 
(n=9) 
 
3.1 (2.0-4.6) 
1.6 (1.0-2.3) 
(n=25) 
 
2.1 (1.5-2.9) 
1.1 (0.7-1.5) 
(n=36) 
 
2.7 (2.1-3.4) 
2.4 (1.9-3.1) 
(n=74) 
All cause excluding suicide 
Scotland SMR  
Glasgow SMR  
 
0 (1-47.1) 
0 (0-50.2) 
(n=0) 
 
6.0 (3.2-10.2) 
5.4 (2.9-9.3) 
(n=13) 
 
3.0 (2.0-4.3) 
1.9 (1.2-2.7) 
(n=28) 
 
2.4 (1.8-3.1) 
1.6 (1.2-2.0) 
(n=63) 
 
2.0 (1.6-2.4) 
1.3 (1.0-1.6) 
(n=92) 
 
2.3 (2.0-2.7) 
1.5 (1.3-1.8) 
(n=196) 
Cardiovascular disease  
Scotland SMR  
Glasgow SMR  
 
0 (0-6587.3) 
0 (0-11938.1) 
(n=0) 
 
9.6 (0.2-53.2) 
16.7 (0.4-93.1) 
(n=1) 
 
1.8 (0.4-5.2) 
2.5 (0.5-7.4) 
(n=3) 
 
1.1 (0.5-2.2) 
1.6 (0.7-3.0) 
(n=9) 
 
1.4 (0.8-2.1) 
1.8 (1.1-2.7) 
(n=21) 
 
1.4 (0.9-1.9) 
1.8 (1.3-2.5) 
(n=34) 
Cerebrovascular disease  
Scotland SMR  
Glasgow SMR 
 
0 (0-6587) 
0 (0-2386.1) 
(n=0) 
 
0 (0-49.8) 
0 (0-123.2) 
(n=0) 
 
1.6 (0.04-8.97) 
2.7 (0.7-15.1) 
(n=1) 
 
1.7 (0.5-4.3) 
2.2 (0.6-5.6) 
(n=4) 
 
0.7 (0.1-2.1) 
1.0 (0.2-2.9) 
(n=3) 
 
1.1 (0.5-2.2) 
1.5 (0.7-3.0) 
(n=8) 
Cancer  
Scotland SMR  
Glasgow SMR   
 
0 (0-399.2) 
0 (0-628.0) 
(n=0) 
 
4.8 (0.6-17.4) 
9.7 (1.2-35.2) 
(n=2) 
 
0.9 (0.2-2.5) 
1.6 (0.3-4.7) 
(n=3) 
 
0.5 (0.2-0.9) 
0.8 (0.3-1.5) 
(n=8) 
 
0.5 (0.3-0.8) 
0.8 (0.5-1.2) 
(n=20) 
 
0.6 (0.4-0.8) 
0.9 (0.6-1.2) 
(n=33) 
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8.7.4 Comparison of Age and Primary Cause of death in 
Schizophrenia versus Bipolar Disorder:  
6.3% of individuals with schizophrenia (163 from a sample of 2583) and 4.9% of 
individuals with bipolar disorder (67 from a sample of 1355) (p=0.086) died during the 5 
year study period.  Suicide occurred more frequently in individuals with bipolar disorder 
than in individuals with schizophrenia (22% vs. 11.7% p=0.04). All other causes of death 
occurred at similar rates (Table 8-6). There was no difference in death rate by 
socioeconomic quintile between individuals with schizophrenia and bipolar disorder. 
 
Table 8-6 Demographics of deceased PsyCIS Cohort (Schizophrenia vs. Bipolar 
Disorder) 
Bold if significant (p<0.05) 
1 
(Chi squared Schizophrenia vs. Bipolar Disorder)
 2
 (Chi squared 
males vs. female) 
 
Schizophrenia 
(n=163) 
 
Bipolar Disorder  
(n=67) 
 
 
p value 
Death Rate (n, %) 
All (males + females) 
 
Males 
Female 
 
 
 
163/2583 (6.3%) 
 
120/1854 (6.5%) 
43/729 (5.9%) 
p= 0.653
2 
 
67/1655 (5%) 
 
36/534 (7%) 
31/821 (4%) 
p=0.015
2 
 
0.086
1 
 
Mean age of death, (standard deviation)  
Males 
Females  
 
 
49.3 (0.79) 
52.2 (1.45) 
p=0.1077
2 
 
 
50.2 (1.57) 
51.7 (1.79) 
p= 0.1962
2 
 
 
Cause of death (n, %) 
Cerebrovascular Disease 
Cardiovascular Disease 
Cancer 
Respiratory disease
 
Alcohol Related 
Accidental  
Suicide  
Mental & behavioural disorder due to drugs  
Other 
 
6 (3.7%) 
25 (15.3%) 
25 (15.3%) 
19 (11.7%) 
11 (6.7%) 
8 (4.9%) 
19 (11.7%) 
14 (8.6%) 
36 (22.1%) 
 
2 (3%) 
9 (13%) 
8 (12%) 
5 (8%) 
4 (6%) 
3 (5%) 
15 (22%) 
4 (6%) 
17 (25%) 
 
 0.794
1 
 0.712
1 
0.504
1 
 0.345
1 
0.828
1 
0.889
1 
0.037
1 
0.502
1 
0.591
1 
 
Ethnicity White (n, %) 
 
158 (96.9% ) 66 (99%)  0.675
1
 
Death Rate/Quintile (n, %) 
5      Most affluent 
4 
3 
2 
2- Most deprived  
 
 
3/147 (2.0%) 
10/271 (3.7%) 
24/490 (4.9%) 
45/619 (7.3%) 
81/1056 (7.7%) 
 
8/178 (5%) 
5/216 (2%) 
10/290 (3%) 
19/287 (7%) 
25/384 (7%) 
 
 0.223
1 
 0.383
1
 
 0.338
1 
 0.723
1 
0.456
1
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In individuals with schizophrenia aged <25, 25-34 and 35-44, suicide was the leading 
cause of death (100%, 28.6% and 22.2% of deaths respectively) (Figure 8-4). In 
individuals with bipolar disorder aged <25 and 35-44, suicide was also the leading cause of 
death (100% and 36% of deaths respectively), although drug-misuse related deaths (75%) 
were the leading cause of death in the 25-34 age group (Figure 8-4).  
Deaths due to cardiovascular disease accounted for 7.1% of deaths in individuals with 
schizophrenia aged 25-34 and remained an important cause of death as age increased: 7.4% 
of deaths in the 35-44 age group, 10.7% of deaths in the 45-54 age group and 25.0% of 
deaths in the 55-64 age group (Figure 8-4). Deaths due to respiratory disease occurred at a 
younger age in the schizophrenia cohort compared to the bipolar disorder cohort (11.1%, 
12.5% and 14.1% in the 35-44, 45-54 and 55-64 age groups in the schizophrenia cohort 
respectively vs. none in the 35-44 and 54-54 age groups  and 14% in the 55-64 age group 
in the bipolar disorder cohort) (Figure 8-4).  
Suicide was an important cause of death throughout the life-span of individuals with 
bipolar disorder, accounting for 19% of deaths in the 45-54 age group and 17% of deaths 
in the 55-64 age group. Notably, rates of suicide were significantly higher in individuals 
with bipolar disorder aged 55-64 compared to individuals of the same age with 
schizophrenia (17% vs. 1.2% p=0.009) (Figure 8-4).  
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Figure 8-4 Cause of death in individuals with Schizophrenia and Bipolar Disorder by age group 
(Where SCZ= schizophrenia and BP= bipolar disorder)
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For all causes of death for men and women, the calculated Scotland and Glasgow SMR 
were elevated across all age groups for individuals with schizophrenia and bipolar disorder 
(Table 8-7). For individuals with schizophrenia the Scotland and Glasgow SMR were 
consistently higher than those calculated for the bipolar disorder group, although the 
absolute difference appeared to be small. For example for all cause of death for all ages 
Scotland SMR for individuals with schizophrenia was 3.0 (95% CI 2.5-3.4) versus 2.2 
(95% CI 1.7-2.8) for all cause of death for all ages in individuals with bipolar disorder 
(Table 8-7 & Figure 8-5).  When suicide was excluded as a cause of death, the Scotland 
and Glasgow SMR for both the schizophrenia and bipolar group were consistently elevated 
in individuals aged over 25.   
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Table 8-7  Standardised Mortality Ratios (SMR) for individuals with Schizophrenia and Bipolar Disorder 
 
 
 <25 25-34 35-44 45-54 55-64 All ages 
Sc
h
iz
o
p
h
re
n
ia
 G
ro
u
p
 
All cause (M+F)  
Scotland SMR (95% CI) 
Glasgow SMR (95% CI) 
 
51.0 (6.2-184.3) 
54.5 (6.6-196.8) 
(n=2) 
 
9.9 (5.4-16.7) 
9.0 (4.9-15.1) 
(n=14) 
 
4.2 (2.7-6.1) 
2.6 (1.7-3.8) 
(n=27) 
 
3.2 (2.4-4.2) 
2.1 (1.6-2.8) 
(n=56) 
 
2.2 (1.8-2.9) 
1.5 (1.1-1.9) 
(n=64) 
 
3.0 (2.5-3.4) 
2.0 (1.7-2.3) 
(n=163) 
All Cause  Excluding suicide (M+F) 
Scotland SMR (95% CI) 
Glasgow SMR (95% CI) 
 
0 (0-39.6) 
0 (0-100.5) 
(n=0) 
 
7.1 (3.4-13.0) 
6.4 (3.1-11.9) 
(n=10) 
 
3.2 (2.0-5.0) 
2.0 (1.3-3.1) 
(n=21) 
 
2.9 (2.1-3.8) 
1.9 (1.3-3.1) 
(n=50) 
 
2.2 (1.7-2.8) 
1.4 (1.1.-1.8) 
(n=63) 
 
2.7 (2.3-3.1) 
2.8 (1.5-2.1) 
(n=144) 
All cause Male Scotland SMR (95% CI) 
All cause Male Glasgow SMR (95% CI)  
40.6 (4.9-146.8) 
63.5 (7.7-229.5) 
(n=2) 
6.4 (3.2-11.5) 
8.5 (4.2-15.2) 
(n=11) 
3.3 (2.1-5.0) 
2.8 (1.7-4.2) 
(n=22) 
2.6 (1.8-3.5) 
2.1 (1.5-2.9) 
(n=39) 
2.1 (1.5-2.7) 
1.6 (1.2-2.2) 
(n=46) 
2.6 (2.2-3.1) 
3.3 (2.7-3.9) 
(n-120) 
All cause Female Scotland SMR (95% CI) 
All cause Female Glasgow SMR (95% CI)  
0 (0-1152.8) 
0 (0-703.2) 
(n=0) 
23.6 (4.9-69.1) 
11.6 (2.4-33.9) 
(n=3) 
4.9 (1.6-11.5) 
2.1 (0.7-4.9) 
(n=5) 
4.2 (2.4-6.7) 
2.1 (1.2-3.4) 
(n=17) 
2.2 (1.3-3.5) 
1.1 (0.7-1.8) 
(n=18) 
3.2 (2.3-4.4) 
3.0 (2.2-4.0) 
(n=43) 
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All Cause (M+F) 
Scotland SMR (95% CI) 
Glasgow SMR (95% CI) 
 
25.5 (0.6-142.1) 
27.2 (6.9-1517.3) 
(n=1) 
 
5.2 (1.4-13.3) 
4.7 (1.3-12.1) 
(n=4) 
 
3.9 (1.9-6.9) 
2.4 (1.3-4.3) 
(n=11) 
 
1.8 (1.0-2.9) 
1.2 (0.7-2.0) 
(n=16) 
 
1.9 (1.4-2.7) 
1.3 (0.9-1.8) 
(n=35) 
 
2.2 (1.7-2.8) 
1.4 (1.1-1.8) 
(n=67) 
All Cause  Excluding suicide(M+F) 
Scotland SMR (95% CI) 
Glasgow SMR (95% CI) 
 
0 (0-94.4) 
0 (0-100.5) 
(n=0) 
 
3.9 (0.8-11.4) 
3.5 (0.7-10.3) 
(n=3) 
 
2.5 (1.0-5.1) 
1.5 (0.6-3.2) 
(n=7) 
 
1.5 (0.8-2.5) 
1.0 (0.5-1.7) 
(n=13) 
 
1.6(1.1-2.3) 
1.0 (0.7-1.5) 
(n=29) 
 
1.7 (1.3-2.2) 
1.1 (0.8-1.5) 
(n=52) 
All cause Male Scotland SMR (95% CI) 
All cause Male Glasgow SMR (95% CI) 
0 (0-224.9) 
0 (0-351.6) 
(n=0) 
8.6 (2.3-21.9) 
8.5 (1.8-24.9) 
(n=4) 
4.3 (1.7-8.8) 
2.1 (0.6-5.3) 
(n=7) 
1.8 (0.8-3.5) 
1.3 (0.5-2.7) 
(n=8) 
2.2 (1.3-3.5) 
1.5 (0.9-2.5) 
(n=17) 
2.5 (1.8-3.5) 
2.8 (1.9-4.0) 
(n=36) 
All cause Female Scotland SMR (95% CI) 
All cause Female Glasgow SMR (95% CI) 
62.5 (1.6-348.2) 
38.1 (0-140.6) 
(n=1) 
0 (0-15.2) 
0 (0-7.5) 
(n=0) 
3.6 (1.6-9.3) 
1.2 (0.2-3.4) 
(n=4) 
2.0 (0.9-3.9) 
0.8 (0.3-1.7) 
(n=8) 
2.0 (1.2-3.1) 
0.8 (0.4-1.3) 
(n=18) 
2.2 (1.5-3.0) 
1.4 (0.9-2.1) 
(n=31) 
225 
 
 
0
1
2
3
4
5
6
7
8
St
an
d
ar
d
is
e
d
 M
o
rt
al
it
y 
R
at
io
 (
SM
R
)
<25              25-34            35-44              45-54            55-64           All Ages
Calculated Scotland & Glasgow SMR Schizophrenia vs. Bipolar Disorder 
All cause of Death Excluding Suicide
Schizophrenia
Scotland SMR
Schizophrenia
Glasgow SMR
Bipolar Scotland
SMR
Bipolar Glasgow
SMR
Figure 8-5 Calculated All cause of death excluding suicide Scotland & Glasgow SMR for 
Schizophrenia vs. bipolar disorder  
 
8.8 Discussion: 
This cohort of individuals with MMI had higher mortality rates compared to both the local 
Glasgow and wider Scottish populations, consistent with several other studies which have 
used similar secondary care mental health registers (Baxter, 1996). SMR in individuals 
with MMI were elevated in all age categories across both sexes and were profoundly 
elevated in younger age groups. The proportion of deaths by age group was similar to that 
seen in the local Glasgow population, but differed from that of the wider Scottish 
population, with a larger proportion of deaths occurring in individuals aged 25-44 years 
with MMI. As occurs in the general population, increasing socioeconomic deprivation 
appeared to be associated with an increased overall rate of death in MMI.  
8.8.1 Differences in the rate, age and cause of death: 
Although individuals with MMI died at a younger age than individuals in the Scottish 
population, the age at death was similar to the local Glasgow population. This is potentially 
in keeping with the “Glasgow Effect” whereby average age at death in Glasgow is lower 
than the Scottish average. However despite this, differences in cause and rate of death 
between the MMI and Glasgow groups were apparent.  
226 
 
In particular, deaths due to cancer were lower in the MMI group compared to the Glasgow 
group. To date, the literature surrounding cancer deaths in individuals with MMI has been 
mixed, with some studies reporting elevated rates (Kisely et al., 2015; Tran et al., 2009), 
while others report lower rates of cancer deaths (Oksbjerg et al., 2003). A recent meta-
analysis of incidence of cancer (Catt et al., 2008), reported that pooled overall rates of 
cancer incidence were not significantly increased in individuals with schizophrenia 
compared to controls (Standardised Incidence Rate (SIR) 1.05, 95% CI 0.95-1.15) and 
although incidence of lung cancer was increased, when adjusted for smoking there was no 
difference in incidence rates. This study also reported that the incidence of several cancers 
unrelated to smoking was reduced in individuals with schizophrenia (Catt et al., 2008). 
Given the current inconsistent evidence in this area, there is a need for further longitudinal 
research.  
The finding of a lower proportion of alcohol related deaths in MMI, compared to the local 
Glasgow and wider Scottish populations was also surprising, especially given the high 
rates of comorbid alcohol and illicit substance misuse reported in individuals with MMI 
(Rosenberg et al., 1998). This may in part be explained by the elevated population levels of 
alcohol related deaths in Scotland compared to other countries: for example in 2011 the 
Scottish male alcohol mortality rate was 28.4/100,000 compared to the UK average of 
17.2/100,000 while in women the Scottish alcohol mortality rate was 13.9/100,000 
compared to the UK average of 8.3/100,000. (Alcohol Related Mortality, Institute of 
Alcohol Studies, 2013). The finding of a trend towards significantly higher proportions of 
drug related and “other” causes of death (which included a wide range of causes) within 
the MMI cohort may also partly explain this finding. Given that only the primary cause of 
death was obtained from the GRO, rates of alcohol as a secondary cause of death within 
this cohort are unknown. This may also explain our finding of lower rates of primary cause 
of death being due to alcohol in this cohort.  
Increased suicide rates in the under 25s explained the large increase in SMR in this age 
group but did not account for the excess mortality in the other age groups to the same 
extent (when suicide was excluded as a cause of death, SMR remained significantly 
elevated in the 25-34, 35-44, 45-54 and 55-64 age groups). The proportion of 
cardiovascular disease deaths in MMI was only marginally higher compared to Glasgow 
and Scotland, with a trend towards an increase in deaths from cardiovascular disease in 
younger age groups (25-34 and 35-44). This is in keeping with other studies which have 
found similar rates of cardiovascular deaths in individuals with MMI compared to their 
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local population (Colton and Manderscheid, 2006). However given the small sample size 
in this study the ability to draw definitive conclusions is limited.   
8.8.2 Overall mortality rates across the life-span:  
In this cohort, the magnitude of the raised SMR (both the Scotland and Glasgow SMR) 
appeared to reduce as age increased in both the schizophrenia and bipolar disorder cohorts. 
This apparent diminution of mortality with age has been described in other cohorts (Chang 
et al., 2010). Chang and colleagues, (2010) reported a SMR of 4.47 95 % CI 3.49-5.64 in 
individuals aged 15-44 compared to a SMR of 3.1 95% CI 2.61-3.66 in individuals aged 
45-64, although this was for any MMI and for all-cause mortality. The finding of a trend 
towards a greater elevation in mortality rates from cardiovascular disease and cancer in the 
25-34 and 35-44 age groups in this cohort is also of particular interest given that many 
physical health screening programmes are focused on older patient groups.  
The apparent reduction in magnitude of premature mortality associated with MMI across 
the lifespan is likely to be multifactorial. It may be due in part to differences in the nature 
of the underlying mental illness in people presenting at different ages or may be due to 
differences in levels of engagement and treatment compliance with both mental and 
physical health services. 
8.8.3 The role of deprivation: 
In this cohort, as with the local Glasgow and wider Scottish populations, rate of death in 
individuals with MMI increased as deprivation increased. The magnitude of the elevation 
in mortality associated with deprivation was similar; however, when suicide was excluded 
as a cause of death, the magnitude of increase in mortality associated with deprivation was 
greatest for the MMI cohort. This association between deprivation and mortality in 
individuals with MMI appear similar to that reported in the general population.   
Of important clinical note, was the finding of a significantly higher proportion of suicide in 
MMI in both the least and most deprived quintiles. While a negative correlation between 
suicide and socioeconomic status has been found in Australia (Taylor et al., 1998) and the 
US (Kposowa, 1999), a more complex relationship has been identified by others in the UK 
(Hawton et al., 2001; Osborn et al., 2008). In particular, Osborn and colleagues, (2008) 
reported that although suicide rates were increased across all age groups of individuals 
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with MMI, individuals who were least socially deprived were particularly at risk (Osborn 
et al., 2008). 
Despite the negative impact of deprivation on health outcomes: for example, individuals 
living in the most deprived areas are more likely to have unplanned admissions to hospital 
than individuals living in the most affluent areas (Payne et al., 2013) as well as the 
premature onset of multimorbidity (Barnett et al., 2012), studies investigating the 
relationship between socioeconomic status and mortality in individuals with MMI are 
limited. While there are studies looking at the impact of socioeconomic status on 
parasuicide (Gunnell et al., 1995), suicide (Osborn et al., 2008; Congdon 2013) and cause 
of death in major depressive disorder (Surtees et al., 2008; Scafato 2012), generalised 
anxiety disorder (Phillips et al., 2009) and alcohol misuse (Singh and Hoyert, 2000), only 
one study specifically focused on the impact of socioeconomic status on mortality in 
bipolar disorder (Schneider et al., 2001) and no studies have specifically focused on the 
impact of socioeconomic status on mortality in schizophrenia. The study which explored 
the impact of socioeconomic factors on cause and rate of death in bipolar disorder was 
limited due its small sample size of only 30 deaths (Schneider et al., 2001). 
8.8.4 The “Scottish” and the “Glasgow” Effects: 
Life expectancy and health behaviours have improved in Glasgow over the past 50 years; 
but the rates of improvement have differed depending on the individuals’ socioeconomic 
status.  As Scotland’s ranking in terms of European mortality rates have worsened over 
time, so too has the gap in life expectancy between the most affluent and most deprived 
areas within Scotland (SPHSU, 2007). This inequality associated with socioeconomic 
status has been mirrored by an inequality in life expectancy associated with MMI: whereby 
the gap in life expectancy between individuals with MMI and individuals without MMI 
appears to be increasing (Saha et al., 2007; Hoye et al., 2011; Walker et al., 2015). 
As detailed above, although the impact of deprivation on health and mortality is marked, 
the differences in life expectancy in Scotland compared to the rest of Europe, and in 
Glasgow compared to the rest of Scotland, cannot be fully explained by deprivation alone.  
The “Scottish” and “Glasgow Effects” were reflected in this study, where the gap in 
mortality rate for individuals living in the most deprived cohort with MMI was highest.  
This “Glasgow Effect” appeared in our study, where mortality rates for those with MMI 
were even higher than both the Scottish and Glasgow averages. The differences in 
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mortality between individuals with MMI and individuals without MMI also appeared 
largest for those living in the most deprived quintiles.     
This study of all-cause mortality in individuals with MMI in Glasgow has identified a trend 
towards increasing mortality associated with worsening deprivation; however more work is 
required to investigate this relationship further. It remains unclear the extent to which each 
factor (deprivation and MMI) contribute to the increased mortality observed and whether 
these effects are cumulative as deprivation worsens.    
8.8.5 Inverse Care Law: 
Inequalities in health outcomes based on social status have long been recognised. As early 
as 1842 Edwin Chadwick reported this relationship in Aberdeen. With the advent of a free 
at the point of access healthcare system in 1948, it was thought that these inequalities 
would improve. However in 1968 Titmuss reported that “from 15 years’ experience of the 
Health Service (we have learned) that the higher income groups know how to make better 
use of the service; they tend to receive more specialist attention; occupy more of the beds 
in better equipped and staffed hospitals; receive more elective surgery; have better 
maternal care, and are more likely to get psychiatric help and psychotherapy than low-
income groups- particularly the unskilled” (Titmuss, 1968). This inequality in access to 
healthcare was further described by Julian Tudor Hart in 1971 who described the Inverse 
Care Law whereby “the availability of good medical care tends to vary inversely with the 
need for the population served” (Tudor Hart, 1971). 
It is widely recognised that individuals living in deprived areas have higher rates of long 
term illness and disability compared to individuals in more affluent areas (The Kerr Report 
2005). Multimorbidity is more common and occurs 10-15 years earlier in the most 
deprived areas compared to the most affluent areas (Barnett et al., 2012: Salisbury et al., 
2011). The level of deprivation influences not only the amount of multimorbidty but also 
the type of multimorbidity which influences the complexity of care (Mercer et al., 2012). 
Despite the steep gradients in health needs by socioeconomic status that occur in Scotland 
(Barnett et al., 2012), number of General Practioners (GPs) remains stable across 
socioeconomic status (MacKay et al., 2005). This can lead to longer time in accessing 
primary care with subsequent lower satisfaction with access to care in the most deprived 
areas compared to the more affluent ones (Mercer and Watt, 2007). While it is also 
recognised that patients in the most deprived areas often have more problems to discuss 
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(especially psychosocial problems) clinical encounter length is often shorter (Mercer and 
Watt, 2007).  
This high burden of morbidity in deprived areas leads to high demands on primary care. 
This can paradoxically result in poorer access to care, shorter consultation time, lower 
patient enablement (specifically for encounters for psychosocial problems) and higher GP 
stress (Mercer and Watt, 2007). This can then lead to negative impacts on patient 
outcomes. For example in a recent study of individuals with depression, for those living in 
deprived areas, depression was more common and early outcomes were poorer compared 
with affluent areas (Jani et al., 2012). While patient-centered consulting appears to 
improve early outcomes, it is recognised that this is difficult to achieve in deprived areas 
because of the inverse care law and the burden of multimorbidity (Jani et al., 2012). This 
therefore suggests that even in today’s National Health Service (NHS) the Inverse Care 
Law still exists and impacts on patients.  
The Inverse Care Law is reported throughout Europe (Pederson and Vedsted 2014) and 
New Zealand (Sandiford et al., 2015) and is therefore not only a phenomenon associated 
with the NHS. For individuals with MMI who tend to experience downward social drift 
(Aro et al., 1995) the Inverse Care Law may be especially pertinent. With current plans in 
NHS England to distribute healthcare resources based on age, there is the potential for a 
worsening in the manifestations of the Inverse Care Law: where such a change would in 
essence take money away from practices in deprived areas, where fewer people survive 
into old age (Hawkes, 2012).  
8.8.6 Differences between the schizophrenia and bipolar cohorts: 
No significant difference in rate of death for individuals with schizophrenia and bipolar 
disorder was found in this cohort. This highlights the similarities in the level of increased 
mortality experienced by individuals with schizophrenia and bipolar disorder and 
challenges the idea that bipolar disorder has a better prognosis than schizophrenia. 
Although the pattern of rate of death and age at death was more similar in the bipolar 
disorder and schizophrenia cohorts compared to that of the broader Scottish population, a 
number of notable differences were identified. Suicide was more common in the bipolar 
disorder cohort compared to the schizophrenia cohort, there were more drug related deaths 
in the schizophrenia cohort (except the 25-34 age group) and there were more deaths due 
to respiratory disease at a younger age in the schizophrenia cohort. The higher mortality 
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due to respiratory disease in individuals schizophrenia is in keeping with the higher 
smoking rates reported in individuals with schizophrenia compared to individuals with 
bipolar disorder (Dikerson et al., 2013) and the higher suicide rate in individuals with 
bipolar disorder has also been reported elsewhere (Ilgen et al., 2010; Nordentoft et al., 
2013). The higher drug related deaths observed in the schizophrenia cohort is of note given 
the general consensus that substance misuse is more prevalent amongst individuals with 
bipolar disorder than schizophrenia (Regier et al., 1990) and this warrants further 
investigation. 
8.9 Strengths and Limitations: 
In this study the primary cause of death throughout the life-span of individuals with MMI 
was described and compared to both the local Glasgow and wider Scottish population in 
detail, allowing patterns of cause of mortality to be reported by age. Standardised mortality 
rates with suicide excluded as a cause of death were calculated and described by ICD 10 
diagnosis, gender and age group. This approach is novel and helps improve the 
understanding of premature mortality patterns throughout the adult life-span and may help 
aid the development of age specific strategies to improve the life expectancy of individuals 
with MMI. The local nature of this study is also valuable for clinicians working within 
NHS Greater Glasgow and Clyde, as much of the mortality research to date has been 
carried out in Sweden, Denmark, Western Australia and Canada, although some research 
undertaken in London has been published.  
The finding of a gradient in level of deprivation and magnitude of increase in mortality in 
MMI is also novel. To my knowledge, this is the first study to investigate the impact of 
deprivation on rate and cause of death in schizophrenia and bipolar disorder and as such 
may help inform the development of population-based strategies to improve the life 
expectancy of individuals with MMI. Additional strengths of this study include the large, 
comprehensive and prospective nature of the PsyCIS database, which is representative of a 
large clinical population accessing mental health services in a defined urban area. Regular 
checks of data accuracy are carried out by the senior medical practitioners involved in case 
management, thereby maintaining the reliability of diagnoses along with clinical and 
sociodemographic data.  
Limitations of this work include the relatively small number of deaths which occurred 
during our limited study timeframe. Further limitations include the exclusion of a small 
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number of individuals with psychosis who are managed exclusively in primary care. As 
PsyCIS is a database set within secondary care, inclusion of all individuals with psychosis 
in the geographical area would require linkage of the database to primary care records, 
which is not currently possible. Although some individuals with psychosis live 
independently in the community without input from secondary services, further study is 
required to ascertain the numbers of such individuals living in Glasgow. PsyCIS also 
excludes individuals who are under 16, over 65 years old and who are not managed by 
general adult community services, such as individuals whose psychotic illness is managed 
exclusively in addictions psychiatry, old age psychiatry or learning disability services. 
These numbers are likely to be relatively small because the majority of individuals of 
working age with a psychotic disorder are managed by general adult psychiatric services. 
SIMD is a relative measure of deprivation and given the impact of socioeconomic drift in 
the PsyCIS cohort, wider Glasgow and Scottish population during our five year timeframe, 
its use has a number of limitations. A further limitation was that of the impact of age on 
death rates - although adjustment for age profile of the populations were made, full 
standardisation was not possible due to small sample sizes.   
Although the PsyCIS cohort contains information for individuals aged 18-25, the GRO 
mortality data used to calculate Scotland SMR for under 25s included individuals aged 15, 
16 and 17. This may have resulted in an artificial reduction in the Scotland SMR calculated 
for the under 25s and represents a limitation in the study. However, given the small 
numbers of deaths in the wider Scottish population under the age of 25, and in particular 
between the ages of 15, 16 and 17, inclusion of this data was felt to be important.  
Standardised Mortality Ratios (SMR) are used to indirectly standardise for confounding 
effects of age and gender, and are often compared across different age groups and by 
gender. However changes in SMR may reflect changes in the mortality rate within the 
general population rather than the population being studied. In this study calculating SMR 
using data from both a local and national level, occurred with the aim of limiting this 
effect. 
Although SIMD is recognised as a reliable method for describing deprivation, it is worth 
noting that the health domain contains information regarding mortality, morbidity and rates 
of psychotropic medication prescribing. As mortality was an outcome of this study, and 
individuals with a diagnosis of bipolar disorder or schizophrenia will likely be prescribed 
psychotropic medication, perhaps a single domain within SIMD (such as income) could 
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have been used to measure deprivation. A sensitivity analysis could have been carried out 
to determine if this had an effect on results. While this does represent a limitation of the 
study, it is also worth noting that within the SIMD model, the health domain is one of 6 
other domains and carries a weight of only 14%.  
8.10 Conclusion: 
In this cohort of individuals with MMI the rate and cause of death differed from that of the 
local Glasgow and wider Scottish populations. Within individuals with MMI, cause of 
death varied across the life span and by ICD 10 diagnosis. Standardised mortality rates 
were increased for men and women with MMI in all age groups. In the under 25s, suicide 
accounted for the majority of the increase in SMR but in the 25-34 and 35-45 age groups, 
deaths from cardiovascular disease, cerebrovascular disease and cancer were all increased. 
There also appeared to be a gradient effect of deprivation on mortality, which was largest 
for individuals with MMI when suicide was excluded as a cause of death. This pattern of 
rising mortality across deprivation categories may represent evidence of inequalities in 
health outcomes for the most deprived individuals with MMI and more work is required to 
investigate this relationship further. These findings may help inform age and deprivation 
specific interventions for health care organisation, health promotion and screening for 
individuals with MMI in Glasgow and in Scotland.  
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Chapter 9 Conclusion: 
 
 Chapter Overview: 
This concluding chapter will discuss the main findings of each of the studies carried out in 
Chapters 4 through 8. It will discuss how the findings are related to the main themes of this 
thesis and it will discuss the extent to which the original aims have been met. The 
limitations of the work carried out will also be discussed and the implications of the 
findings at both a research and clinical level will be highlighted. Potential directions for 
future research will also be outlined.  
9.1 Summary of Main Findings and Clinical Implications: 
The findings in Chapter 4, which detail the patterns of increased physical health 
comorbidities in individuals with schizophrenia and bipolar disorder, complements existing 
literature in this area. Using the SPICE data of the thirty two most common physical health 
conditions investigated, sixteen occurred significantly more frequently in individuals with 
schizophrenia and fourteen occurred more frequently in individuals with bipolar disorder. 
In particular viral hepatitis, constipation, Parkinson’s disease, diabetes, bronchitis and 
chronic pain occurred most frequently. Due to the large nature of the dataset used in this 
study, adjustment for age, sex and socioeconomic status was possible and so these findings 
help to enrich the limited data which is available in this field and adds to the understanding 
of the type and pattern of physical health comorbidity reported in individuals with 
schizophrenia and bipolar disorder. This also has important clinical implications in that 
clinicians need to more readily consider potential co-existing physical illness in this group 
of patients. Clinicians should also be vigilant for physical symptoms which may be due to 
undiagnosed physical illness and always be aware of the potential for diagnostic over-
shadowing.  
The finding of significantly increased rates of multimorbidity in individuals with 
schizophrenia and bipolar disorder that is also detailed in this chapter is novel, and is of 
scientific and clinical importance given the paucity of literature in this field. 
Evidence for inequalities in access to healthcare, which may partly contribute to the gap in 
life expectancy experienced by individuals with MMI, were found within the studies 
included in this thesis. Chapter 4 provided evidence of under-reporting of cardiovascular-
related conditions in individuals with schizophrenia and bipolar disorder in primary care in 
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Scotland and also provided evidence for less intensive prescribing patterns for individuals 
with schizophrenia and bipolar disorder who had comorbid hypertension and coronary 
heart disease (CHD) compared to individuals with hypertension and CHD who did not 
have schizophrenia or bipolar disorder. This too has important clinical implications in that 
an opportunity to deliver the best evidence-based practice is being lost.  
Further evidence for inequalities in access to care, was explored in Chapter 5, where there 
was evidence that despite higher smoking rates, the rate of recording of smoking cessation 
advice in MMI was significantly lower compared to that in diabetes, hypertension and 
CHD. Evidence for inequalities in prescribing, similar to those reported in Chapter 5, was 
then further reinforced by the finding of a significantly lower odds ratio of  NRT 
prescription in individuals with MMI without diabetes compared to individuals with 
diabetes without MMI. Similarly when rates of NRT prescription in individuals with MMI 
without CHD and MMI without hypertension were compared to individuals with CHD 
without MMI and individuals with hypertension without MMI, rates of NRT prescription 
were significantly lower in the MMI cohort. The presence of a physical comorbidity 
improved rates of recording of smoking cessation advice and NRT prescription in 
individuals with MMI. This appears to reinforce evidence of inequalities in prescribing 
between patient groups.  
Additional evidence of inequalities in access to healthcare was explored at a National 
Level, through analysis of incentivised QOF data and is detailed in Chapters 6 and 7. In 
particular across the UK, payment and population achievement rates for the recording of 
BMI and BP in MMI were significantly reduced compared to payment and population 
achievement rates for the recording of BMI and BP in diabetes and chronic kidney disease. 
In Scotland there was also evidence of higher exception rates for most of the individual 
and composite mental health indicators compared to their proxy individual comparator and 
composite physical health indicators. The inequalities reported in Scotland appear to have 
persisted over the past nine years since the inception of the QOF and despite evidence of 
some improvement in certain indicators (for example comprehensive care plan recording), 
there remain significant and clinically important gaps in indicators associated with 
preventative interventions in particular the recording of BMI and BP. While inequalities in 
screening have been reported for individuals with MMI, the findings of inequality in access 
to incentivised healthcare, on a UK wide basis using QOF data is novel. These findings 
therefore enhance the current available literature and understanding of potential reasons 
and sources of health inequalities.  
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Finally, in keeping with the literature described in Chapter 1, an increase in Standardised 
Mortality Ratios (SMR) for individuals with MMI was found in Chapter 8 using data from 
the PsyCIS cohort. Similarly these data also showed that SMR in individuals with MMI 
were elevated in all age categories across both sexes and were more profoundly elevated in 
younger age groups. The finding that increasing socioeconomic deprivation appeared to be 
associated with an increased overall rate of death in MMI is novel and to date has not been 
explicitly explored in other linkage studies. The differences in primary cause of death by 
deprivation quintile for individuals with MMI compared to the local Glasgow and wider 
Scottish populations detailed in Chapter 8, is again novel. While some patterns in cause of 
mortality were perhaps predicted; for example higher drug-related deaths in individuals 
with MMI living in the most deprived quintile compared to the local Glasgow and wider 
Scottish population rates, some were more surprising: for example a lower proportion of 
deaths due to cancer in individuals with MMI living in the most deprived quintile and a 
higher proportion of suicides in individuals with MMI living in the most affluent quintile 
relative to the local Glasgow and wider Scottish populations. These findings add to the 
limited studies investigating mortality in MMI in a Scottish setting and are of local clinical 
and wider scientific importance. 
This study also reported no significant difference in rate of death for individuals with 
schizophrenia and bipolar disorder and challenges the preconception that bipolar disorder 
has a better prognosis than schizophrenia. Although suicide occurred more frequently in 
individuals with bipolar disorder than in individuals with schizophrenia, all other causes of 
death occurred at similar rates. These findings add to the limited research currently 
available comparing causes of death in individuals with schizophrenia and bipolar disorder.  
9.2 Revisit of Aims & Research Questions: 
Throughout the body of this thesis, I have attempted to address its aims as fully as possible. 
The narrative review of the literature set the thesis in context and allowed gaps in current 
knowledge and research, to became apparent. This allowed the generation of the research 
questions around which the remaining thesis aims were addressed. 
The second aim of this thesis was to gain a more detailed understanding of the patterns of 
multiple physical health comorbidities in individuals with schizophrenia and bipolar 
disorder. Optimisation of the SPICE database have, been helpful in contributing to a 
greater understanding of patterns of physical health comorbidities in individuals with 
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schizophrenia and bipolar disorder. An introductory exploration into rates of 
multimorbidity in individuals with MMI has also been undertaken-although this is an area 
which warrants much further in-depth study. 
The third aim of this thesis was to better understand possible explanations for the health 
inequalities that are reported in individuals with schizophrenia and bipolar disorder. By 
examining prescribing data from primary care and national incentivised QOF data an 
attempt to explore possible reasons for the inequalities reported has been undertaken. 
Inequalities in prescribing for individuals with MMI across a range of clinical settings, 
within Scottish primary care were found. Evidence of inequalities in payment, population 
achievement and exception rates for a wide range of incentivised aspects of health care in 
Scotland and indeed across the whole of the UK across a number of years were also found. 
Therefore through analysis of these data the third aim of this thesis has been addressed.  
The final aim of this thesis was to gain a more detailed understanding of the causes of 
premature mortality in individuals with schizophrenia and bipolar disorder. Using the 
PsyCIS database this has been explored in detail and a novel finding of the impact of 
socioeconomic status on rate and primary cause of death has also been detailed.  
9.3 Limitations: 
As this thesis compromised largely of retrospective, cross-sectional, epidemiological 
secondary data, there are a number of limitations which require to be acknowledged. In 
addition to the limitations detailed at the end of each Chapter, there are a number of 
general limitations to this work; firstly in the datasets used and secondly in the design of 
the studies included in this thesis. 
The SPICE dataset used in Chapters 4 and 5, is a primary care dataset, which contains 
information from approximately one third of the Scottish Population. While all general 
practices in Scotland were invited to participate 314 practices opted in. Differences 
between participating and not participating general practices (non response bias) need to be 
considered and potentially could affect generalisability. The data is anonymised and arises 
from the primary care clinical record and so the quality of the data retrieved is reliant on 
the quality of the data entry and completeness of the contributing General Practices- this is 
likely to vary across the whole of Scotland and may therefore affect results. The data used 
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in the studies were extracted in March 2007 and so are now almost eight years old and 
represents a further limitation of this work.  
The QOF data analysed in Chapters 6 and 7, are collected nationally as a payment rather 
than quality monitoring system and thus quality and accuracy of data is reliant on type of 
clinical computing system used and also on local practice factors. These may vary across 
geographical location. Data was also available only at a practice level and so consideration 
at patient level was not possible.  
The PsyCIS dataset used in Chapter 8, was originally designed as a clinical governance 
and audit tool, and although has undergone significant diagnostic validation, there is 
nevertheless the possibility for inaccuracies in data recording; either by the clinicians 
locally or when local returns are centrally uploaded. Clinical diagnosis, albeit by an 
experienced Consultant Psychiatrist, rather than by a structured interview was used for 
diagnostic stratification and so represents a limitation of the data. Limitations within the 
construct of the PsyCIS database (i.e. exclusion of under 16s and over 65s) are also 
acknowledged. The factors outlined above are all limitations of the datasets utilised in this 
thesis.  
In terms of study design, all studies included were cross-sectional in nature, and so no 
directionality or temporality can be attributed to the association between factors 
investigated, nor can any association confirm a causal relationship. Although this is a 
limitation for all the studies detailed in Chapters 4 through 8 given the datasets that were 
available and the gaps in current knowledge, each study design was felt to be the most 
pragmatic one possible. The findings highlighted in this thesis however I feel can be used 
to form the basis for further prospective and longitudinal studies.   
9.4 Implications of Findings: 
The findings of the studies included in this thesis have shown that while mortality rates, 
causes of death and patterns of physical health comorbidity are different in individuals 
with MMI compared to the general population, there is evidence of inequalities in: access 
to healthcare advice, prescribing patterns and recording of basic health indices in 
individuals with MMI.  This has important implications at both a clinical and research 
level.  
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Adequate healthcare resources at both a primary and secondary care level need to be 
targeted in response to the increased burden of physical health comorbidity identified by 
the studies included in this thesis. In particular primary care, has an important role in 
translating policy into evidence based practice (Planner et al., 2014). In a healthcare system 
which has become increasingly specialised and at times fragmented, greater attention is 
needed to ensure that the healthcare that is being delivered by all clinicians is as holistic 
and efficient as possible. System design which often leads to separation between physical 
and mental healthcare also needs to be addressed. Druss and Newcomer (2007) described 
four types of separation: geographic (whereby there is a lack of co-located physical and 
mental health services), financial (whereby there are separate finding streams for physical 
and mental health service), organisational (whereby there is difficulty sharing information 
and expertise across these systems) and lastly cultural (whereby providers focus on 
symptoms or single disorders, rather than the whole patient) (Druss and Newcomer, 2007). 
Strategies therefore to ensure that healthcare systems have enough flexibility to respond to 
the challenges of multimorbidity, stigma and variability in help seeking behaviour also 
require to be developed.  
For psychiatric inpatients pathways to improve access to non-urgent secondary care need 
to be developed (Moore et al., 2015). Integrated healthcare teams and records would 
potentially make this easier, as there is evidence that within secondary care, merging 
medical and psychiatric electronic records, can lead to lower readmission rates and shorter 
lengths of stay (Kozubal et al., 2013). For outpatients, integrating care may in some ways 
be more challenging. The debate over who should be responsible for the monitoring of 
physical health in individuals with MMI should be resolved. Mental health providers 
although may be the primary point of healthcare contact for individuals with MMI, may 
not be familiar with the current monitoring of physical health issues. This can inadvertently 
lead to sub-standard care. GPs, may have difficulty engaging individuals with MMI and 
the short appointment times make it challenging to address the physical healthcare needs of 
patients with MMI who may lack motivation and concentration and be thought disordered 
(Moore et al., 2015).  Therefore strategies to address this need to be developed.  
For clinicians in both primary and secondary care, an increased awareness of the impact of 
age and socioeconomic status on cause of death for individuals with MMI is important to 
help target resources and ensure that both the physical and mental health needs of all 
individuals are being met. At a wider level, public health strategies, in combination with 
healthcare policies need to take into account these unique healthcare needs in order to 
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ensure that there is no further worsening of the health inequalities and widening of the gap 
in life expectancy experienced by individuals with MMI compared to individuals without 
MMI.  
The findings of inequality in access to care, at a healthcare advice, prescribing and health 
indices recording level are also important for clinicians to be aware of. Raising awareness 
of the potential bias that may occur in the delivery of patient care may be helpful in 
changing practice to reduce bias and improve equality in health care.    
For researchers, the relationship between deprivation, mortality rate and cause of death 
requires further exploration using other cross sectional data. More in-depth study to 
investigate the mechanisms underpinning the findings of increased morbidity and mortality 
in individuals with MMI is required to allow the development of interventions aimed at 
reducing the gap in mortality. A better understanding of the possible reasons for 
inequalities in healthcare delivery is also required in order to inform potential strategies 
aimed at reducing this inequality. 
9.5 Future Work: 
Given the identification of elevated rates of physical health comorbidity and elevated rates 
of multimorbidity, further prospective longitudinal studies to investigate the temporal 
relationship between physical and mental health comorbidity would be helpful to 
determine if the comorbid medical conditions assessed predated or precipitated the 
diagnosis of schizophrenia or bipolar disorder (and conversely whether schizophrenia or 
bipolar disorder was an antecedent for some of the medical conditions).  
Mechanistic studies to determine possible genetic and/or epigenetic factors associated with 
comorbid mental and physical illnesses could also be undertaken to help better understand 
possible common pathways in the development of these conditions. Further studies 
investigating the role of inflammation in the development of comorbidity and 
multimorbidty may also be helpful.      
Finally, consideration to the modification of healthcare services from the current single, 
disease orientated, hierarchical nature of care, to a more integrated collaborative approach 
should occur. As the current single, disease orientated system can lead to fragmented care, 
greater integration of psychiatric services with primary care and with specialist medical 
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services may be helpful in achieving better, more holistic and more effective healthcare. 
Strategies such as Community Engagement (CE) which have been shown to be effective in 
engaging hard to reach individuals (Lamb et al., 2014) should be evaluated in the context 
of MMI. Collaborative care, which aims to develop closer working relationships between 
primary and secondary care (Reilly et al., 2013) is an important strategy which may 
improve the quality of care for individuals with MMI.  While collaborative care models 
have been used in the management of depression (Coventry et al., 2015), only one study 
looking at collaborative care in MMI has been undertaken (Bauer et al., 2006). Therefore  
more work is required to develop, design and evaluate an integrated model of care for 
individuals with MMI and physical health comorbidity.  
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Appendices 
Appendix 1 Narrative review search methodology: 
For the literature search for evidence of increased physical health comorbidity in Major 
Mental Illness (MMI) the same terms to search for MMI were: Major Mental Illness 
(MMI), Severe Mental Illness (SMI), schizophrenia, bipolar disorder and bipolar affective 
disorder. Physical health comorbidity was searched using the terms: physical health, 
comorbidity, multimorbidity and morbidity. Titles and abstracts of identified papers were 
reviewed and suitability was based on definition of MMI, definition of comorbidity and 
cohort size. Given the overlap in the literature pertaining to schizophrenia and bipolar 
disorder, searches using both terms were performed, although papers relevant to either 
condition were considered and reported separately.  
For Evidence for inequalities in health outcomes experienced by individuals with Major 
Mental Illness (MMI) the same terms to search for MMI were used. To search for 
inequalities in healthcare, the terms: inequality, inequities, disparity, healthcare, health 
promotion, screening, prescribing, outcomes were used. Titles and abstracts of identified 
papers were reviewed and their suitability was assessed.  
For the search regarding evidence of premature mortality in Major Mental Illness (MMI) 
search terms included were: premature mortality, mortality, deaths, Major Mental Illness 
(MMI), Severe Mental Illness (SMI), Serious Mental Illness, schizophrenia, bipolar 
disorder and bipolar affective disorder. Titles and abstracts of identified papers were 
reviewed. Given the overlap in the literature pertaining to schizophrenia and bipolar 
disorder, searches using both terms were performed, although papers relevant to either 
condition were considered and reported separately. Study suitability was based on 
definition of MMI, measure of premature mortality, length of follow up and cohort size 
This allowed a systematic narrative review of the literature surrounding premature 
mortality in MMI to be undertaken.  
The initial search was performed in June 2014 and was updated in July 2015. 
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Appendix 2: List of the thirty two most common 
physical health conditions and there definitions 
assessed in Chapters 4 and 5 
Condition Definition  
Atrial Fibrillation (AF) Read code ever recorded 
Hypertension Read Code ever Recorded 
Coronary Heart Disease (CHD) Read code ever recorded 
Cancer Read code first recorded in last 5 years 
Peripheral Vascular Disease (PVD) Read code ever recorded 
Rheumatoid Arthritis (RA) Read code ever recorded 
Prostate Disease Read code ever recorded 
Glaucoma Read code ever recorded 
Multiple Sclerosis (MS) Read code ever recorded 
Chronic Kidney Disease (CKD) Read code ever recorded 
Diverticular Disease Read code ever recorded 
Bronchiectasis Read code ever recorded 
Crohn’s Disease Read code ever recorded 
Stroke Read code ever recorded 
Sinusitis Read code ever recorded 
Heart Failure Read code ever recorded 
Hearing Loss Read code ever recorded 
Asthma Read code ever recorded AND any prescription in last 
12 months 
Migraine ≥ 4 prescription only medicine anti-migraine 
prescriptions in last year 
Chronic Obstructive Pulmonary 
Disease (COPD)/Bronchitis 
Read code ever recorded 
Psoriasis or Eczema Read code ever recorded AND ≥ 4 related prescriptions 
in last 12 months (excluding simple emollients) 
Pain ≥4 prescription only medicine analgesic prescriptions in 
last 12 months OR ≥4 specified anti-epileptics in the 
absence of an epilepsy Read code in last 12 months 
Thyroid Disease Read code ever recorded 
Blindness Read code ever recorded 
Diabetes Read code ever recorded 
Irritable Bowel Syndrome (IBS) Read code ever recorded OR ≥ 4 prescription only 
medicine antispasmodic prescription in last 12 months 
Liver Disease Read code ever recorded 
Dyspepsia ≥ 4 prescriptions in last 12 months BNF 0103% 
excluding antacids AND NOT (≥4 NSAIDS OR ≥4 
aspirin/clopidogrel) 
Epilepsy Read code ever recorded AND antiepileptic prescription 
in last 12 months 
Parkinson’s Disease Read code ever recorded 
Constipation ≥4 laxative prescriptions in last year 
Viral Hepatitis Read code ever recorded 
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Appendix 3: Detailed breakdown of Scottish Index 
of Multiple Deprivation (SIMD) Domains: 
Income Domain: 
 
Count or proportion of people defined as income deprived. This is a combined count of 
claimants on the following benefits:            
 Adults and Children in Income Support (IS) or Income-based Employment and 
Support Allowance Households;  
 Adults and Children in Job Seekers Allowance (JSA) households;  
 Adults in Guarantee Pension Credit Households; 
 Adults and Children in Tax Credit Households on low incomes 
Each person will only be counted once.   
 
Employment Domain: 
 
Count or proportion of people defined as employment deprived. This is a combined count 
of claimants on the following benefits:        
 Working Age Unemployment Claimant Count averaged over 12 months;  
 Working Age Incapacity Benefit claimants, or Employment and Support Allowance 
recipients; 
 Working Age Severe Disablement Allowance claimants; 
Each person will only be counted once.   
 
Crime Domain: 
Rate of recorded crime taken from the following:  
 Recorded Crimes of Violence      
 Recorded Sexual Offences 
 Recorded Domestic housebreaking 
 Recorded Vandalism 
 Recorded Drugs Offences 
 Recorded Common Assault 
Sum of the recorded crimes/offences in each of the above indicators. 
 
Education Domain: 
The Education Domain gives an education deprivation rank using the following indicators:  
 School pupil absences 
 Pupil performance on SQA at stage 4 
 Working age people with no qualifications 
 17-21 year olds enrolling into higher education 
 People aged 16-19 not in education, employment or training 
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Health Domain: 
The Health Domain gives a Health deprivation rank using the following indicators:  
 Standardised Mortality Ratio 
 Hospital stays related to alcohol use 
 Hospital stays related to drug use 
 Comparative Illness Factor 
 Emergency stays in hospital 
 Estimated proportion of population being prescribed drugs for anxiety, depression 
or psychosis 
 Proportion of live singleton births of low birth weight, <2500g 
 
Housing Domain: 
 
The Housing Domain uses rates for the following:  
 Persons in households without central heating 
 Persons in households that are overcrowded 
To calculate housing deprivation.  
Geographical Access to services Domain: 
 
This indicator is intended to capture the issues of financial cost, time and inconvenience of 
having to travel to access basic services and uses the population weighted average drive 
time in minutes as a measure of geographical access to services. This is based on  
 drive time to: GPs, shopping facilities, a petrol station, schools and a post office 
and  
 public transport time to GPs, a post office and to shopping facilities.  
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Appendix 4: Possible Smoking Status Read Codes 
 
Read Code  coding       
137D. Admitted tobacco cons untrue ? 0 
137J. Cigar smoker 1 
137P. Cigarette smoker 1 
137L. Current non-smoker 3 
137R. Current smoker 1 
137O. Ex-cigar smoker 2 
137N. Ex-pipe smoker 2 
137S. Ex-smoker 2 
137A. Ex-heavy smoker (20-39/day) 2 
1378. Ex-light smoker (1-9/day 2 
1379. Ex-moderate smoker (10-19/day) 2 
137F. Ex-smoker - amount unknown 2 
1377. Ex-trivial smoker (<1/day) 2 
137B. Ex-very heavy smoker (40+/day) 2 
1375. Heavy smoker - 20-39 cigs/day 1 
137C. Keeps trying to stop smoking 1 
1373. Light smoker - 1-9 cigs/day 1 
1374. Moderate smoker - 10-19 cigs/d 1 
1371. Never smoked tobacco 3 
137I. Passive smoker 0 
137H. Pipe smoker 1 
137M. Rolls own cigarettes 1 
137Q. Smoking started 1 
137K. Stopped smoking 2 
137.. Tobacco consumption 1 
137Z. Tobacco consumption NOS 1 
137E. Tobacco consumption unknown 0 
1372. Trivial smoker - < 1 cig/day 1 
137G. Trying to give up smoking 1 
1376. Very heavy smoker - 40+cigs/day 1 
 
Missing/excluded data =0, current smoker =1, ex-smoker=2, never smoked=3 
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Appendix 5: Possible Smoking Cessation Advice 
Read Codes 
Read Code Descriptor Coding 
13P1. Smoking status at 4 weeks 1 
13p.. Smoking cessation milestones 1 
13p0. Negotiated date for cessation of smoking 1 
13p1. Smoking status at 4 weeks 1 
13p2. Smoking status between 4 and 52 weeks 1 
13p3. Smoking status at 52 weeks 1 
13p4. Smoking-free weeks 1 
13p5. Smoking cessation programme start date 1 
6791 Health education - smoking 1 
67A3. Pregnancy smoking advice 1 
67H1. Lifestyle advice re: smoking 1 
8B2B. Nicotine replacement therapy 1 
8B3F. Nicotine replacement therapy provided free 1 
8B3Y. Over-the-counter nicotine replacement therapy provided free 1 
8B3y. Over-the-counter nicotine replacement therapy provided free 1 
8CAL. Smoking cessation advice 1 
8CAl. Smoking cessation advice 1 
8H7I. Referral to smoking cessation adviser 1 
8H7i. Referral to smoking cessation adviser 1 
8HTK. Referral to stop-smoking clinic 1 
8HTk. Referral to stop-smoking clinic 1 
9N2k. Seen by smoking cessation adviser 1 
9N4M. Did not attend smoking cessation advice 0 
9OO.. Anti-smoking monitoring administration 1 
9OO1. Attends stop-smoking monitor 1 
9OO2. Refuses stop-smoking monitor 1 
9OO3. Stop-smoking monitor default 1 
9OO7. Stop-smoking monitor verbal interview 1 
9OO9. Stop-smoking monitoring deletion 1 
9OOA. Stop-smoking monitor check done 1 
9OOZ. Stop-smoking monitor administration NOS 1 
9Oo.. Anti-smoking monitoring administration 1 
 
Where 0= no smoking cessation advice and 1= smoking cessation advice given 
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Appendix 6: Possible Prescription Format of NRT  
LastNicotineRep Code 
NICORETTE 1 
NICORETTE CHEWING GU 2-P42 1 
NICORETTE CHEWING GUM 1 
NICORETTE GUM 1 
NICORETTE INHALATOR 1 
NICORETTE NASAL SPRA LIQ 500-P42 1 
NICORETTE NASAL SPRAY 10MG/ML-P42 1 
NICORETTE PATCH 1 
NICORETTE PATCH 10-P42 1 
NICORETTE PATCH 15-P42 1 
NICORETTE PATCHES 1 
NICORETTE chewing gum 2mg-P42 1 
NICORETTE inhalator cartridge 10mg-P42 1 
NICORETTE patch 10mg-P42 1 
NICORETTE patch 15mg-P42 1 
NICORETTE patch PAT 15mg-P42 1 
NICORETTE plus chewing gum 4mg-P42 1 
NICORETTE-P42 1 
NICOTINE REPLACEMENT THERAPY 1 
NICOTINE TRANSDERMAL PATCH 30CM-P42 1 
NICOTINE cartridge - (for inhalation) 1 1 
NICOTINE chewing gum 2mg fruit-P42 1 
NICOTINE inh cartridge 10mg-P42 1 
NICOTINE patch 10mg-P42 1 
NICOTINE patch 14mg-P42 1 
NICOTINE patch 15mg-P42 1 
NICOTINE patch 21mg-P42 1 
NICOTINE patch 7mg-P42 1 
NICOTINELL 1 
NICOTINELL 10 TTS-P42 1 
NICOTINELL 20 TTS-P42 1 
NICOTINELL 30 TTS-P42 1 
NICOTINELL GUM 1 
NICOTINELL LOZENGES 1 
NICOTINELL PATCHES 1 
NICOTINELL TTS 1 
NICOTINELL TTS 30 patch NON NHS 11/97-P 1 
NICOTINELL TTS PATCH 1 
NICOTINELL TTS PATCH 20 SQ CM-P42 1 
NICOTINELL TTS PATCHES 1 
NICOTINELL TTS patch 10 square cm-P42 1 
NICOTINELL TTS patch 30 square cm-P42 1 
NICOTINELL TTS patch PAT 10 sq cm-P42 1 
NICOTINELL TTS patch PAT 20 sq cm-P42 1 
NICOTINELL TTS patch PAT 30 sq cm-P42 1 
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NIQUITIN 1 
NIQUITIN CQ 1 
NIQUITIN CQ 21MG PATCHES 1 
NIQUITIN CQ PATCH 1 
NIQUITIN CQ PATCH 24 HRS 1 
NIQUITIN CQ PATCHES 1 
NIQUITIN CQ patch 14mg-P42 1 
NIQUITIN CQ patch 21mg-P42 1 
NIQUITIN CQ patch 7mg clear-P42 1 
NIQUITIN CQ patch 7mg-P42 1 
NIQUITIN CQ patch PAT 14mg-P42 1 
NIQUITIN CQ patch PAT 21mg-P42 1 
NIQUITIN CQ patch PAT 7mg-P42 1 
NIQUITIN LOZENGES 1 
Nicotine Patches 14mg 1 
NiQuitin CG 1 
NiQuitin CQ 1 
NiQuitin CQ 14mg 1 
NiQuitin CQ 21mg 1 
NiQuitin CQ 7mg 1 
NiQuitin CQ PATCHES 1 
NiQuitin CQ Patches 1 
NiQuitin CQ clear 1 
NiQuitin CQ pastilles 1 
NiQuitin Lozenges 1 
NiQuitin QC 1 
Nicorette 1 
Nicorette 10mg patches 1 
Nicorette 15mg Patches 1 
Nicorette 15mg patches 1 
Nicorette 16hr patch 1 
Nicorette 5mg patches 1 
Nicorette Chewing Gum 1 
Nicorette Gum 1 
Nicorette Inhalator 1 
Nicorette Microtab 1 
Nicorette Nasal Spray 1 
Nicorette Patch 1 
Nicorette Patch 5mg-P42 1 
Nicorette Patches 1 
Nicorette Step 1 1 
Nicorette inhalator cartridge refill pa 1 
Nicorette microtabs 1 
Nicorette patch 1 
Nicotine 1 
Nicotine CQ Patches 1 
Nicotine Chewing Gum (as resin) 1 
Nicotine Chewing Gum 2mg-P42 1 
Nicotine Inhalation 1 
274 
 
Nicotine Inhalation Cartridge 1 
Nicotine Lozenge 1mg-P42 1 
Nicotine Lozenge 2mg 1 
Nicotine Lozenge 4mg 1 
Nicotine Medicated Chewing Gum 2mg 1 
Nicotine Medicated Chewing Gum 4mg 1 
Nicotine Patch 1 
Nicotine Patches 1 
Nicotine Patches 15mg 1 
Nicotine Patches 16 Hours 1 
Nicotine Patches 16 hours 1 
Nicotine Patches 24 Hours 1 
Nicotine Patches 24 hours 1 
Nicotine Replacement Lozenges 1 
Nicotine Replacement Therapy 1 
Nicotine TTS Patches 1 
Nicotine Transdermal Patch 10mg in 16hr 1 
Nicotine Transdermal Patch 14mg in 24hr 1 
Nicotine Transdermal Patch 15mg in 16hr 1 
Nicotine Transdermal Patch 21mg in 24hr 1 
Nicotine Transdermal Patch 5mg in 16hrs 1 
Nicotine Transdermal Patch 7mg in 24hrs 1 
Nicotine chewing gum 1 
Nicotine lozenges 1 
Nicotine microtab 1 
Nicotine patches 1 
Nicotine replacement therapy 1 
Nicotinell 1 
Nicotinell  patches 1 
Nicotinell 14mg Patch 1 
Nicotinell 14mgs 1 
Nicotinell 21mgs 1 
Nicotinell Chewing Gum 1 
Nicotinell Gum 1 
Nicotinell Lozenge 1 
Nicotinell Mint Lozenge 1 
Nicotinell Patches 1 
Nicotinell TTS 1 
Nicotinell TTS 20 1 
Nicotinell TTS Patch 1 
Nicotinell TTS Patches 1 
Nicotinell Tts 10 1 
Nicotinell Tts 20 1 
Nicotinell Tts 30 1 
Nicotinell programme 1 
Nicotinelle 1 
Niquitin 1 
Niquitin 21mg 1 
Niquitin CQ 1 
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Niquitin CQ Lozenge 1 
Niquitin CQ Patches (10 week course) 1 
Niquitin CQ Patch 1 
Niquitin CQ Patch 14mg-P42 1 
Niquitin CQ Patch 21mg-P42 1 
Niquitin CQ Patch 7mg-P42 1 
Niquitin CQ Patches 1 
Niquitin CQ Tab 1 
Niquitin CQ patches 1 
Niquitin Cq 1 
Niquitin Cq Lozenge 1 
Niquitin patches 1 
nicorette 1 
nicorette 16hr 1 
nicorette 5mg patches 1 
nicorette gum 1 
nicorette gum 2mg 1 
nicorette inhalator 1 
nicorette inhalator refills 1 
nicorette microtab 1 
nicorette microtabs 1 
nicorette nasal spray 1 
nicorette patch 10mgms 16hr 1 
nicorette patches 1 
nicorette patches 10mg 1 
nicorette patches 15mg 1 
nicotine 1 
nicotine  patch 1 
nicotine gum 1 
nicotine patch 1 
nicotine patches 1 
nicotine patches 1 
nicotine replacement 1 
nicotine replacement therapy 1 
nicotine replacement therapy patches 1 
nicotine sublingual tabs 1 
nicotine transdermal 1 
nicotinell 1 
nicotinell 14 mg 1 
nicotinell 20 1 
nicotinell 30 1 
nicotinell TTS 1 
nicotinell TTS  24hr patch 1 
nicotinell TTS 30 1 
nicotinell gum 1 
nicotinell gum 1mg 1 
nicotinell patch 1 
nicotinell patches 1 
nicotinell tts 10 1 
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nicotinelle 1 
nicotinelle patches 1 
niquitin CQ 1 
niquitin CQ lozenge 1 
niquitin CQ lozenges 1 
niquitin cq 1 
niquitin cq lozenges 2 mgms 1 
niquitin cq lozenges 4mgms 1 
niquitin cq patches 1 
niquitin cq patches mg 1 
 
